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Abstract 
Spontaneous preterm birth complicates about 3% of pregnancies before 34 weeks’ gestation 
and 7 – 12% before 37 weeks’ gestation. It is an important issue to public health worldwide. 
The aim of this thesis was to identify test(s) which would predict spontaneous preterm birth in 
early pregnancy when women are asymptomatic and in later pregnancy when they present 
with symptoms of threatened preterm labour, using systematic reviews and meta-analysis. If 
women at risk can be identified whether early in pregnancy or when they present with 
threatened preterm labour, interventions can be deployed to prevent or delay birth and to 
improve subsequent neonatal mortality/morbidity. Initially 40,243 title and abstract citations 
were scrutinised, resulting in shortlist of 1,650 full articles in which 319 were included in the 
systematic reviews, encompassing 22 tests. The quality of studies and accuracy of tests 
measured with likelihood ratio (LR) was generally poor. There were only a handful of studies 
for most of the tests. Few tests reached LR+ point estimates >5. In asymptomatic antenatal 
women these were ultrasonographic cervical funnelling and length measurement, cervico-
vaginal prolactin and cervico-vaginal fetal fibronectin screening for predicting spontaneous 
preterm birth before 34 weeks’ gestation. In this group, tests with LR- point estimates 
approaching <0.2 were detection of uterine contraction (by mammary stimulating test) and 
amniotic fluid CRP measurement. In symptomatic women with threatened preterm labour 
tests with LR+ point estimate >5 were absence of fetal breathing movements, cervical length 
measurement, amniotic fluid IL6 and IL8, serum CRP and cervico-vaginal hcg for predicting 
birth within 2-7 days of testing. In this group tests with LR- point estimate <0.2 were 
measurement of cervico-vaginal hcg, cervical length measurement, absence of fetal breathing 
movement, amniotic fluid IL6 and IL8, and serum CRP for predicting birth within 2 - 7 days 
of testing. In conclusion, no exceptional, but many promising tests for predicting spontaneous 
preterm birth was identified to aid the development of evidence based practice. 
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Chapter 1 Thesis summary 
Background 
A viable preterm birth is defined as any delivery of a pregnancy at less than 37 completed 
weeks (<259 days) and more than 23 completed weeks of gestation. It is a heterogeneous 
condition where up to 30 - 40% of all cases of preterm births are due to elective delivery for a 
maternal or a fetal complication. The remaining 60 – 70% of preterm births occurs 
spontaneously, which is the focus of this thesis. It complicates about 3% of pregnancies 
before 34 weeks’ gestation and between 7 – 12% before 37 weeks’ gestation. The former 
particularly has serious effects on mother, child and society, which makes preterm birth an 
important issue to public health worldwide. If women can be identified to be at high risk in 
early pregnancy, they can be targeted for more intensive antenatal surveillance and 
prophylactic interventions. When women present with symptoms of threatened preterm 
labour, if the likelihood of having spontaneous preterm birth can be determined, interventions 
can be deployed to prevent or delay birth and to improve subsequent neonatal 
mortality/morbidity. 
Objective 
The aim of this thesis was to identify test(s) which would accurately predict spontaneous 
preterm birth in asymptomatic antenatal women in early pregnancy and in women 
symptomatic with threatened preterm labour in later pregnancy by undertaking a series of 
systematic reviews of accuracy of tests. 
Methods 
Protocols were developed for performing the systematic reviews of test accuracy using 
standard review methods including: literature searches without language restrictions, study 
quality assessment and meta-analysis where appropriate. Two populations of interest were 
defined: asymptomatic antenatal women and women symptomatic with threatened preterm 
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labour. Literature was identified from several sources (up to September 2005 inclusive), 
including databases: PUBMED (MEDLINE), EMBASE (Ovid), DARE, CENTRAL, 
MEDION, contact with experts including the Cochrane Pregnancy and Childbirth Group and 
checking of reference lists of review articles and papers that were eligible for the systematic 
reviews included in this thesis. Included were cohorts or case control studies of any pregnant 
women where the index test was compared to the reference standard of spontaneous preterm 
birth and a 2x2 table could be calculated. Quality assessment was based on modified 
QUADAS criteria. Meta-analyses of likelihood ratios (LR’s) using random effects model and 
of sensitivity and specificity using the bivariate models were performed. In general, the higher 
the LR+ >1 (i.e. the likelihood ratio for a positive test) the more accurate is the test in ruling 
in the condition while the lower the LR- <1 (i.e. the likelihood ratio for a negative test) the 
more accurate is the test in ruling out the condition. 
Results 
Initially 40,243 title and abstract citations were scrutinised, resulting in the short listing of 
1,650 full articles for which 319 were included for the systematic reviews, encompassing 22 
tests that were evaluated in this thesis. The quality of studies and accuracy of tests was 
generally poor. For asymptomatic women, only testing for asymptomatic bacteriuria, cervico-
vaginal fibronectin, assessment for periodontitis and bacterial vaginosis, and serum β-hcg 
were evaluated in more than 10 studies while for symptomatic women, aside from fetal 
fibronectin, and amniotic fluid IL6 which has been evaluated in 31 and 10 studies 
respectively, the remainder had only been evaluated in a handful of studies. Some tests were 
able to achieve high predictive value when positive, but at the expense of compromised low 
predictive value when negative. Only a few tests reached LR+ point estimates >5. In 
asymptomatic antenatal women these were ultrasonographic cervical funnelling and length 
measurement, cervico-vaginal prolactin and cervico-vaginal fetal fibronectin screening for 
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predicting spontaneous preterm birth before 34 weeks’ gestation. In this group, tests with LR- 
point estimates approaching <0.2 were detection of uterine contraction (by mammary 
stimulating test) and amniotic fluid CRP measurement. For predicting spontaneous preterm 
birth before 37 weeks’ gestation, only cervico-vaginal fibronectin achieved and serial salivary 
estriol testing achieved LR+ >5.0, while only home uterine activity monitoring and amniotic 
fluid CRP measurement achieved LR- <0.2. In symptomatic women with threatened preterm 
labour tests with LR+ point estimate >5 were absence of fetal breathing movements, cervical 
length measurement, amniotic fluid IL6 and IL8, serum CRP and cervico-vaginal hcg (for 
predicting birth within 2-7 days of testing); and serum CRP, amniotic fluid IL6, and MMP-9, 
cervico-vaginal fetal fibronectin and cervico-vaginal hcg (for predicting spontaneous preterm 
birth before 34 or 37 weeks’ gestation). In this group tests with LR- point estimate <0.2 were 
measurement of cervico-vaginal hcg, cervical length measurement, absence of fetal breathing 
movement, amniotic fluid IL6 and IL8, and serum CRP (for predicting birth within 2 - 7 days 
of testing); and cervico-vaginal fetal fibronectin and amniotic fluid IL6 (for predicting 
spontaneous preterm birth before 34 or 37 weeks’ gestation). 
Conclusions 
There are a number of promising tests identified by this thesis. The prominence of the 
detection of absence of fetal breathing movement, cervical funnelling and cervical length 
measurement provide a stronger impetus for a universal provision for high quality ultrasound 
machine in labour wards for predicting spontaneous preterm birth among women with a 
viable pregnancy who present with threatened preterm labour to direct management (e.g. 
administration of tocolytics, corticosteroids and in-utero transfer). Nevertheless, provision for 
round the clock trained personnel to perform such a scan in the interim is a challenge. 
Additionally, the feasibility and acceptability to mothers and health providers of such tests 
including more invasive (but potentially more accurate amniotic fluid assessment of IL6 and 
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8) strategies needs to be explored. Rigorous evaluation is needed of tests with minimal cost or 
invasiveness whose initial assessments suggest that they may have high levels of accuracy. 
Similarly, there is a need for high quality, adequately powered randomized controlled trials to 
investigate whether interventions are indeed effective in reducing (in asymptomatic women) 
and/or delaying (in symptomatic women with threatened preterm labour) spontaneous preterm 
birth. In future, an economic model should be developed which considers not just 
spontaneous preterm birth, but other related outcomes, particularly those relevant to the infant 
like perinatal death and shorter and longer term outcomes amongst survivors. Such a 
modelling project should make provision for primary data collection on the safety of 
interventions and their associated costs. 
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Chapter 2 Introduction 
Definition of preterm birth 
Textbooks define preterm birth as any delivery of a viable pregnancy at less than 37 
completed weeks of gestation (<259 days), the lower limit of viability ex-utero being 
generally accepted to be at 23 completed weeks. Births before 23 completed weeks of 
gestation are classified as either miscarriages or abortions. 
Aetiology of preterm birth 
Preterm birth is a heterogeneous condition where up to 30 - 40% of all cases of preterm birth 
are due to elective delivery for a maternal or a fetal complication where it is judged that the 
baby is better delivered in the mother’s interest or that of its own e.g. hypertension, diabetes, 
intra-uterine growth restriction.1 The remaining 60 – 70% of preterm birth are likely due to 
covert or sub-clinical infective/inflammatory processes, cervical dysfunction, idiopathic 
(unknown), multiple gestations and possible social, nutritional, and environmental 
interactions.2 This thesis focuses on the latter group of so called ‘spontaneous’ preterm birth 
among singletons regardless of aetiology. 
Consequences of preterm birth 
Preterm births, particularly those before 34 weeks’ gestation, account for three-quarters of 
neonatal mortality and one-half of long term neurological impairment in children.3-5 Many of 
the surviving infants also suffer from other serious short and long-term morbidity,4;6;7 such as 
respiratory distress syndrome, broncho-pulmonary dysplasia, intraventricular haemorrhage, 
retrolental fibroplasia and developmental problems. Even those premature infants that are 
classified as developmentally ‘normal’ or classified as having ‘mild’ developmental problem, 
in the longer term, have higher rate of multiple problems that do affect their life.8 Although 
complications of prematurity are significantly reduced after 32-34 weeks’ gestation, minor 
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morbidities, which often lengthen hospitalisation, remain for neonates born between 34 –37 
weeks’ gestation.9-13 
Burden of disease due to preterm birth 
Spontaneous preterm birth before 37 weeks' gestation occurs in 7-12% of pregnancies14-16 and 
it occurs in about 4% of pregnancies before 34 weeks’ gestation.17 Thus far advances in 
perinatal healthcare have not reduced the rate of spontaneous preterm birth.15 Extrapolation 
from live births data in England and Wales (2004) live births data,18 shows that an estimated 
76,000 and 26,000 spontaneous preterm births occur before 37 weeks’ and 34 weeks’ 
gestation respectively. 
Economically, preterm birth has a major and significant direct and indirect cost. There is a 
direct cost in terms of clinical resources use, e.g. intensive and often prolonged neonatal care 
as in-patient followed by higher rate of re-hospitalisation following discharge,19;20 and 
emotional, psychological, and financial burden to the parents who are usually the main carers. 
There is also an indirect cost to the society where scarce public resources are utilized for long 
term care of the handicapped premature child and the fact that one or both parents may have 
to give up full time employment to care for their premature child. 
Therefore, accurate prediction of the risk of preterm birth among asymptomatic pregnant 
women and those symptomatic with threatened preterm labour may offer the opportunity to 
target care at those most likely to benefit. 
Potential clinical applications of output from this thesis 
Antenatal care in the UK is a complex care package, within which screening for women at 
risk of preterm birth is an integral component. Often this is linked to screening for conditions 
(e.g. pre-eclampsia) that might predispose to the need for elective preterm delivery. Currently 
there is no routine screening test for spontaneous preterm birth apart from obtaining history of 
previous pregnancies. Once women are identified to be at risk, they may be able to be either 
 
 
27
recruited for further intervention(s) or measure(s) to prevent spontaneous preterm birth or be 
targeted for more intensive antenatal surveillance and prophylactic measures that are currently 
available, as primary, secondary or tertiary preventions. 
Primary prevention is preventing the onset of spontaneous preterm labour in asymptomatic 
women e.g. administration of maternal progestational agents injection or ensuring and 
maintaining healthy maternal genito-urinary tract and periodontal status. Secondary 
prevention is steps that can be taken to attenuate, stop or reverse the progress of spontaneous 
preterm labour in its early stages, well before advanced cervical dilatation, e.g. by 
administration of tocolytic agents. Tertiary prevention is measures aimed at preventing 
neonatal complications associated with prematurity, e.g. maternal administration of antenatal 
corticosteroids to accelerate fetal lung maturity. This thesis focuses on primary and secondary 
prevention. 
Delineation of the problem 
Assessment of pregnant women’s risk for preterm birth based on a combination of patients’ 
characteristics, symptoms, physical signs and investigations, is important. This is because 
without an accurate assessment, clinicians are handicapped in the management of women at 
risk of preterm birth regarding institution of timely antenatal interventions. Wrong or delayed 
diagnosis can put mother and baby at risk of an adverse outcome whereas correct prediction 
of spontaneous preterm birth will provide an opportunity to institute effective interventions. 
This thesis will address these issues using systematic reviews to estimate the accuracy of tests 
for predicting spontaneous preterm birth. 
There are two target populations of pregnant women that need to be tested for the risk of 
spontaneous preterm birth (Figure 1). The first is a population of antenatal asymptomatic 
women carrying a singleton gestation having routine care. In this important, and by far the 
largest epidemiological target of pregnant population, women are generally in a healthy state, 
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anticipating a normal course of pregnancy. They are usually regarded as 'low-risk’ unless 
there are antecedent or current factor(s) and history that might increase the risk of preterm 
birth. If screening or testing could predict the risk of spontaneous preterm birth among these 
women, preventative measure(s) may be more appropriately targeted. For example if 
ultrasonographic measurement of cervical length in these women identifies shortened cervical 
length,21 then cervical cerclage may be deployed to prevent progression to spontaneous 
preterm birth.22 For these women, the key outcome measure would be prevention of 
spontaneous preterm birth before 34 and 37 weeks’ gestation. 
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Figure 1 Target populations and outcomes in the course of pregnancy for diagnostic research on 
spontaneous preterm birth 
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The second population of interest is that of symptomatic women with singleton gestation who 
present with threatened preterm labour. For these women, there is a need to identify those 
who will go on to deliver prematurely as the key clinical decisions following testing relates to 
immediate management and outcome. For example, if cervico-vaginal fetal fibronectin testing 
could predict spontaneous preterm birth among these women before advanced cervical 
dilatation,23 antenatal maternal intramuscular corticosteroid injection may be administered to 
accelerate fetal lung maturity to prevent respiratory distress syndrome.24 In-utero transfer to a 
tertiary intensive neonatal care unit able to care for the premature neonate may also be 
considered.25;26 Such a transfer, which may take some time to arrange (because of logistics, 
geography or lack of neonatal intensive care cots), would be inappropriate if birth were 
imminent, as this would risk delivery en-route. In such cases, knowledge of a higher 
likelihood of imminent birth may allow rational use of tocolytics agents, which aim to 
suppress or diminish contractions allowing time for antenatal corticosteroid administration to 
exert its beneficial effects.27 Antenatal corticosteroids have maximal effectiveness in 
preventing neonatal complications of prematurity delivered within 2-7 days after 
administration.24 Given the duration of time required for corticosteroids to exert beneficial 
effects and the potential for in-utero transfer and tocolytic administration, knowledge of 
impending birth within 48 hours to 7 days of testing would be a clinically meaningful 
outcome measure among women symptomatic of threatened preterm labour.
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Aim 
The aim of this thesis was to systematically review the evidence on tests that identify women 
with singleton pregnancy at risk of spontaneous preterm birth which would allow for the 
institution of measures to improve neonatal outcome. 
Objectives 
Considering the above background and aim, the research was undertaken to meet the 
following objectives: 
1. To determine, among asymptomatic women with singleton gestation in early 
pregnancy (before 23 completed weeks of gestation) the accuracy of various tests (history, 
examination and investigations) for predicting the risk of spontaneous preterm birth and  
2. To determine, among women with a viable singleton pregnancy (after 23 completed 
weeks of gestation), symptomatic of threatened preterm labour with intact amniotic 
membrane and before advance cervical dilatation (less than 2-3 cm dilatation) the accuracy of 
various tests (history, examination and investigations) for predicting the risk of imminent 
preterm birth. 
From this work, the thesis aims to identify areas where evidence is strong enough to generate 
recommendations for clinical practice in addition to identifying key areas and research 
questions requiring further primary research. 
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Chapter 3 Methods 
Protocol development 
This thesis is based on systematic reviews, a scientific, replicable method of evidence 
synthesis explicitly describing the objectives, the search strategy for relevant literature, and 
the methods for processing information and deriving conclusions.28 The process followed key 
steps involved in health technology assessment (HTA) of a diagnostic test.29-31 Systematic 
reviews of accuracy of tests were carried out using contemporaneous methodology,32-34 which 
is in line with the recommendations of the Centre for Reviews and Dissemination (CRD),35 
and the Cochrane Collaboration including those of Cochrane Methods Working Group on 
Screening and Diagnostic tests.36 The research was based on a prospective protocol, which 
included reviews of existing test accuracy, updating those which were out-of-date; and 
performing reviews of topics not reviewed in the literature. 
Research question 
The following structured question was addressed: 
Populations: Asymptomatic low-risk pregnant women with singleton gestation in early 
pregnancy and low-risk women symptomatic of threatened preterm labour with a viable 
singleton pregnancy. Singleton pregnancies were the focus because it represents an 
epidemiological significant pregnant population and because multiple gestations fall in a 
higher risk category that represents a different disease spectrum. 
Tests: List of tests available for determining the risk of spontaneous preterm birth in 
asymptomatic pregnant women and those available for determining the risk of imminent birth 
in women symptomatic of threatened preterm labour (Appendix I). 
Outcomes (reference standards): Spontaneous preterm birth <37 weeks’ gestation and <34 
weeks’ gestation in asymptomatic pregnant women, and birth within 24, 48 hours and up to 7 
- 10 days of testing or presentation in women symptomatic of threatened preterm labour.  
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Study designs: Test accuracy studies (observational: prospective or retrospective) of defined 
non-randomised populations in which the results of the test of interest were compared with 
the outcomes (reference standards) to generate 2x2 tables to compute indices of test accuracy. 
Study identification and selection 
Existing reviews were first identified, assessed for their quality and examined their currency. 
Through this process gaps were identified where reviews did not exist and where they needed 
updating. To fill these gaps, systematic reviews were performed where none was available or 
non-current existing reviews were updated where required. Therefore a formal search was 
undertaken to identify existing reviews of accuracy of tests for spontaneous preterm birth. The 
search strategy can be found in Appendix II. The Cochrane Library, the National Research 
Register (NRR), the Health Technology Assessment (HTA) database, the National Guideline 
Clearinghouse and a range of other guideline and effectiveness collections were searched for 
systematic reviews, guidelines and ongoing research using Medical Subject Headings (MeSH) 
terms and text words. A database of published and unpublished literature was assembled from 
update searches using an existing search strategy,37 as well as hand searching, contacting 
manufacturers and consultation with experts in the area. No language restrictions were applied 
to electronic searches.  
The following databases were searched for primary studies: MEDLINE, EMBASE, BIOSIS, 
MEDION, Pascal, Science Citation Index, and Cochrane Database of Systematic Reviews 
(CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts 
of Reviews of Effects (DARE) and HTA database. In addition, information on studies in 
progress, unpublished research or research reported in the grey literature was sought by 
searching a range of relevant databases including Inside Conferences, Systems for 
Information in Grey Literature (SIGLE), Dissertation Abstracts, Clinical Trials.gov and the 
NRR. Citations captured by the search were scrutinised for inclusion in the review in a two-
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stage process using predefined and explicit criteria regarding populations, index tests, target 
conditions and study designs. First, a master database of the literature searches was 
constructed by amalgamation of all the citations from various database sources. The citation 
were scrutinised by two reviewers. Copies of full manuscripts of all citations that were likely 
to meet the selection criteria were obtained. Two reviewers then independently selected the 
studies, which met the predefined criteria. These criteria were pilot tested using a sample of 
papers. Disagreements were resolved by consensus and/or arbitration involving a third 
reviewer.  
The search revealed a number of test accuracy reviews at various levels of currency (Chapter 
4: Identification of accuracy literature and Appendix I). Most of the identified reviews were 
updated, where experts surveyed for this thesis decided the priority on clinical grounds, and a 
few new rapid reviews were carried out to fill the identified gaps. To be included in updated 
systematic reviews, any recent systematic reviews or primary studies had to fulfil the 
individual criteria as stated in the original reviews, including the following criteria: 
Population: Asymptomatic antenatal women and women symptomatic of threatened preterm 
labour with singleton gestation to allow interventions, which delay delivery and improve 
neonatal outcome for prematurely born infants. 
Index Tests: Tests that purported to predict spontaneous preterm birth (Table 1). 
Reference standards and other outcomes: Any outcomes as reported in the individual reviews. 
However, only data relating to the following outcome measures were used in the thesis: 
spontaneous preterm birth < 37 weeks gestation, <34 weeks gestation or within 2-7 days of 
testing, and resource use. If relevant outcomes were not reported in the original reviews this is 
noted. 
Study designs: Systematic reviews of test accuracy studies were included; all reviews were of 
a standard quality accepted by DARE produced by the CRD, University of York (UK). For 
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primary studies, observational cohort studies were looked for and or, if unavailable, ‘case-
control’ studies of test accuracy. 
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Table 1 List of tests that purported to predict spontaneous preterm birth 
 
Type of tests or 
investigation  
Predictive and diagnostic tests for preterm birth 
  
History Previous history of either spontaneous preterm birth* 
 
  
Examination Abdominal palpation+ 
 
 Cervical digital examination+ 
 
  
Biochemistry Cervico-vaginal glycoproteins:  
Interleukins (IL-6, IL-8)+ 
β-hcg+ 
Fetal fibronectin*+  
Phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1)+ 
 
 Serum glycoprotein: α-fetoprotein, human chorionic gonadotrophin (as part of Down’s screening)* 
 
 Endocrine hormones: 
Salivary estriol+ 
Corticotrophin releasing hormone+ 
 
 Inflammatory markers (serum):  
C-reactive protein*+ 
Matrix metalloprotease (MMP)+ 
Interleukins*+ 
 
  
Microbiology Detection of bacterial vaginosis*+ 
Periodontal screening* 
Midstream urine culture*+ 
 
  
Physiological Uterine activity monitoring* 
Rheobase+ 
Mammary stimulation test+ 
 
  
Ultrasound scan Absence of fetal breathing movements+ 
 
 Measurement of cervical length*+ 
 
  
*Test applied on asymptomatic women 
+Test applied on symptomatic women 
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Study quality assessment and data extraction 
For existing reviews, quality was assessed using existing guidance on conducting test 
accuracy reviews.35;36;38 The methodological quality of the selected primary studies was 
assessed using predefined criteria based on elements of study design, conduct and analysis 
which are likely to have a direct relationship to bias in a test accuracy study (derived from 
‘QUADAS’ (Quality Assessment of Diagnostic Accuracy Studies) criteria (of which, these: 
clear description of population selection and enrolment criteria, complete verification of 
outcome using the same reference standard, sufficient test description for replication and 
blinding of assessors) were used).39-42 In addition to using study quality as a possible 
explanation for differences (i.e. heterogeneity) in results, the extent to which primary research 
met methodological standards is important per se for assessing the strength of any conclusions 
that are reached. Data extraction pro-forma can be found in Appendix III. In the main text of 
the thesis, graphical summaries of the five most important quality items were provided for 
while others can be extracted from tables of study characteristics for the individual test 
(Appendix IV). 
Any randomized trials of effectiveness of test-treatment combinations were assessed for 
validity separately to the diagnostic accuracy studies. Studies’ findings were extracted in 
duplicate for 10% of randomly selected studies, while the remaining were done by the author, 
using pre-designed and piloted data extraction forms, which were developed and used in 
previously published reviews.21;23;43-45 Previous reviews had assessed studies and extracted 
data in duplicate. For missing information attempt was made to obtain data from original 
investigators only if it was crucial to subsequent analysis. To avoid introducing bias, 
unpublished information was coded in the same fashion as published information. If there was 
a suspicion of double data counting (consequent from e.g. studies or publications from the 
same population for a particular test for different outcomes), clarification was sought from the 
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corresponding authors so that only information pertinent to the more significant outcomes e.g. 
birth before 34 weeks’ gestation for asymptomatic women and within 7-10 days of testing 
were used in the situation. 
Data synthesis 
A brief narrative review of findings and quality was undertaken for each test considered. This 
was followed by exploration for the causes of variation in results from study to study (i.e. 
heterogeneity) and synthesis of results from individual studies (meta-analysis) if appropriate. 
Accuracy results were computed separately for different populations, tests and reference 
standards. Heterogeneity of results between studies was graphically assessed in forest plots of 
likelihood ratios (LR’s) and distribution of sensitivity and specificity in summary receiver 
operating characteristics (ROC) space (for the latter only those reviews of ‘more accurate 
tests’ with the relevant clinical outcomes are shown in this thesis). The latter showed the 
trade-off between sensitivity and specificity across different studies with explicit or implicit 
variation in thresholds. A general guide for interpreting summary LR’s is shown in Table 2. 
Table 2 Guide to the likelihood ratio (LR) interpretation of a test’s accuracy 
 
Category of test 
accuracy usefulness 
Likelihood ratio for a 
positive test result (LR+) 
Likelihood ratio for a 
negative test result (LR-) Interpretation 
    
Very useful >10 <0.1 
Likely to generate large (and often) conclusive 
changes from pre-test to post-test probabilities 
Useful 5 – 10 0.1 – 0.2 
Likely to generate moderate shifts in pre-test to 
post-test probabilities 
May be useful 2 – 5 0.2 – 0.5 
Likely to generate small but sometimes important 
changes in pre-test to post-test probabilities 
Not useful 1 – 2 0.5 - 1 
May alter pre-test to post-test probabilities to a 
small (and rarely important) degree 
    
Derived from Jaeschke, Grimes and Fagan et al 46-48 
In any specific context however the value of LR below which positive result and above which negative result will be useless depends on how effective, safe and expensive the interventions 
that follow relative to costs and outcome of false negative cases. 
 
Subgroup analyses were planned a-priori to explore causes of heterogeneity to check whether 
variations in populations, index test characteristics, target conditions and study quality affect 
the estimation of accuracy. Individual factors explaining heterogeneity were also analysed 
using meta-regression where there were more than 10 studies in a review to determine their 
unique contribution, allowing for other factor. Conclusions regarding the typical estimate of 
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accuracy were interpreted cautiously if there was significant heterogeneity.49 
In addition to meta-analyses that generated summary estimates primarily of LR’s, summary 
sensitivity and specificity using the bivariate model50;51 and summary ROC curves using the 
hierarchical summary receiver operating characteristic (HSROC) model50;52 were also 
generated where on balance, they would add to the interpretation of the results.53 LR’s are 
considered more clinically meaningful as measures of test accuracy46-48 and would allow 
estimation of probabilities for use in a decision analytic modelling. These post test 
probabilities can be used to calculate the absolute effects of interventions according to test 
results.54 Publication and related biases were assessed using funnel plots of diagnostic odds 
ratio (dOR) against corresponding variances amongst reviews with more than 10 studies.35 
Appendix V aids for the interpretation of summary ROC curves and funnel plots. Stata 
version 8.2 software was used in the statistical analyses. The procedural flow chart for 
systematic reviews of test accuracy is shown in Figure 2. 
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Figure 2 Flow chart of procedures for reviews of test accuracy studies 
 
Information sought from 
each study:
•Inclusion & exclusion 
criteria
•Study design quality
•Description of 
populations, index test, 
and reference standards
Asymptomatic 
antenatal women 
with singleton 
pregnancy
Symptomatic 
women with 
threatened 
preterm labour 
(singleton 
pregnancy)
Birth before 34 
weeks’ gestation
Birth before 37 
weeks’ gestation
Birth before 37 
weeks’ gestation
Birth within 2 - 7 
days of testing
List of tests
(Appendix II)
List of tests
(Appendix II)
Birth before 34 
weeks’ gestation
Heterogeneity analysis 
(Graphical/statistical)
•Forest plots of likelihood ratios (LR’s)
•Threshold analysis
•Sensitivity/specificity plots in ROC space
•χ2 test
•Meta-regression, funnel plot analysis if 
>10 studies (minimum exploratory 
variables: quality (high/low))
Meta-analysis
•If no significant heterogeneity use 
summary LR’s
•If significant heterogeneity, summary 
LR’s is not provided but:
• if ≥2 ideal quality* studies available, 
pooled these (random effects model) 
and provide summary LR’s from 
these highest quality studies 
• if 1 ideal quality study is available, 
use this LR estimates
•if no ideal quality study is available, 
use the highest quality study 
available and if there is ≥2 of them, 
use the largest study by sample size
*Ideal study = consecutive, cohort, prospective, blinding in place, and 
adequate test description to allow  for replication
Data extraction Delineation of separate populations, tests and reference standards Data syntheses
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Chapter 4 Results 
Literature selection 
List of tests reviewed and their currency can be found on Appendix I. The reviews of tests’ 
accuracy were divided into history, examination and investigations. 40,243 title and abstract 
electronic citations were obtained from the comprehensive literature searches from the various 
databases. These citations were scrutinised, with duplicates and those citations which do not 
meet the inclusion criteria excluded, resulted in the short listing of 1,650 citations for which 
the full article was requested. Upon further scrutiny of the full article, 319 were finally 
included for the systematic reviews, encompassing 22 tests that were evaluated in this thesis. 
The 22 tests aimed at the prediction of spontaneous preterm birth in asymptomatic women in 
early pregnancy and in women symptomatic with threatened preterm labour in the later part of 
their pregnancy. Figure 3 summarizes the process of the identification of literature reviews for 
test accuracy studies. 
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Figure 3 Identification of test accuracy literatures for systematic reviews in this thesis 
 
 
 
REVIEWS 
References identified from search 
strategy: N = 69 
PRIMARY STUDIES 
References identified from search 
strategies: N = 40,174 
References excluded on the 
basis of reviewing title and 
abstract only: N= 60 
References excluded on the basis 
of reviewing title and abstract 
only: N = 38,524 
Full copy of papers ordered for more 
detailed evaluation: N= 9 
(2 additional identified from reference 
list) 
Full copy of papers ordered for more 
detailed evaluation: N = 1,650 
 
Papers excluded on the basis of 
reviewing full paper. N= 5 
Papers excluded on the basis of 
reviewing full paper. N= 1,331 
Included reviews: N= 6* 
 
*Including 4 reviews that were updated in 
this thesis 
Included papers: N= 319 
 
Of which: 
Included studies: N= 321 
 
Total citations identified from electronic searches (MEDLINE, EMBASE, BIOSIS, MEDION, Pascal, Science Citation Index, 
Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of 
Abstracts of Reviews of Effects (DARE) and HTA database) to capture primary articles on all tests for predicting spontaneous 
preterm birth: n= 40,243 
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Previous history of spontaneous preterm birth 
Previous medical history of having spontaneous preterm birth is clinically used as a predictor 
for another spontaneous preterm birth. With the advent of dating scan, this history can be 
accurately assessed at antenatal booking consultation. 
Study characteristics and quality 
There were 10 studies evaluating the accuracy of previous history of spontaneous preterm 
birth among asymptomatic antenatal women in predicting spontaneous preterm birth in the 
subsequent pregnancy (n=55,885).55-64 One study65 was excluded on closer inspection because 
it used the same population as another included study.61 Table 10 summarized the salient 
characteristics of the included studies. There were no studies on symptomatic women with 
threatened preterm labour. Most of the studies did not differentiate between previous single or 
more episodes of spontaneous preterm birth. Two studies evaluated the accuracy of two 
against one previous history of spontaneous preterm births histories,58;64 while one study 
evaluated the accuracy of gestation at which the previous spontaneous preterm birth occurred 
in predicting spontaneous preterm birth in subsequent pregnancy.62 
None of the study fulfilled the criteria of ideal quality study. None of the studies reported 
blinding and consecutive enrolment. The quality features were summarized in Figure 4. Aside 
from two studies,59;61 the remaining studies reported birth before 37 weeks’ gestation as their 
outcomes. 
Accuracy of previous history of spontaneous preterm birth in 
asymptomatic women 
For predicting spontaneous preterm birth before 34 weeks’ gestation, previous history of 
spontaneous preterm birth had an LR+ 4.62 (95% CI 3.28 - 6.52) and LR- 0.68 (95% CI 0.56 
- 0.82).59 For predicting spontaneous preterm birth before 37 weeks’ gestation, previous 
history of spontaneous preterm birth had a range of LR+ from 0.52 (95% CI 0.42 - 0.64)58 
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with one previous spontaneous preterm birth to 10.12 (95% CI 4.54 - 22.59)58 with two 
previous spontaneous preterm births and a range of LR- from 0.45 (95% CI 0.33 - 0.61)62 
with previous history of spontaneous preterm birth before 26 weeks’ gestation to LR- 1.38 
(95% CI 1.27 - 1.49)58 with one previous spontaneous preterm birth. The highest quality study 
has LR+ 2.26 (95% CI 1.86 - 2.74) and LR- 0.72 (95% CI 0.64 - 0.81) Goldenberg et al.61 
The accuracy estimates of previous history of spontaneous preterm birth in predicting 
subsequent spontaneous preterm birth is shown in Figure 5 while Figure 6 showed plot of 
sensitivities and specificities and their summary estimates for the accuracy of previous history 
of spontaneous preterm birth in asymptomatic woman in predicting spontaneous preterm 
birth. Individual accuracy data are summarized in Table 11. Figure 7 showed an asymmetric 
funnel plot indicating possible presence of publication or related biases for studies of the 
accuracy of previous history of spontaneous preterm birth in asymptomatic women. 
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Figure 4 Methodological quality of studies of previous history of spontaneous preterm birth in predicting 
subsequent spontaneous preterm birth included in the systematic review. Data presented as 100% stacked 
bars. Figures in the stacks represent number of studies. 
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Figure 5 Forest plots of likelihood ratios (LR’s) of the accuracy of previous history of spontaneous 
preterm birth in asymptomatic women for predicting spontaneous preterm birth stratified according to 
outcome gestation* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
2.26 ( 1.86, 2.74) 9.0 
2.49 ( 2.09, 2.98) 9.0 
2.65 ( 1.88, 3.74) 8.6 
2.64 ( 1.60, 4.37) 7.9 
0.85 ( 0.12, 5.99) 2.6 
5.78 ( 4.47, 7.46) 8.8 
3.76 ( 3.32, 4.26) 9.1 
0.52 ( 0.42, 0.64) 9.0 
10.12 ( 4.54, 22.59) 6.4 
2.42 ( 2.18, 2.68) 9.2 
4.28 ( 2.60, 7.06) 7.9 
7.18 ( 2.52, 20.46) 5.3 
3.00 ( 1.57, 5.72) 7.2 
4.62 ( 3.28, 6.52) 100.0
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Goldenberg 0.72 ( 0.64, 0.81) 7.2 
Iams+ 0.45 ( 0.33, 0.61) 3.0 
Iams++ 0.77 ( 0.66, 0.89) 6.2 
Iams+++ 0.88 ( 0.79, 0.97) 7.7 
Botsis 1.02 ( 0.83, 1.24) 5.0 
Kristensen 0.84 ( 0.80, 0.89) 9.0 
Berkowitz 0.75 ( 0.71, 0.79) 9.0 
Carr-Hillx 1.38 ( 1.27, 1.49) 8.3 
Carr-Hillxx 0.89 ( 0.81, 0.97) 8.0 
Ancel 0.90 ( 0.89, 0.91) 9.5 
Weidingerx 0.87 ( 0.83, 0.91) 9.1 
Weidingerxx 0.95 ( 0.92, 0.97) 9.4 
deHaas 0.89 ( 0.83, 0.96) 8.5 
<37 weeks
<34 weeks
deCarvalho 0.68 ( 0.56, 0.82) 100.0 
<37 weeksxx
 
χ2 heterogeneity test p = 0.00012 for LR+ and p = 0.0017 for LR- of spontaneous preterm birth before 37 weeks’ gestation 
* Studies are listed in descending order of quality 
+ Previous spontaneous preterm birth before 26 weeks’ gestation 
++ Previous spontaneous preterm birth before 31 weeks’ gestation 
+++ Previous spontaneous preterm birth before 36 weeks’ gestation 
x One previous spontaneous preterm birth 
xx Two previous spontaneous preterm birth 
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Figure 6 Plot of sensitivity against specificity including summary values of the accuracy of previous 
history of spontaneous preterm birth in asymptomatic women for predicting spontaneous preterm birth 
before 37 weeks’ gestation 
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Figure 7 Funnel plot analysis of accuracy studies evaluating previous history of spontaneous preterm 
birth in asymptomatic women for predicting spontaneous preterm birth before 37 weeks’ gestation 
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Digital examination 
Physical examination is one of the cornerstones of medicine. Vaginal digital examination to 
assess the cervix is simple to do but its accuracy in the assessment of either asymptomatic 
antenatal women or symptomatic pregnant with threatened preterm labour to predict 
spontaneous preterm birth has not been evaluated in a systematic review. 
Study characteristics and quality 
There were 10 studies that evaluated the accuracy of cervical digital examination in predicting 
spontaneous preterm birth, 9 in asymptomatic antenatal women (n = 12,325)66-74 and 1 study 
in symptomatic women symptomatic (n = 90) with threatened preterm labour.75 There was a 
variation in testing gestation, frequency of testing and thresholds’ selection among the 
included studies. Noticeably, for all of the studies, testing gestation commenced after 24 
weeks’ gestation, currently accepted lower limit of neonatal viability. Aside from three 
studies, which used birth before 34 and 35 weeks’ gestation69-71 as their outcome 
measurement, the other studies used 37 weeks’ gestation. Individual study characteristics are 
summarized in Table 12. 
One study fulfilled the criteria for ideal quality study;70 otherwise the remaining studies 
lacked one or more criteria for ideal quality study with consecutive enrolment being the most 
commonly absent feature. Blinding was only reported by 4 studies in asymptomatic women. 
Methodological quality of the included study is summarized in Figure 8. 
Accuracy of digital examination in asymptomatic women 
There was a wide variation in the accuracy of digital examination in asymptomatic antenatal 
women in predicting spontaneous preterm birth (Figure 9). For predicting spontaneous 
preterm birth before 34 weeks’ gestation, digital examination showed an LR+ 9.25 (95% CI 
3.91 - 21.85) and LR- 0.46 (95% CI 0.19 - 1.08) in a mixed population of nulliparous and 
multiparous antenatal asymptomatic women and a threshold of >2cm cervical dilatation.70 For 
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predicting spontaneous preterm birth before 37 weeks’ gestation, LR+ ranged from 0.46 (95% 
CI 0.03 - 6.85) in multiparous women with a threshold of >2-3 cm cervical dilatation73 to 9.17 
(95% CI 0.52 - 160.08) in a mixed population of nulliparous and multiparous antenatal 
asymptomatic women with a centrally positioned cervix and >1.5 cm dilatation,68 and LR- 
ranged from 0.42 (95% CI 0.26 - 0.68) in a nulliparous antenatal women with soft cervix66 to 
2.46 (95% CI 0.11 - 55.35) in a mixed population of nulliparous/multiparous antenatal 
asymptomatic women and a threshold of posterior cervix >1.5 cm dilatation.68 The highest 
quality study from Parikh et al has LR+ 1.15 (0.86 - 1.53) and LR- 0.89 (0.68 - 1.16), which 
evaluated digital examination in a mixed population of nulliparous and multiparous women 
using the threshold of admitting a finger at cervical internal os.72 Individual accuracy results 
are summarized in Table 13. 
Accuracy of digital examination in symptomatic women 
For predicting spontaneous preterm birth before 37 weeks’ gestation digital examination in 
symptomatic women with threatened preterm labour had a range of LR+ from 2.01 (95% CI 
1.26 - 3.22) to 2.38 (95% CI 1.46 - 3.87) and LR- from 0.47 (95% CI 0.29 - 0.79) to 0.54 
(95% CI 0.34 - 0.88) corresponding to a choice of threshold >2 cm cervical dilation or >40% 
effacement (the latter threshold correspond to the less accurate results).75 Individual accuracy 
results are summarized in Table 13. 
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Figure 8 Methodological quality of studies included in the systematic review of accuracy of digital 
examination in predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in 
the stacks represent number of studies. 
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Figure 9 Forest plots of likelihood ratios (LR’s) of digital examination in predicting spontaneous preterm birth as a predictor of spontaneous preterm birth 
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Cervico-vaginal fetal fibronectin (fFN) 
Cervico-vaginal fetal fibronectin (fFN) is a glycoprotein, present in trace quantity that is 
usually undetectable in the cervical vaginal secretion. Higher quantity has been purported to 
be an indication of imminent labour onset. The test is readily available in the form of 
commercial rapid test kit. A cotton swab is used to collect samples of cervico-vaginal 
secretions during a speculum examination. The result is either positive (fFN is present), or 
negative (fFN is not present) obtained within 10 – 15 minutes of performing the test. These 
commercial preparations used positivity threshold of 50ng/mL. 
Study characteristics and quality 
There were 58 primary studies (n = 22,905 women) on the accuracy of bedside cervico-
vaginal fetal fibronectin testing, comprising of 18 studies on asymptomatic antenatal women 
(n = 18,696) and 40 studies on symptomatic women with presented with threatened preterm 
labour (n = 4,209). Table 14 summarizes each study’s salient features, stratified according to 
population of women tested, i.e. asymptomatic antenatal women and women with symptoms 
of threatened preterm labour. The studies’ enrolment ranged from 20 to 6,508 women76;77 
with a median of 147 women in asymptomatic population and from 26 to 725 women78;79 with 
a median of 86 women in symptomatic women. All the included studies had used cervico-
vaginal fetal fibronectin specimen taken either from the posterior fornix or the cervix.  
There were three studies in asymptomatic women80-82 and five studies in symptomatic women 
that fulfil the definition of high quality test accuracy studies.78;83-86 The methodological 
quality of the included primary studies is summarized in Figure 10. There were seven and 
fifteen studies that reported the accuracy of the test for predicting spontaneous preterm birth 
before 3476;81;87-91 and 37 weeks’ gestation76;77;80;82;87;88;90;92-99 respectively in asymptomatic 
women. For symptomatic women presenting with threatened preterm labour, eighteen 
studies79;83;85;86;100-113 reported the accuracy of the test in predicting spontaneous preterm birth 
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within 7-10 days of testing in addition to 8 studies that reported birth before 3486;108;114-119 and 
31 studies that reported birth before 37 weeks’ gestation.78;79;83;84;86;96;97;99;101-103;105;107-
109;111;113;116-118;120-130  
Accuracy of fFN in asymptomatic women 
For predicting spontaneous preterm birth before 34 weeks’ gestation, the range of LR+ was 
from 2.57 (95% CI 2.07 - 3.19) to 86.60 (95% CI 6.26 - 1198.92) with a summary LR+ of 
7.65 (95% CI 3.93 to 14.86) (χ2 heterogeneity test 0.00073) and the range of LR- was from 
0.28 (95% CI 0.05 – 1.52) to 0.80 (95% CI 0.52 – 1.24) with a summary LR- of 0.80 (95% CI 
0.73 – 0.88) (χ2 heterogeneity test p = 0.082) (Figure 11). For predicting spontaneous preterm 
birth before 37 weeks’ gestation, the range of LR+ was from 0.43 (95% CI 0.07 – 2.78) to 
26.38 (95% CI 1.73 – 402.99) with a summary LR+ of 3.17 (95% CI 2.00 – 5.02) (χ2 
heterogeneity test p = 0.00021) and the range of LR- was from 0.28 (95% CI 0.03 – 3.07) to 
1.20 (95% CI 0.93 -1.54) with a summary LR- of 0.87 (95% CI 0.77 – 0.97) (χ2 heterogeneity 
test p = 0.00037) (Figure 12). Figure 13 and Figure 14 showed plot of sensitivities and 
specificities and their summary estimates for the accuracy of fFN in predicting spontaneous 
preterm birth before 34 and 37 weeks’ gestation respectively. Individual test accuracy results 
from the included studies for asymptomatic women can be found in Table 15. 
Accuracy of fFN in symptomatic women 
For predicting spontaneous preterm birth within 7 – 10 day of testing, the range of LR+ was 
from 2.12 (95% CI 1.05 – 4.28) to 9.29 (95% CI 5.06 – 17.06) with a summary LR+ of 4.10 
(95% CI 3.37 – 4.98) (χ2 heterogeneity test p = 0.0021) and the range of LR- from 0.09 (95% 
CI 0.01 – 0.58) to 0.59 (95% CI 0.25 – 1.39) with a summary LR- of 0.35 (95% CI 0.27 – 
0.46) (χ2 heterogeneity test = 0.042) (Figure 15). For predicting spontaneous preterm birth 
before 34 weeks’ gestation, the range of LR+ was from 1.57 (95% CI 0.53 – 4.60) to 5.70 
(95% CI 2.88 – 11.28) with a summary LR+ of 3.58 (95% CI 2.56 – 5.00) (χ2 heterogeneity 
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test p = 0.052) and the range of LR- from 0.12 (95% CI 0.02 – 0.79) to 0.91 (95% CI 0.69 – 
1.20) with summary LR- of 0.34 (95% CI 0.17 – 0.68) (χ2 heterogeneity test p = 0.0020) 
(Figure 16). For predicting spontaneous preterm birth before 37 weeks’ gestation the range of 
LR+ was from 1.00 (95% CI 0.44 - 2.30)78 to 14.36 (95% CI 5.81 - 35.47)111 with summary 
LR+ of 3.62 (95% 3.02 - 4.33) (χ2 heterogeneity test p = 0.00021) and the range of LR- from 
0.08 (95% CI 0.01 - 0.54)118 to 1.00 (95% 0.44 - 2.30)78 with a summary LR- of 0.50 (95% 
0.43 - 0.59) (χ2 heterogeneity test p = 0.00019) (Figure 17). Figure 18, Figure 19 and Figure 
20 showed plot of sensitivities and specificities and their summary estimates for the accuracy 
of fFN in predicting spontaneous preterm birth within 7-10 days of testing and before 34 and 
37 weeks’ gestation respectively in symptomatic women. Figure 21 showed absence of large 
studies with higher level of accuracy missing in the funnel plot analysis for studies of the 
accuracy of fFN in predicting spontaneous preterm birth within 7 – 10 days of testing in 
symptomatic women. Figure 22 did not show asymmetry in the funnel plot analysis of the 
accuracy of fFN in predicting spontaneous preterm birth before 37 weeks’ gestation in 
symptomatic women. Individual test accuracy results from the included studies for 
symptomatic women can be found in Table 16. 
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Figure 10 Methodological quality of studies included in the systematic review of accuracy of bedside test 
for cervico-vaginal fetal fibronectin in predicting spontaneous preterm birth among asymptomatic 
antenatal women and symptomatic women with threatened preterm labour. Data presented as 100% 
stacked bars. Figures in the stacks represent number of studies 
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Figure 11 Forest plots of likelihood ratios (LR’s) for cervico-vaginal fetal fibronectin bedside testing on 
asymptomatic antenatal women as a predictor of spontaneous preterm birth before 34 weeks’ gestation*+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
86.60 ( 6.26, 1198.92)4.8 
10.18 ( 6.56, 15.80)17.9 
57.00 ( 11.57, 280.92)9.2 
3.58 ( 2.20, 5.82) 17.6 
7.27 ( 4.97, 10.63) 18.2 
2.57 ( 2.07, 3.19) 19.0 
7.50 ( 2.74, 20.51) 13.4 
7.65 ( 3.93, 14.86)100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Arinami 0.80 ( 0.52, 1.24) 4.0 
Heath 0.69 ( 0.56, 0.85) 13.4 
Chang 0.50 ( 0.23, 1.12) 1.3 
Goldenberg 0.78 ( 0.65, 0.93) 15.8 
Goldenberg 0.80 ( 0.72, 0.88) 28.5 
Goldenberg 0.87 ( 0.83, 0.92) 36.6 
Hux 0.28 ( 0.05, 1.52) 0.3 
Overall 0.80 ( 0.73, 0.88) 100.0 
 
*Studies are arranged in descending order of methodological quality  
+χ2 heterogeneity test p = 0.00073 for LR+ and p = 0.082 for LR- 
 
Figure 12 Forest plots of likelihood ratios (LR’s) for cervico-vaginal fetal fibronectin bedside testing on 
asymptomatic antenatal women as a predictor of spontaneous preterm birth before 37 weeks’ gestation*+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
26.38 ( 1.73, 402.99) 1.8 
0.43 ( 0.07, 2.78) 3.2 
6.22 ( 1.97, 19.60) 5.8 
4.10 ( 2.11, 7.95) 8.5 
18.00 ( 3.21, 100.86) 3.6 
21.37 ( 10.98, 41.57) 8.5 
2.03 ( 1.68, 2.46) 10.9 
1.83 ( 1.22, 2.74) 10.0 
3.91 ( 1.94, 7.87) 8.3 
1.02 ( 0.26, 4.01) 4.8 
2.15 ( 1.64, 2.83) 10.6 
0.60 ( 0.04, 9.28) 1.7 
4.50 ( 1.92, 10.57) 7.3 
1.72 ( 0.95, 3.11) 8.9 
7.50 ( 2.54, 22.14) 6.1 
3.40 ( 2.29, 5.05) 100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Arinami 0.94 ( 0.83, 1.07) 13.7 
Crane 1.20 ( 0.93, 1.54) 8.4 
Faron 0.77 ( 0.56, 1.04) 6.7 
Hellemans 0.47 ( 0.22, 1.00) 1.6 
Chang 0.84 ( 0.68, 1.03) 10.1 
Garcia 0.19 ( 0.09, 0.42) 1.5 
Goldenberg 0.92 ( 0.89, 0.95) 17.2 
Goldenberg 0.93 ( 0.87, 0.99) 16.4 
Greenhagen 0.45 ( 0.18, 1.10) 1.2 
Inglis 0.99 ( 0.74, 1.34) 6.9 
Lockwood 0.54 ( 0.38, 0.77) 5.5 
Ruiz 1.05 ( 0.84, 1.32) 9.5 
DiStefano 0.39 ( 0.13, 1.22) 0.8 
Zamora 0.37 ( 0.06, 2.23) 0.3 
Vercoustre 0.28 ( 0.03, 3.07) 0.2 
Overall 0.87 ( 0.78, 0.96) 100.0 
 
*Studies are arranged in descending order of methodological quality  
+χ2 heterogeneity test p = 0.00021 for LR+ and p = 0.00037 for LR- 
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Figure 13 Plot of sensitivity against specificity including summary values of the accuracy of cervico-
vaginal fetal fibronectin bedside testing on women presenting with symptoms of threatened preterm 
labour as a predictor of spontaneous preterm birth before 34 weeks’ gestation 
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Figure 14 Plot of sensitivity against specificity including summary values of the accuracy of cervico-
vaginal fetal fibronectin bedside testing on women presenting with symptoms of threatened preterm 
labour as a predictor of spontaneous preterm birth before 37 weeks’ gestation 
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Figure 15 Forest plots of likelihood ratios (LR’s) for cervico-vaginal fetal fibronectin bedside testing on 
women presenting with symptoms of threatened preterm labour as a predictor of spontaneous preterm 
birth within 7-10 days of testing*+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
3.52 ( 2.36, 5.23) 7.7 
4.17 ( 2.20, 7.89) 5.0 
6.78 ( 2.68, 17.16) 3.1 
2.12 ( 1.05, 4.28) 4.5 
4.80 ( 1.77, 13.00) 2.8 
2.55 ( 1.35, 4.80) 5.1 
9.29 ( 5.06, 17.06) 5.3 
3.54 ( 2.34, 5.33) 7.5 
3.62 ( 1.28, 10.27) 2.6 
5.17 ( 3.66, 7.30) 8.4 
8.16 ( 4.20, 15.87) 4.8 
3.08 ( 1.71, 5.53) 5.5 
5.18 ( 4.19, 6.40) 10.1 
5.88 ( 1.26, 27.30) 1.4 
2.71 ( 1.75, 4.21) 7.1 
2.22 ( 1.36, 3.62) 6.6 
4.53 ( 2.84, 7.20) 6.8 
5.63 ( 3.19, 9.94) 5.7 
4.12 ( 3.40, 4.98) 100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Tekesin 0.24 ( 0.07, 0.83) 4.1 
Closset 0.21 ( 0.03, 1.25) 2.0 
LaShay 0.44 ( 0.15, 1.29) 5.5 
Luzzi 0.59 ( 0.25, 1.39) 8.5 
Senden 0.24 ( 0.04, 1.40) 2.1 
Bartnicki 0.35 ( 0.06, 1.94) 2.3 
Benattar 0.12 ( 0.02, 0.78) 1.9 
Gomez 0.44 ( 0.26, 0.72) 23.2 
Hansen 0.41 ( 0.08, 2.04) 2.5 
Iams 0.09 ( 0.01, 0.58) 1.8 
Malak 0.22 ( 0.06, 0.77) 4.2 
McKenna 0.23 ( 0.04, 1.38) 2.0 
Peaceman 0.12 ( 0.03, 0.43) 3.7 
Plaut 0.55 ( 0.14, 2.19) 3.4 
Giles 0.42 ( 0.20, 0.87) 11.6 
Sakai 0.54 ( 0.30, 0.97) 17.2 
Foxman 0.18 ( 0.03, 1.08) 2.0 
Lopez 0.13 ( 0.02, 0.84) 1.9 
Overall 0.36 ( 0.28, 0.47) 100.0 
 
*Studies are arranged in descending order of methodological quality  
+χ2 heterogeneity test p = 0.0021 for LR+ and p = 0.424 for LR- 
 
Figure 16 Forest plots of likelihood ratios (LR’s) for cervico-vaginal fetal fibronectin bedside testing on 
women presenting with symptoms of threatened preterm labour as a predictor of spontaneous preterm 
birth before 34 weeks’ gestation*+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
4.33 ( 1.82, 10.29) 9.5 
3.90 ( 2.57, 5.93) 18.7 
1.62 ( 0.93, 2.83) 15.2 
4.73 ( 2.08, 10.75) 10.2 
3.92 ( 1.90, 8.06) 11.8 
4.91 ( 2.77, 8.70) 14.9 
1.57 ( 0.53, 4.60) 7.1 
5.70 ( 2.88, 11.28) 12.6 
3.58 ( 2.56, 5.00) 100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Musaad 0.21 ( 0.03, 1.25) 8.4 
Tekesin 0.35 ( 0.19, 0.63) 16.3 
Burrus 0.25 ( 0.07, 0.88) 11.7 
Goffeng 0.42 ( 0.19, 0.93) 15.0 
Parker 0.18 ( 0.03, 1.13) 8.2 
Chuileannain 0.12 ( 0.02, 0.79) 8.0 
Cox 0.91 ( 0.69, 1.20) 17.9 
Lopez 0.31 ( 0.13, 0.71) 14.6 
Overall 0.34 ( 0.17, 0.68) 100.0 
 
*Studies are arranged in descending order of methodological quality  
+χ2 heterogeneity test p = 0.052 for LR+ and p = 0.0020 for LR- 
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Figure 17 Forest plots of likelihood ratios (LR’s) for cervico-vaginal fetal fibronectin bedside testing on women presenting with symptoms of threatened preterm 
labour as a predictor of spontaneous preterm birth before 37 weeks’ gestation*+ 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
7.97 ( 4.88, 13.03) 4.3 
4.96 ( 1.81, 13.56) 2.1 
1.00 ( 0.43, 2.30) 2.7 
9.71 ( 3.92, 24.05) 2.4 
3.09 ( 1.33, 7.15) 2.7 
3.24 ( 1.50, 7.02) 2.9 
3.00 ( 0.90, 10.01) 1.6 
6.94 ( 3.33, 14.49) 3.1 
3.96 ( 1.76, 8.93) 2.8 
3.13 ( 1.10, 8.91) 2.0 
1.78 ( 0.55, 5.74) 1.7 
3.15 ( 1.88, 5.26) 4.2 
4.81 ( 1.15, 20.18) 1.3 
2.60 ( 1.45, 4.66) 3.8 
2.99 ( 1.41, 6.32) 3.0 
4.66 ( 2.62, 8.28) 3.9 
14.36 ( 5.81, 35.47) 2.4 
3.17 ( 2.41, 4.18) 5.5 
3.88 ( 2.31, 6.52) 4.2 
2.31 ( 1.41, 3.76) 4.3 
2.46 ( 1.54, 3.93) 4.4 
4.38 ( 2.65, 7.26) 4.2 
2.53 ( 1.61, 3.97) 4.5 
1.89 ( 1.06, 3.37) 3.8 
1.87 ( 0.87, 4.02) 3.0 
7.43 ( 3.66, 15.08) 3.2 
7.09 ( 3.58, 14.04) 3.3 
2.82 ( 1.49, 5.31) 3.5 
7.06 ( 2.72, 18.34) 2.3 
2.86 ( 1.94, 4.20) 4.9 
4.37 ( 1.38, 13.80) 1.8 
3.62 ( 3.02, 4.33) 100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Tekesin 0.13 ( 0.05, 0.32) 1.9 
Closset 0.53 ( 0.34, 0.83) 3.8 
Grandi 1.00 ( 0.43, 2.30) 2.1 
Hincz 0.31 ( 0.13, 0.71) 2.1 
LaShay 0.78 ( 0.62, 0.98) 4.9 
Morrison 0.14 ( 0.02, 0.91) 0.6 
Musaad 0.60 ( 0.31, 1.15) 2.8 
Bartnicki 0.36 ( 0.23, 0.57) 3.7 
Benattar 0.70 ( 0.52, 0.95) 4.6 
Goffeng 0.73 ( 0.54, 0.98) 4.6 
Hansen 0.82 ( 0.50, 1.34) 3.5 
Iams 0.66 ( 0.52, 0.82) 4.9 
Inglis 0.62 ( 0.39, 0.97) 3.8 
Irion 0.43 ( 0.23, 0.82) 2.8 
Langer 0.55 ( 0.32, 0.93) 3.3 
Lockwood 0.22 ( 0.13, 0.38) 3.3 
Malak 0.39 ( 0.24, 0.63) 3.5 
Peaceman 0.65 ( 0.56, 0.76) 5.3 
Rizzo 0.23 ( 0.13, 0.43) 3.0 
Rozenberg 0.43 ( 0.22, 0.86) 2.6 
Stevens 0.66 ( 0.52, 0.84) 4.9 
Calda 0.12 ( 0.03, 0.45) 1.1 
Giles 0.49 ( 0.27, 0.89) 3.0 
Sakai 0.75 ( 0.58, 0.96) 4.8 
Vetr 0.63 ( 0.30, 1.35) 2.4 
Chuileannain 0.08 ( 0.01, 0.54) 0.6 
Dolinska 0.29 ( 0.17, 0.50) 3.3 
Mansouri 0.59 ( 0.39, 0.90) 3.9 
Topete 0.33 ( 0.19, 0.56) 3.3 
Vercoustre 0.11 ( 0.02, 0.75) 0.6 
Lopez 0.70 ( 0.56, 0.88) 4.9 
Overall 0.50 ( 0.43, 0.59) 100.0 
 
*Studies are arranged in descending order of methodological quality  
+χ2 heterogeneity test p = 0.00021 for LR+ and p = 0.000 for LR- 
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Figure 18 Plot of sensitivity against specificity including summary values of the accuracy of cervico-
vaginal fetal fibronectin bedside testing on women presenting with symptoms of threatened preterm 
labour as a predictor of spontaneous preterm birth within 7-10 days of testing 
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Figure 19 Plot of sensitivity against specificity including summary values of the accuracy of cervico-
vaginal fetal fibronectin bedside testing on women presenting with symptoms of threatened preterm 
labour as a predictor of spontaneous preterm birth before 34 weeks’ gestation 
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Figure 20 Plot of sensitivity against specificity including summary values of the accuracy of cervico-
vaginal fetal fibronectin bedside testing on women presenting with symptoms of threatened preterm 
labour as a predictor of spontaneous preterm birth before 37 weeks’ gestation 
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Figure 21 Funnel plot analysis of accuracy studies evaluating the accuracy of cervico-vaginal fetal 
fibronectin in symptomatic women in predicting spontaneous preterm birth within 7-10 days of testing 
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Figure 22 Funnel plot analysis of accuracy studies evaluating the accuracy of cervico-vaginal fetal 
fibronectin in asymptomatic women in predicting spontaneous preterm birth before 37 weeks’ gestation 
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Cervico-vaginal prolactin 
During pregnancy, prolactin is produced by the decidua (in addition to the maternal 
adenohypophysis and the fetal pituitary. Disruption of the decidua-membrane matrix during 
labour whether preterm or term, may allow the secreted prolactin to leak to the cervix and 
vagina where it would be available for detection. It is purported that detection of this cervico-
vaginal prolactin is a reliable predictor of the onset of spontaneous preterm labour and hence 
spontaneous preterm birth.131 A cotton swab is used to collect samples of cervico-vaginal 
secretions during a speculum examination, which was then sent for laboratory assay.  
Study characteristics and quality 
There were 5 primary studies, 2 evaluating the test in asymptomatic women population (n = 
80)131;132 and 5 evaluating the test in symptomatic women (n = 265),131-135 presenting with 
threatened preterm labour, including two studies that evaluated the test in both 
populations.131;132 The study enrolment ranged from 35132 to 66 women.135 In asymptomatic 
women, the test was carried between 24 and 32 weeks’ gestation. The studies’ enrolment for 
asymptomatic women ranged from 35 to 66 women132;135 with a median of 40 women.131 
Only two studies, both in symptomatic women, used the same threshold of abnormality of 2.0 
ng/ml.131;134 The remaining studies used 1.5 ng/ml,132 1.8 ng/ml,133 and 50 ng/ml thresholds.135 
All the studies evaluated cervico-vaginal prolactin test on a single occasion rather than as a 
serial test. 
None of the studies reported consecutive enrolment and only 3 studies, one in asymptomatic 
population131 and two in symptomatic population131;134 reported blinding. The methodological 
quality of the included primary studies is summarized in Figure 23. None of the studies 
fulfilled the definition of ideal quality test accuracy study design. One study each reported 
outcome of spontaneous preterm birth before 34 weeks’131 and 37 weeks’ gestation.132 One 
study reported outcome within 7 days of testing,131 3 studies reported outcome before 34 
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weeks’ gestation131;132;134 and all studies reported outcome before 37 weeks’ gestation in 
symptomatic women.131-135 Information on individual study characteristics can be found in 
Table 17, which summarizes each study’s salient features, stratified according to population 
of women tested, i.e. asymptomatic antenatal women and women with symptoms of 
threatened preterm labour. 
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Figure 23 Methodological quality of studies included in the systematic review of accuracy of cervico-
vaginal prolactin in predicting spontaneous preterm birth among asymptomatic antenatal women and 
symptomatic women with threatened preterm labour. Data presented as 100% stacked bars. Figures in 
the stacks represent number of studies 
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Accuracy of cervico-vaginal prolactin in asymptomatic women 
In the single study evaluating the test on asymptomatic women for predicting spontaneous 
preterm birth before 34 weeks’ gestation, LR+ was 19.00 (95% CI 1.76 - 205.15) and LR- 
was 0.51 (95% CI 0.13 - 2.06)131 while before 37 weeks’ gestation the LR was 3.15 (95% CI 
1.62 - 6.12) and LR- was 0.23 (95% CI 0.038 - 1.37)132 (Figure 24). The accuracy measures of 
the test in predicting spontaneous preterm births in asymptomatic women are summarized in 
Table 18.  
Accuracy of cervico-vaginal prolactin in symptomatic women 
For predicting spontaneous preterm birth within 7days of testing, LR+ was 1.48 (95% CI 0.81 
- 2.70) and LR- was 0.61 (95% CI 0.23 - 1.62) (Figure 24). The accuracy for predicting 
spontaneous preterm birth before 34 weeks’ gestation ranged from LR+ 2.42 (95% CI 1.22 - 
4.77) and LR- 0.34 (95% CI 0.12 - 0.95)132 to LR+ 4.65 (95% CI 1.81 - 11.97) and LR- 0.49 
(95% CI 0.21 - 1.16).134 Jotterand et al134 represented the largest higher quality available. The 
accuracy for predicting spontaneous preterm birth before 37 weeks’ gestation ranged from 
LR+ 2.43 (95% CI 0.87 - 6.76) and LR- 0.52 (95% CI 0.30 - 0.92)131 to LR+ 36.77 (95% CI 
2.31 - 584.80) and LR- 0.45 (95% CI 0.31 - 0.65)135 (Figure 24). The largest higher quality 
study (Jotterand et al)134 however had LR+ 2.50 (95% CI 0.88 - 7.10) and LR- 0.79 (95% CI 
0.56 - 1.11) for this reference standard. Heterogeneity assessment of the LR’s did not reveal 
significant graphical or statistical heterogeneity of the accuracy results except for either 
positive or negative test results in predicting spontaneous preterm birth before 34 and 37 
weeks’ gestation in symptomatic women. The accuracy measures of the test in predicting 
spontaneous preterm births in symptomatic women are summarized in Table 18. 
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Figure 24 Forest plots of likelihood ratios (LR’s) of rapid test for cervico-vaginal prolactin as a predictor 
of spontaneous preterm birth according to population and outcome gestations*+ 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
19.00 ( 1.76, 205.15) 100
3.15 ( 1.62, 6.12) 100
1.48 ( 0.81, 2.70) 100 
4.65 ( 1.81, 11.97) 30.0 
2.96 ( 1.20, 7.26) 49.2
2.42 ( 1.22, 4.77) 20.8
2.50 ( 0.88, 7.10) 29.8 
2.43 ( 0.87, 6.76) 17.3
36.77 ( 2.31, 584.80) 27.9
13.00 ( 2.83, 59.76) 12.8
3.50 ( 1.22, 10.02) 12.2
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
O'Brien
0.51 ( 0.13, 2.06) 100 
Koca 0.23 ( 0.04, 1.37) 100 
O'Brien 0.61 ( 0.23, 1.62) 100
Jotterand 0.49 ( 0.21, 1.16) 27.4
O'Brien 0.40 ( 0.20, 0.78) 47.8
Koca 0.34 ( 0.12, 0.95) 24.8
Jotterand 0.79 ( 0.56, 1.11) 25.4 
O'Brien 0.52 ( 0.30, 0.92) 25.9 
Leylek 0.45 ( 0.31, 0.65) 6.8 
Guvenal 0.52 ( 0.26, 1.04) 16.7 
Koca 0.38 ( 0.18, 0.77) 25.2 
<34 weeks’ gestation
Asymptomatic women
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Symptomatic women
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*Studies are arranged in descending order of methodological quality 
+χ2 heterogeneity test for 34 weeks’ gestation p = 0.54 for LR+ and p = 0.86 for LR-, and for 37 weeks’ gestation p = 0.13 for LR+ and p = 0.16 for LR- 
 
Figure 25 Plot of sensitivity against specificity including summary values of the accuracy of cervico-
vaginal prolactin testing on women presenting with symptoms of threatened preterm labour as a predictor 
of spontaneous preterm birth before 37 weeks’ gestation 
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Cervico-vaginal phIGFBP-1 
The phosphorylated form of insulin-like growth factor binding protein 1 (phIGFBP-1) is 
produced by placental decidual cells. It is released and leaks into the cervix during the onset 
of parturition, whether term or preterm, and thus has been purported as a reliable predictor of 
the onset of preterm labour and hence spontaneous preterm birth. The novel test is an 
immune-chromatographic dipstick test based on monoclonal antibodies that detects the 
presence of phosphorylated form of IGFBP-1 release from the decidual cells. The test is 
readily available in the form of a commercial rapid test kit.136 A cotton swab is used to collect 
samples of cervico-vaginal secretions during a speculum examination. The result is either 
positive (phIGFBP-1 is present) (threshold exceeded 30μg/L), or negative (phIGFBP-1 less 
than 30μg/L) obtained within 10 – 15 minutes of performing the test. 
Study characteristics and quality 
There were 10 primary studies, involving altogether, a total of 568 women. One potentially 
eligible study for inclusion was excluded because data was unobtainable.137 Table 19 
summarizes each study’s salient features, stratified according to population of women tested, 
i.e. asymptomatic antenatal women (1 study)138 and women with symptoms of threatened 
preterm labour (9 studies).136-146 The single study included on asymptomatic antenatal 
population had targeted the test, which was performed 3 weekly between 24 to 34 weeks’ 
gestation, at women who has previous spontaneous preterm birth. The studies’ enrolment 
ranged from 32 – 135 women, with a median of 46 women.  
Only one study reported consecutive enrolment139 and only two studies reported blinding to 
test results and or reference standards.140;144 Otherwise all studies used cohort of pregnant 
women, where all except two reported prospective data collection design,145;146 and with one 
exception,145 had provided adequate test description. The methodological quality of the 
included primary studies is summarized in Figure 26. The only study on asymptomatic 
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women had reported spontaneous preterm birth before 37 weeks’ gestation as the reference 
standard. For studies on symptomatic women, all studies have reported birth before 37 weeks’ 
gestation as their reference standards. Additionally, 3 studies also reported birth within 48 
hours of testing,139;140;144 4 studies reported birth within 7 days of testing,139;140;143;144 and 3 
studies reported birth before 34 weeks’ gestation.136;143;144  
Accuracy of phIGFBP-1 in asymptomatic women 
In the single study evaluating the test on asymptomatic women for predicting spontaneous 
preterm birth before 37 weeks’ gestation, LR+ was 4.17 (95% confidence interval (CI) 2.44 - 
7.13) and LR- was 0.21 (95% CI 0.08 - 0.51).138 
Accuracy of phIGFBP-1 in symptomatic women 
For predicting spontaneous preterm birth within 48 hours of testing, summary LR+ was 2.53 
(95% CI 1.17 – 5.48) and summary LR- was 0.32 (95% CI 0.15 – 0.66) (Figure 27). There 
were two studies of equal size and representing higher quality studies giving a summary LR+ 
1.73 (95% CI 0.92 - 3.25) and summary LR- 0.59 (95% CI 0.24 - 1.45).139;144 The accuracy 
for predicting spontaneous preterm birth within 7 days of testing was shown in Figure 28, 
where the summary LR+ was 3.29 (95% CI 2.24 – 4.83) and summary LR- was 0.20 (95% CI 
0.10 – 0.41). For this reference standard (i.e. spontaneous preterm birth within 7 days of 
testing), the summary LR+ 2.83 (95% CI 1.57 - 5.09) and summary LR- 0.371 (95% CI 0.13 - 
1.04) as there were two higher quality studies of equal size.139;144 The accuracy for predicting 
spontaneous preterm birth before 34 weeks’ gestation was shown in Figure 29, where the 
summary LR+ was 2.96 (95% CI 2.02 – 4.33) and summary LR- was 0.22 (95% CI 0.08 – 
0.64). The largest higher quality study had LR+ 4.15 (95% CI 1.43 - 11.99) and LR- 0.31 
(95% CI 0.03 - 3.38).144 Summary LR+ for predicting spontaneous preterm birth before 37 
weeks’ gestation was 4.26 (95% CI 2.54 – 7.17) and summary LR- was 0.28 (95% CI 0.20 – 
0.38) (Figure 30). The highest quality study has LR+ 3.87 (95% CI 1.54 - 9.72) and LR- 0.33 
 
 
69
(95% CI 0.15 - 0.71) for this outcome.144 Heterogeneity assessment of the likelihood ratios 
did not reveal significant graphical or statistical heterogeneity for most of the accuracy results 
except for positive test results in predicting spontaneous preterm birth before 37 weeks’ 
gestation in this clinically similar group of women. The accuracy measures of the test in 
predicting spontaneous preterm births in symptomatic women were summarized in Table 20. 
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Figure 26 Methodological quality of studies included in the systematic review of accuracy of rapid test for 
phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) in cervical secretion in 
predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in the stacks 
represent number of studies. 
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Figure 27 Forest plots of likelihood ratios (LR’s) of rapid test for phosphorylated insulin-like growth 
factor binding protein-1 (phIGFBP-1) in cervical secretion as a predictor of spontaneous preterm birth 
within 48 hours of testing*+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
2.38 ( 0.52, 10.82) 18.9 
1.62 ( 0.81, 3.24) 45.0 
4.59 ( 1.87, 11.31) 36.0 
2.53 ( 1.17, 5.48) 100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Elizur 0.63 ( 0.16, 2.56) 29.8 
Kwek 0.57 ( 0.18, 1.82) 37.8 
Lembet 0.15 ( 0.04, 0.57) 32.4 
Overall 0.38 ( 0.15, 0.96) 100.0 
 
*Studies are arranged in descending order of methodological quality  
+χ2 heterogeneity test p = 0.150 for LR+ and p = 0.22 for LR- 
 
Figure 28 Forest plots of likelihood ratios (LR’s) of rapid test for phosphorylated insulin-like growth 
factor binding protein-1 (phIGFBP-1) in cervical secretion as a predictor of spontaneous preterm birth 
within 7 days of testing*+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
2.38 ( 0.52, 10.82) 18.9 
1.62 ( 0.81, 3.24) 45.0 
4.59 ( 1.87, 11.31) 36.0 
2.53 ( 1.17, 5.48) 100.0 
Likelihood ratio (LR) for negative test
0.1 0 .2 0.5 1 2
Study
LR-
(95% CI) % Weight
Elizur 0.63 ( 0.16, 2.56) 29.8 
Kwek 0.57 ( 0.18, 1.82) 37.8 
Lembet 0.15 ( 0.04, 0.57) 32.4 
Overall 0.38 ( 0.15, 0.96) 100.0 
 
*Studies are arranged in descending order of methodological quality  
+χ2 heterogeneity test p = 0.57 for LR+ and p = 0.29 for LR- 
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Figure 29 Forest plots of likelihood ratios (LR’s) of rapid test for phosphorylated insulin-like growth 
factor binding protein-1 (phIGFBP-1) in cervical secretion as a predictor of spontaneous preterm birth 
before 34 weeks’ gestation*+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
3.52 ( 1.24, 9.99) 13.4 
2.66 ( 1.54, 4.60) 48.7 
2.76 ( 1.48, 5.14) 37.8 
2.80 ( 1.91, 4.10) 100.0 
Likelihood ratio (LR) for negative test
0.1 0 .2 0.5 1 2
Study
LR-
(95% CI) % Weight
Elizur 0.41 ( 0.08, 2.05) 29.7 
Park 0.26 ( 0.07, 0.94) 47.5 
Shine 0.21 ( 0.03, 1.29) 22.9 
Overall 0.28 ( 0.12, 0.68) 100.0 
 
*Studies are arranged in descending order of methodological quality  
+χ2 heterogeneity test p = 0.76 for LR+ and p = 0.85 for LR- 
 
Figure 30 Forest plots of likelihood ratios (LR’s) of rapid test for phosphorylated insulin-like growth 
factor binding protein-1 (phIGFBP-1) in cervical secretion as a predictor of spontaneous preterm birth 
before 37 weeks’ gestation*+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
2.00 ( 0.68, 5.91) 10.2 
3.87 ( 1.54, 9.72) 11.7 
15.21 ( 2.26, 102.48)5.3 
6.09 ( 2.34, 15.82) 11.4 
1.47 ( 0.82, 2.62) 15.0 
19.32 ( 2.79, 133.58)5.2 
3.52 ( 1.53, 8.08) 12.5 
4.64 ( 2.62, 8.23) 15.1 
7.31 ( 3.56, 15.01) 13.6 
4.26 ( 2.54, 7.17) 100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Elizur 0.50 ( 0.15, 1.70) 6.5 
Kwek 0.33 ( 0.15, 0.71) 16.0 
Lembet 0.11 ( 0.03, 0.42) 5.6 
Akercan 0.25 ( 0.09, 0.68) 9.5 
Choi 0.56 ( 0.16, 1.87) 6.6 
Park 0.24 ( 0.11, 0.51) 16.2 
Shine 0.26 ( 0.07, 0.91) 6.1 
Halle 0.26 ( 0.13, 0.53) 18.9 
Paternoster 0.34 ( 0.15, 0.77) 14.5 
Overall 0.29 ( 0.21, 0.39) 100.0 
 
*Studies are arranged in descending order of methodological quality  
+χ2 heterogeneity test p = 0.0037 for LR+ and p = 0.79 for LR- 
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Figure 31 Plot of sensitivity against specificity including summary values of the accuracy of 
phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) in cervical secretion testing on 
women presenting with symptoms of threatened preterm labour as a predictor of spontaneous preterm 
birth before 37 weeks’ gestation 
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Serum α-fetoprotein (MSAFP) 
A high level of maternal serum α-fetoprotein (MSAFP) in the first half of pregnancy has been 
associated with prematurity for the past three decades. However its utility as a serum marker 
for predicting spontaneous preterm birth has never been fully evaluated in a systematic review 
despite it being commonly used as a screening test for fetal neural tube defect and as an 
integral part of screening for trisomy 21. 
Study characteristics and quality 
There were 20 primary accuracy articles that met the selection criteria, all in asymptomatic 
women. Table 21 summarises each study’s salient features.147-165 One citation contributed to 
two separate studies and results.150 The most common testing gestation was in the mid-
trimester (14-28 weeks). The threshold at which studies commonly reported their results were 
2.0 and 2.5 MoMs. The commonest reference standard was spontaneous preterm birth before 
37 weeks’ gestation with only 5 studies reporting spontaneous preterm birth before 34 weeks’ 
gestation.148;151;153;154;162 The methodological quality of the included primary studies is 
summarised in Figure 32 where it is shown that all the included studies were missing one or 
more ideal quality features. 
Accuracy of maternal serum α-fetoprotein (MSAFP) in asymptomatic 
women 
For predicting spontaneous preterm birth before 34 weeks’ gestation MSAFP with a most 
commonly used threshold of 2.5 MoM, had a range of LR+ from 3.03 (95% CI 2.30 – 4.01)154 
to 4.99 (95% CI 3.97 – 6.28)162 and a range of LR- from 0.14 (95% CI 0.02 – 0.91)154 to 0.95 
(95% CI 0.94 – 0.97).162 Waller et al represented the higher quality study available.162 
For predicting spontaneous preterm birth before 37 weeks’ gestation MSAFP, two thresholds 
used more commonly than others i.e. 2.0 MoM and 2.5 MoM. With threshold of 2.0 MoM, it 
had a range of LR+ from 0.97 (95% CI 0.51 – 1.85)158 to 4.21 (95% CI 3.47 -5.09)159 and a 
range of LR- from 0.45 (95% CI 0.20 – 1.02)147 to 1.01 (95% CI 0.86 – 1.17).158 The higher 
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quality study from Tanaka et al had LR+ 1.63 (95% CI 0.81 – 3.27) and LR- 0.96 (95% CI 
0.89 – 1.03).160 With a threshold of 2.5 MoM, LR+ ranged from 1.50 (95% CI 1.03 – 2.17)157 
to 70.23 (95% CI 21.78 – 226.38) and LR- form 0.34 (95% CI 0.17 – 0.69)154 to 0.99 (95% CI 
0.97 – 1.00).156 Morssink et al represented the higher quality study available.156 Figure 33 and 
Figure 35 summarized the accuracy of both thresholds in predicting spontaneous preterm 
birth. Individual accuracy results are summarized in Table 22. 
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Figure 32 Methodological quality of studies included in the systematic review of accuracy of maternal 
serum α-fetoprotein in predicting spontaneous preterm birth among asymptomatic antenatal women. 
Data presented as 100% stacked bars. Figures in the stacks represent number of studies. 
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Figure 33 Forest plots of likelihood ratios (LR’s) of maternal serum α-fetoprotein (MSAFP) in 
asymptomatic women (threshold of 2.0 MoM) as a predictor of spontaneous preterm birth before 37 
weeks’ gestation* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
1.63 ( 0.81, 3.27) 9.7 
0.97 ( 0.51, 1.85) 10.3 
3.23 ( 2.95, 3.55) 16.0 
4.21 ( 3.47, 5.09) 15.4 
2.36 ( 1.55, 3.61) 13.0 
1.35 ( 0.51, 3.56) 7.1 
2.18 ( 1.46, 3.26) 13.3 
1.43 ( 1.16, 1.76) 15.2 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Tanaka 0.96 ( 0.89, 1.03) 11.2 
Simpson 1.01 ( 0.86, 1.17) 4.2 
Waller 0.90 ( 0.89, 0.91) 26.5 
Spencer 0.94 ( 0.92, 0.95) 26.2 
Hsieh 0.96 ( 0.93, 0.99) 23.1 
Brazerol 0.97 ( 0.88, 1.08) 7.7 
Akinbiyi 0.45 ( 0.20, 1.02) 0.2 
Williams 0.64 ( 0.45, 0.90) 0.9 
 
* Studies are arranged in descending order of methodological quality 
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Figure 34 Plot of sensitivity against specificity including summary values of the accuracy of maternal 
serum α-fetoprotein (MSAFP) in asymptomatic women (threshold of 2.0 MoM) as a predictor of 
spontaneous preterm birth before 37 weeks’ gestation 
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Figure 35 Forest plots of likelihood ratios (LR’s) of maternal serum α-fetoprotein (MSAFP) in 
asymptomatic women (threshold of 2.5 MoM) as a predictor of spontaneous preterm birth before 34 and 
37 weeks’ gestation* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
4.99 ( 3.97, 6.28) 51.0 
3.03 ( 2.30, 4.01) 49.0 
2.63 ( 1.35, 5.10) 10.6
70.23 ( 21.78, 226.38) 8.3 
4.09 ( 3.43, 4.88) 12.1 
3.17 ( 1.59, 6.30) 10.5 
48.41 ( 29.74, 78.82) 11.3 
3.64 ( 2.68, 4.95) 11.8 
1.50 ( 1.03, 2.17) 11.6 
1.76 ( 1.38, 2.25) 12.0 
2.74 ( 2.01, 3.72) 11.8 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Waller 0.95 ( 0.94, 0.97) 61.3 
Hamilton 0.14 ( 0.02, 0.91) 38.7
Morssink 0.99 ( 0.97, 1.00) 18.6 
Davis 0.72 ( 0.64, 0.81) 7.2 
Waller 0.97 ( 0.96, 0.97) 18.9 
Yaron 0.99 ( 0.98, 1.00) 18.8 
Davis 0.82 ( 0.79, 0.86) 15.9 
Wenstorm 0.93 ( 0.91, 0.95) 17.8 
Sharara 0.77 ( 0.56, 1.05) 1.6 
Cho 0.50 ( 0.33, 0.76) 0.9 
Hamilton 0.34 ( 0.17, 0.69) 0.3 
<37 weeks’ gestation
<34 week’ gestation
 
* Studies are arranged in descending order of methodological quality 
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Figure 36 Plot of sensitivity against specificity including summary values of the accuracy of maternal 
serum α-fetoprotein (MSAFP) in asymptomatic women (threshold of 2.5 MoM) as a predictor of 
spontaneous preterm birth before 37 weeks’ gestation 
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Serum relaxin 
Relaxin is a peptide hormone produced by the corpus luteum and known to soften and ripen 
the human cervix. Hyper-relaxinemia has been associated with prematurity.166 Therefore it is 
purported that measurement of maternal serum relaxin may predict the impending preterm 
labour that leads to spontaneous preterm birth.  
Study characteristics and quality 
There were five primary studies on the accuracy of maternal serum relaxin measurements; 
four were on asymptomatic women (n=3549)153;166-168 while one on symptomatic women with 
threatened preterm labour (n=34).169 One study evaluated the test’s serial testing accuracy in 
predicting spontaneous preterm birth in asymptomatic women.166 Table 23 summarizes each 
study’s salient features. 
There were no studies included within the systematic review of the accuracy of maternal 
serum relaxin testing in predicting spontaneous preterm births that fulfil the ideal definition of 
high quality test accuracy studies either in asymptomatic or symptomatic women. Blinding 
was absent in all but one study.168 However, all studies have adequate test description report. 
The methodological quality of the included primary studies is summarized in Figure 37. 
Accuracy of maternal serum relaxin in asymptomatic women 
For predicting spontaneous preterm birth before 34 weeks’ gestation serum relaxin had an 
LR+1.60 (95% CI 1.24 - 2.06) and LR- 0.84 (95% CI 0.74 - 0.95).153 For predicting 
spontaneous preterm birth before 37 weeks’ gestation serum relaxin had an LR+ 1.21 (95% 
CI 0.73 - 2.10) and LR- 0.74 (95% CI 0.29 - 1.95).166 These studies represented the largest 
higher quality studies for the respective outcomes. The accuracy results are summarized in 
Figure 38. Individual accuracy results are summarized in Table 24. 
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Accuracy of maternal serum relaxin in symptomatic women 
For predicting spontaneous preterm birth before 34 weeks’ gestation, maternal serum relaxin 
had an LR+ of LR+ 1.48 (95% CI 0.26 - 8.31) and LR- 0.861 (95% CI 0.38 - 1.96) and before 
37 weeks’ gestation it had LR+ 0.80 (95% CI 0.19 - 3.31) and LR- 1.07 (95% CI 0.72 - 1.57) 
Figure 38).169 Individual accuracy results for symptomatic women can be found in Table 24. 
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Figure 37 Methodological quality of studies included in the systematic review of accuracy of maternal 
serum relaxin in predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in 
the stacks represent number of studies. 
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Figure 38 Forest plots of likelihood ratios (LR’s) of maternal serum relaxin measurement in predicting 
spontaneous preterm birth stratified according to population and outcomes* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
1.71 ( 1.06, 2.78) 33.7 
0.56 ( 0.34, 0.93) 33.2 
1.48 ( 0.26, 8.31) 40.3 
0.80 ( 0.19, 3.31) 59.7 
1.21 ( 0.73, 2.01) 33.1 
1.60 ( 1.24, 2.06) 100 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Vogel 0.90 ( 0.80, 1.01) 43.8 
Vogel 2.82 ( 1.35, 5.89) 31.1 
Vogel 0.86 ( 0.38, 1.96) 18.1 
Vogel 1.07 ( 0.72, 1.57) 81.9 
Weiss 0.74 ( 0.28, 1.95) 26.1 
Goldenberg 0.84 ( 0.74, 0.95) 100 
Asymptomatic women
<34 weeks’
<37 weeks’
Symptomatic women
<37 weeks’
 
*Studies are arranged in descending order of methodological quality 
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Serum corticotrophin releasing hormone (CRH) 
Corticotrophin-releasing hormone (CRH) is a peptide produced by the hypothalamus that in 
pregnancy is also produced by the placenta. Its role in pregnancy has been postulated to as 
one of the primary endocrine mediators of parturition and possibly also of fetal development. 
Its rise in the maternal serum has been observed to precede the development of labour and 
therefore its measurement was purported to predict spontaneous preterm birth.  
Study characteristics and quality 
There were 6 primary studies (n = 5,034 women) on the accuracy of CRH testing, comprising 
of 5 studies on asymptomatic antenatal women (n = 4,940)153;170-173 and 1 studies on 
symptomatic women with presented with threatened preterm labour (n = 94).174 Table 25 
summarizes each study’s salient features, stratified according to population of women tested, 
i.e. asymptomatic antenatal women and women with symptoms of threatened preterm labour. 
One study was not included because it included multiple gestations in its population and 
iatrogenic preterm birth in its outcome.175 The studies’ enrolment for asymptomatic women 
ranged from 181 to 2,929 women153;171 with a median of 396 women.170 
There were no studies included within the systematic review of the accuracy of CRH testing 
in predicting spontaneous preterm births that fulfil the ideal definition of high quality test 
accuracy studies either in asymptomatic or symptomatic women. None of the studies in both 
population reported using consecutive enrolment of women into the study. However, all 
studies have adequate test description report. Retrospective and case-control study design was 
used in two studies in asymptomatic women.153;171 Blinding of carers to the results of CRH 
tests were absent from two studies on asymptomatic women.170;172 The methodological quality 
of the included primary studies is summarized in Figure 39.  
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Only two studies used the same threshold of abnormality, one each on asymptomatic and 
symptomatic women, of greater than 90th percentile value. Four studies, including the lone 
study on symptomatic women, used CRH as a single test,171-174 whilst the remaining utilized it 
as a serial test. For asymptomatic women, one study used spontaneous preterm birth before 32 
weeks’ gestation, 153 34 weeks’ gestation,173 two each used 35 weeks’ gestation,153;171 and 37 
weeks’ gestation as the reference standard.170;172  
Figure 39 Methodological quality of studies included in the systematic review of accuracy of CRH in 
predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in the stacks 
represent number of studies 
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Accuracy of CRH in asymptomatic women 
For predicting spontaneous preterm birth before 34 weeks’ gestation, a single CRH testing 
had an LR+ of 3.36 (95% CI 2.30 - 4.92) and LR- of 0.35 (95% CI 0.13 - 0.91).173 For 
predicting spontaneous preterm birth before 37 weeks’ gestation, CRH had a range of LR+ 
from 1.43 (95% CI 0.86 - 2.36) to 25.74 95% CI 5.428 - 122.07) and LR- from 0.81 (95% CI 
0.68 - 0.97) to 0.89 (95% CI 0.74 - 1.08) (Figure 40).170;172 The largest higher quality study of 
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the reference standard was from Berkowitz et al.170 Individual accuracy results can be found 
in Table 26. 
Accuracy of CRH in symptomatic women 
For predicting spontaneous preterm birth within 10 days of testing, CRH had an LR+ of 3.12 
(95% CI 1.42 - 6.84) and LR- of 0.63 (95% CI 0.38 - 1.05). For predicting spontaneous 
preterm birth before 37 weeks’ gestation, it had an LR+ of and LR- of 0.68 (95% CI 0.51 - 
0.91) (Figure 40). Individual accuracy results can be found in Table 26. 
Figure 40 Forest plots of likelihood ratios (LR’s) of CRH in predicting spontaneous preterm birth within 
7-10 days of testing and 37 weeks’ gestation in symptomatic women and before 34 and 37 weeks’ gestation 
strain asymptomatic women* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
3.12 ( 1.42, 6.84) 100
4.06 ( 1.68, 9.81) 100
3.36 ( 2.30, 4.92) 100
1.43 ( 0.86, 2.36) 53.3 
25.74 ( 5.43, 122.07) 46.7 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Coleman 0.63 ( 0.38, 1.05) 100
Coleman 0.68 ( 0.51, 0.91) 100
Leung 0.35 ( 0.13, 0.91) 100
Berkowitz** 0.89 ( 0.73, 1.08) 44.4 
Inder** 0.81 ( 0.68, 0.97) 56.6 
<10 days of testing
<37 weeks’ gestation
<37 weeks’ gestation
<34 weeks’ gestation
Symptomatic women
Asymptomatic women
 
*Studies are arranged in descending order of methodological quality 
**Serial testing 
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β-human chorionic gonadotrophin (β-hcg) 
The hormone β-hcg manufactured by the feto-placental unit is known to be present in high 
concentrations in the amniotic fluid and maternal serum during pregnancy. Disruption of the 
chorion and the decidua as occurs when onset of labour was imminent has been postulated as 
the mechanism for testing for the presence of the cervico-vaginal secretions,133 in addition to 
its presence in the maternal serum.155 Measurement of β-hcg can be done either by taking 
maternal blood serum sample during asymptomatic antenatal period usually as part of ‘triple 
test’ to screen for Down syndrome or a cotton-tipped swab of cervico-vaginal secretions 
specimen obtained from speculum examination.  
Study characteristics and quality 
There were 23 primary articles, in which 19 evaluated the use of mid-trimester maternal 
serum hcg as a predictor of spontaneous preterm birth (n = 177,730 
women)151;152;155;156;159;160;165;176-187 while an article evaluated it in early first trimester (n = 
169),188 and three articles evaluated cervico-vaginal hcg as a predictor of spontaneous preterm 
birth in women who presented with symptoms of threatened preterm labour (n = 
248).133;189;190 Table 27 summarises each study’s salient features, stratified according to 
population of women tested, i.e. asymptomatic antenatal women and symptomatic women 
with threatened preterm labour.  
None of the studies fulfilled ideal quality study design. There were nine case-control studies 
in asymptomatic159;176;177;180-184;186 and one in symptomatic women.133 Four studies in 
asymptomatic women reported consecutive enrolments,151;160;185;187 while none was reported 
in symptomatic women. There were thirteen retrospective studies in asymptomatic 
women152;155;159;165;176;177;180-184;186;188 while all the studies in symptomatic women were 
prospective. None of the studies on asymptomatic women reported blinding and only one 
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study in symptomatic women reported it.190 The methodological quality of the included 
primary studies is summarized in Figure 41. 
Most of the study in asymptomatic women reported their thresholds in terms of multiples of 
median (MoM), except for three studies,179;185;188 which used percentiles. The commonest 
threshold used was 2.0 MoM, above of which abnormal was defined. The three studies that 
evaluated cervico-vaginal hcg had used 25 – 27 mIU/ml to define their thresholds for an 
abnormal result. Except for three studies in asymptomatic women, which used birth before 32 
weeks’151;179 and 34 weeks’ gestation,185 the remainder used birth before 37 weeks’ gestation 
as their reference standard. One study reported birth within 7 days of testing in symptomatic 
women,189 while the remainders reported before 37 weeks’ gestation as their reference 
standard. There was graphical (Figure 42) and statistical evidence of heterogeneity in the 
accuracy results (χ2 heterogeneity test p = 0.00017 for LR+ and χ2 heterogeneity test p = 
0.00011 for LR-) for studies using the commonest clinical characteristics (asymptomatic 
women, mid-trimester testing gestation, threshold of 2.0 MoM and birth before 37 weeks’ 
gestation as the reference standard). 
Accuracy of β-hcg in asymptomatic women 
Maternal mid-trimester serum β-hcg, which used threshold of 2.0 MoM showed variable 
accuracy in predicting spontaneous preterm birth before 37 weeks’ gestation in asymptomatic 
women. The likelihood ratio for positive tests (LR+) ranged from 0.92 (95% confidence 
interval (CI) 0.77 - 1.11)187 to 3.76 (95% CI 2.56 - 5.52)184 and for negative tests, LR- ranged 
from 0.50 (95% CI 0.28 - 0.88)182 to 1.30 (95% CI 0.79 - 2.12)187 (Figure 42). The largest 
better quality study reported LR+ 2.77 (95% CI 2.07 - 3.69) and LR- 0.984 (95% CI 0.98 - 
0.99) when first percentile was used as threshold to define abnormality.179 Figure 44 showed 
plot of sensitivities and specificities and their summary estimates for the accuracy of β-hcg in 
asymptomatic woman in predicting spontaneous preterm birth. Figure 45 funnel plot analysis 
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showed asymmetry indicating presence of publication or related biases. The individual 
accuracy results for asymptomatic women are summarized in Table 28. 
Accuracy of β-hcg in symptomatic women 
In a study that reported birth within 7 days of testing, the LR+ was 6.07 (95% confidence 
interval (CI) 3.07 - 11.99) and LR- was 0.04 (95% CI 0.01 - 0.16).189 Summary LR+ for birth 
before 37 weeks’ gestation was 2.11(95% CI 1.61 - 2.77) (χ2 heterogeneity test p = 0.42) and 
summary LR- was 0.45 (95% CI 0.31 - 0.66) (χ2 heterogeneity test p = 0.57) (Figure 43). The 
largest higher quality study has LR+ 2.19 (95% CI 1.35 - 3.57) and LR- 0.51 (95% CI 0.30 - 
0.85).190 The individual accuracy results for symptomatic women are summarized in Table 28. 
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Figure 41 Methodological quality of studies included in the systematic review of accuracy of human 
chorionic gonadotrophin in predicting spontaneous preterm birth among asymptomatic antenatal women 
and symptomatic women with threatened preterm labour. Data presented as 100% stacked bars. Figures 
in the stacks represent number of studies. 
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Figure 42 Forest plots of likelihood ratios (LR’s) of serum β-human chorionic gonadotrophin (β-hcg) 
testing in asymptomatic pregnant women as a predictor of spontaneous preterm birth before 37 weeks’ 
gestation*+ 
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Brajenovic 0.98 ( 0.89, 1.07) 8.5 
Lieppman 0.50 ( 0.28, 0.88) 0.4 
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Shieh 0.98 ( 0.94, 1.01) 20.9 
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Likelihood ratio for positive test
.4 1 2 5 10
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0.92 ( 0.77, 1.11) 13.8 
1.44 ( 1.24, 1.67) 14.2 
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1.63 ( 0.81, 3.27) 6.1 
1.28 ( 0.55, 3.00) 4.7 
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1.14 ( 1.01, 1.28) 14.6 
1.14 ( 0.41, 3.20) 3.6 
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χ2 heterogeneity test p = 0.0022 for LR+ and χ2 heterogeneity test p = 0.0049 for LR- 
 
 
Figure 43 Forest plots of likelihood ratios (LR’s) of cervico-vaginal β-human chorionic gonadotrophin (β-
hcg) testing in symptomatic pregnant women as a predictor of spontaneous preterm birth before 37 
weeks’ gestation*+ 
 
Likelihood ratio for positive test
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2.19 ( 1.35, 3.56) 31.4 
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2.11 ( 1.61, 2.77) 100.0 
Likelihood ratio for negative test
0.1 0.2 0.5 1.3
Study
LR-
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Gurbuz 0.44 ( 0.25, 0.75) 45.9 
Guvenal 0.19 ( 0.03, 1.21) 4.0 
Overall 0.45 ( 0.31, 0.66) 100.0 
 
χ2 heterogeneity test p = 0.42 for LR+ and χ2 heterogeneity test p = 0.57 for LR- 
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Figure 44 Plot of sensitivity against specificity including summary values of serum β-human chorionic 
gonadotrophin (β-hcg) testing in asymptomatic pregnant women as a predictor of spontaneous preterm 
birth before 37 weeks’ gestation 
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Figure 45 Funnel plot analysis of accuracy studies evaluating the accuracy of serum β-human chorionic 
gonadotrophin (β-hcg) testing in asymptomatic pregnant women as a predictor of spontaneous preterm 
birth before 37 weeks’ gestation 
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Estriol 
Estriol is produced by both mother and fetus in pregnancy. There is a surge in the maternal 
levels of estriol, which occurs several weeks prior to the onset of spontaneous labour. 
Measurement of either salivary and serum estriol was thus purported to be a predictor of 
spontaneous preterm birth.191 
Study characteristics and quality 
There were 7 primary studies (n = 60,722 women) on the accuracy of estriol testing as 
predictor of spontaneous preterm birth, comprising of 6 studies on asymptomatic antenatal 
women (n = 60,417)151;152;165;192-194 and 2 studies on symptomatic women with presented with 
threatened preterm labour (n = 305).191;192 Table 29 summarizes each study’s salient features, 
stratified according to population of women tested, i.e. asymptomatic antenatal women and 
women with symptoms of threatened preterm labour. The studies’ enrolment for 
asymptomatic women ranged from 399 to 33,145 women151;194 with a median of 601 
women,192 while that of symptomatic women ranged from 115 to 190 women.191;192 Two 
studies evaluated salivary estriol191;192 while the remaining evaluated maternal serum 
estriol.151;152;165;193;194 One study contributed to both asymptomatic and symptomatic 
population.192 
There were no studies included within the systematic review of the accuracy of estriol testing 
in predicting spontaneous preterm births that fulfil the ideal definition of high quality test 
accuracy studies either in asymptomatic or symptomatic women. None of the studies in both 
population reported using consecutive enrolment of women into the study. However, all 
studies have adequate test description report. Retrospective data collection was used in three 
studies in asymptomatic women.152;165;194 Blinding of carers to the results of estriol tests were 
absent from five studies on asymptomatic women151;152;165;193;194 and one study on 
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symptomatic women.191 The methodological quality of the included primary studies is 
summarized in Figure 46.  
Three studies used the same threshold of abnormality of 0.75 MoM in asymptomatic 
women152;193;194 while the two studies in symptomatic women used 2.1 ng/ml as their 
thresholds.191;192 Two studies in asymptomatic women used 0.5 MoM as their thresholds151;165 
and one study in symptomatic women explored the accuracy of 1.4 ng/ml threshold cut-off in 
predicting spontaneous preterm birth.192 One study in asymptomatic women evaluated the 
accuracy of repeat test in predicting spontaneous preterm birth.192 For asymptomatic women, 
one study used spontaneous preterm birth before 32 weeks’ gestation,151 whilst the remaining 
reported 37 weeks’ gestation as the reference standard. In symptomatic women, one study 
reported birth within 14 days of testing while another reported 37 weeks’ gestation. 
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Figure 46 Methodological quality of studies included in the systematic review of accuracy of estriol in 
predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in the stacks 
represent number of studies 
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Accuracy of estriol in asymptomatic women 
For predicting spontaneous preterm birth before 37 weeks’ gestation, a single salivary estriol 
testing had an LR+ 2.55 (95% CI 1.73 - 3.77) and LR- of 0.56 (95% CI 0.35 - 0.89) while a 
repeat test, where one positive result indicated positivity had an LR+ of 5.46 (95% CI 3.18 - 
9.40) and LR- of 0.61 (95% CI 0.43 - 0.88) (Figure 47).192 For predicting spontaneous 
preterm birth before 37 weeks’ gestation, serum estriol test had a range of LR+ from 0.76 
(95% CI 0.58 - 1.00) to 2.17 (95% CI 1.33 - 3.53) and LR- from 0.77 (95% CI 0.60 - 0.99) to 
1.02 (95% CI 1.00 - 1.04) (Figure 47).152;165 Estimates from Yaron et al165 and Kim et al193 
represented the largest higher quality studies of the reference standard, with commonly used 
thresholds of 0.75 MoM and 0.5 MoM respectively. There was no study which reported 
spontaneous preterm birth before 34 weeks’ gestation. Individual accuracy results can be 
found in Table 30. 
Accuracy of estriol in symptomatic women 
For predicting spontaneous preterm birth before 37 weeks’ gestation, salivary estriol had an 
LR+ of 2.31 (95% CI 1.64 - 3.24) and LR- of 0.40 (95% CI 0.20 - 0.79) (Figure 47).191 There 
is no study evaluating serum estriol in predicting spontaneous preterm birth in symptomatic 
women. Individual accuracy results can be found in Table 30. 
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Figure 47 Forest plots of likelihood ratios (LR’s) of salivary and serum estriol in predicting spontaneous 
preterm birth before 37 weeks’ gestation for asymptomatic and symptomatic women* 
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Kim 0.98 ( 0.89, 1.07) 20.1 
Duric 0.77 ( 0.60, 0.99) 25.5
Kowalczyk 1.04 ( 0.87, 1.23) 24.4 
McGregor 0.40 ( 0.20, 0.79) 100
Asymptomatic women
Salivary specimen
Serum specimen
Symptomatic women
Salivary specimen
 
*Studies are arranged in descending order of methodological quality 
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C-reactive protein (CRP) 
C-reactive protein (CRP) is an acute phase reactant associated with presence of systemic 
infections and may be, if raised, an indicator of risk for spontaneous preterm birth. It is an 
easily detectable and reliably measured serological marker obtained from a sample of 
maternal serum from venepuncture or amniotic fluid from amniocentesis. It is produced by 
the hepatocytes in response to the circulating inflammatory cytokines released by the presence 
of infections.195 
Study characteristics and quality 
There were 13 primary articles, involving altogether, a total of 2,142 women.195-207 
summarises each study’s salient features, stratified according to population of women tested, 
i.e. asymptomatic antenatal women and women with symptoms of threatened preterm labour 
and route of testing i.e. either amniotic sample from an amniocentesis or blood serum from 
venepuncture. Two studies reported on CRP measurement in amniotic fluid among 
asymptomatic women obtained at mid-trimester gestation,200;205 whilst remaining studies used 
maternal blood plasma serum level of CRP obtained either at mid-trimester gestation for 
asymptomatic women or at presentation for women whom presented with symptoms of 
threatened preterm labour. The study population ranged from 34 – 506 women, with a median 
of 69 women. Table 31 summarized the individual study characteristics. 
Only one study reported prospective data collection design205 and only seven of the thirteen 
included studies reported consecutive enrolment.195;196;199;201;204;205;207 Most of the studies had 
provided adequate test description but blinding was evident in only four studies.195;196;200;201 
The methodological quality of the included primary studies is summarised in Figure 48. There 
was no uniform test threshold used, which ranged from 1 ng/ml to 110 ng/ml, in the included 
studies. The most commonly used reference standard for asymptomatic women was birth 
before 37 weeks’ gestation, with one study reporting birth before 34 weeks’ gestation,200 
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while for symptomatic women with threatened preterm labour, they were birth within 7 days 
of testing,196;198;201;207 34 weeks’ and 37 weeks’ gestation.  
Accuracy of CRP in asymptomatic women 
In one study of amniotic fluid CRP level obtained at mid-trimester for predicting preterm 
birth before 34 weeks’ gestation, the LR+ was 2.63 (95% Confidence interval (CI) 1.85 - 
3.75) and LR- was 0.29 (95% CI 0.08 - 0.99).200 In another study, for predicting spontaneous 
preterm birth before 37 weeks’ gestation, the LR+ was 4.37 (95% CI 3.03 – 6.29) and LR- 
was 0.09 (95% CI 0.01 to 0.60).205 In three studies of maternal plasma CRP level 
measurement on asymptomatic women at mid-trimester for predicting preterm birth before 37 
weeks’ gestation the range of LR+ was 1.55 (95% CI 1.22 – 2.13) to 2.06 (95% CI 1.29 to 
3.29) and that of LR- was 0.77 (95% CI 0.65 – 0.91) to 0.86 (95% CI 076 – 0.98).202;203;206 
Summary LR+ for the accuracy of maternal serum level of CRP measurement in predicting 
spontaneous preterm birth before 37 weeks’ gestation was 1.73 (95% CI 1.38 - 2.16) 
(heterogeneity test χ2 = 1.06, p = 0.59) and LR- was 0.83 (95% CI 0.76 - 0.91) (χ2 = 1.20, p 
= 0.55) (Figure 49). The accuracy of CRP test in predicting spontaneous preterm births in 
asymptomatic women is summarized in Table 32 and Table 33.  
Accuracy of CRP in symptomatic women 
In four studies of maternal plasma CRP level measurement on women with threatened 
preterm labour for predicting preterm birth within 7 days of testing, the range of LR+ was 
1.35 (95% CI 0.71 – 2.55) to 34.36 (95% CI 4.86 – 243.09) and that of LR- was 0.17 (95% CI 
0.05 – 0.62) to 0.89 (95% CI 0.69 – 1.15).196;198;201;207 Summary LR+ for the accuracy of 
maternal serum level CRP measurement in predicting spontaneous preterm birth within 7 days 
of testing in symptomatic women with threatened preterm labour was 4.538 (95% CI 1.48 - 
13.91) (χ2 heterogeneity test p = 0.0017) and summary LR- was 0.296 (95% CI 0.08 - 1.15) 
(χ2 heterogeneity test p = 0.00021) (Figure 50). A study on maternal measurement plasma 
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CRP level in women symptomatic with threatened preterm labour used 34 weeks’ gestation 
had an LR+ of 6.75 (95% CI 1.34 – 34.00) and an LR- of 0.66 (0.38 – 1.14).199 In four studies 
of maternal plasma CRP level measurement on women with threatened preterm labour for 
predicting preterm birth before 37 weeks’ gestation, the range of LR+ was 1.67 (95% CI 0.76 
– 3.66) to 4.20 (95% CI 1.10 – 15.98) and that of LR- was 0.47 (95% CI 0.25 – 0.87) to 0.76 
(95% CI 0.48 – 1.21).195-197;204 Summary LR+ for spontaneous preterm birth before 37 weeks’ 
gestation was 2.29 (95% CI 1.57 - 3.35) (χ2 heterogeneity test p=0.66) and summary LR- was 
0.60 (95% CI 0.46 - 0.79) (χ2 = 2.23, p=0.53) (Figure 51). Cammu’s196 result represented the 
largest higher quality study. Figure 52 showed plot of sensitivities and specificities and their 
summary estimates for serum CRP in symptomatic women predicting spontaneous preterm 
birth within 7days of testing. The accuracy of CRP test in predicting spontaneous preterm 
births in symptomatic women who presented with threatened preterm labour is summarized in 
Table 32 and Table 33. 
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Figure 48 Methodological quality of studies of C-reactive protein in predicting spontaneous preterm birth 
included in the systematic review. Data presented as 100% stacked bars. Figures in the stacks represent 
number of studies. 
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Figure 49 Forest plots of likelihood ratios (LR’s) of the accuracy of mid-trimester maternal serum CRP 
level measurement in asymptomatic women for predicting spontaneous preterm birth before 37 weeks’ 
gestation*+ 
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2.06 ( 1.29, 3.29) 23.2 
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Overall 0.83 ( 0.76, 0.91)100.0 
Likelihood ratio for negative test  
*χ2 heterogeneity test p = 0.59 for LR+ and p = 0.55 for LR- 
+Studies are arranged in descending order of methodological quality 
 
Figure 50 Forest plots of likelihood ratios (LR’s) of the accuracy of maternal serum CRP level 
measurement in symptomatic women with threatened labour for predicting spontaneous preterm birth 
within 7 days of testing*+ 
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0.5 1 2 5 10
LR+
(95% CI) % Weight
34.36 ( 4.86, 243.09) 16.4 
7.83 ( 3.01, 20.32) 26.5 
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Likelihood ratio for negative test
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Handwerker 0.17 ( 0.05, 0.62) 23.2 
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*χ2 heterogeneity test p = 0.0017 for LR+ and p = 0.00021 for LR- 
+Studies are arranged in descending order of methodological quality 
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Figure 51 Forest plots of likelihood ratios (LR’s) for maternal serum CRP level measurement in 
symptomatic women with threatened labour for predicting spontaneous preterm birth before 37 weeks’ 
gestation*+ 
 
Likelihood ratio for positive test
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(95% CI) % Weight
2.32 ( 1.43, 3.76) 61.3 
4.20 ( 1.10, 15.98) 8.1 
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Potkul 0.51 ( 0.31, 0.82) 32.0 
Cylwik 0.69 ( 0.33, 1.44) 14.1 
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Overall 0.60 ( 0.46, 0.79) 100.0 
 
*χ2 heterogeneity test p = 0.66 for LR+ and p = 0.53 for LR- 
+Studies are arranged in descending order of methodological quality 
 
 
 
103
Figure 52 Plot of sensitivity against specificity including summary values of the maternal serum 
measurement of C-reactive protein (CRP) studies in symptomatic women with threatened preterm labour 
for predicting spontaneous preterm birth within 7 days of testing 
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Interleukin-6 (IL6) 
Interleukin 6 (IL6) is a protein compound produced in response to presence of inflammation 
usually in response to presence of an infection. It can be found in amniotic fluid, cervical 
secretion and in maternal blood serum. Their presence or increasing values have been 
purported to predict spontaneous preterm birth in symptomatic women who presented with 
threatened preterm labour.208 
Study characteristics and quality 
There were 26 primary studies (n = 2,594 women) on the accuracy of IL6 testing in predicting 
spontaneous preterm birth. However one study,209 which evaluated cervical IL6 as predictor 
of spontaneous preterm birth in women who presented with symptoms of threatened preterm 
labour were excluded as the author was not able to provide the data within the time constraint 
of the thesis. The number of women enrolled ranged from 7396 to 290210 with a median of 161 
in asymptomatic women 211 and from 18114 to 146208 with a median of 73 in symptomatic 
women.96 There were 12 studies evaluating amniotic level of IL6, two in asymptomatic 
women210;212 and ten in symptomatic women114;208;213-220 as a predictor for spontaneous 
preterm birth. There were 10 studies evaluating cervical IL6, three in asymptomatic 
women96;211;221 and seven in symptomatic women83;96;222-226 as predictor of spontaneous 
preterm birth in women. One study evaluated serial testing of cervical IL6 in asymptomatic 
women.211 There were six studies, all in symptomatic women who presented with threatened 
preterm labour, which evaluated serum IL6 as a predictor for spontaneous preterm birth.225;227-
231 Two studies provided information to more than one categories of either population96 or 
type of IL6 specimen.225 Table 34 summarized individual study characteristics. 
Three studies fulfilled the ideal definition of high quality test accuracy studies.96;211;217 All 
studies in both asymptomatic and symptomatic women provided adequate test description. 
However, out of 20 studies on symptomatic women, most were lacking in reporting of 
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consecutive enrolment with only three studies reported consecutive enrolment96;217;223 and 
blinding of test results, where only eight studies reported it.83;96;114;214;215;217;228;229 The 
methodological quality of the included primary studies is summarized in Figure 53. No two 
studies had reported using the same threshold. Three studies on asymptomatic women 
reported birth before 37 weeks’ gestation as their reference standard96;210;211 and one each for 
birth before 34 weeks’212 and 35 weeks’ gestation.221 For symptomatic women, one study 
reported spontaneous preterm birth within 24 hours,231 five studies within 48 
hours114;213;215;228;230 and four studies reported birth within 5 - 7 days of testing,216;226;229;232 
while the remainder reported birth before 35-37 weeks’ gestation.83;96;208;214;217-220;223;225 
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Figure 53 Methodological quality of studies included in the systematic review of accuracy of interleukin-6 
(IL6) in predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in the 
stacks represent number of studies. 
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Accuracy of IL6 in asymptomatic women 
For predicting spontaneous preterm birth before 34 weeks’ gestation, a single amniotic fluid 
IL6 measurement had a range of LR+ of 2.65 (95% CI 1.37 - 5.14) 210 to 2.95 (95% CI 0.96 - 
9.04)212 (χ2 heterogeneity test p = 0.87) and LR- of 0.84 (95% CI 0.62 - 1.13)212 to 0.91 (95% 
CI 0.84 - 0.98)210 (χ2 heterogeneity test p = 0.57) (Figure 54). For predicting spontaneous 
preterm birth before 37 weeks’ gestation, a single amniotic fluid IL6 measurement had an 
LR+ of 1.91 (95% CI 0.99 - 3.67) and LR- of 0.95 (95% CI 0.90 - 1.00) (Figure 54),210 the 
latter represented the largest higher quality study available for amniotic fluid IL6 in 
asymptomatic women for predicting spontaneous preterm birth before 34 and 37 weeks’ 
gestation.210 Serial testing of cervical IL6 in asymptomatic women had an LR+ of 3.34 (95% 
CI 1.96 - 5.70) and LR- of 0.59 (0.42 - 0.83) for predicting spontaneous preterm birth before 
37 weeks’ gestation.211 Single testing of cervical IL6 in asymptomatic women had a range of 
LR+ from 0.564 (95% CI 0.08 - 3.97) 96 to 2.08 (95% CI 1.10 - 3.96)221 and a range of LR- 
from 0.88 (95% CI 0.80 - 0.98)221 to 1.08 (95% CI 0.87 - 1.35)96 for predicting spontaneous 
preterm birth before 37 weeks’ gestation (χ2 heterogeneity test p = 0.14 for LR+ and p = 
0.003 for LR-) where the two studies represented the largest higher quality study available for 
cervical IL6 in asymptomatic women for preterm birth before 37 weeks’ gestation for single 
and serial testings.96;211. Figure 54 summarized the accuracy results for amniotic fluid IL6 in 
predicting spontaneous preterm birth in asymptomatic women. There is no information on 
birth before 34 weeks’ gestation using cervical IL6 testing. Individual accuracy results can be 
found in Table 35. 
Accuracy of IL6 in symptomatic women 
For predicting spontaneous preterm birth within 7 – 10 days of testing, cervical IL6 had a 
range of LR+ from 2.40 (95% CI 1.37 - 4.23)224 to 4.01 (95% CI 2.02 - 7.96)226 and a range of 
LR- from 0.12 (95% CI 0.01 - 1.72)224 to 0.66 (95% CI 0.51 - 0.85),226 where the latter 
 
 
108
represented the largest higher quality cervical IL6 study available in symptomatic women for 
predicting spontaneous preterm birth within 7-10 days of testing.226 Amniotic fluid 
measurement of IL6 had a range of LR+ from 2.43 (95% CI 1.36 - 4.36)216 to 7.01 (95% CI 
2.75 - 17.90)215 and a range of LR- from 0.17 (95% CI 0.06 - 0.49)215 to 0.24 (0.09 - 0.61)216 
LR estimates from Greci et al,215 the largest higher quality study for this reference standard. 
Serum measurement of IL6 had an LR+ of 3.34 (95% CI 1.48 - 7.53) and LR- of 0.44 (95% 
CI 0.30 - 0.66).230 The accuracy results for the different types of IL6 sources are shown in 
Figure 55. 
For predicting spontaneous preterm birth before 34 weeks’ gestation (Figure 56), amniotic 
fluid IL6 had an LR+ of 7.44 (95% CI 2.01 - 27.52) and LR- of 0.14 (95% CI 0.06 - 0.36).216 
For predicting spontaneous preterm birth before 34 weeks’ gestation, cervical IL6 had a range 
of LR+ from 2.63 (95% CI 1.44 - 4.79)224 to 4.92 (95% CI 1.80 - 13.46) and LR- from 0.097 
(95% CI 0.01 - 1.45)224 to 0.74 (95% CI 0.63 - 0.87);226 the latter represented the largest 
higher quality study of cervical IL6 in this reference standard. Serum IL6 had an LR+ of 1.44 
(95% CI 0.86 - 2.41) and LR- of 0.59 (95% CI 0.22 - 1.58) for predicting spontaneous 
preterm birth before 34 weeks’ gestation.228  
For predicting spontaneous preterm birth before 37 weeks’ gestation, amniotic fluid IL6 had a 
range of LR+ from 4.92 (95% CI 1.26 - 19.29)219 to 28.62 (95% CI 1.78 - 461.04)217 and LR- 
from 0.05 (95% CI 0.003 - 0.76)220 to 0.66 (95% CI 0.54 - 0.80),217 the latter represented the 
largest higher quality study for this reference standard. For the same reference standard, 
cervical IL6 had a range of LR+ from 1.83 (95% CI 0.79 - 4.25)96 to 14.0 (95% CI 2.03 - 
96.62)225 and LR- from 0.10 (95% CI 0.01 - 1.45)224 to 1.29 (95% CI 0.75 - 2.20) (Figure 
56).83 Estimates from Inglis et al96 represented the sole ideal quality study within this sub-
group of reference standard of spontaneous preterm birth before 37 weeks’ gestation. Serum 
IL6 had an LR+ of 1.13 (95% CI 0.55 - 2.32) and LR- of 0.92 (95% CI 0.54 - 1.56).225 Figure 
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57 showed plot of sensitivities and specificities and their summary estimates for the accuracy 
of amniotic and cervical fluid in symptomatic women in predicting spontaneous preterm 
births within 7 days of testing.The accuracy of IL6 in predicting spontaneous preterm birth in 
asymptomatic and symptomatic women was summarized in Table 35. 
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Figure 54 Forest plots of likelihood ratios (LR’s) of amniotic fluid interleukin-6 (IL6) measurement as a 
predictor of spontaneous preterm birth before 34 and 37 weeks’ gestation in asymptomatic women*+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
2.65 ( 1.37, 5.14) 15.0 
2.95 ( 0.96, 9.04) 5.2 
3.33 ( 0.98, 11.38) 4.4 
1.91 ( 1.00, 3.67) 15.4 
3.34 ( 1.96, 5.70) 23.0 
3.30 ( 1.84, 5.90) 19.4 
0.56 ( 0.08, 3.97) 1.7 
2.08 ( 1.10, 3.96) 15.9 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Wenstorm1 0.91 ( 0.84, 0.98) 20.1 
Ghidini1 0.83 ( 0.62, 1.13) 6.3 
Goepfert2 0.85 ( 0.72, 0.99) 13.3 
Wenstorm1 0.95 ( 0.90, 1.00) 21.6 
Lockwood2,3,4 0.59 ( 0.42, 0.83) 5.1 
Lockwood2,3,5 0.65 ( 0.47, 0.88) 6.1 
Inglis2 1.08 ( 0.87, 1.35) 9.7 
Goepfert2 0.88 ( 0.80, 0.98) 17.7 
34 weeks’ gestation
37 weeks’ gestation
 
*Studies are arranged in descending order of methodological quality for each type of test 
+For individual thresholds see Table x 
1. Amniotic fluid measurement of IL6, 2. Cervico-vaginal measurements of IL6, 3. Serial measurement (repeated after 3-4 weeks interval), 4. Threshold 250 pg/ml, 5. Threshold 125 pg/ml 
 
Figure 55 Forest plots of likelihood ratios (LR’s) of IL6 measurement from amniotic fluid and cervical 
specimen as a predictor of spontaneous preterm birth within 7 - 10 days of testing in symptomatic 
women* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
7.01 ( 2.75, 17.90) 7.6 
2.43 ( 1.36, 4.36) 16.6 
28.50 ( 1.78, 456.57)1.0 
2.53 ( 1.38, 4.64) 15.6 
4.01 ( 2.02, 7.96) 12.9 
3.73 ( 2.21, 6.33) 19.2 
2.40 ( 1.37, 4.23) 17.4 
3.34 ( 1.48, 7.53) 9.8 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Greci1 0.17 ( 0.06, 0.49) 8.4 
Hillier1 0.24 ( 0.09, 0.61) 9.6 
Allbert1 0.26 ( 0.06, 1.03) 5.7 
Dudley1 0.47 ( 0.30, 0.75) 18.1 
Trebeden2 0.66 ( 0.51, 0.85) 22.5 
Holst2 0.30 ( 0.16, 0.58) 14.2 
Lange2 0.12 ( 0.01, 1.72) 1.8 
Turhan3 0.44 ( 0.30, 0.66) 19.6 
 
*Studies are arranged in descending order of methodological quality for each type of test 
1. Amniotic fluid measurement of IL6, 2. Cervico-vaginal measurements of IL6, 3. Serum measurement of IL6 
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Figure 56 Forest plots of likelihood ratios (LR’s) of IL6 measurement from amniotic fluid, cervical swab 
and serum specimen as a predictor of spontaneous preterm birth before 34 and 37 weeks’ gestation* 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
7.44 ( 2.01, 27.52) 6.3 
4.92 ( 1.80, 13.46) 7.5 
2.63 ( 1.44, 4.79) 9.1 
1.44 ( 0.86, 2.41) 9.4 
28.62 ( 1.78, 461.04) 2.7 
6.79 ( 2.95, 15.64) 8.2 
4.92 ( 1.26, 19.29) 6.1 
5.41 ( 3.55, 8.22) 9.7 
1.83 ( 0.79, 4.25) 8.2 
0.88 ( 0.65, 1.19) 10.0 
1.85 ( 1.15, 2.95) 9.6 
14.00 ( 2.03, 96.62) 4.3 
1.13 ( 0.55, 2.32) 8.7 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Hillier1 0.14 ( 0.06, 0.36) 6.3 
Trebeden2 0.74 ( 0.63, 0.87) 12.7 
Lange2 0.10 ( 0.01, 1.45) 1.3 
Alvarez-de-la-Rosa3 0.58 ( 0.22, 1.58) 5.9 
Rizzo1 0.66 ( 0.54, 0.80) 12.4 
Coultrip1 0.22 ( 0.12, 0.40) 9.1 
Silver1 0.44 ( 0.22, 0.90) 8.0 
Romero1 0.05 ( 0.00, 0.76) 1.3 
Inglis2 0.69 ( 0.40, 1.19) 9.5 
LaShay2 1.28 ( 0.75, 2.20) 9.6 
Kurkinen-Raty2 0.45 ( 0.17, 1.20) 5.9 
Sozmen2 0.32 ( 0.16, 0.62) 8.3 
Sozmen3 0.92 ( 0.54, 1.56) 9.7 
34 weeks’ gestation
37 weeks’ gestation
 
*Studies are arranged in descending order of methodological quality for each type of test 
1. Amniotic fluid measurement of IL6, 2. Cervico-vaginal measurements of IL6, 3. Serum measurement of IL6 
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Figure 57 Plot of sensitivity against specificity including summary values of the accuracy of amniotic fluid 
and cervico-vaginal interleukin – 6 (IL6) studies in symptomatic women with threatened preterm labour 
in predicting spontaneous preterm birth within 7 days of testing 
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Interleukin-8 (IL8) 
Similar to IL6, interleukin-8 (IL8) is a protein compound produced in response to presence of 
inflammation usually in response to presence of an infection. It can be found in amniotic 
fluid, cervical secretion and in maternal blood serum. Their presence in cervico-vaginal 
secretion209 or increasing values in maternal serum213 have been purported to predict 
spontaneous preterm birth in symptomatic women who presented with threatened preterm 
labour. 
Study characteristics and quality 
There were 5 primary studies, involving altogether, a total of 568 women. Three potentially 
eligible studies for inclusion were excluded because their data were unobtainable.209;231;233 
Table 36 summarizes each study’s salient features, stratified according to population of 
women tested, i.e. asymptomatic antenatal women (2 studies)234;235 and women with 
symptoms of threatened preterm labour (3 studies).213;222;223 One of the included studies on 
asymptomatic antenatal population had the test performed 2 weekly between 24 to 28 weeks’ 
gestation.235 Except for one study,213 the remaining studies evaluated IL8 in cervico-vaginal 
specimen. 
None of the studies fulfilled the ideal definition of high quality test accuracy studies. Blinding 
and consecutive enrolment were absent from four studies – none of the studies on 
symptomatic women reported blinding213;222;223 and only one study, in symptomatic women, 
reported consecutive enrolment.223 All studies in both asymptomatic and symptomatic women 
provided adequate test description. The methodological quality of the included primary 
studies is summarized in Figure 58. No two studies had reported using the same threshold, 
which varied widely. The two studies on asymptomatic women reported birth before 37 
weeks’ gestation as their reference standard but one of them235 additionally reported birth 
before 32 and 34 weeks’ gestation and had performed their performed their test serially with a 
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two-weekly interval. For symptomatic women, one study reported spontaneous preterm birth 
within 24 hours,231 five studies within 48 hours114;213;215;228;230 and four studies reported birth 
within 5 - 7 days of testing,216;226;229;232 while the remainder reported birth before 35-37 
weeks’ gestation.83;96;208;214;217-220;223;225 There were insufficient number of studies for 
statistical heterogeneity analysis to be conducted in the case of IL8. 
Accuracy of IL8 in asymptomatic women 
In the single study that evaluated the test for predicting spontaneous preterm birth before 34 
weeks’ gestation on asymptomatic women but which serial testing of cervical IL8 was used, 
LR+ was 2.23 (95% CI 1.46 - 3.41) and LR- 0.69 (0.50 - 0.97).235 For predicting spontaneous 
preterm birth before 37 weeks’ gestation, the LR+ ranged from 1.38 (95% CI 1.04 - 1.81)235 
to LR+ 2.75 (95% CI 1.68 - 4.52)234 while LR- from 0.68 (95% CI 0.49 - 0.95)234 to 0.91 
(95% CI 0.82 - 1.01),235 where the latter represented the largest higher quality study available 
for the population. Figure 59 showed the forest plots of the accuracy of the IL8 test in 
predicting spontaneous preterm birth. Individual accuracy measures of the test are 
summarized in Table 37.  
Accuracy of IL8 in symptomatic women 
For predicting spontaneous preterm birth within 48 hours of testing, LR+ was 36.00 (95% CI 
2.30 - 564.54) and LR- 0.10 (95% CI 0.007 - 1.42).213 The accuracy for predicting 
spontaneous preterm birth within 7 days of testing was shown in Figure 59, where the LR+ 
ranged from 2.34 (95% CI 1.42 - 3.84) (cervical IL8)232 to 28.5 (95% CI 1.78 - 456.57) 
(amniotic fluid IL8)213 and LR- ranged from 0.26 (95% CI 0.06 - 1.03) (amniotic fluid IL8)213 
to 0.52 (95% CI 0.32 - 0.84) (cervical IL8).232 LR+ from Holst et al232 represented the largest 
higher quality study. For predicting spontaneous preterm birth before 37 weeks gestation, 
LR+ was 1.4 (95% CI 0.83 - 2.35) and LR- 0.67 (95% CI 0.30 - 1.50).223 Figure 59 showed 
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the forest plots of the accuracy of the IL8 test in predicting spontaneous preterm birth. 
Individual accuracy measures of the test are summarized in Table 37. 
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Figure 58 Methodological quality of studies included in the systematic review of accuracy of test for 
interleukin-8 (IL8) in predicting spontaneous preterm birth. Data presented as 100% stacked bars. 
Figures in the stacks represent number of studies. 
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Figure 59 Forest plots of likelihood ratios (LR’s) of interleukin-8 (IL8) measurement from amniotic fluid 
and cervical specimen as a predictor of spontaneous preterm birth stratified according to population and 
outcome* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
1.94 ( 1.08, 3.48) 13.6 
2.23 ( 1.46, 3.41) 17.2 
1.38 ( 1.04, 1.82) 20.8 
2.75 ( 1.68, 4.52) 15.5 
36.00 ( 2.30, 564.54) 1.3 
2.34 ( 1.42, 3.84) 15.5 
28.50 ( 1.78, 456.57) 1.3 
1.40 ( 0.83, 2.35) 15.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Sakai1 0.76 ( 0.53, 1.10) 16.3 
Sakai1 0.69 ( 0.50, 0.97) 17.5 
Sakai1 0.91 ( 0.82, 1.01) 26.7 
Sakai 0.68 ( 0.49, 0.95) 17.7 
Allbert2 0.10 ( 0.01, 1.42) 0.7 
Holst 0.52 ( 0.32, 0.84) 12.3 
Allbert2 0.26 ( 0.06, 1.03) 2.5 
Kurkinen 0.67 ( 0.30, 1.50) 6.2 
Asymptomatic women
Symptomatic women
< 32 weeks
< 34 weeks
< 37 weeks
< 48 hours
< 7 days
< 37 weeks
 
*Studies are arranged in descending order of methodological quality and unless otherwise stated, were single testing, using samples obtained from cervico-vaginal swabs 
1. Serial testing. 2. Amniotic fluid specimen. 
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Matrix metalloproteases-9 (MMP-9) 
During pregnancy, MMP-9 is produced by the decidua, chorion and amnion. Its expression is 
increased in the choriodecidual membranes during active labour. It is purported that during 
the process of labour, which involved the disruption of decidua-membrane interface, 
measurement of MMP-9 may served as marker for impending preterm labour that lead to 
spontaneous preterm birth.236 
Study characteristics and quality 
There were 2 primary studies (n = 35) on the accuracy of MMP-9 testing, both were on 
symptomatic women with threatened preterm labour. One study evaluated MMP-9 in 
maternal plasma (n = 15)236 while the other (n = 20) evaluated it in maternal plasma and urine 
specimens.237 There were no study on asymptomatic women. Table 38 summarizes each 
study’s salient features. 
There were no studies included within the systematic review of the accuracy of MMP-9 
testing in predicting spontaneous preterm births that fulfil the ideal definition of high quality 
test accuracy studies either in asymptomatic or symptomatic women. None of the studies in 
both population reported using consecutive enrolment of women into the study or blinding of 
test results to carers or assessors. However, all studies have adequate test description report. 
The methodological quality of the included primary studies is summarized in Figure 60.  
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Figure 60 Methodological quality of studies included in the systematic review of accuracy of matrix 
metalloproteases-9 (MMP-9) in predicting spontaneous preterm birth. Data presented as 100% stacked 
bars. Figures in the stacks represent number of studies. 
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Accuracy of MMP-9 in symptomatic women 
For predicting spontaneous preterm birth before 37 weeks’ gestation, maternal plasma MMP-
9 had an LR+ of 7.33 (95% CI 1.07 - 50.27)236 and an LR- of 0.37 (95% CI 0.14 - 0.94)237 
while maternal urinary MMP-9 had a range of LR+ from 6.00 (95% CI 0.87 - 41.44) to 7.33 
(95% CI 1.07 - 50.27)237 and LR- from 0.37 (95% CI 0.14 - 0.94)237 to LR- of 0.38 (95% CI 
0.12 - 1.19) (Figure 61).236 Estimates from Makrakis et al237 represented the largest higher 
quality study for this reference standard. Individual accuracy results for symptomatic women 
can be found in Table 39. 
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Figure 61 Forest plots of likelihood ratios (LR’s) of MMP-9 in predicting spontaneous preterm birth 
before 37 weeks’ gestation in symptomatic women* 
 
Likelihood ratio (LR) for positive test
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LR+
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6.00 ( 0.87, 41.44) 49.8 
7.33 ( 1.07, 50.27) 50.2 
7.33 ( 1.07, 50.27)100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
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LR-
(95% CI) % Weight
Agrez 0.38 ( 0.12, 1.19) 40.0 
Makrakis 0.37 ( 0.14, 0.94) 60.0 
Makrakis 0.37 ( 0.14, 0.94) 100.0 
Maternal plasma
Maternal urine
 
*Studies are arranged in descending order of methodological quality 
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Periodontal assessment 
Periodontal health care is provided for free at the point of delivery to pregnant women within 
the UK. It examines the oral cavities for signs of periodontal disease (e.g. periodontitis), 
which has been purported to predispose to spontaneous preterm birth.238 
Study characteristics and quality 
There were 13 primary articles evaluating the accuracy of the state of antenatal periodontal 
health in asymptomatic women or in the immediate postnatal period as predictor of 
spontaneous preterm birth (n = 3,900 women).238-250 The number of women enrolled ranged 
from 36240 to 1,313238 with a median of 128. Two studies published their preliminary results 
(n = 176 women), full results of which were not available at the time of writing.242;249 The 
accuracy of one study was not evaluated further as data was not extractable from the 
publication and the corresponding author was not able to provide it within the time scale of 
this thesis.244 There was no study evaluating the accuracy of periodontal assessment as a 
predictor of spontaneous preterm birth in women who presented with threatened preterm 
labour. Table 40 summarises each study’s salient features, stratified according to population 
of women tested, i.e. asymptomatic antenatal women and symptomatic women with 
threatened preterm labour.  
None of the studies fulfilled ideal quality study designs. There were ten studies that reported 
prospective data collection238-242;244;246-248;250 and six that reported case-control 
design.239;241;243;245;247;249 Consecutive enrolment was only evident in one study.238 Blinding 
was reported in eight studies.238;239;241;244;246-249 Overall, there were adequate reports of test 
description from the studies. The methodological quality of the included primary studies is 
summarised in Figure 62. 
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All but one study assessed women’s periodontal status for presence of periodontitis. The one 
study assessed women’s antibodies serology for Prophyromonas gingivalis, the predominant 
organism implicated in periodontitis in general population.239 Seven studies performed their 
periodontal assessment in 2nd trimester238-240;242;244;246;250 while six studies performed theirs 
within 2 - 5 days of delivery.241;243;245;247-249 There were as many criteria for determining 
periodontitis as the number of studies. No two studies had used the same criteria for 
determining periodontitis. Except for two studies, which used 32 weeks’ gestation,241;246 most 
studies had used 37 weeks’ gestation as their reference standard.
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Figure 62 Methodological quality of studies included in the systematic review of accuracy of periodontal 
health status in predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in 
the stacks represent number of studies. 
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Accuracy of periodontal assessment in asymptomatic women 
The presence of periodontal disease showed variable accuracy in predicting spontaneous 
preterm birth (Figure 63). The likelihood ratio for positive tests (LR+) ranged from 0.38 (95% 
confidence interval (CI) 0.04 - 3.33)247 to 5.00 (95% CI 2.22 - 11.28)240 and the LR- ranged 
from 0.22 (95% CI 0.09 - 0.57)248 to 1.13 (95% CI 0.90 - 1.42).242 The largest higher quality 
study reported LR+ 2.26 (95% CI 1.35 - 3.79) and LR- 0.79 (95% CI 0.65 - 0.96).238 Figure 
64 showed of sensitivity against specificity including summary values of the accuracy of 
periodontal health status in predicting spontaneous preterm birth before 37 weeks’ gestation 
in asymptomatic women. Funnel plot analysis (Figure 65) showed presence of asymmetry 
indicating presence of publication or related biases. Individual accuracy result of the state of 
periodontal health in predicting spontaneous preterm birth in asymptomatic women was 
summarized in Table 41. Meta-analysis was not performed because of the clinical 
heterogeneity in the criteria defining periodontal disease. 
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Figure 63 Forest plots of likelihood ratios (LR’s) of periodontal health status in predicting spontaneous 
preterm birth before 37 weeks’ gestation in asymptomatic women* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
2.26 ( 1.35, 3.79) 11.9 
1.13 ( 0.85, 1.50) 14.3 
1.62 ( 1.08, 2.44) 13.1 
0.39 ( 0.03, 5.90) 1.7 
3.34 ( 2.35, 4.73) 13.7 
0.76 ( 0.07, 8.23) 2.1 
3.04 ( 1.68, 5.52) 11.1 
5.00 ( 2.22, 11.28) 8.9 
1.21 ( 0.73, 2.02) 12.0 
1.18 ( 0.66, 2.09) 11.3 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Offenbacher 0.79 ( 0.65, 0.96) 12.7 
Moore 0.88 ( 0.63, 1.23) 11.4 
Offenbacher 0.24 ( 0.09, 0.63) 5.4 
Holbrook 1.13 ( 0.90, 1.42) 12.4 
Rajapakse 0.39 ( 0.24, 0.63) 9.8 
Moore 1.01 ( 0.96, 1.05) 13.4 
Radnai 0.45 ( 0.22, 0.92) 7.4 
Dortbudak 0.20 ( 0.03, 1.20) 2.2 
Jarjoura 0.94 ( 0.81, 1.10) 13.0 
Konopka 0.93 ( 0.74, 1.18) 12.4 
 
*Studies are arranged in descending order of methodological quality 
 
Figure 64 Plot of sensitivity against specificity including summary values of the accuracy of periodontal 
health status in predicting spontaneous preterm birth before 37 weeks’ gestation in asymptomatic women 
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Figure 65 Funnel plot analysis of accuracy studies evaluating periodontal health status in predicting 
spontaneous preterm birth before 37 weeks’ gestation in asymptomatic women 
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Asymptomatic bacteriuria assessment 
Screening for asymptomatic bacteriuria has been a routine component of an antenatal care. Its 
finding has been purported to increase the risk of spontaneous preterm birth. The usual 
specimen obtained was a mid-stream urine specimen sent for bacterial culture and sensitivity 
analysis. In light of recognised contribution of vaginal colonization in development of 
spontaneous preterm labour, there is even a call to re-evaluate the usefulness of screening for 
asymptomatic bacteriuria.251 One systematic review had been done before.252 
Study characteristics and quality 
There were 26 studies (n=66,824) evaluating the accuracy of screening for asymptomatic 
bacteriuria in predicting spontaneous preterm birth.253-278 Three of the included studies 
(n=11,520) evaluated the accuracy of asymptomatic Group B Streptococcus bacteriuria 
exclusively.265;266;277 All the studies had used birth before 37 weeks’ gestation as their 
outcome measurement. Table 42 summarized the characteristic of the included studies. 
None of the studies fulfilled the criteria for an ideal quality study, specifically blinding was 
absent from all the studies. Only 6 and 9 studies used consecutive enrolment262;265;266;269;274;278 
and prospective data collection respectively.262;265;266;268;269;274;275;278 Figure 66 summarized the 
methodological quality of the included studies. 
Accuracy of asymptomatic bacteriuria in asymptomatic women 
Screening for asymptomatic bacteriuria showed a variable accuracy in predicting spontaneous 
preterm birth before 37 weeks’ gestation (Figure 67). LR+ ranged from 0.10 (95% CI 0.01 - 
1.70)256 to 3.83 (95% 2.22 - 6.59)260 while LR- ranged from 0.43 (95% CI 0.19 - 0.94) to 1.17 
(95% CI 0.64 - 2.13)254 for asymptomatic bacteriuria. For asymptomatic GBS bacteriuria, 
LR+ ranged from 1.52 (95% CI 0.80 - 2.86)277 to 2.69 (95% CI 1.51 - 4.76)266 and LR- ranged 
from 0.96 (95% CI 0.88 - 1.04)265 to 0.99 (95% CI 0.98 - 1.01).277 The higher quality study 
available reported LR+ 2.63 (95% CI 1.54 - 4.50) and LR- 0.96 (95% CI 0.92 - 0.99) was 
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from Wren et al278. Figure 68 showed plot of sensitivities and specificities and their summary 
estimates for the accuracy of asymptomatic bacteriuria assessment in predicting spontaneous 
preterm birth before 37 weeks’ gestation. Figure 69 did not show asymmetry in the funnel 
plot analysis of the accuracy of asymptomatic bacteriuria assessment in predicting 
spontaneous preterm birth before 37 weeks’ gestation. Individual accuracy data is 
summarized in Table 43. 
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Figure 66 Methodological quality of studies included in the systematic review of accuracy of asymptomatic 
bacteriuria assessment in predicting spontaneous preterm birth among asymptomatic antenatal women. 
Data presented as 100% stacked bars. Figures in the stacks represent number of studies. 
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Figure 67 Forest plots of likelihood ratios (LR’s) of asymptomatic bacteriuria assessment in asymptomatic women as a predictor of spontaneous preterm birth 
before 37 weeks’ gestation stratified according to the type of asymptomatic bacteriuria* 
 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Wren 0.96 ( 0.92, 0.99) 8.4 
Robertson 0.91 ( 0.82, 1.01) 3.8 
Uncu 0.81 ( 0.62, 1.05) 0.9 
Layton 1.09 ( 0.74, 1.59) 0.4 
Versia 0.99 ( 0.97, 1.01) 9.3 
Versib 1.00 ( 0.99, 1.01) 9.9 
Patrick 0.86 ( 0.69, 1.06) 1.2 
Schieve 0.97 ( 0.96, 0.98) 9.8 
LeBlanc 0.98 ( 0.94, 1.01) 8.4 
Gold 1.03 ( 1.01, 1.04) 9.8 
Kass 0.83 ( 0.75, 0.92) 3.9 
Hoja 1.01 ( 0.97, 1.05) 8.3 
Stuart 0.89 ( 0.81, 0.98) 4.1 
Henderson 0.95 ( 0.92, 0.99) 8.5 
Low 1.01 ( 0.93, 1.11) 4.6 
Forkman 1.01 ( 0.91, 1.12) 3.9 
Kincaid 0.74 ( 0.59, 0.92) 1.2 
Schamadan 0.83 ( 0.69, 1.01) 1.5 
Whalley 1.06 ( 0.81, 1.39) 0.8 
Sleigh 1.00 ( 0.58, 1.72) 0.2 
Norden 1.01 ( 0.70, 1.47) 0.5 
Kubicki 0.43 ( 0.19, 0.94) 0.1 
Bryant 1.17 ( 0.64, 2.13) 0.2 
AbdulJabbar 0.93 ( 0.64, 1.35) 0.5 
Asymptomatic bacteriuria
Asymptomatic bacteriuria (GBS)
Moller 0.96 ( 0.93, 0.99) 34.7
McDonald 0.96 ( 0.88, 1.04) 8.6 
White 0.99 ( 0.98, 1.01) 56.8
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
2.63 ( 1.54, 4.50) 4.7 
1.91 ( 1.15, 3.19) 4.9 
2.63 ( 1.16, 5.96) 3.0 
0.85 ( 0.37, 1.97) 2.9 
1.14 ( 0.83, 1.56) 6.6 
1.00 ( 0.57, 1.76) 4.5 
2.01 ( 1.02, 3.97) 3.8 
1.40 ( 1.24, 1.57) 8.0 
2.28 ( 0.94, 5.55) 2.7 
0.10 ( 0.01, 1.70) 0.4 
3.24 ( 2.16, 4.87) 5.8 
0.71 ( 0.10, 5.21) 0.7 
2.04 ( 1.30, 3.21) 5.4 
2.20 ( 1.21, 3.99) 4.3 
0.89 ( 0.37, 2.10) 2.8 
0.87 ( 0.13, 6.06) 0.8 
3.83 ( 2.22, 6.59) 4.7 
2.64 ( 1.36, 5.11) 3.9 
0.90 ( 0.54, 1.49) 5.0 
1.00 ( 0.58, 1.72) 4.7 
0.98 ( 0.61, 1.58) 5.2 
1.59 ( 1.22, 2.08) 7.0 
0.78 ( 0.24, 2.49) 1.8 
1.07 ( 0.77, 1.49) 6.4 
2.68 ( 1.51, 4.76) 47 
2.14 ( 0.77, 5.93) 14.9 
1.52 ( 0.80, 2.86) 38.1
 
*Studies are in descending order of quality 
a. Caucasian population, b. Bangladeshi population 
χ2 heterogeneity test for asymptomatic bacteriuria p = 0.0019 for LR+ and p = 0.0026 for LR-; for asymptomatic bacteriuria (GBS) p = 0.42 for LR+ and p = 0.16 for LR- 
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Figure 68 Plot of sensitivity against specificity including summary values of the accuracy of asymptomatic 
bacteriuria assessment in asymptomatic women as a predictor of spontaneous preterm birth before 37 
weeks’ gestation 
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Figure 69 Funnel plot analysis of the accuracy of asymptomatic bacteriuria assessment in asymptomatic 
women as a predictor of spontaneous preterm birth before 37 weeks’ gestation 
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Bacterial vaginosis (BV) 
BV is a condition in women where the normal balance of bacteria in the vagina is disrupted 
and replaced by an overgrowth of anaerobic bacteria. The condition has been purported to 
predispose to spontaneous preterm birth. The condition can be tested by taking high vaginal 
swab specimen during speculum examination for either clinical evaluation (Amsel criteria),279 
Gram staining (Nugent280 or Spiegel281 criteria), or standard microbiological culture.  
Study characteristics and quality 
There were 25 primary studies (n = 35,652 women) on the accuracy of BV testing, 
comprising of 17 studies on asymptomatic antenatal women (n = 33,628)92;282-298 and 8 studies 
on symptomatic women who presented with threatened preterm labour (n = 2,024)232;299-305. 
Table 44 summarizes each study’s salient features, stratified according to population of 
women tested, i.e. asymptomatic antenatal women and women with symptoms of threatened 
preterm labour. The studies’ enrolment ranged from 103 to 12,937 women282;284 with a 
median of 646 women in asymptomatic population and from 87 to 753 women232;299 with a 
median of 211 women.  
There were no studies included within the systematic review of the accuracy of BV testing in 
predicting spontaneous preterm births that fulfil the ideal definition of high quality test 
accuracy studies. Blinding of carers to the results of BV tests were often absent from studies 
on asymptomatic282;285-290 and symptomatic women.232;299;301-303 For symptomatic women, six 
studies had used case-control design to assess the accuracy of BV testing in predicting 
spontaneous preterm births in symptomatic women.232;299;301;303-305 The methodological quality 
of the included primary studies is summarized in Figure 70.  
The commonly used criterion to diagnose BV was Gram staining using Nugent’s criteria in 
the included studies, otherwise the other two methods that were used infrequently included 
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Gram staining using Spiegel’s232;301;305 and bedside diagnosis using Amsel’s clinical 
criteria.92;283;290;303 Three studies evaluated the accuracy or serial BV testing in asymptomatic 
pregnant women for predicting spontaneous preterm births289;291;292 while the remainders 
evaluated a single BV testing, usually performed at mid-trimester.92;282;284-287;289;291-295  
One study in asymptomatic antenatal women collected data for prediction of spontaneous 
preterm births at 23 – 26 weeks’ gestation but which was not published.284 Otherwise, most 
studies reported births before 37 weeks’ gestation as their reference standards with two 
exceptions; a study used birth before 32 and 34 weeks’ gestation as their reference standard287 
whilst another study used birth 35 weeks’ gestation as its reference standard.288 Similarly, for 
symptomatic women, the most commonly used reference standard was births before 37 
weeks’ gestation, except for 3 studies that reported births within 7 days of testing and before 
33 weeks’ gestation,300 birth before 34 weeks’ gestation232 and births before 35 weeks’ 
gestation.302 One studies reported birth within 7 days of testing.300  
Accuracy of BV in asymptomatic women 
For predicting spontaneous preterm birth before 37 weeks’ gestation, a single BV testing 
(using Nugent’s criterion) had a range of LR+ from 0.49 (95% CI 0.07 - 3.16) to 5.31 (95% 
CI 3.84 - 7.33) with a summary LR+ of 1.77 (95% CI 1.03 to 3.03) (χ2 heterogeneity test p = 
0.0033) and a range of LR- from 0.32 (95% CI 0.23 – 0.43) to 1.15 (95% CI 0.90 – 1.48) with 
a summary LR- of 0.80 (95%CI 0.69 – 0.93) (χ2 heterogeneity test p = 0.0029) (Figure 71). 
LR+ 0.80 (95% CI 0.38 - 1.72) and LR- 1.04 (95% CI 0.92 - 1.17) represented LR from the 
sole ideal quality study.285 For predicting spontaneous preterm birth before 37 weeks’ 
gestation, serial BV testing (using Nugent’s criterion) had a range of LR+ from 1.15 (95% CI 
0.67 - 1.96) to 1.92 (95% 0.63 – 5.92) with a summary LR+ of 1.38 (95% CI 0.92 – 2.07) (χ2 
heterogeneity test p = 0.56) and a range of LR- from 0.87 (95% 0.49 – 1.56) to 0.94 (95% 
0.85 -1.04) with a summary LR- of 0.94 (95% 0.86 – 1.02) (χ2 heterogeneity test p = 0.96) 
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(Figure 72). The largest higher quality study has LR+ 1.92 (95% CI 0.63 - 5.92) and LR- 0.93 
(95% CI 0.79 - 1.10).292 For predicting spontaneous preterm birth before 37 weeks’ gestation, 
a single BV testing (using Amsel’s clinical criterion) had a range of LR+ from 0.87 (95% CI 
0.48 – 1.59)283 to 1.62 (95% CI 0.44 – 5.91)92 (χ2 heterogeneity test p = 0.67) and LR- from 
0.90 (95% CI 0.63 – 1.29)92 to 1.02 (95% CI 0.93 – 1.12) (χ2 heterogeneity test p = 0.79) 
(Figure 75).283 Figure 73 showed plot of sensitivities and specificities and their summary 
estimates for the accuracy of a single 2nd trimester BV testing using Nugent’s criteria in 
asymptomatic pregnant women as a predictor of spontaneous preterm birth before 37 weeks’ 
gestation while Figure 74 did not show asymmetry in the funnel plot analysis in this group. 
Individual accuracy results can be found in Table 45. 
Accuracy of BV in symptomatic women 
For predicting spontaneous preterm birth before 37 weeks’ gestation, BV testing (using 
Nugent’s criterion) had a range of LR+ from 0.91 (95% CI 0.57 - 1.45) to 1.86 (95% CI 1.31 - 
2.65) with a summary LR+ of 1.28 (95% CI 0.72 to 2.20) (χ2 heterogeneity test p = 0.04) and 
a range of LR- from 0.89 (95% CI 0.84 – 0.95) to 1.04 (95% CI 0.87 – 1.23) with a summary 
LR- of 0.95 (95%CI 0.86 – 1.05) (χ2 heterogeneity test p = 0.10) (Figure 76). For predicting 
spontaneous preterm birth before 37 weeks’ gestation, BV testing (using Spiegel’s criterion) 
had a range of LR+ from 1.00 (95% 0.76 – 1.32) to 3.68 (95% CI 1.13 - 11.97) with a 
summary LR+ of 1.30 (95% CI 0.95 – 1.77) (χ2 heterogeneity test p = 0.25) and a range of 
LR- from 0.66 (95% 0.46 – 0.96) to 1.00 (95% 0.73 -1.36) with a summary LR- of 0.94 (95% 
0.87 – 1.01) (χ2 heterogeneity test p = 0.04) (Figure 76). Individual accuracy results can be 
found in Table 45. 
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Figure 70 Methodological quality of studies included in the systematic review of accuracy of bacterial 
vaginosis (BV) testing in predicting spontaneous preterm birth among asymptomatic antenatal women 
and symptomatic women who presented with threatened preterm labour. Data presented as 100% stacked 
bars. Figures in the stacks represent number of studies. 
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Figure 71 Forest plots of likelihood ratios (LR’s) of a single 2nd trimester bacterial vaginosis (BV) testing 
using Nugent’s criteria in asymptomatic pregnant women as a predictor of spontaneous preterm birth 
before 37 weeks’ gestation 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
0.80 ( 0.38, 1.72) 7.8 
0.49 ( 0.07, 3.16) 4.4 
1.74 ( 1.08, 2.82) 8.6 
1.42 ( 1.07, 1.90) 9.0 
2.44 ( 1.68, 3.54) 8.9 
1.26 ( 0.62, 2.57) 8.0 
5.15 ( 4.53, 5.86) 9.2 
1.57 ( 1.20, 2.06) 9.1 
5.31 ( 3.84, 7.33) 9.0 
0.95 ( 0.75, 1.20) 9.1 
1.66 ( 1.04, 2.64) 8.7 
2.07 ( 1.06, 4.05) 8.1 
1.77 ( 1.03, 3.03) 100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Oakeshott 1.04 ( 0.92, 1.17) 10.0 
Crane 1.15 ( 0.90, 1.48) 8.2 
DeSeta 0.85 ( 0.71, 1.02) 9.3 
Govender 0.61 ( 0.36, 1.01) 4.7 
Gratacos 0.69 ( 0.53, 0.89) 8.1 
Helou 0.96 ( 0.82, 1.12) 9.6 
Hillier 0.32 ( 0.23, 0.43) 7.3 
Klebanoff 0.94 ( 0.90, 0.98) 10.7 
Purwar 0.54 ( 0.42, 0.71) 8.1 
Balu 1.02 ( 0.93, 1.13) 10.2 
Riduan 0.88 ( 0.75, 1.02) 9.7 
Mascagni 0.66 ( 0.37, 1.17) 4.1 
Overall 0.80 ( 0.69, 0.93) 100.0 
 
χ2 heterogeneity test for Nugent’s criteria p = 0.0033 for LR+ and p = 0.0029 for LR- 
 
Figure 72 Forest plots of likelihood ratios (LR’s) of serial bacterial vaginosis (BV) testing using Nugent’s 
criteria in asymptomatic pregnant women as a predictor of spontaneous preterm birth before 37 weeks’ 
gestation 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
1.15 ( 0.67, 1.96) 56.6 
1.92 ( 0.63, 5.92) 12.8 
1.70 ( 0.82, 3.52) 30.5 
1.38 ( 0.92, 2.07) 100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Gratacos 0.87 ( 0.49, 1.56) 2.1 
Helou 0.93 ( 0.79, 1.10) 27.9 
Riduan 0.94 ( 0.85, 1.04) 70.0 
Overall 0.94 ( 0.86, 1.02) 100.0 
 
χ2 heterogeneity test for Nugent’s criteria p = 0.56 for LR+ and p = 0.96 for LR- 
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Figure 73 Plot of sensitivity against specificity including summary values of the accuracy of a single 2nd 
trimester bacterial vaginosis (BV) testing using Nugent’s criteria in asymptomatic pregnant women as a 
predictor of spontaneous preterm birth before 37 weeks’ gestation 
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Figure 74 Funnel plot analysis of accuracy studies evaluating the accuracy of a single 2nd trimester 
bacterial vaginosis (BV) testing using Nugent’s criteria in asymptomatic pregnant women as a predictor of 
spontaneous preterm birth before 37 weeks’ gestation 
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Figure 75 Forest plots of likelihood ratios (LR’s) of a single 2nd trimester bacterial vaginosis (BV) testing 
using Amsel’s criteria in asymptomatic pregnant women as a predictor of spontaneous preterm birth 
before 37 weeks’ gestation 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
1.62 ( 0.44, 5.91) 8.0 
0.87 ( 0.53, 1.43) 54.6 
0.87 ( 0.48, 1.59) 37.4 
0.92 ( 0.64, 1.32) 100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Crane 0.90 ( 0.63, 1.29) 2.6 
Thorsen 1.02 ( 0.95, 1.10) 56.6 
Cauci 1.02 ( 0.93, 1.12) 40.8 
Overall 1.02 ( 0.96, 1.08) 100.0 
 
χ2 heterogeneity test for Nugent’s criteria p = 0.67 for LR+ and p = 0.79 for LR- 
 
Figure 76 Forest plots of likelihood ratios (LR’s) of bacterial vaginosis (BV) testing in symptomatic 
women as a predictor of spontaneous preterm birth before 37 weeks’ gestation 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
0.99 ( 0.37, 2.64) 100.0 
1.00 ( 0.36, 2.76) 19.0 
1.86 ( 1.31, 2.65) 43.1 
0.91 ( 0.57, 1.45) 37.9 
1.22 ( 0.77, 1.94) 100.0 
3.68 ( 1.13, 11.97) 15.0 
1.53 ( 0.97, 2.41) 38.5 
1.00 ( 0.76, 1.32) 46.6 
1.43 ( 0.84, 2.45) 100.0 
Likelihood ratio (LR) for negative test
0.1 0 .2 0.5 1 2
Study
LR-
(95% CI) % Weight
Subtil 1.00 ( 0.86, 1.17) 100.0 
Goffinet 1.00 ( 0.88, 1.13) 30.9 
Carlini 0.89 ( 0.84, 0.95) 43.1 
Krohn 1.04 ( 0.87, 1.23) 37.9 
Overall 0.96 ( 0.88, 1.04) 100.0 
Amsel
Nugent
Holst 0.66 ( 0.46, 0.96) 21.3 
Martius 0.85 ( 0.69, 1.03) 49.9 
Elliot 1.00 ( 0.73, 1.36) 28.8 
Overall 0.84 ( 0.70, 1.02) 100.0 
Spiegel
 
χ2 heterogeneity test for Nugent’s criteria p = 0.04 for LR+ and p = 0.10 for LR-; for Spiegel’s criteria p = 0.25 for LR+ and p = 0.04 for LR- 
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Mammary stimulation test 
Antenatal mammary stimulation test is a provocative test of uterine contractility, which 
purported to identify asymptomatic women at high risk for spontaneous preterm birth. The 
presence of easily provoked uterine contractility supposed to be an indication of higher risk of 
spontaneous preterm birth. 
Study characteristics and quality 
There were 2 studies evaluating mammary stimulation test, both in asymptomatic antenatal 
women (n = 341).306;307 Both studies enrolled their population at the early third trimester. One 
study evaluated the accuracy in predicting spontaneous preterm birth before 34 weeks’ 
gestation307 while both evaluated the accuracy for prediction before 37 weeks’ gestation. 
None of the studies fulfilled the criteria for ideal quality study with consecutive enrolment 
being absent from both studies. Figure 77 summarizes the methodological quality of the 
included study. Both studies used the same test threshold. Individual study characteristics can 
be found in Table 46 
Figure 77 Methodological quality of studies included in the systematic review of accuracy of mammary 
stimulation test in asymptomatic women for predicting spontaneous preterm birth. Data presented as 
100% stacked bars. Figures in the stacks represent number of studies. 
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Accuracy of mammary stimulation test in asymptomatic women 
For predicting spontaneous preterm birth before 34 weeks’ gestation, mammary stimulation 
test had an LR+ 4.63 (95% CI 2.95 - 7.25) and LR- 0.27 (0.08 - 0.91).307 For predicting 
spontaneous preterm birth before 37 weeks’ gestation mammary stimulation test had a range 
of LR+ from 2.04 (95% CI 1.45 - 2.84)306 to 3.30 (95% CI 1.54 – 7.08)307 and LR- from 0.23 
(0.06 – 0.85)306 for those with high Creasy risk score to 0.49 (0.17 – 1.43) (Figure 78).307 The 
largest higher quality study was Guinn et al.307 Individual accuracy results can be found in 
Table 47. 
 
Figure 78 Forest plots of likelihood ratios (LR’s) of mammary stimulation test as a predictor of 
spontaneous preterm birth in asymptomatic women stratified according to outcome 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI)
4.63 ( 2.95, 7.25)
3.30 ( 1.54, 7.08)
2.04 ( 1.46, 2.84)
2.25 ( 1.71, 2.95)
2.54 ( 1.38, 4.68)
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI)
Guinn 0.27 ( 0.08, 0.91)
Guinn 0.49 ( 0.17, 1.43)
Eden 0.27 ( 0.09, 0.77)
Eden 0.07 ( 0.00, 1.02)
Eden* 0.23 ( 0.06, 0.85)
<37 weeks
<34 weeks
<5 days of testing
 
*High-risk women according Creasy’ risk scoring system 
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Uterine activity monitoring 
Presence of increasingly co-ordinated, frequent and progressively stronger uterine activities 
often preceded the development of labour. It was thus purported that if uterine activities may 
be monitored, advance warning of impending onset of labour, whether at term or specifically 
preterm may be predicted. 
Study characteristics and quality 
There were 4 studies evaluating uterine activities, 2 asymptomatic antenatal women (n = 370) 
and 2 in symptomatic women with threatened preterm labour (n = 114).69;308-310 3 studies 
utilized tocograph while 1 utilized emerging technology electromyographic recording of 
uterine activities.310 There was no consensus on threshold defining abnormality. Aside from 
one study which used birth before 35 weeks’ gestation as its outcome,69 the remaining study 
used birth before 37 weeks’ gestation. None of the studies fulfilled the criteria for ideal 
quality study, consecutive enrolment was absent from any of the studies and blinding were 
absent from three studies. Figure 79 summarizes the methodological quality of the included 
study. Individual study characteristics are summarized in Table 48. 
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Figure 79 Methodological quality of studies included in the systematic review of of home uterine activity 
monitoring in predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in the 
stacks represent number of studies. 
 
Asymptomatic women
1
2
2
2
1
2
Blinding
Adequate test description
Consecutive recruitment
Prospective design
Cohort
 
Symptomatic women
2
1
2
2
2
1
Blinding
Adequate test description
Consecutive recruitment
Prospective design
Cohort
Yes No, unclear or unreported
 
 
 
 
142
Accuracy of uterine activity monitoring in asymptomatic women 
For predicting spontaneous preterm birth, uterine activity monitoring had a range of LR+ 
from 0.51 (95% CI 0.03 - 9.24)69 when the threshold was set for detection of significant 
uterine activities during the day time, to 4.90 (95% CI 2.99 - 8.04)309 when 4 significant 
contractions were detected within an hour period, and a range of LR- from 0.15 (95% CI 0.04 
- 0.56)309 when 4 significant contractions were detected within an hour period to 1.01 (95% CI 
0.98 - 1.05)69 for detection of significant uterine activities during the day time. The higher 
quality study from Iams et al has LR+ 2.41 (95% CI 0.76 - 7.68) and LR- 0.95 (95% CI 0.86 - 
1.04).69 Figure 80 summarized the accuracy results while Table 49 showed individual 
accuracy results for each study. 
Accuracy of uterine activity monitoring in symptomatic women 
For predicting spontaneous preterm birth before 37 weeks’ gestation, uterine activity 
monitoring had a range of LR+ from 4.13 (95% CI 1.04 - 16.32)308 to 10.40 (95% CI 3.34 - 
32.38)310 and a range of LR- from 0.31 (95% CI 0.05 - 1.71)308 to 0.48 (95% CI 0.34 - 0.67)310 
when using tocographic and electromyographic recording respectively. Bell et al represented 
the higher quality study available.308 Figure 80 summarized the accuracy results while Table 
49 showed individual accuracy results for each study. 
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Figure 80 Forest plots of likelihood ratios (LR’s) of uterine activity monitoring as a predictor of 
spontaneous preterm birth before 37 weeks’ gestation* stratified according to populations 
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Iamsb 1.01 ( 0.98, 1.05)
Maner 0.48 ( 0.34, 0.67)
Bell 0.31 ( 0.05, 1.71)
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a. Uterine activities at night-time, b. uterine activities in day-time 
*. Unless otherwise stated 
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Rheobase 
Rheobase in the context of a test to predict spontaneous preterm birth is measurement of the 
minimum strength of an electrical stimulus (electrical current) of that is able to cause 
excitation of a muscle, e.g. tibialis anterior muscle in symptomatic women with threatened 
preterm labour, which would show a higher threshold compared to a quiescent uterus. Mass 
electrical uterine activities in a genuine spontaneous labour would require greater electrical 
current to generate muscular excitation in genuine case of threatened preterm labour 
(compared to the relatively smaller current required when uterus is quiescent) and hence the 
purported ability of rheobase to predict spontaneous preterm birth in symptomatic women 
with threatened preterm labour by measuring these greater electrical current. 
Study characteristics and quality 
There was only one study evaluating rheobase in symptomatic women with threatened 
preterm labour (n = 176).311 Two different thresholds were evaluated (2.8 and 3.4 mA) and 
outcome of spontaneous preterm birth before 37 weeks’ gestation was used. The study 
characteristics can be found Table 50. Methodological quality was summarized in Figure 81. 
Accuracy of rheobase measurement in symptomatic women 
Depending on the thresholds being used, rheobase had an LR+ that ranged from 2.29 (95% CI 
1.50 to 3.52) when 2.8 mA was used to 2.36 (95% CI 1.73 to 3.20) when 3.4 mA was used, 
and an LR- that ranged from 0.36 (95% CI 0.19 to 0.66) when 3.4 mA was used to 0.60 (95% 
CI 0.41 to 0.88) when 2.8 mA was used (Figure 82). Individual accuracy results were 
summarized in Table 51. 
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Figure 81 Methodological quality of studies included in the systematic review of accuracy of rheobase 
testing in predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in the 
stacks represent number of studies 
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Figure 82 Forest plots of likelihood ratios (LR’s) of rheobase measurement as a predictor of spontaneous 
preterm birth in symptomatic women stratified according to thresholds 
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Absence of fetal breathing movements on ultrasound 
A decrease in fetal breathing movements observed during a 20 minutes observation with real-
time ultrasound at the time of admission for threatened preterm labour has been purported to 
be a predictor of progression to spontaneous preterm birth.312 
Study characteristics and quality 
There were 8 primary accuracy articles that met the selection criteria, which included a total 
of 328 women.85;312-318 (Table 52). All of them evaluated fetal breathing movements for a 
sustained period of 15-20 seconds in a 30-45 minute period with real time ultrasound. The 
absence of breathing movements, defined when no sustained fetal breathing movements were 
noted in the time period, indicated a positive result. In all the studies, the test was carried out 
once, on the delivery suite, at the time of admission. All the studies were of small size, with 
enrolment ranging from 24312 to 70318 women. One study fulfilled the ideal quality criteria.85 
Methodological quality was summarized in Figure 83. 
Accuracy of absence of fetal breathing movement in symptomatic 
women 
For predicting preterm birth within 48 hours (Figure 84) and within 7 days of testing (Figure 
85), there was a wide variation in the accuracy results. Statistical heterogeneity was not 
detected in the accuracy results of positive test for birth within 7 days of testing (χ2 
heterogeneity test p = 0.57) and of negative test for birth within 48 hours of testing (χ2 
heterogeneity test p=0.64). However, within each reference standard sub-group, the studies 
were of variable methodological quality and heterogeneity was present for the corresponding 
negative and positive LR’s respectively. The ideal quality study from Senden et al,85 showed a 
LR+ of 4.00 (95% confidence interval (CI) 0.73 - 21.84) and a LR- of 0.67 (95% CI 0.32 - 
1.38) for predicting spontaneous preterm birth within 7 days of testing (Figure 85). For 
predicting preterm birth within 48 hours of testing, where the studies were lacking in one or 
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more ideal quality features, the LR for a positive test estimated from a better quality study 
was LR+ 16.08 (95% CI 5.22 - 49.55) and for a negative test of LR- 0.16 (95% CI 0.05 - 
0.58)318 (Figure 84). Figure 86 Individual accuracy results from the included studies are 
summarized in Table 53.  
Figure 83 Methodological quality of studies included in the systematic review of the accuracy of fetal 
breathing movements in predicting spontaneous preterm birth. Data presented as 100% stacked bars. 
Figures in the stacks represent number of studies. 
 
Symptomatic women
1
8
2
6
8
7
6
2
Blinding
Adequate test description
Consecutive recruitment
Prospective design
Cohort
Yes No, unclear or unreported
 
 
 
 
148
Figure 84 Forest plots of likelihood ratios (LR’s) for the absence of fetal breathing movements in 
predicting spontaneous preterm birth within 48 hours of testing in women presenting with threatened 
preterm labour* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
16.08 ( 5.22, 49.55)34.5 
18.69 ( 2.64, 132.33)28.0 
2.11 ( 1.11, 4.00) 37.5 
7.84 ( 1.12, 54.99)100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Schreyer 0.16 ( 0.05, 0.58) 25.3 
Besinger 0.32 ( 0.14, 0.72) 61.6 
Kanaan 0.32 ( 0.05, 1.90) 13.1 
Overall 0.27 ( 0.14, 0.51) 100.0 
 
*χ2 heterogeneity test = 17.44, p = 0.00 for LR+ and χ2 = 0.89, p = 0.64 for LR- 
+Studies are arranged in descending order of methodological quality 
 
Figure 85 Forest plots of likelihood ratios (LR’s) for the absence of fetal breathing movements in 
predicting spontaneous preterm birth within 7 days of testing in women presenting with threatened 
preterm labour* 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
4.00 ( 0.73, 21.84) 25.3 
20.25 ( 5.05, 81.23)37.8 
24.75 ( 1.55, 396.04)9.5 
15.00 ( 0.77, 292.61)8.3 
37.19 ( 2.33, 593.09)9.5 
32.69 ( 2.04, 522.93)9.5 
14.80 ( 6.30, 34.79)100.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Senden 0.67 ( 0.32, 1.38) 15.6 
Schreyer 0.26 ( 0.11, 0.61) 13.8 
Castle 0.32 ( 0.11, 0.90) 11.4 
Devoe 0.82 ( 0.63, 1.07) 22.8 
Agustsson 0.46 ( 0.31, 0.67) 21.2 
Markwitz 0.35 ( 0.17, 0.75) 15.3 
Overall 0.47 ( 0.29, 0.76) 100.0 
 
*χ2 heterogeneity test = 3.84, p = 0.57 for LR+ and χ2 = 21.10, p = 0.0013 for LR- 
+Studies are arranged in descending order of methodological quality 
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Figure 86 Plot of sensitivity against specificity including summary values of the absence of fetal breathing 
movements in predicting spontaneous preterm birth within 7 days of testing in women presenting with 
threatened preterm labour 
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Cervical ultrasound assessment 
Antenatal cervical length shortening319 and opening of the internal os (funnelling)320 has been 
purported to increase the risk in asymptomatic women and the likelihood of spontaneous 
preterm birth in women who presented with threatened spontaneous preterm labour.  
Study characteristics and quality 
There were a total of 31 studies comprising 13 primary studies on asymptomatic women (n = 
21555 women)59;321-332 and 19 primary studies (n = 2849 women)57;75;106;223;235;333-347 on 
symptomatic women with threatened preterm labour evaluating the accuracy of transvaginal 
ultrasound measurement of cervical length in predicting spontaneous preterm birth. Table 54 
and Table 55 summarized individual study characteristics of the included studies of cervical 
length measurement in predicting spontaneous preterm birth, evaluating antenatal 
asymptomatic women and women with threatened preterm labour respectively.  
Additionally, there were 11 studies, comprising 6 primary studies on asymptomatic women (n 
= 12855 women)319;322;326;327;329;331 and 5 primary studies (n = 509 women)223;320;333;337;340 on 
the accuracy of symptomatic women with threatened preterm labour evaluating the accuracy 
of transvaginal ultrasound assessment and measurement of cervical funnelling in predicting 
spontaneous preterm birth. Table 56 summarized individual study characteristics of the 
included studies of cervical funnelling assessment in predicting spontaneous preterm birth 
among asymptomatic antenatal women and symptomatic women with threatened preterm 
labour. 
There was a wide variation in gestation at which ultrasound cervical length measurement was 
carried out in asymptomatic antenatal women and the definition for thresholds of abnormality. 
The most common gestation at which ultrasound measurement of cervical length was carried 
was in the late second trimester, between 20 – 24 weeks’ gestation. The most common 
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threshold used in asymptomatic women was 25mm at this gestation and was evaluated in 2 
ideal quality studies.319;322 The outcome frequently used by studies on asymptomatic women 
was 37 weeks’ gestation but amongst ideal quality studies, the outcome frequently used was 
spontaneous preterm birth before 34 weeks’ gestation. Among symptomatic women, the most 
common threshold used was 15mm and the most common outcome used was spontaneous 
preterm birth within 7 days of testing using this threshold. 
There were 5 studies on asymptomatic women322;323;326;328;332 and 2 studies on symptomatic 
women on cervical length measurement that fulfilled ideal definition of high quality 
study333;337 and 3 studies on asymptomatic women319;322;326 and 2 studies on symptomatic 
women evaluating cervical funnelling that fulfilled ideal definition of high quality study.333;337 
The methodological quality of the included primary studies is summarized in Figure 87.  
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Figure 87 Methodological quality of studies included in the systematic review of accuracy of cervical 
length in predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures in the 
stacks represent number of studies. 
 
Asymptomatic women
6
13
9
12
12
7
4
1
1
Blinding
Adequate test description
Consecutive recruitment
Prospective design
Cohort
 
Symptomatic women
10
19
3
18
19
9
16
1
Blinding
Adequate test description
Consecutive recruitment
Prospective design
Cohort
Yes No, unclear or unreported
 
 
 
 
153
Accuracy of cervical length and funnelling in asymptomatic women 
When cervical length measurement was performed before 20 weeks’ gestation using a 
threshold of 25 mm (commonest threshold evaluated at this gestation) for predicting 
spontaneous preterm birth before 34 weeks’ gestation, it had sLR+ of 13.38 (95% CI 6.90 - 
25.96) (χ2 heterogeneity test p = 0.07) and sLR- of 0.80 (95% CI 0.71 - 0.90) (χ2 
heterogeneity test p = 0.91).322;326;328 Figure 88 showed forest plot of ideal quality studies for 
cervical length measurement before 20 weeks’ gestation in predicting spontaneous preterm 
birth before 34 weeks’ gestation in asymptomatic antenatal women. When performed between 
20 -24 weeks’ gestation, again using a threshold of 25mm (commonest threshold evaluated at 
this gestation) it had sLR+ 4.68 (95% CI 3.64 - 6.03) (χ2 heterogeneity test p = 0.54) and 
sLR- 0.68 (95% CI 0.60 - 0.78) (χ2 heterogeneity test p = 0.93).319;322 Cervical funnelling 
screening in asymptomatic had variable LR’s depending on the chosen threshold (some 
studies did not indicate their threshold, merely indicating presence of the ‘funnelling’ 
appearance on ultrasound imaging) (Figure 92). LR+ 4.63 (95% CI 3.31 - 6.48) and LR- 0.79 
(95% CI 0.71 - 0.87) from Iams et al using 5mm protrusion of amniotic membrane into the 
cervical canal as their threshold as predictor for spontaneous preterm birth before 34 weeks’ 
gestation represented higher quality study available for this threshold and reference 
standard.319 
There was no more than a single study of small sample size for any of the evaluated threshold 
for cervical measurement performed before 20 weeks’ gestation in predicting spontaneous 
preterm birth before 37 weeks (Figure 90). When cervical length was measured between 20 – 
24 weeks’ gestation for predicting before 37 week’s gestation (Figure 91) using threshold of 
32.5mm, it had an LR+ of 3.99 (95% CI 2.84 - 5.62) and LR- of 0.33 (95% CI 0.17 - 0.66).332 
Individual accuracy results are summarized in Table 57 and Table 59. 
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Accuracy of cervical length and funnelling in symptomatic women 
For predicting spontaneous preterm birth within 48 hours of testing, cervical length 
measurement in symptomatic women with threatened preterm labour had a variable LR’s 
depending on the threshold abnormality chosen (Figure 93). LR+ 6.43 (95% CI 5.17 - 8.00) 
and LR- 0.027 (95% CI 0.0017 - 0.42) from Tsoi et al represented higher quality study 
available for the relatively more common threshold used (15 mm) and reference standard 
(birth within 48 hours of testing).346 For predicting spontaneous preterm birth within 7 days of 
testing, cervical length measurement in symptomatic women with threatened preterm labour 
had a variable LR’s depending on the threshold abnormality chosen (Table 58). Figure 94 
showed the forest plot of LR’s for the most commonly used threshold (<15mm) for the 
reference standard of spontaneous preterm birth within 7 days of testing. LR+ 8.61 (95% CI 
6.65 - 11.14) and LR- 0.026 (95% CI 0.0038 - 0.182) from Tsoi et al represented higher 
quality study available for the aforementioned threshold and reference standard.346  
For predicting spontaneous preterm birth before 34 weeks’ gestation, cervical length 
measurement in symptomatic women with threatened preterm labour had a variable LR’s 
depending on the threshold abnormality chosen (Table 58). Figure 95 showed the forest plot 
of LR’s for the most commonly used threshold (<30mm) for the reference standard of 
spontaneous preterm birth before 34 weeks’ gestation. LR+ 1.879 (95% CI 1.36 – 2.59) and 
LR- 0.30 (95% CI 0.083 – 1.07) from Crane et al represented the ideal quality study available 
for the aforementioned threshold and reference standard.333 For predicting spontaneous 
preterm birth before 37 weeks’ gestation, cervical length measurement in symptomatic 
women with threatened preterm labour had a variable LR’s depending on the threshold 
abnormality chosen (Figure 95). LR+ 3.36 (95% CI 1.73 - 6.54) and LR- 0.35 (95% CI 0.17 - 
0.70) from Gomez et al with threshold of <18mm and LR+ 2.29 (1.68 - 3.12 & LR- 0.29 
(95% CI 0.15 - 0.58) from Crane et al with threshold of <30mm represented ideal quality 
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study available for the reference standard.333 Cervical funnelling screening in symptomatic 
had variable LR’s depending on the chosen threshold (some studies did not indicate their 
threshold, merely indicating presence of the funnelling appearance on ultrasound imaging) 
(Figure 97). LR+ 4.70 (95% CI 1.90 - 11.66) and LR- 0.61 (95% CI 0.34 - 1.10) for 
predicting spontaneous preterm birth before 34 weeks’ gestation and LR+ 2.53 (95% CI 1.02 - 
6.25) and LR- 0.86 (95% CI 0.71 – 1.03) for predicting spontaneous preterm birth before 37 
weeks’ gestation from Crane et al using the presence of ‘V-shaped’ ultrasonographic 
appearance as threshold for funnelling represented ideal quality study available for this 
threshold and reference standard in symptomatic women. 333 Individual accuracy results for 
cervical length and funnelling measurement symptomatic women can be found in Table 58 
and Table 59. 
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Figure 88 Forest plots of likelihood ratios (LR’s) from ideal quality studies for cervical length 
measurement before 20 weeks’ gestation (listed in ascending order of thresholds of abnormality) in 
predicting spontaneous preterm birth before 34 weeks’ gestation in asymptomatic antenatal women  
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
698.33 ( 34.56, 14109.00) 4.2 
30.53 ( 1.72, 542.02) 4.5 
73.30 ( 14.23, 377.66) 8.0 
14.47 ( 1.73, 120.69) 6.4 
21.94 ( 1.25, 384.29) 4.5 
15.27 ( 6.80, 34.30) 11.1 
8.44 ( 2.38, 29.88) 9.4 
26.81 ( 1.57, 457.07) 4.6 
9.25 ( 4.95, 17.26) 11.7 
3.56 ( 1.94, 6.54) 11.7 
1.73 ( 0.95, 3.15) 11.7 
1.72 ( 1.20, 2.47) 12.3 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Leung 15mm 0.88 ( 0.75, 1.03) 10.9 
Owen 15mm 0.89 ( 0.81, 0.98) 18.4 
Leung 20mm 0.90 ( 0.78, 1.04) 12.1 
Owen 20mm 0.90 ( 0.81, 0.99) 18.4 
Andrew 22mm 0.73 ( 0.53, 0.99) 3.7 
Leung 25mm 0.76 ( 0.59, 0.98) 5.3 
Owen 25mm 0.83 ( 0.72, 0.95) 12.9 
Andrew 25mm 0.66 ( 0.47, 0.95) 2.9 
Leung 27mm 0.68 ( 0.49, 0.93) 3.5 
Leung 30mm 0.72 ( 0.52, 0.99) 3.5 
Owen 30mm 0.85 ( 0.69, 1.05) 7.1 
Leung 35mm 0.61 ( 0.36, 1.05) 1.3 
 
 
Figure 89 Forest plots of likelihood ratios (LR’s) from ideal quality studies for cervical length 
measurement between 20 - 24 weeks’ gestation (listed in ascending order of thresholds of abnormality) in 
predicting spontaneous preterm birth before 34 weeks’ gestation in asymptomatic antenatal women 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
7.64 ( 5.21, 11.20) 23.9 
4.51 ( 1.15, 17.64) 10.8 
4.77 ( 3.68, 6.19) 25.3 
3.38 ( 1.16, 9.91) 13.9 
2.28 ( 1.91, 2.71) 26.1 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Iams 20mm 0.79 ( 0.72, 0.87) 33.5 
Andrews 22mm 0.74 ( 0.51, 1.08) 9.4 
Iams 25mm 0.68 ( 0.59, 0.78) 28.3 
Andrews 25mm 0.69 ( 0.45, 1.08) 7.1 
Iams 30mm 0.60 ( 0.50, 0.73) 21.7 
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Figure 90 Forest plots of likelihood ratios (LR’s) from ideal quality studies for cervical length 
measurement before 20 weeks’ gestation (listed in ascending order of thresholds of abnormality) in 
predicting spontaneous preterm birth before 37 weeks’ gestation in asymptomatic antenatal women 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
8.74 ( 3.82, 19.96) 20.5 
5.87 ( 3.27, 10.53) 24.4 
3.77 ( 2.55, 5.56) 27.4 
1.86 ( 1.30, 2.66) 27.8 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Hibbard 22mm 0.88 ( 0.81, 0.96) 37.0 
Hibbard 27mm 0.83 ( 0.74, 0.92) 33.5 
Hibbard 30mm 0.73 ( 0.63, 0.85) 27.4 
Andersen 39mm 0.40 ( 0.17, 0.96) 2.1 
 
 
Figure 91 Forest plots of likelihood ratios (LR’s) from ideal quality studies for cervical length 
measurement between 20 – 24 weeks’ gestation (listed in ascending order of thresholds of abnormality) in 
predicting spontaneous preterm birth before 37 weeks’ gestation in asymptomatic antenatal women 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
3.99 ( 2.84, 5.62) 54.0 
6.22 ( 4.09, 9.48) 46.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Yazici 32.5mm
0.33 ( 0.17, 0.66) 61.5 
Dilek 33.15mm
0.25 ( 0.11, 0.60) 38.5 
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Figure 92 Forest plots of likelihood ratios (LR’s) for cervical funnelling between 20 – 24 weeks’ gestation 
in predicting spontaneous preterm birth stratified according to reference standards (outcomes) in 
asymptomatic antenatal women 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
5.03 ( 2.53, 9.97) 8.7 
5.61 ( 3.50, 8.99) 17.1 
26.81 ( 1.57, 457.07) 0.5 
7.93 ( 4.79, 13.12) 15.2 
7.97 ( 5.14, 12.35) 19.3 
4.63 ( 3.31, 6.48) 29.6 
2.71 ( 0.85, 8.64) 3.2 
8.11 ( 2.63, 25.01) 3.4 
4.35 ( 1.31, 14.42) 3.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Leung* 0.74 ( 0.56, 0.99) 11.4 
Mara* 0.26 ( 0.08, 0.88) 1.1 
Andrews* 0.66 ( 0.47, 0.95) 8.8 
Mara* 0.36 ( 0.22, 0.59) 5.8 
To 5mm width 0.75 ( 0.65, 0.88) 18.1 
Iams 5mm membrane protrusion 0.79 ( 0.71, 0.87) 21.0 
Andrews* 0.78 ( 0.54, 1.14) 8.2 
Pires* 0.75 ( 0.52, 1.08) 8.6 
Pires* 0.89 ( 0.74, 1.06) 16.9 
<34 weeks’ gestation
<37 weeks’ gestation
 
+ Studies are arranged in descending order of quality *Any definition of funnelling unless otherwise stated 
 
Figure 93 Forest plots of likelihood ratios (LR’s) from ideal quality studies for cervical length 
measurement in predicting spontaneous preterm birth within 48 hours of testing in symptomatic women 
with threatened preterm labour 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
19.05 ( 8.87, 40.94) 13.9 
12.77 ( 8.57, 19.03) 16.8 
6.43 ( 5.17, 8.00) 17.8 
6.74 ( 3.88, 11.72) 15.7 
3.18 ( 2.75, 3.69) 18.1 
1.88 ( 1.50, 2.36) 17.8 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Tsoi 5mm 0.58 ( 0.40, 0.85) 24.6 
Tsoi 10mm 0.20 ( 0.08, 0.49) 20.6 
Tsoi 15mm 0.03 ( 0.00, 0.42) 7.7 
Gomez 15mm 0.39 ( 0.20, 0.74) 22.7 
Tsoi 20mm 0.03 ( 0.00, 0.51) 7.7 
Gomez 30mm 0.22 ( 0.06, 0.82) 16.7 
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Figure 94 Forest plots of likelihood ratios (LR’s) for cervical length measurement utilizing commonly 
chosen threshold (15mm) in predicting spontaneous preterm birth within 7 days of testing in symptomatic 
women with threatened preterm labour+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
8.61 ( 6.65, 11.14) 20.2 
3.90 ( 2.42, 6.27) 14.2 
9.88 ( 6.13, 15.95) 14.1 
8.73 ( 4.78, 15.96) 11.3 
9.39 ( 4.91, 17.97) 10.4 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Tsoi 15mm 0.03 ( 0.00, 0.18) 10.9 
Schmitz 15mm 0.55 ( 0.36, 0.85) 20.7 
Fuchs 15mm 0.21 ( 0.09, 0.50) 18.0 
Gomez 15mm 0.42 ( 0.27, 0.67) 20.6 
Botsis 15mm 0.10 ( 0.02, 0.65) 11.3 
 
+ Studies are arranged in descending order of quality 
 
Figure 95 Forest plots of likelihood ratios (LR’s) for cervical length measurement utilizing commonly 
chosen threshold (30mm) in predicting spontaneous preterm birth before 34 weeks’ gestation in 
symptomatic women with threatened preterm labour+ 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
2.29 ( 1.68, 3.12) 16.5 
1.61 ( 1.40, 1.85) 21.7 
2.05 ( 1.66, 2.52) 19.7 
2.94 ( 2.08, 4.16) 15.3 
2.91 ( 1.93, 4.38) 13.4 
2.05 ( 1.36, 3.09) 13.4 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Crane 30mm 0.29 ( 0.15, 0.58) 33.7 
Schmitz 30mm 0.23 ( 0.10, 0.54) 27.7 
Gomez 30mm 0.21 ( 0.08, 0.52) 24.7 
Daskalakis* 30mm 0.02 ( 0.00, 0.30) 4.5 
Daskalakis** 30mm 0.03 ( 0.00, 0.45) 4.5 
Rageth 30mm 0.18 ( 0.01, 2.50) 4.9 
 
+ Studies are arranged in descending order of quality 
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Figure 96 Forest plots of likelihood ratios (LR’s) from ideal quality studies for cervical length 
measurement in predicting spontaneous preterm birth before 37 weeks’ gestation in symptomatic women 
with threatened preterm labour 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
3.36 ( 1.73, 6.54) 15.9 
2.29 ( 1.68, 3.12) 31.6 
1.66 ( 1.33, 2.07) 36.4 
3.24 ( 1.68, 6.25) 16.1 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Gomez 18mm 0.35 ( 0.17, 0.70) 26.4 
Crane 30mm 0.29 ( 0.15, 0.58) 28.0 
Venditelli 30mm 0.35 ( 0.21, 0.61) 43.8 
Murakawa 30mm 0.06 ( 0.00, 0.90) 1.8 
 
 
Figure 97 Forest plots of likelihood ratios (LR’s) for cervical funnelling between 24 – 36 weeks’ gestation 
in predicting spontaneous preterm birth stratified according to reference standards (outcomes) in 
symptomatic women with threatened preterm labour 
 
Likelihood ratio (LR) for positive test
0.5 1 2 5 10
LR+
(95% CI) % Weight
4.70 ( 1.90, 11.66) 8.7 
2.75 ( 1.40, 5.40) 13.3 
1.68 ( 1.11, 2.55) 22.3 
7.86 ( 2.58, 23.90) 6.3 
2.46 ( 1.44, 4.20) 17.6 
2.53 ( 1.02, 6.25) 8.8 
2.21 ( 1.48, 3.29) 23.0 
Likelihood ratio (LR) for negative test
0.1 0.2 0.5 1 2
Study
LR-
(95% CI) % Weight
Crane V-shaped 0.61 ( 0.34, 1.10) 14.6 
Gomez 6mm width 0.44 ( 0.23, 0.83) 13.9 
Gomez* 0.42 ( 0.18, 0.96) 11.5 
Gomez 9mm length 0.31 ( 0.16, 0.62) 13.3 
Okitsu 5mm width 0.43 ( 0.19, 0.98) 11.4 
Crane V-shaped 0.86 ( 0.71, 1.04) 19.4 
Rizzo 5mm width 0.41 ( 0.25, 0.67) 15.9 
<34 weeks’ gestation
<37 weeks’ gestation
 
Studies are arranged in descending order of quality *Any definition of funnelling unless otherwise stated 
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Chapter 5 Overview and summary of test accuracy results 
There were a large number of studies reviewed but not many promising tests were identified. 
The numbers of studies for most test were small and of poor quality with few exceptions. The 
median number of studies was 5 (range 0 - 26) for asymptomatic and was 2 (range 0 - 40) for 
symptomatic women. It was planned a-priori to perform meta-analysis only for highest 
quality studies to improve the validity of the results. This meant that the number of tests meta-
analyzable were small (cervico-vaginal fetal fibronectin and cervical ultrasound) and the 
number of studies per meta-analysis was similarly small (median = 3), introducing 
imprecision in estimation of accuracy for these tests. 
The overall quality of studies within reviews was variable. There were deficiencies in many 
areas of methodology (Figure 98) but two quality items, consecutive enrolment and blinding, 
were more frequently unreported than the other items. No test had universally high quality 
data, but in some tests e.g. fibronectin, cervico-vaginal phIGFBP-1 or cervical length, a 
number of high quality studies was available. Overall quality of test accuracy studies in 
symptomatic women tend to be better than those in asymptomatic women (χ2 test p ≤ 0.001). 
The interpretations of the accuracy data on all tests were negatively affected by poor reporting 
and potential threats to validity identified in assessment of study quality. Although the 
reviews were restricted to singleton pregnancies, some of the included studies where they 
have not specifically recruited singleton pregnancies were suspected to have included patients 
across other clinical risk spectrum (e.g. multiple pregnancies). There could be thus, when 
assessing the published results, uncertainties about the reported predictive ability of the test. 
In evaluation of many tests, the limited number of quality studies and the limited number of 
cases with preterm birth per study seriously constrained conclusions. As spontaneous preterm 
birth has lower prevalence particularly for important outcomes such as birth before 34 weeks’ 
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gestation or birth with 48 hours of presentation, the small absolute numbers of affected cases 
introduced imprecision(i.e. by increasing the variance and therefore widen the calculated 
confidence intervals). 
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Figure 98 Summary of methodological quality of studies included in the systematic review of accuracy of 
rheobase testing in predicting spontaneous preterm birth. Data presented as 100% stacked bars. Figures 
in the stacks represent number of studies* 
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*Some studies are reported twice because of their contributions to multiple reviews 
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The main accuracy results are summarised in Figure 99, Figure 100 and Figure 101 
representing prediction of spontaneous preterm birth before 34 and 37 weeks’ gestation in 
asymptomatic women, within 48 hours and 7 days of testing, and before 34 and 37 weeks’ 
gestation in symptomatic women respectively. For most of the tests evaluated, results were 
not pooled due to lack of high quality studies. Where studies were pooled, random effects 
model were used. This method accounts for statistical heterogeneity that is left unexplained 
after attempts to identify its sources, where feasible. It produced a more conservative estimate 
of the confidence intervals.  
The forest plots below summarize tests’ accuracies for the 22 tests for the asymptomatic (for 
predicting birth before 34 and 37 weeks’ gestation) and symptomatic (for predicting birth 
within 48 hours and 7 days of testing and before 34 and 37 weeks’ gestation ) population. The 
more the LR values depart away from 1.0 the greater the change they would bring in post-test 
probability. As proposed by Jaeschke et al,46 a useful test should at least have an accuracy of 
LR+ >5.0 and LR- <0.2. These estimates require at least a moderate disease prevalence for 
post-test probabilities to show substantial change from pre-test probabilities. In this situation, 
when a test produces a positive result it will predict with greater likelihood the later 
development of the condition i.e. spontaneous preterm birth. When the test result is negative, 
it would provide reassurance that the condition will not likely develop later. Clinically, 
however, most tests tend to have a greater usefulness for either LR+ or LR-, not both together. 
This trade-off was apparent from the accuracy reviews. Considering the point estimates of 
LR’s, screening for spontaneous preterm birth in asymptomatic antenatal women tended to be 
more useful for a positive test result compared to a negative test result, i.e. LR+ tended to be 
further away from 1.0. This meant that it was unlikely that negative test result would rule out 
the likelihood of spontaneous preterm birth confidently. In symptomatic women, similarly, 
there was a predominance of more useful LR+ results compared to LR- results. 
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Figure 99 Summary forest plots of likelihood ratios (LR’s) of various tests accuracy as a predictor of 
spontaneous preterm birth in asymptomatic women stratified according to reference standards (outcome 
of spontaneous preterm birth before 34 and 37 weeks’ gestation), tests and selected thresholds*  
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*LR values above are those that were based on results of highest quality studies. 
 
 
 
166
Figure 100 Summary forest plots of likelihood ratios (LR’s) of various tests accuracy as a predictor of 
spontaneous preterm birth in symptomatic women stratified according to reference standards (outcome 
spontaneous preterm birth within 48 hours and 7 days of testing), tests and selected thresholds* 
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*LR values above are those that were based on results of highest quality studies. 
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Figure 101 Summary forest plots of likelihood ratios (LR’s) of various tests accuracy as a predictor of 
spontaneous preterm birth in symptomatic women stratified according to reference standards (outcome 
spontaneous preterm birth before 34 and 37 weeks’ gestation), tests and selected thresholds* 
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*LR values above are those that were based on results of highest quality studies. 
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Screening typically involves use of a confirmatory test after initial testing, prior to institution 
of an intervention. This was not the case in this research thesis where testing was used to 
identify a risk group in which preventative interventions (both intensive monitoring and or 
treatments) will be employed directly after test results are known. In this situation, for a test to 
serve as a good tool for screening, it should perform well.46 However, given that there is often 
a trade-off between LR+ and LR-, the balance between LR+ and LR- that is preferable 
depends largely on the outcomes of the disease and costs (including potential mortality and 
morbidity) associated with the intervention(s). The consequences of false positive results 
include both costs of intensive monitoring and treatment associated morbidity, and costs 
among otherwise normal women. Thus it is important that LR+ is suitably high, since 
erroneously providing interventions to falsely positive cases leads to unwarranted 
inconvenience, expense and morbidity when the likelihood of spontaneous preterm birth does 
not change compared to the background risk due to low LR+ values. Given the consequences 
of false negative results (both costs and morbidity of cases of spontaneous preterm birth 
resulting due to lack of treatment), it is important that LR- is suitably low. This is because 
erroneously withholding effective interventions from falsely negative results lead to excessive 
morbidity and expense in the face of spontaneous preterm birth. If available effective 
interventions are convenient, inexpensive, and without adverse effects (to both mother and 
child), it is better to have the accuracy trade-offs in favour of LR- i.e. a test with a low LR- 
than a high LR+ and vice-versa. 
Figure 99, Figure 100 and Figure 101 demonstrate that considering the point estimates of and 
imprecision in the LR’s, most tests perform either poorly or the level of their performance is 
uncertain (i.e. with a wide confidence intervals). A few tests in asymptomatic antenatal 
women reached LR+ >5, putting them in the useful tests category in predicting spontaneous 
preterm birth. These were ultrasonographic cervical length and funnelling measurement, and 
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cervico-vaginal fetal fibronectin screening. For LR-, only two tests in asymptomatic women 
had an LR- <0.2. These were detection of uterine contractions (by home uterine monitoring 
device) and amniotic fluid CRP measurement. In symptomatic women with threatened 
preterm labour, there were more tests with LR+ >5 compared to asymptomatic women. These 
were absence of fetal breathing movements, cervical length and funnelling, amniotic fluid 
IL6, serum CRP for predicting spontaneous preterm birth within 48 hours or 7 days of testing; 
and MMP-9, amniotic fluid IL6, cervico-vaginal fetal fibronectin and cervico-vaginal hcg 
testing for predicting spontaneous preterm birth before 34 or 37 weeks’ gestation. For 
symptomatic women with threatened preterm labour: measurement of cervico-vaginal IL8, 
cervico-vaginal hcg, cervical length measurement, absence of fetal breathing movement, 
amniotic fluid IL6, and serum CRP all showed LR- <0.2 for predicting spontaneous preterm 
birth within 48 hours or 7 days of testing. Only cervico-vaginal fetal fibronectin and amniotic 
fluid IL6 had an LR- <0.2 in predicting spontaneous preterm birth before 34 or 37 weeks’ 
gestation. Depending on level of effectiveness of various interventions and their associated 
inconvenience, costs and morbidity, a threshold analysis (a subject for further research) will 
be required to determine which thresholds of accuracy are required to make testing cost-
effective in prevention of spontaneous preterm birth. Tabular summary of the tests’ accuracies 
for the respective reference standards can be found as Table 3 – Table 8. 
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Table 3 Summary of tests’ accuracy results for predicting spontaneous preterm birth before 34 weeks’ 
gestation in asymptomatic antenatal women 
 
Test (threshold) No. of studies LR+ (95% CI) LR- (95% CI) 
    
Cervical length (15mm @14-20 weeks) 3 142.86 (3.58 - 5709.07) 0.89 (0.82 - 0.97) 
Cervical length (20mm @14-20 weeks) 3 35.36 (4.32 - 289.68 0.90 (0.83 - 0.98) 
Cervico-vaginal prolactin (2.0ng/ml) 5 19.00 (1.76 - 205.15) 0.51 (0.13 - 2.06) 
Cervical length (25mm @14-20 weeks) 3 13.38 (6.90 - 25.96 0.80 (0.71 - 0.90) 
Cervico-vaginal fetal fibronectin 7 10.18 (6.56 - 15.80 0.69 (0.56 - 0.85) 
Cervical length (20mm @20-24 weeks) 2 7.64 (15.21 - 1.20) 0.79 (0.72 - 0.87) 
Cervical funnelling (5mm @16-20 weeks) 1 5.03 (2.53 - 9.97) 0.74 (0.56 - 0.99) 
Serum α-fetoprotein (2.5 MoM) 9 4.99 (3.97 - 6.28) 0.95 (0.94 - 0.97) 
Cervical length (25mm 20-24) 2 4.68 (3.64 - 6.03) 0.68 (0.60 - 0.78) 
Cervical funnelling (5mm @20-24 weeks) 1 4.63 (3.31 - 6.48) 0.79 (0.71 - 0.87) 
History of spontaneous preterm birth 10 4.62 (3.28 - 6.52) 0.68 (0.56 - 0.82) 
Mammary stimulation test 2 4.62 (2.95 - 7.25) 0.27 (0.08 - 0.91) 
Cervical length (22mm @20-24 weeks) 5 4.51 (1.16 - 17.64 0.74 (0.51 - 1.08) 
Serum CRH (1.9MoM) 5 3.36 (2.30 - 4.92) 0.35 (0.13 - 0.91) 
Amniotic fluid IL6 (2.9ng/ml) 2 2.65 (1.37 - 5.14) 0.91 (0.84 - 0.98) 
Amniotic fluid CRP (110ng/ml) 1 2.63 (1.85 - 3.75) 0.29 (0.08 - 0.99) 
Cervical length (30mm @14-20 weeks) 3 2.48 (1.19 - 5.19) 0.81 (0.68 - 0.97) 
HUAM (≥4 contractions/h at night time) 1 2.41 (0.76 - 7.68) 0.95 (0.86 - 1.04) 
Cervical length (30mm @20-24) 5 2.28 (1.91 - 2.71) 0.60 (0.50 - 0.73) 
Cervico-vaginal IL8 (360ng/ml) 4 2.23 (1.46 - 3.41) 0.69 (0.50 - 0.97) 
Serum relaxin (90th centile) 5 1.60 (1.24 - 2.06) 0.84 (0.74 - 0.95) 
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Table 4 Summary of tests’ accuracy results for predicting spontaneous preterm birth before 37 weeks’ 
gestation in asymptomatic antenatal women 
 
Test (threshold) No. of studies LR+ (95% CI) LR- (95% CI) 
    
Cervico-vaginal fetal fibronectin 15 26.38 (1.73 - 402.99) 0.94 (0.83 - 1.07) 
Salivary estriol (serial) 2 5.46 (3.18 - 9.40) 0.61 (0.43 - 0.88) 
HUAM (≥4 contractions/h at night time) 3 4.90 (2.99 - 8.04) 0.15 (0.04 - 0.56) 
Amniotic fluid CRP (6.5ng/ml) 3 4.37 (3.03 - 6.29) 0.09 (0.01 - 0.60) 
phIGFBP-1 1 4.17 (2.44 - 7.13) 0.21 (0.08 - 0.51) 
Cervical length (32.5mm @20-24 weeks) 1 3.99 (2.84 - 5.62) 0.33 (0.17 - 0.66) 
Cervico-vaginal IL6 (250pg/ml) 3 3.34 (1.96 - 5.70) 0.59 (0.42 - 0.83) 
Mammary stimulation test 2 3.30 (1.54 - 7.08) 0.49 (0.17 - 1.43) 
Cervico-vaginal prolactin (2.0ng/ml) 5 3.15 (1.62 - 6.12) 0.23 (0.04 - 1.37) 
Serum β-hcg (10th centile) 2 2.77 (2.07 - 3.69) 0.98 (0.98 - 0.99) 
Asymptomatic bacteriuria testing 26 2.63 (1.54 - 4.50) 0.96 (0.92 - 0.99) 
Serum α-fetoprotein (2.5MoM) 9 2.63 (1.35 - 5.10) 0.99 (0.97 - 1.00) 
Salivary estriol (single) 2 2.55 (1.73 - 3.77) 0.56 (0.35 - 0.89) 
Moderate to severe periodontitis 13 2.26 (1.35 - 3.79) 0.79 (0.66 - 0.96) 
History of spontaneous preterm birth 10 2.26 (1.86 - 2.74) 0.72 (0.64 - 0.81) 
Serum CRP (positive or negative) 1 2.06 (1.29 - 3.29) 0.77 (0.65 - 0.91) 
Bacterial vaginosis (Nugent serial) 3 1.92 (0.63 - 5.92) 0.93 (0.79 - 1.10) 
Amniotic fluid il6 (2.9ng/ml) 2 1.91 (1.00 - 3.67) 0.95 (0.90 - 1.00) 
Serum α-fetoprotein (2.0MoM)) 9 1.63 (0.81 - 3.27) 0.96 (0.89 - 1.03) 
Bacterial vaginosis (Amsel single) 3 1.62 (0.44 - 5.91) 0.90 (0.63 - 1.29) 
Serum CRH (234 pg/ml) 5 1.43 (0.86 - 2.36) 0.89 (0.74 - 1.08) 
Cervico-vaginal IL8 (360ng/ml) 4 1.38 (1.04 - 1.82) 0.91 (0.82 - 1.01) 
Serum relaxin (>3SD) 5 1.21 (0.73 - 2.10) 0.74 (0.29 - 1.95) 
Serum estriol (<0.75MoM) 5 1.19 (0.58 - 2.44) 0.98 (0.89 - 1.08) 
Serum β-hcg (2.0MoM) 10 0.92 (0.77 - 1.11) 1.30 (0.79 - 2.12) 
Bacterial vaginosis (Nugent single) 12 0.80 (0.38 - 1.72) 1.04 (0.92 - 1.17) 
Serum estriol (<0.5MoM) 5 0.76 (0.58 - 1.00) 1.02 (1.00 - 1.04) 
Cervico-vaginal IL6 (50pg/ml) 3 0.56 (0.08 - 3.97) 1.08 (0.87 - 1.35) 
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Table 5 Summary of tests’ accuracy results for predicting spontaneous preterm birth within 48 hours of 
testing in symptomatic women with threatened preterm labour  
 
Test (threshold) No. of studies LR+ (95% CI) LR- (95% CI) 
    
Amniotic fluid IL8 (15ng/ml) 4 36.00 (2.30 - 564.54) 0.10 (0.01 - 1.42) 
Absence of fetal breathing movement 3 16.08 (5.22 - 49.55) 0.16 (0.05 - 0.58) 
Cervical length (15mm) 2 6.43 (5.17 - 8.00) 0.03 (0.00 - 0.42) 
Amniotic fluid IL6 (7.5ng/ml) 10 3.76 (2.14 - 6.61) 0.11 (0.02 - 0.73) 
Serum IL6 (30pg/ml) 5 2.05 (0.85 - 4.93) 0.66 (0.32 - 1.35) 
Cervico-vaginal IL6 (20pg/ml) 7 1.90 (1.08 - 3.34) 0.23 (0.02 - 3.17) 
phIGFBP-1 3 1.73 (0.92 - 3.25) 0.59 (0.24 - 1.45) 
    
 
Table 6 Summary of tests’ accuracy results for predicting spontaneous preterm birth within 7 – 10 days of 
testing in symptomatic women with threatened preterm labour 
 
Test (threshold) No. of studies LR+ (95% CI) LR- (95% CI) 
    
Serum CRP (12.5ng/ml) 4 34.36 (4.86 - 243.09) 0.19 (0.05 - 0.65) 
Amniotic fluid IL8 (15ng/ml) 4 28.50 (1.78 - 456.57) 0.26 (0.06 - 1.03) 
Cervical length (15mm) 6 8.61 (6.65 - 11.14) 0.03 (0.00 - 0.18) 
Amniotic fluid IL6 (7.5ng/ml) 10 7.01 (2.75 - 17.90) 0.17 (0.06 - 0.49) 
Cervico-vaginal β-hcg (30mIU/ml) 3 6.07 (3.07 - 11.99) 0.04 (0.01 - 0.16) 
Cervico-vaginal IL6 (20pg/ml) 7 4.01 (2.02 - 7.96) 0.66 (0.51 - 0.85) 
Absence of fetal breathing movement 6 4.00 (0.73 - 21.84) 0.67 (0.32 - 1.38) 
Cervico-vaginal fetal fibronectin 18 3.52 (2.36 - 5.23) 0.24 (0.07 - 0.83) 
Serum IL6 (8.30pg/ml) 5 3.34 (1.49 - 7.53) 0.44 (0.30 - 0.66) 
Serum CRH (90th centile) 1 3.12 (1.42 - 6.84) 0.63 (0.38 - 1.05) 
phIGFBP-1 3 2.83 (1.57 - 5.09) 0.37 (0.13 - 1.04) 
Cervico-vaginal IL8 (7.7ng/ml) 4 2.34 (1.42 - 3.84) 0.52 (0.32 - 0.84) 
Cervico-vaginal prolactin (2.0ng/ml) 5 1.48 (0.81 - 2.70) 0.61 (0.23 - 1.62) 
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Table 7 Summary of tests’ accuracy results for predicting spontaneous preterm birth before 34 weeks’ 
gestation in symptomatic women with threatened preterm labour 
 
Test (threshold) No. of studies LR+ (95% CI) LR- (95% CI) 
    
Amniotic fluid IL6 (1500pg/ml) 10 7.44 (2.01 - 27.52) 0.14 (0.06 - 0.36) 
Serum CRP (15ng/ml) 1 6.75 (1.34 - 34.00) 0.66 (0.38 - 1.14) 
Cervico-vaginal IL6 (20pg/ml) 7 4.92 (1.80 - 13.46) 0.74 (0.63 - 0.87) 
Cervical funnelling (V-shaped) 1 4.70 (1.90 - 11.66) 0.61 (0.34 - 1.10) 
Cervico-vaginal prolactin (2.0ng/ml) 5 4.65 (1.81 - 11.97) 0.49 (0.21 - 1.16) 
phIGFBP-1 3 4.15 (1.44 - 11.99) 0.31 (0.03 - 3.38) 
Cervico-vaginal fetal fibronectin 8 3.98 (2.73 - 5.80) 0.33 (0.19 - 0.58) 
Cervical length (30mm) 4 1.88 (1.36 - 2.59) 0.30 (0.08 - 1.07) 
Serum relaxin (300pg/ml) 5 1.48 (0.26 - 8.31) 0.86 (0.38 - 1.96) 
Serum IL6 (10pg/ml) 5 1.44 (0.86 - 2.41) 0.59 (0.22 - 1.58) 
    
 
Table 8 Summary of tests’ accuracy results for predicting spontaneous preterm birth before 37 weeks’ 
gestation in symptomatic women with threatened preterm labour 
 
Test (threshold) No. of studies LR+ (95% CI) LR- (95% CI) 
    
Amniotic fluid IL6 (50pg/ml) 10 28.62 (1.78 - 461.04) 0.66 (0.54 - 0.81) 
Cervico-vaginal fetal fibronectin 31 7.97 (4.88 - 13.03) 0.13 (0.05 - 0.32) 
Serum MMP-9 (68.43ng/ml) 2 7.33 (1.07 - 50.27) 0.37 (0.14 - 0.94) 
Serum CRH (90th centile) 1 4.06 (1.68 - 9.81) 0.68 (0.51 - 0.91) 
phIGFBP-1 9 3.87 (1.54 - 9.72) 0.33 (0.15 - 0.71) 
Cervical length (18mm) 1 3.36 (1.73 - 6.54) 0.35 (0.17 - 0.70) 
Cervical funnelling (V-shaped) 1 2.53 (1.02 - 6.25) 0.86 (0.71 - 1.03) 
Cervico-vaginal prolactin (2.0ng/ml) 5 2.50 (0.88 - 7.10) 0.79 (0.55 - 1.11) 
Digital vaginal examination (2cm dilatation) 10 2.38 (1.46 - 3.87) 0.47 (0.29 - 0.79) 
Rheobase (>3.4 mA) 1 2.36 (1.74 - 3.20) 0.36 (0.19 - 0.66) 
Serum CRP (12.5ng/ml) 4 2.32 (1.43 - 3.76) 0.47 (0.25 - 0.87) 
Salivary estriol (2.1ng/ml) 2 2.31 (1.64 - 3.24) 0.40 (0.20 - 0.79) 
Cervical length (30mm) 3 2.29 (1.68 - 3.12) 0.29 (0.15 - 0.58) 
Rheobase (>2.8mA) 1 2.29 (1.50 - 3.52) 0.60 (0.41 - 0.88) 
Cervico-vaginal β-hcg (25mIU/ml) 3 2.19 (1.35 - 3.56) 0.51 (0.30 - 0.85) 
Cervico-vaginal IL8 (50pg/mL) 7 1.83 (0.79 - 4.25) 0.69 (0.40 - 1.20) 
Cervico-vaginal IL8 (3.739ng/ml) 4 1.40 (0.83 - 2.35) 0.67 (0.30 - 1.50) 
Serum IL6 (5pg/ml) 5 1.13 (0.55 - 2.32) 0.92 (0.54 - 1.56) 
Bacterial vaginosis (Nugent) 8 1.00 (0.36 - 2.76) 1.00 (0.88 - 1.13) 
Serum relaxin (300pg/ml) 5 0.80 (0.19 - 3.31) 1.07 (0.72 - 1.57) 
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Chapter 6 Discussion 
Methodological quality of the reviews undertaken for the thesis 
The strength of the inferences derived from this thesis depends upon the rigor of the 
methodology and the reliability of the accuracy estimates. In undertaking the research for this 
thesis, all contemporaneous criteria for performing a quality systematic review were followed 
(Chapter 3). A range of databases were searched and no language restriction was applied. 
Cognizant of the fact that reviews of test accuracy studies are often fraught with difficulty due 
to poor methodological quality of the primary studies, each of the selected studies were 
scrutinised for their methodological quality. However, some of the methodological issues that 
have empirically been shown to overestimate accuracy such as the absence of test descriptions 
and the use of different reference tests were generally not applicable to the studies selected for 
review due to the clinical nature of spontaneous preterm birth. 
Limitations arising from problems with primary data 
The interpretations of the accuracy data on tests are affected by threats to validity identified in 
assessment of study quality (Figure 98). Only a few tests had been evaluated and reported in 
studies which met generally accepted definition of ideal study design as defined in the method 
section, both in asymptomatic and symptomatic women. The following tests were evaluated 
in at least one ideal quality study: cervical length and funnelling, IL6, and cervico-vaginal 
fetal fibronectin in asymptomatic women, with the addition of absence of fetal breathing 
movement in symptomatic women. The overall quality of studies within reviews was variable 
with deficiencies in many areas of methodology (Figure 98). Association between design 
quality components and diagnostic performance has been empirically studied.42;348 It cannot 
be stressed enough that before any measures of test accuracy (whatever their magnitude) 
count as scientific evidence, it would require adequate reporting of the study’s population 
(clinical spectrum), design and execution in evaluating the test’s accuracy. Idealistic 
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expectations of the level of detail that should be provided in the literature of the primary 
studies including adherence to the current standards of reporting for diagnostic studies, were 
perhaps unrealistic given that initiatives to improve test accuracy study design and its 
subsequent reporting are only recent phenomena. 
In evaluating many of included studies for the reviews, blinding and consecutive enrolment, 
in particular, were often either unreported or were not part of the study design. The extent to 
which these deficiencies have impact on accuracy estimates depends on a number of factors. 
In both asymptomatic antenatal women and symptomatic women with threatened preterm 
labour, there is a time interval between (screening) testing and potential outcome of 
spontaneous preterm birth. In this situation, the absence of blinded assessment may lead to 
alteration(s) of usual antenatal care that would affect the outcome i.e. spontaneous preterm 
birth, which in turn would influence the final accuracy estimates. This is known as ‘treatment 
paradox’349 where test positive women given effective treatments leading to prevention of 
spontaneous preterm birth, makes an otherwise reasonable test appears inaccurate.  
Lack of consecutive enrolment may have resulted in differing clinical spectrum of women 
being enrolled in the study, leading to a spectrum bias potentially influencing the final 
accuracy estimates. Spectrum bias refers to the possibility that a test’s LR+ and/or LR- may 
vary in groups of patients with differing risks of spontaneous preterm birth. In other words, 
spectrum bias refers to variation across subgroups, (or, to use the technical term, effect 
measure modification). This effect can be minimized, not withstanding the inherent study 
design and reporting inadequacy, by constraining the inclusion criteria for the reviews to 
singleton and low-risk pregnancies. 
Where studies were available, absence of primary data in key areas (e.g. description of 
population, threshold, or outcome) limited the ability to extract and explore the data as 
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completely as would have been desired. As an example, some studies reported mean ± SD for 
non-Gaussian distributions of index test results and did not provide 2x2 tables. Such study 
had to be excluded from the review. Attempts to minimize this problem by writing to the 
corresponding author(s) for the required data met with variable results: An initial (usually via 
e-mail) communiqué followed by another a week later in case of non-response. Generally, co-
operation was obtained but for some, their work commitment schedules meant that they were 
not able to extend co-operation where they would have otherwise liked to. In some 
circumstances, data were no longer available, accessible or simply no response was 
forthcoming. Only after this approach was exhausted, were the studies excluded that would 
otherwise have met the inclusion criteria. Indeed, from the preceding discussion, better quality 
primary test accuracy studies with better reporting would have improved the assessment of the 
test accuracy. 
This discussion would be remiss without touching on the issue of interpreting a test’s 
accuracy in light of information obtained by any preceding test(s), which has so far been 
overlooked in diagnostic research. Diagnostic confounding, which refers to one or more tests 
having predictive abilities that are related to each other and the outcome, such that it is 
difficult to assess the independent prediction from each of the tests on the diagnosis of the 
outcome can occur in this situation. Additionally, it remains to be elucidated whether the very 
act of performing some the tests within the vaginal and cervical milieu (e.g. cervical digital 
examination, transvaginal ultrasound scanning or obtaining samples for subsequent assays) 
may contribute to the cascading process that manifest eventually as spontaneous preterm 
birth. This thesis did not assess these emerging issues. There may or may not be increased 
accuracy when two or more tests were combined in the prediction of spontaneous preterm 
birth depending on the overlap of information between test. These issues may only be 
optimally dealt with by multivariable analysis of the primary studies or Individual Patient 
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Data (IPD) meta-analyses. Such an analysis would generate probabilities of spontaneous 
preterm birth for patient characteristics and test results to obtain a predictive probability for 
each profile, e.g. the probability of spontaneous preterm birth from a cervical length 
measurement in a nulliparous obese woman. If no multivariable analysis is planned, such 
confounding may be attenuated by selection of patient groups that are as homogeneous as 
possible with respect to their other characteristics (e.g. patient history and obstetric risk 
profile in multiparous women). However, such an approach is difficult given the large amount 
of clinical information that usually exists (e.g. age, parity, and co-morbidities to name a few). 
Limitations arising from review methods  
The accuracy review was carried out using a comprehensive search strategy so as to minimise 
the risk of missing tests and studies. Nevertheless the amount of research identified per test 
was often of variable quality and insufficient to produce precise estimates of accuracy in 
either or both groups of populations of asymptomatic antenatal women and symptomatic 
women with threatened preterm labour. For both asymptomatic women and symptomatic 
women populations, only three tests had >20 accuracy studies: asymptomatic bacteriuria (26 
studies), serum β-hcg (20 studies) and serum α-fetoprotein for asymptomatic women (20 
studies); cervico-vaginal fetal fibronectin (58 studies), cervical length and funnelling (42 
studies), and IL6 (22 studies) for symptomatic women. Where there was scarcity of primary 
studies, it was not surprising that some of the LR estimates were affected by imprecision. 
Thus when assessing their results about the range of reported predictive ability (accuracy) of 
the tests especially when there was only a small number of studies with small sample size in 
each could not be ascertain with a high degree of confidence. 
Thus far, the thesis in carrying the systematic reviews had already made explicit the 
deficiencies in the quality of studies (see above). In light of this, it would have been preferred 
to base any inferences on high quality studies e.g. ideal quality features in asymptomatic 
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antenatal women population, using a single threshold and outcome (reference standard). To 
that end, it was planned a-priori subgroup analyses according to study quality within 
predefined populations and outcomes. However, due to the low number of included studies 
per test or per specific threshold, compounded by oft lack of reporting clarity, such subgroup 
analyses were often not possible or had insufficient power. In cases where it had been 
possible e.g. cervico-vaginal fetal fibronectin and cervical length measurement, their 
subgroup analyses were based on small number of studies. 
Variation in test thresholds for determining abnormality meant that generating summaries of 
findings was not straightforward. For some tests e.g. cervical ultrasound measurement of 
either length or funnelling, the same study may have provided estimates from different 
thresholds. This precluded valid statistical comparison of these indices due to violation of the 
principle that the compared study samples should be statistically independent. For some other 
tests e.g. CRP and interleukins, none of the studies had used the same thresholds, thus 
limiting the ability to compare and infer the accuracy estimates obtained. In these situations, a 
systematic attempt (see methods section) was made at translating results in a summary ROC 
space into clinically relevant information. For pooling test results that can be pooled, a 
random effects approach was used where unexplained statistical heterogeneity is formally 
taken into account. Detailed exploration of reasons for heterogeneity was constrained largely 
because poor reporting and the small number of studies per test would have rendered use of 
explorative statistical methods such as meta-regression underpowered. If the pooled results 
amalgamate heterogeneous individual estimates, these should be interpreted with caution. In 
situations where it was not sensible to pool given the absence of high quality studies, an 
arbitrarily chosen accuracy estimates from the largest higher quality study available for the 
particular test would have been shown for comparison. The thesis conservative method and 
judgement, given the uncertain impact of these study design issues on the magnitudes of the 
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accuracy estimates, would likely to have generated summaries of the best available results for 
clinical interpretation.  
Limitations arising from things not done (omissions)  
For some tests where only few studies (e.g. rheobase (1 study), mammary stimulation test (2 
studies), MMP-9 (2 studies)) were found, besides reporting their individual accuracy 
estimates no meaningful analyses could be carried out. It had been expected, at the inception 
of the thesis research, that there would be some studies on the accuracy of abdominal 
palpation for uterine contractions in symptomatic women with threatened preterm labour as a 
predictor for spontaneous preterm birth. However within the extensive literature searches, no 
studies were found on this aspect of physical examination, which forms the cornerstone of 
daily clinical practice. For some tests, and this has to be borne in mind, researchers were only 
just beginning to make headway in evaluating their accuracies where the relevant studies were 
only just emerging (e.g. periodontal assessment, serum relaxin, phIGFBP-1). Additionally as 
understanding of the aetiology, physiology and pathology of spontaneous preterm birth 
evolves, more tests would appear that may not have been included in the current review.  
Interpretation of the findings 
Typically, confirmatory test usually follows the initial screening, before institution of therapy. 
In the research for this thesis, this is not the case. Screening is used to identify a risk group 
that may benefit from preventative interventions (e.g. intensive monitoring and treatments), 
which will be employed directly when screening results are known, and without further 
confirmatory test(s). Screening and tests, which offer high LR+ have the potential to minimise 
unwarranted inconvenience, expense and morbidity associated with false positive results, 
which led to unnecessary interventions; while those, which offer low LR- have the potential to 
minimise unwarranted inconvenience, expense and morbidity associated with false negative 
results, which led to spontaneous preterm births. Additionally, tests that detect changes of the 
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final common pathway of spontaneous preterm labour (irrespective of the initial stimulus e.g. 
be it sub-clinical infection or a cervical structural abnormality) e.g. cervical 
shortening/funnelling or vaginal fibronectin are more likely to be accurate than screening e.g. 
for infection. Once these tests become positive it may be less likely that an intervention would 
be effective. 
Given the quality, level and precision of the accuracy evidence, the thesis found that no single 
test emerged as a front runner neither in predicting spontaneous preterm births when the test 
result was positive nor to exclude it when the test result was negative. On a few occasions, 
this was due to imprecision of the LR estimates i.e. given a useful LR point estimate; its CI’s 
should not be wide enough so as to make the LR less useful due to its imprecision. For 
example absence of fetal breathing movement had an LR+ 6.08 (95% CI 5.22 - 49.55) which 
would have made it a useful test in predicting spontaneous preterm birth within 48 hours 
testing when the result is positive. However, it had and LR- 0.16 (95% CI 0.05 - 0.58) where 
the upper limit of its confidence would have made it less than a useful test when the test result 
is negative. Had the estimate of the LR- including its CI’s be <0.2, absence of fetal breathing 
movement would have been a useful test indeed. It may well be that no single screening or 
testing modality would suffice in the prediction of spontaneous preterm birth and that an IPD 
to better delineate the accuracy of test combinations has to be considered in the absence of a 
novel accurate test.  
Recommendations for practice 
How, and before, accuracy results from this thesis are considered for incorporation into 
clinical practice, there are several factors to be appraised. They include dealing with 
challenges relating to the systematic review process (covered above), patient acceptance and 
preferences as well as cost-effectiveness’ analysis of any interventions (taking account both 
the tests’ and interventions’ benefits and harmful side-effects to both mother and fetus 
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(newborn)). Notwithstanding such challenges, one such consideration for application of thesis 
is modelling the integration of accuracy results with results from effectiveness studies to 
derive corresponding number needed to treat (NNTreat) and number needed to test (NNTest), 
which will aid and inform decision making. Of patients’ acceptance and preference, the issues 
have not been explored in the literature especially in relation to more invasive tests yet 
potentially accurate (e.g. amniotic fluid measurement of interleukins). One of the key issues 
concerning screening or predictive tests for spontaneous preterm birth is that, if available 
effective interventions are convenient, inexpensive, and without particular risk of harm or side 
effects, it is better to have tests with better LR- than LR+ values. It is worth speculating that 
in preventing spontaneous preterm birth, it may be difficult from a clinical and patient 
perspective to distinguish between false positive and false negative results and so from this 
perspective the optimal screening or testing modality will be one which minimizes both false 
positive (i.e. the test showed a high LR+) and false negative (i.e. the test showed a low LR-) 
results. Where screening and or testing have low LR- than high LR+, they are unlikely to 
improve cost-effectiveness when used in combination with cheap, safe and effective 
treatments. Similarly, where screening and or testing have higher LR+ it will minimize the 
unwarranted cost, complications from exposure of women and the fetus to treatments. 
Depending on the cost-effectiveness’ analysis, there is a small risk of overlooking potentially 
accurate screening or testing modalities in the face of cheap, safe and effective interventions 
to prevent spontaneous preterm birth. Data provided in Figure 99 - Figure 101 would be ideal 
for consideration into a cost-effectiveness’ future research analysis because it provided the 
most robust estimates, which was either derived from meta-analysis of ideal quality studies or 
from the largest higher quality study available for the particular test. Such a cost-effective 
analysis would have shown the level of LR+ and LR- that would be required to make testing 
cost-effective in prevention of spontaneous preterm birth. Until such a consideration (i.e. cost-
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effectiveness), there are no practical recommendations for clinicians for prevention of 
spontaneous preterm birth with testing performed before preventative treatment, beyond 
stating, which of those available tests that are accurate and are thus worthy for further 
considerations.  
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Table 9 Testing among symptomatic pregnant women for risk of spontaneous preterm birth and number 
of women needed to be tested and treated with antenatal maternal administration of corticosteroids to 
prevent respiratory distress syndrome before 34 weeks’ gestation for anticipated birth within 7 days of 
testing, based on a prevalence of spontaneous preterm birth of 4.5%, risk of respiratory distress syndrome 
(RDS) of 53% and relative risk treatment effect of corticosteroids of 0.661  
 
 
Probability of 
spontaneous 
preterm birth 
after testing 
positive (%) 
Probability 
of RDS 
without 
treatment 
(%)2 
Probability 
of RDS 
after 
treatment 
(%) 
NNTreat3 NNTest4 
      
No test, no treatment − 2.4 2.4 − − 
No test, treat all − 2.4 1.6 123 − 
      
Test all, treat positives      
Serum CRP 61.8 32.8 21.6 9 112 
Cervical length (15mm) 28.9 15.3 10.1 19 48 
Amniotic fluid IL6 (7.5ng/ml) 24.8 13.2 8.7 22 56 
Cervico-vaginal HCG (30mIU/mL) 22.2 11.8 7.8 25 49 
Absence of fetal breathing movement 15.9 8.4 5.9 29 65 
Cervico-vaginal fetal fibronectin 14.2 7.5 5.6 39 58 
phIGFBP-1 11.8 6.2 4.1 48 95 
      
      
1. Risk of RDS at this gestation was derived from Usher et al350 and Sinclair et al351 while that of corticosteroids treatment 
effect was derived from Roberts et al.352 
2. Further detail for the calculation for probability of RDS can be found from Honest et al.23 
3. Number needed to treat (NNTreat) to prevent one additional case of an adverse outcome  was calculated by 1/(post-test 
disease probability after tested positive – probability of disease after tested positive & received treatment). 
4. Number needed to test (NNTest) to prevent one additional case of an adverse outcome with the treatment of test 
positive case was calculated by 1/(true positives as a proportion of population (TP) – (TP * RR)). 
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Recommendations for research 
• New more robustly designed test accuracy studies are required to develop tests that 
have superior LR- values. 
• Such studies should evaluate the added value of new test using multivariable analyses 
and include cost-effectiveness’ analysis taking into account subsequent interventions together 
with both tests and interventions benefits and side-effects profile as well as women’s 
acceptance and preference. 
• Where such studies are not forthcoming, individual patient data (IPD) of test accuracy 
meta-analysis should be considered as an alternative. 
Chapter 7 Conclusions 
There are a number of promising tests identified by this thesis in spite of the aforementioned 
provisos and limitation. For asymptomatic women, only testing for asymptomatic bacteriuria, 
cervico-vaginal fibronectin, assessment for periodontitis and bacterial vaginosis, and serum β-
hcg were evaluated in more than 10 studies while for symptomatic women, aside from fetal 
fibronectin, and amniotic fluid IL6 which has been evaluated in 31 and 10 studies 
respectively, the remainder have only been evaluated in a handful of studies. Some tests were 
able to achieve high predictive value when positive, but at the expense of compromised low 
predictive value when negative. Only a few tests reached LR+ point estimates >5. In 
asymptomatic antenatal women these were ultrasonographic cervical funnelling and length 
measurement, cervico-vaginal prolactin and cervico-vaginal fetal fibronectin screening for 
predicting spontaneous preterm birth before 34 weeks’ gestation. In this group, tests with LR- 
point estimates approaching <0.2 were detection of uterine contraction (by mammary 
stimulating test) and amniotic fluid CRP measurement. In symptomatic women with 
threatened preterm labour tests with LR+ point estimate >5 were absence of fetal breathing 
movements, cervical length measurement, amniotic fluid IL6 and IL8, serum CRP and 
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cervico-vaginal hcg (for predicting birth within 2-7 days of testing); and serum CRP, amniotic 
fluid IL6, and MMP-9, cervico-vaginal fetal fibronectin and cervico-vaginal hcg (for 
predicting spontaneous preterm birth before 34 or 37 weeks’ gestation). In this group tests 
with LR- point estimate <0.2 were measurement of cervico-vaginal hcg, cervical length 
measurement, absence of fetal breathing movement, amniotic fluid IL6 and IL8, and serum 
CRP (for predicting birth within 2 - 7 days of testing); and cervico-vaginal fetal fibronectin 
and amniotic fluid IL6 (for predicting spontaneous preterm birth before 34 or 37 weeks’ 
gestation). 
The prominence of the detection of absence of fetal breathing movement, cervical funnelling 
and cervical length measurement provide a stronger impetus for a universal provision for high 
quality ultrasound machine in labour wards for predicting spontaneous preterm birth among 
women with a viable pregnancy who present with threatened preterm labour to direct 
management (e.g. administration of tocolysis, corticosteroids and in-utero transfer). 
Nevertheless, provision for round the clock trained personnel to perform such a scan in the 
interim is a challenge. Additionally, the feasibility and acceptability to mothers and health 
providers of such tests including more invasive (but potentially more accurate amniotic fluid 
assessment of IL6 and 8) strategies needs to be explored. Rigorous evaluation is needed of 
tests with minimal cost (i.e. tests that are ‘inexpensive’) or invasiveness whose initial 
assessments suggest that they may have high levels of accuracy. Similarly, there is a need for 
high quality, adequately powered randomized controlled trials to investigate whether 
interventions are indeed effective in reducing (in asymptomatic women) and/or delaying (in 
symptomatic women with threatened preterm labour) spontaneous preterm birth. In future, an 
economic model (cost-effectiveness) should be developed which considers not just 
spontaneous preterm birth, but other related outcomes, particularly those relevant to the infant 
like perinatal death and shorter and longer term outcomes amongst survivors. Such a 
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modelling project should make provision for primary data collection on the safety of 
interventions and their associated costs. 
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Appendices 
Appendix I - List of tests 
List of tests for predicting spontaneous preterm birth 
Type of tests or 
investigation  
Predictive and diagnostic tests for preterm birth Last updated 
   
History Previous history of either spontaneous preterm birth* 
 
 
   
Examination Abdominal palpation+ 
 
 
 Cervical digital examination+ 
 
 
   
Biochemistry Cervico-vaginal glycoproteins:  
Interleukins (IL-6, IL-8)+ 
β-hcg+ 
Fetal fibronectin*+  
Phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1)+ 
 
2001 
 Serum glycoproteins: α-fetoprotein, human chorionic gonadotrophin (as part of Down’s 
screening)* 
 
 
 Endocrine hormones: 
Salivary estriol+ 
Corticotrophin releasing hormone+ 
 
 
 Inflammatory markers (serum):  
C-reactive protein*+ 
Matrix metalloprotease (MMP)+ 
Interleukins*+ 
 
 
   
Microbiology Detection of bacterial vaginosis*+ 
Periodontal screening* 
Midstream urine culture*+ 
 
2002 
2006 
1989 
   
Physiological Uterine activity monitoring* 
Rheobase+ 
Mammary stimulation test+ 
 
 
   
Ultrasound scan Absence of fetal breathing movements+ 
 
2003 
 Measurement of cervical length*+ 
 
2003 
   
*Test applied on asymptomatic women 
+Test applied on symptomatic women 
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Appendix II - Search strategies 
MEDLINE (Ovid Gateway).  2000-2005/Aug week 1.  10th August 2005. 
 
186 records were retrieved.   
 
1. Meta-Analysis/ 
2. Review-Literature/ 
3. meta analysis.pt. 
4. review literature.pt. 
5. (meta analy$ or metaanaly$ or meta-analy$).tw. 
6. (systematic adj4 (review$ or overview$)).tw. 
7. (data adj synthesis).ti,ab. 
8. (published adj studies).ti,ab. 
9. (data adj extract$).ti,ab. 
10. or/1-9 
11. letter.pt. 
12. comment.pt. 
13. editorial.pt. 
14. 11 or 12 or 13 
15. Animal/ 
16. Human/ 
17. 15 not (15 and 16) 
18. 10 not (14 or 17) 
19. Labor, Premature/ 
20. ((premature or preterm or pre term or pre-term) adj3 birth$).ti,ab. 
21. ((premature or preterm or pre term or pre-term) adj3 deliver$).ti,ab. 
22. ((preterm or pre term or pre-term) adj3 (labor or labour)).ti,ab. 
23. (premature adj3 (labor or labour or parturition)).ti,ab. 
24. Fetal Membranes, Premature Rupture/ 
25. ((premature or preterm or pre term or pre-term) adj3 rupture$).ti,ab. 
26. (PROM or PPROM).ti,ab. 
27. or/19-26 
28. 18 and 27 
 
 
MEDLINE (Ovid Gateway). 2002/April-2005/Sep week 1.  20th September 2005. 
 
2858 records were retrieved in MEDLINE and 184 records were retrieved in MEDLINE In-Process & Other Non-Indexed Citations.   
 
1. Labor, Premature/ 
2. ((premature or preterm or pre term) adj3 birth$).ti,ab. 
3. ((premature or preterm or pre term) adj3 deliver$).ti,ab. 
4. ((preterm or pre term) adj3 (labor or labour)).ti,ab. 
5. (premature adj3 (labor or labour or parturition)).ti,ab. 
6. or/1-5 
7. exp Socioeconomic Factors/ 
8. Social Class/ 
9. Ethnic Groups/ 
10. risk factors/ 
11. Life Style/ 
12. exp Substance-Related Disorders/ 
13. exp smoking/ 
14. Pregnancy, High-Risk/ 
15. Pregnancy in Adolescence/ 
16. exp Pregnancy, Multiple/ 
17. Pregnancy Complications/ 
18. Parity/ 
19. Reproductive History/ 
20. Fetal Membranes, Premature Rupture/ 
21. Cervix Incompetence/ 
22. exp Abdominal Pain/ 
23. Uterine Contraction/ 
24. Uterine Hemorrhage/ 
25. Cervical Ripening/ 
26. Treponema pallidum/ 
27. Neisseria gonorrhoeae/ 
28. Chlamydia trachomatis/ 
29. exp Sexually Transmitted Diseases, Bacterial/ 
30. exp Bacteroidaceae Infections/ 
31. exp Chlamydiaceae Infections/ 
32. exp Herpes Genitalis/ 
33. Vaginosis, Bacterial/ 
34. mobiluncus/ 
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35. Streptococcus agalactiae/ 
36. Mycoplasma hominis/ 
37. Trichomonas vaginalis/ 
38. Bacteroides Infections/ 
39. Gardnerella vaginalis/ 
40. Bacteriuria/ 
41. Granuloma Inguinale/ 
42. exp Mycoplasmatales Infections/ 
43. exp Neisseriaceae Infections/ 
44. exp Treponemal Infections/ 
45. exp Staphylococcal Infections/ 
46. exp Streptococcal Infections/ 
47. Ureaplasma Infections/ 
48. exp Lactobacillus/ 
49. exp Urinary Tract Infections/ 
50. exp "Diagnostic Techniques, Obstetrical and Gynecological"/ 
51. exp Diagnostic Equipment/ 
52. exp Diagnostic Imaging/ 
53. Diagnostic Tests, Routine/ 
54. exp Reagent Kits, Diagnostic/ 
55. exp Ultrasonography, Prenatal/ 
56. Medical History Taking/ 
57. Risk Assessment/ 
58. exp Physical Examination/ 
59. Uterine Monitoring/ 
60. exp Culture Techniques/ 
61. exp Body Constitution/ 
62. Body Temperature/ 
63. exp fever/ 
64. Palpation/ 
65. exp Corpus Luteum Hormones/ 
66. Relaxin/ 
67. exp Prostaglandins/ 
68. exp Estrogens/ 
69. exp Inhibins/ 
70. exp Estradiol/ 
71. exp Estriol/ 
72. exp Estrone/ 
73. exp Estrogen Receptor Modulators/ 
74. exp Receptors, Estrogen/ 
75. exp Prostaglandin Antagonists/ 
76. exp Receptors, Prostaglandin/ 
77. exp Leukotrienes/ 
78. exp Thromboxanes/ 
79. exp Collagenases/ 
80. Fetal Proteins/ 
81. Fibronectins/ 
82. exp Acute-Phase Proteins/ 
83. exp Immunoproteins/ 
84. Platelet-Derived Growth Factor/ 
85. Tumor Necrosis Factor-alpha/ 
86. Chorioamnionitis/ 
87. Esterases/ 
88. exp Cytokines/ 
89. exp Amniotic Fluid/ 
90. exp Leukocytes/ 
91. Saliva/ 
92. exp Biological Markers/ 
93. Corticotropin-Releasing Hormone/ 
94. (risk factor$ or socioeconomic factor$ or socioeconomic status).ti,ab. 
95. (occupation$ or socioeconomic or ethnic or ethnicity or manual work or long hours).ti,ab. 
96. (cocaine or heroin or narcotics or crack or dope or cannabis or substance abuse$ or addiction).ti,ab. 
97. (substance disorder$ or smoking or tobacco or alcohol$ or lifestyle$ or life-style$).ti,ab. 
98. (low adj3 pregnancy adj3 weight).ti,ab. 
99. high parity.ti,ab. 
100. (early adj3 bleeding adj3 pregnancy).ti,ab. 
101. vaginal bleeding.ti,ab. 
102. ((uterine or antepartum) adj3 (hemorrhage or haemorrhage)).ti,ab. 
103. (abdominal pain or uterine contraction$).ti,ab. 
104. (pyrexia or febrile or fever).ti,ab. 
105. (short adj3 pregnancies).ti,ab. 
106. (interpregnancy interval$ or inter-pregnancy interval$).ti,ab. 
107. (older women or elderly women).ti,ab. 
108. (adolescent$ or teenage$).ti,ab. 
109. (clinical histor$ or patient histor$ or patient record$ or pregnan$ histor$ or birth histor$ or reproductive histor$).ti,ab. 
110. (obstetric histor$ or previous preterm or repeat preterm).ti,ab. 
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111. (premature adj3 rupture adj3 membrane$).ti,ab. 
112. Chorioamnionitis.ti,ab. 
113. (estriol or plasma crf or vaginal infection$).ti,ab. 
114. ((biophysical or biochemical) adj3 marker$).ti,ab. 
115. (bishop$ adj1 (score or scores)).ti,ab. 
116. (cervical adj1 (change$ or length or measurement)).ti,ab. 
117. (endocervical adj1 (effacement or assessment or examination)).ti,ab. 
118. (cervical adj1 (effacement or assessment or state or examination$)).ti,ab. 
119. (risk scor$ or physical examination$).ti,ab. 
120. (physical exam or physical exams or cervical dilation or (cervix adj3 length)).ti,ab. 
121. (dilation adj3 cervix).ti,ab. 
122. tocodynamo$.ti,ab. 
123. (uterine tocography or uterine anomal$ or tocometry).ti,ab. 
124. ((cervical or cervix) adj3 (abnormal$ or incompetence or incompetent)).ti,ab. 
125. ((cervical or cervix) adj3 (ultrasound or ultrasonography or sonography)).ti,ab. 
126. ((vaginal or endovaginal or transvaginal or obstetric) adj3 (ultrasound or ultrasonography or sonography)).ti,ab. 
127. (uterine activity or huam or uterine excitability).ti,ab. 
128. ((myometrial or myometrium) adj3 excitability).ti,ab. 
129. ((oncofetal or c-reactive) adj3 protein$).ti,ab. 
130. fibronectin.ti,ab. 
131. (asymptomatic bacteriuria or genital tract infection$).ti,ab. 
132. (leucocyte esterase$ or cytokines).ti,ab. 
133. (culture$ adj3 (amniotic or blood or genital or vaginal or cervical or urine)).ti,ab. 
134. (timp or collagenase or relaxin or tissue inhibitor$).ti,ab. 
135. plasma corticotropin releasing hormone$.ti,ab. 
136. (estrogen or oestrogen or progestogen).ti,ab. 
137. (glucose concentration$ adj3 amniotic).ti,ab. 
138. (zinc adj3 amniotic).ti,ab. 
139. or/7-138 
140. exp "Sensitivity and Specificity"/ 
141. ROC Curve/ 
142. Logistic Models/ 
143. Likelihood Functions/ 
144. exp Diagnostic Errors/ 
145. (predictive value$ or reproducibility or logistic regression).ti,ab. 
146. (ability adj3 predict$).ti,ab. 
147. (logistic model$ or sroc or roc or positive rate or positive rates).ti,ab. 
148. (likelihood ratio$ or negative rate or negative rates).ti,ab. 
149. (receiver operating characteristic or correlation or correlated).ti,ab. 
150. ((tests or test) adj3 accuracy).ti,ab. 
151. (curve or curves or test outcome).ti,ab. 
152. ((pretest or pre-test or posttest or post-test) adj3 probabilities).ti,ab. 
153. diagnosis.ti,ab. 
154. or/140-153 
155. 6 and 139 and 154 
156. 6 and 139 
157. Animals/ 
158. Humans/ 
159. 157 not (157 and 158) 
160. 155 not 159 
161. 156 not 159 
162. (200204$ or 200205$ or 200206$ or 200207$ or 200208$ or 200209$ or 200210$ or 200211$ or 200212$).ed. 
163. (2003$ or 2004$ or 2005$).ed. 
164. 162 or 163 
165. 161 and 164 
 
 
EMBASE (Ovid Gateway). 2002/Mar-2005/week 38.  20th September 2005. 
 
4004 records were retrieved. 
 
1. Premature Labor/ 
2. ((premature or preterm or pre term or pre-term) adj3 birth$).ti,ab. 
3. ((premature or preterm or pre term or pre-term) adj3 deliver$).ti,ab. 
4. ((preterm or pre term or pre-term) adj3 (labor or labour)).ti,ab. 
5. (premature adj3 (labor or labour or parturition)).ti,ab. 
6. Premature Fetus Membrane Rupture/ 
7. ((premature or preterm or pre term or pre-term) adj3 rupture$).ti,ab. 
8. (PROM or PPROM).ti,ab. 
9. or/1-8 
10. exp socioeconomics/ 
11. Social Class/ 
12. Risk Factor/ 
13. exp "Ethnic and Racial Groups"/ 
14. Smoking/ 
15. exp Addiction/ 
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16. Substance Abuse/ 
17. lifestyle/ 
18. High Risk Pregnancy/ 
19. Adolescent Pregnancy/ 
20. parity/ 
21. ANAMNESIS/ 
22. Pregnancy Disorder/ 
23. exp Pregnancy Complication/ 
24. Obstetric Hemorrhage/ 
25. Premature Fetus Membrane Rupture/ 
26. Abdominal Pain/ 
27. Uterus Contraction/ 
28. exp Uterine Complication/ 
29. Uterus Bleeding/ 
30. Fever/ 
31. exp Estrogen/ 
32. Relaxin/ 
33. Treponema Pallidum/ 
34. Neisseria Gonorrhoeae/ 
35. Streptococcus Agalactiae/ 
36. Mycoplasma Hominis/ 
37. Chlamydia Trachomatis/ 
38. Trichomonas Vaginalis/ 
39. bacteroides/ 
40. Vaginitis/ 
41. mobiluncus/ 
42. Gardnerella Vaginalis/ 
43. exp Multiple Pregnancy/ 
44. Uterine Cervix Incompetence/ 
45. Uterine Cervix Ripening/ 
46. Fetoprotein/ 
47. Fibronectin/ 
48. Bacteriuria/ 
49. exp Diagnostic Procedure/ 
50. exp Laboratory Diagnosis/ 
51. Virus Diagnosis/ 
52. Venereal Disease Reaction Test/ 
53. Transvaginal Echography/ 
54. equipment/ 
55. Diagnostic Imaging/ 
56. Test Strip/ 
57. Reagent/ 
58. ultrasound/ 
59. Diagnostic Test/ 
60. Risk Assessment/ 
61. exp Physical Examination/ 
62. exp examination/ 
63. Home Monitoring/ 
64. exp Urogenital System Examination/ 
65. Clinical Observation/ 
66. Fetus Monitoring/ 
67. Esterase/ 
68. exp Tissue Culture/ 
69. exp Cytokine/ 
70. Acute Phase Protein/ 
71. exp Immunoglobulin/ 
72. Platelet Derived Growth Factor/ 
73. Tumor Necrosis Factor/ 
74. Sex Hormone/ 
75. Progesterone/ 
76. Inhibin/ 
77. Estradiol/ 
78. Estriol/ 
79. Estrone/ 
80. exp Estrogen Receptor/ 
81. exp Prostaglandin Receptor Blocking Agent/ 
82. exp Leukotriene/ 
83. exp Thromboxane/ 
84. Collagenase/ 
85. Body Constitution/ 
86. exp "Physical Constitution and Health"/ 
87. exp Body Temperature/ 
88. palpation/ 
89. exp Sexually Transmitted Disease/ 
90. exp bacteroides/ 
91. chlamydiaceae/ 
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92. Granuloma Inguinale/ 
93. mycoplasmatales/ 
94. Gram Negative Infection/ 
95. neisseriaceae/ 
96. Bacterial Infection/ 
97. Staphylococcus Infection/ 
98. Streptococcus Infection/ 
99. exp lactobacillus/ 
100. Genital Herpes/ 
101. exp Urinary Tract Infection/ 
102. exp Chorioamnionitis/ 
103. exp Amnion Fluid/ 
104. exp leukocyte/ 
105. saliva/ 
106. Biological Marker/ 
107. Blood Analysis/ 
108. Blood Culture/ 
109. exp urinalysis/ 
110. Amnion Fluid Analysis/ 
111. Image Analysis/ 
112. Saliva Analysis/ 
113. Sputum Analysis/ 
114. exp assay/ 
115. exp Chemical Analysis/ 
116. Corticotropin Releasing Factor/ 
117. (risk factor$ or socioeconomic factor$ or socioeconomic status).ti,ab. 
118. (occupation$ or socioeconomic or ethnic or ethnicity or manual work or long hours).ti,ab. 
119. (cocaine or heroin or narcotics or crack or dope or cannabis or substance abuse$ or addiction).ti,ab. 
120. (substance disorder$ or smoking or tobacco or alcohol$ or lifestyle$ or life-style$).ti,ab. 
121. (low adj3 pregnancy adj3 weight).ti,ab. 
122. high parity.ti,ab. 
123. (early adj3 bleeding adj3 pregnancy).ti,ab. 
124. vaginal bleeding.ti,ab. 
125. ((uterine or antepartum) adj3 (hemorrhage or haemorrhage)).ti,ab. 
126. (abdominal pain or uterine contraction$).ti,ab. 
127. (pyrexia or febrile or fever).ti,ab. 
128. (short adj3 pregnancies).ti,ab. 
129. (interpregnancy interval$ or inter-pregnancy interval$).ti,ab. 
130. (older women or elderly women).ti,ab. 
131. (adolescent$ or teenage$).ti,ab. 
132. (clinical histor$ or patient histor$ or patient record$ or pregnan$ histor$ or birth history$ or reproductive history$).ti,ab. 
133. (obstetric histor$ or previous preterm or repeat preterm).ti,ab. 
134. (premature adj3 rupture adj3 membrane$).ti,ab. 
135. Chorioamnionitis.ti,ab. 
136. (estriol or plasma crf or vaginal infection$).ti,ab. 
137. ((biophysical or biochemical) adj3 marker$).ti,ab. 
138. (bishop$ adj1 (score or scores)).ti,ab. 
139. (cervical adj1 (change$ or length or measurement)).ti,ab. 
140. (endocervical adj1 (effacement or assessment or examination)).ti,ab. 
141. (cervical adj1 (effacement or assessment or state or examination$)).ti,ab. 
142. (risk scor$ or physical examination$).ti,ab. 
143. (physical exam or physical exams or cervical dilation or (cervix adj3 length)).ti,ab. 
144. (dilation adj3 cervix).ti,ab. 
145. tocodynamo$.ti,ab. 
146. (uterine tocography or uterine anomal$ or tocometry).ti,ab. 
147. ((cervical or cervix) adj3 (abnormal$ or incompetence or incompetent)).ti,ab. 
148. ((cervical or cervix) adj3 (ultrasound or ultrasonography or sonography)).ti,ab. 
149. ((vaginal or endovaginal or transvaginal or obstetric) adj3 (ultrasound or ultrasonography or sonography)).ti,ab. 
150. (uterine activity or huam or uterine excitability).ti,ab. 
151. ((myometrial or myometrium) adj3 excitability).ti,ab. 
152. ((oncofetal or c-reactive) adj3 protein$).ti,ab. 
153. fibronectin.ti,ab. 
154. (asymptomatic bacteriuria or genital tract infection$).ti,ab. 
155. (leucocyte esterase$ or cytokines).ti,ab. 
156. (culture$ adj3 (amniotic or blood or genital or vaginal or cervical or urine)).ti,ab. 
157. (timp or collagenase or relaxin or tissue inhibitor$).ti,ab. 
158. plasma corticotropin releasing hormone$.ti,ab. 
159. (estrogen or oestrogen or progestogen).ti,ab. 
160. (glucose concentration$ adj3 amniotic).ti,ab. 
161. (zinc adj3 amniotic).ti,ab. 
162. or/10-161 
163. Diagnostic Error/ 
164. Diagnostic Accuracy/ 
165. Diagnostic Value/ 
166. Differential Diagnosis/ 
167. Quantitative Diagnosis/ 
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168. exp Statistical Analysis/ 
169. Discriminant Analysis/ 
170. statistics/ 
171. Statistical Model/ 
172. reliability/ 
173. variance/ 
174. Receiver Operating Characteristic/ 
175. Multiple Regression/ 
176. (predictive value$ or reproducibility or logistic regression).ti,ab. 
177. (ability adj3 predict$).ti,ab. 
178. (logistic model$ or sroc or roc or positive rate or positive rates).ti,ab. 
179. (likelihood ratio$ or negative rate or negative rates).ti,ab. 
180. (receiver operating characteristic or correlation or correlated).ti,ab. 
181. ((tests or test) adj3 accuracy).ti,ab. 
182. (curve or curves or test outcome).ti,ab. 
183. ((pretest or pre-test or posttest or post-test) adj3 probabilities).ti,ab. 
184. diagnosis.ti,ab. 
185. (sensitivity or specificity).ti,ab. 
186. or/163-185 
187. 9 and 162 and 186 
188. 9 and 162 
189. exp animal/ 
190. Nonhuman/ 
191. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dogs or dog or cats or bovine or sheep).ti,ab,sh. 
192. 189 or 190 or 191 
193. exp human/ 
194. 192 not (192 and 193) 
195. 187 not 194 
196. 188 not 194 
197. (2002$ or 2003$ or 2004$ or 2005$).em. 
198. 196 and 197 
 
 
BIOSIS (DIALOG). 2002/June-2005/Sep. 22nd September 2005. 
 
1071 records were retrieved. 
 
s (premature or preterm)(3n)birth? ? 
s (premature or preterm)(3n)deliver? 
s (premature or preterm)(3n)(labo?r or parturition) 
s risk(w)factor? ? or socioeconomic(w)factor? ? 
s low(3w)pregnancy(3w)weight 
s high(w)parity 
s early(3n)bleeding(3n)pregnancy 
s vaginal(3n)bleeding 
s (uterine or antepartum)(3w)(hemorrhag? or haemorrhag?) 
s abdominal(w)pain or uterine(w)contraction? ? 
s pyrexia or febrile 
s short(3n)between(3n)pregnancies 
s interpregnancy(w)interval? ? 
s pregnancy(3n)multiple 
s pregnancy(3n)complication? ? 
s pregnancy(3n)(high(w)risk) 
s pregnancy(3n)(adolescen? or teenage?) 
s (older or elderly)(n)women 
s occupation? or socioeconomic or ethnic or ethnicity or manual(w)work or long(w)hours 
s cocaine or heroin or narcotics or crack or dope or cannabis or substance(w)abuse 
s substance(w)disorder? ? or smoking or tobacco or alcohol? or lifestyle? ? 
s estriol or plasma(w)crf or vaginal(3n)infection? ? 
s (biophysical or biochemical)(3w)marker? ? 
s bishop?(w)score? ? 
s cervical(w)(change? or length or measurement) 
s endocervical(w)(effacement or assessment) 
s cervical(w)(effacement or assessment or state) 
s medical(w)histor? or clinical(w)histor? or patient(w)histor? or patient(w)record? ? 
s obstetric(w)histor? or previous(w)preterm or repeat(w)preterm 
s risk(w)scor? or risk(w)assessment 
s physical(w)examination? or cervical(w)dilation or cervix(3n)length 
s dilation(3n)cervix 
s uterine(w)tocography or uterine(w)anomal? or tocometry 
s (cervical or cervix)(3n)(abnormal? or incompetence or incompetent) 
s (cervical or cervix)(3n)(ultrasound or ultrasonography) 
s (vaginal or endovaginal or transvaginal or obstetric)(3n)(ultrasound or ultrasonography) 
s diagnostic(n)(technique? or equipment or test? ?) 
s uterine(3n)activity or huam or uterine(3n)excitability 
s (myometrial or myometrium)(3n)excitability 
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s (oncofetal or c-reactive)(w)(protein?) 
s fibronectin? 
s sexually(w)transmitted(w)disease? 
s asymptomatic(w)bacteriuria or genital(w)tract(w)infection? 
s chlamydia or gonorrhea or herpes 
s leucocyte(w)esterase? or cytokines 
s culture?(3n)(amniotic or blood or genital or vaginal or cervical) 
s timp or collagenase or relaxin or tissue(w)inhibitor? 
s plasma(w)corticotropin(w)releasing(w)hormone? 
s estrogen or oestrogen or progestogen 
s (glucose(w)concentration?)(n)amniotic 
s zinc(n)amniotic 
s s1:s3 
s s4:s51 
s s52 and s53 
s s54/2002-2005 
 
 
PASCAL (DIALOG). 2002/June-2005/Sep. 22nd September 2005. 
 
456 records were retrieved. 
 
s (premature or preterm)(3n)birth? ? 
s (premature or preterm)(3n)deliver? 
s (premature or preterm)(3n)(labo?r or parturition) 
s risk(w)factor? ? or socioeconomic(w)factor? ? 
s low(3w)pregnancy(3w)weight 
s high(w)parity 
s early(3n)bleeding(3n)pregnancy 
s vaginal(3n)bleeding 
s (uterine or antepartum)(3w)(hemorrhag? or haemorrhag?) 
s abdominal(w)pain or uterine(w)contraction? ? 
s pyrexia or febrile 
s short(3n)between(3n)pregnancies 
s interpregnancy(w)interval? ? 
s pregnancy(3n)multiple 
s pregnancy(3n)complication? ? 
s pregnancy(3n)(high(w)risk) 
s pregnancy(3n)(adolescen? or teenage?) 
s (older or elderly)(n)women 
s occupation? or socioeconomic or ethnic or ethnicity or manual(w)work or long(w)hours 
s cocaine or heroin or narcotics or crack or dope or cannabis or substance(w)abuse 
s substance(w)disorder? ? or smoking or tobacco or alcohol? or lifestyle? ? 
s estriol or plasma(w)crf or vaginal(3n)infection? ? 
s (biophysical or biochemical)(3w)marker? ? 
s bishop?(w)score? ? 
s cervical(w)(change? or length or measurement) 
s endocervical(w)(effacement or assessment) 
s cervical(w)(effacement or assessment or state) 
s medical(w)histor? or clinical(w)histor? or patient(w)histor? or patient(w)record? ? 
s obstetric(w)histor? or previous(w)preterm or repeat(w)preterm 
s risk(w)scor? or risk(w)assessment 
s physical(w)examination? or cervical(w)dilation or cervix(3n)length 
s dilation(3n)cervix 
s uterine(w)tocography or uterine(w)anomal? or tocometry 
s (cervical or cervix)(3n)(abnormal? or incompetence or incompetent) 
s (cervical or cervix)(3n)(ultrasound or ultrasonography) 
s (vaginal or endovaginal or transvaginal or obstetric)(3n)(ultrasound or ultrasonography) 
s diagnostic(n)(technique? or equipment or test? ?) 
s uterine(3n)activity or huam or uterine(3n)excitability 
s (myometrial or myometrium)(3n)excitability 
s (oncofetal or c-reactive)(w)(protein?) 
s fibronectin? 
s sexually(w)transmitted(w)disease? 
s asymptomatic(w)bacteriuria or genital(w)tract(w)infection? 
s chlamydia or gonorrhea or herpes 
s leucocyte(w)esterase? or cytokines 
s culture?(3n)(amniotic or blood or genital or vaginal or cervical) 
s timp or collagenase or relaxin or tissue(w)inhibitor? 
s plasma(w)corticotropin(w)releasing(w)hormone? 
s estrogen or oestrogen or progestogen 
s (glucose(w)concentration?)(n)amniotic 
s zinc(n)amniotic 
s s1:s3 
s s4:s51 
s s52 and s53 
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s s54/2002-2005 
 
 
Science Citation Index (SCI) (DIALOG). 2002/June-2005/Sep. 22nd September 2005. 
 
643 records were retrieved. 
 
s (premature or preterm)(3n)birth? ? 
s (premature or preterm)(3n)deliver? 
s (premature or preterm)(3n)(labo?r or parturition) 
s risk(w)factor? ? or socioeconomic(w)factor? ? 
s low(3w)pregnancy(3w)weight 
s high(w)parity 
s early(3n)bleeding(3n)pregnancy 
s vaginal(3n)bleeding 
s (uterine or antepartum)(3w)(hemorrhag? or haemorrhag?) 
s abdominal(w)pain or uterine(w)contraction? ? 
s pyrexia or febrile 
s short(3n)between(3n)pregnancies 
s interpregnancy(w)interval? ? 
s pregnancy(3n)multiple 
s pregnancy(3n)complication? ? 
s pregnancy(3n)(high(w)risk) 
s pregnancy(3n)(adolescen? or teenage?) 
s (older or elderly)(n)women 
s occupation? or socioeconomic or ethnic or ethnicity or manual(w)work or long(w)hours 
s cocaine or heroin or narcotics or crack or dope or cannabis or substance(w)abuse 
s substance(w)disorder? ? or smoking or tobacco or alcohol? or lifestyle? ? 
s estriol or plasma(w)crf or vaginal(3n)infection? ? 
s (biophysical or biochemical)(3w)marker? ? 
s bishop?(w)score? ? 
s cervical(w)(change? or length or measurement) 
s endocervical(w)(effacement or assessment) 
s cervical(w)(effacement or assessment or state) 
s medical(w)histor? or clinical(w)histor? or patient(w)histor? or patient(w)record? ? 
s obstetric(w)histor? or previous(w)preterm or repeat(w)preterm 
s risk(w)scor? or risk(w)assessment 
s physical(w)examination? or cervical(w)dilation or cervix(3n)length 
s dilation(3n)cervix 
s uterine(w)tocography or uterine(w)anomal? or tocometry 
s (cervical or cervix)(3n)(abnormal? or incompetence or incompetent) 
s (cervical or cervix)(3n)(ultrasound or ultrasonography) 
s (vaginal or endovaginal or transvaginal or obstetric)(3n)(ultrasound or ultrasonography) 
s diagnostic(n)(technique? or equipment or test? ?) 
s uterine(3n)activity or huam or uterine(3n)excitability 
s (myometrial or myometrium)(3n)excitability 
s (oncofetal or c-reactive)(w)(protein?) 
s fibronectin? 
s sexually(w)transmitted(w)disease? 
s asymptomatic(w)bacteriuria or genital(w)tract(w)infection? 
s chlamydia or gonorrhea or herpes 
s leucocyte(w)esterase? or cytokines 
s culture?(3n)(amniotic or blood or genital or vaginal or cervical) 
s timp or collagenase or relaxin or tissue(w)inhibitor? 
s plasma(w)corticotropin(w)releasing(w)hormone? 
s estrogen or oestrogen or progestogen 
s (glucose(w)concentration?)(n)amniotic 
s zinc(n)amniotic 
s s1:s3 
s s4:s51 
s s52 and s53 
s s54/2002-2005 
 
 
Inside Conferences (DIALOG). 2002/June-2005/Sep. 22nd September 2005. 
 
12 records were retrieved. 
 
s (premature or preterm)(3n)birth? ? 
s (premature or preterm)(3n)deliver? 
s (premature or preterm)(3n)(labo?r or parturition) 
s risk(w)factor? ? or socioeconomic(w)factor? ? 
s low(3w)pregnancy(3w)weight 
s high(w)parity 
s early(3n)bleeding(3n)pregnancy 
s vaginal(3n)bleeding 
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s (uterine or antepartum)(3w)(hemorrhag? or haemorrhag?) 
s abdominal(w)pain or uterine(w)contraction? ? 
s pyrexia or febrile 
s short(3n)between(3n)pregnancies 
s interpregnancy(w)interval? ? 
s pregnancy(3n)multiple 
s pregnancy(3n)complication? ? 
s pregnancy(3n)(high(w)risk) 
s pregnancy(3n)(adolescen? or teenage?) 
s (older or elderly)(n)women 
s occupation? or socioeconomic or ethnic or ethnicity or manual(w)work or long(w)hours 
s cocaine or heroin or narcotics or crack or dope or cannabis or substance(w)abuse 
s substance(w)disorder? ? or smoking or tobacco or alcohol? or lifestyle? ? 
s estriol or plasma(w)crf or vaginal(3n)infection? ? 
s (biophysical or biochemical)(3w)marker? ? 
s bishop?(w)score? ? 
s cervical(w)(change? or length or measurement) 
s endocervical(w)(effacement or assessment) 
s cervical(w)(effacement or assessment or state) 
s medical(w)histor? or clinical(w)histor? or patient(w)histor? or patient(w)record? ? 
s obstetric(w)histor? or previous(w)preterm or repeat(w)preterm 
s risk(w)scor? or risk(w)assessment 
s physical(w)examination? or cervical(w)dilation or cervix(3n)length 
s dilation(3n)cervix 
s uterine(w)tocography or uterine(w)anomal? or tocometry 
s (cervical or cervix)(3n)(abnormal? or incompetence or incompetent) 
s (cervical or cervix)(3n)(ultrasound or ultrasonography) 
s (vaginal or endovaginal or transvaginal or obstetric)(3n)(ultrasound or ultrasonography) 
s diagnostic(n)(technique? or equipment or test? ?) 
s uterine(3n)activity or huam or uterine(3n)excitability 
s (myometrial or myometrium)(3n)excitability 
s (oncofetal or c-reactive)(w)(protein?) 
s fibronectin? 
s sexually(w)transmitted(w)disease? 
s asymptomatic(w)bacteriuria or genital(w)tract(w)infection? 
s chlamydia or gonorrhea or herpes 
s leucocyte(w)esterase? or cytokines 
s culture?(3n)(amniotic or blood or genital or vaginal or cervical) 
s timp or collagenase or relaxin or tissue(w)inhibitor? 
s plasma(w)corticotropin(w)releasing(w)hormone? 
s estrogen or oestrogen or progestogen 
s (glucose(w)concentration?)(n)amniotic 
s zinc(n)amniotic 
s s1:s3 
s s4:s51 
s s52 and s53 
s s54/2002-2005 
 
 
Cochrane Database of Systematic Reviews (CDSR) and Cochrane Central Register of Controlled Trials (CENTRAL).   Cochrane 
Library, Issue 2:2002-3:2005.  20th September 2005. 
 
1 new protocol was identified in CDSR and 144 records were retrieved in CENTRAL. 
 
Labor, Premature (MeSH) 
(premature or preterm or pre*term) NEAR/3 birth 
(premature or preterm or pre*term) NEAR/3 deliver* 
(preterm or pre*term) NEAR/3 (labour or labor) 
premature NEAR/3 (labour or labor or parturition) 
Fetal Membranes, Premature Rupture (MeSH) 
(premature or preterm or pre*term) NEAR/3 ruptur*  
PROM or PPROM 
#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 
Socioeconomic Factors (MeSH) 
Social Class (MeSH) 
Risk Factors (MeSH) 
Ethnic Groups (MeSH) 
Smoking (MeSH) 
Life Style(MeSH) 
Substance-Related Disorders(MeSH) 
Pregnancy, High-Risk (MeSH) 
Parity (MeSH) 
Reproductive History (MeSH) 
Abdominal Pain (MeSH) 
Pregnancy Complications (MeSH) 
Uterine Contraction (MeSH) 
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Uterine Hemorrhage (MeSH) 
Fever (MeSH) 
Estriol (MeSH) 
Relaxin (MeSH) 
Treponema pallidum (MeSH) 
Neisseria gonorrhoeae (MeSH) 
Streptococcus agalactiae (MeSH) 
Mycoplasma hominis (MeSH) 
Chlamydia trachomatis (MeSH) 
Trichomonas vaginalis (MeSH) 
Bacteroides Infections (MeSH) 
Vaginosis, Bacterial (MeSH) 
Mobiluncus (MeSH) 
Gardnerella vaginalis (MeSH) 
Prostaglandins (MeSH) 
Pregnancy, Multiple (MeSH) 
Cervix Incompetence (MeSH) 
Cervical Ripening (MeSH) 
Fetal Proteins (MeSH) 
Bacteriuria (MeSH) 
Diagnostic Techniques, Obstetrical and Gynecological (MeSH) 
Diagnostic Equipment (MeSH) 
Diagnostic Imaging (MeSH) 
Reagent Kits, Diagnostic (MeSH) 
Ultrasonography, Prenatal (MeSH) 
Diagnostic Tests, Routine (MeSH) 
Medical History Taking (MeSH) 
Risk Assessment (MeSH) 
Physical Examination (MeSH) 
Uterine Monitoring (MeSH) 
Esterases (MeSH) 
Cytokines (MeSH) 
Immunoproteins (MeSH) 
Platelet-Derived Growth Factor (MeSH) 
Tumor Necrosis Factor-alpha (MeSH) 
Gonadal Steroid Hormones (MeSH) 
Corpus Luteum Hormones (MeSH) 
Estrogens (MeSH) 
Inhibins (MeSH) 
Estradiol (MeSH) 
Estrone (MeSH) 
Receptors, Estrogen (MeSH) 
Prostaglandin Antagonists (MeSH) 
Receptors, Prostaglandin (MeSH) 
Leukotrienes (MeSH) 
Receptors, Thromboxane (MeSH) 
Collagenases (MeSH) 
Body Constitution (MeSH) 
Body Temperature (MeSH) 
Palpation (MeSH) 
Sexually Transmitted Diseases, Bacterial (MeSH) 
Bacteroidaceae Infections (MeSH) 
Chlamydiaceae Infections (MeSH) 
Granuloma Inguinale (MeSH) 
Mycoplasmatales Infections (MeSH) 
Neisseriaceae Infections (MeSH) 
Treponemal Infections (MeSH) 
Staphylococcal Infections (MeSH) 
Streptococcal Infections (MeSH) 
Ureaplasma Infections (MeSH) 
Lactobacillus (MeSH) 
Herpes Genitalis (MeSH) 
Urinary Tract Infections (MeSH) 
Chorioamnionitis (MeSH) 
Amniotic Fluid (MeSH) 
Leukocytes (MeSH) 
Saliva (MeSH) 
Biological Markers (MeSH) 
Corticotropin-Releasing Hormone (MeSH)  
(older or elderly) NEAR women 
fibronectin* or tocodynamo* or (risk NEAR factor*) or (socioeconomic NEAR factor*) 
low NEAR pregnancy NEAR weight 
(high NEAR parity) or (early NEAR bleeding) or (vaginal NEAR bleeding) or (uterine or antepartum) NEAR hemorrhage  or (abdominal 
NEAR pain) or (uterine NEAR contraction*) or pyrexia or febrile or fever or short NEAR/3 between NEAR/3 pregnancies  
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interpregnancy and interval* or occupation* or socioeconomic or ethnic or ethnicity or (manual NEAR work) or (long NEAR hours) or 
cocaine or heroin or narcotics or crack or dope or cannabis or (substance NEAR abuse) or smoking or tobacco or alcohol* or lifestyle* or 
estriol or (plasma NEAR crf) or (vaginal NEAR infection*)  
(biophysical or biochemical) and marker* or bishop* and (score or scores) or cervical NEAR (change* or length or measurement) or 
endocervical NEAR (effacement or assessment) or cervical NEAR (effacement or assessment or state)  
(clinical NEAR histor*) or (patient NEAR histor*) or (patient NEAR record*) or (obstetric NEAR histor*) or (previous NEAR preterm) or 
(repeat NEAR preterm) or (risk NEAR scor*) or (physical NEAR examination*) or (physical NEAR exam) or (physical NEAR exams) or 
(cervical NEAR dilation) or (cervix NEAR length) or dilation NEAR cervix  
(uterine NEAR tocography) or (uterine NEAR anomal*) or tocometry or (cervical or cervix) NEAR (abnormal* or incompetence or 
incompetent) or (cervical or cervix) NEAR (ultrasound or ultrasonography) or (vaginal or endovaginal or transvaginal or obstetric) NEAR 
(ultrasound or ultrasonography) or uterine NEAR (activity or huam or excitability)  
(myometrial or myometrium) NEAR excitability or (oncofetal or reactive) NEAR (protein*) or (asymptomatic NEAR bacteriuria) or (genital 
NEAR tract NEAR infection*) or leucocyte NEAR (esterase* or cytokines) or culture* NEAR (amniotic or blood or genital or vaginal or 
cervical)  
timp or collagenase or relaxin or (tissue NEAR inhibitor*) or plasma NEAR corticotropin NEAR releasing NEAR hormone* or estrogen or 
oestrogen or progestogen or glucose NEAR concentration* NEAR amniotic or zinc NEAR amniotic  
#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 
#21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 
OR #38 OR #39 OR #40 
#41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 
OR #58 OR #59 OR #60 
#61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 
OR #78 OR #79 OR #80 
#81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94 OR #95 OR #96 OR #97 
OR #98 OR #99 OR #100 OR #101 
#102 OR #103 OR #104 OR #105 OR #106 
 
 
National Research Register (NRR). (Update Software). 2002:1-2005:3. 21st September 2005. 
 
192 records were retrieved. 
 
LABOR PREMATURE 
((premature next birth) or (preterm next birth) or (preterm next birth)) 
((premature next deliver*) or (preterm next deliver*) or (preterm next deliver*)) 
((preterm next labour) or (preterm next labour)) 
((preterm next labor) or (preterm next labor)) 
((premature next labour) or (premature next labor) or (premature next parturition)) 
#1 or #2 or #3 or #4 or #5 or #6 
SOCIOECONOMIC FACTORS  
SOCIAL CLASS 
RISK FACTORS 
SMOKING 
ETHNIC GROUPS 
SUBSTANCERELATED DISORDERS 
LIFE STYLE 
PREGNANCY HIGHRISK 
PREGNANCY IN ADOLESCENCE 
PARITY 
REPRODUCTIVE HISTORY 
PREGNANCY COMPLICATIONS 
FETAL MEMBRANES PREMATURE RUPTURE 
ABDOMINAL PAIN 
UTERINE CONTRACTION 
UTERINE HEMORRHAGE 
FEVER 
ESTRIOL 
RELAXIN 
TREPONEMA PALLIDUM 
NEISSERIA GONORRHOEAE 
STREPTOCOCCUS AGALACTIAE 
MYCOPLASMA HOMINIS 
CHLAMYDIA TRACHOMATIS 
TRICHOMONAS VAGINALIS 
BACTEROIDES INFECTIONS 
VAGINOSIS BACTERIAL 
MOBILUNCUS 
GARDNERELLA VAGINALIS 
PROSTAGLANDINS 
PREGNANCY MULTIPLE 
CERVIX INCOMPETENCE 
CERVICAL RIPENING 
FETAL PROTEINS 
BACTERIURIA 
DIAGNOSTIC TECHNIQUES OBSTETRICAL AND GYNECOLOGICAL 
DIAGNOSTIC EQUIPMENT 
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DIAGNOSTIC IMAGING 
REAGENT KITS DIAGNOSTIC 
ULTRASONOGRAPHY PRENATAL 
DIAGNOSTIC TESTS ROUTINE 
MEDICAL HISTORY TAKING 
RISK ASSESSMENT 
PHYSICAL EXAMINATION 
UTERINE MONITORING 
ESTERASES 
CYTOKINES 
TISSUE CULTURE 
ACUTEPHASE PROTEINS 
IMMUNOPROTEINS 
PLATELETDERIVED GROWTH FACTOR 
TUMOR NECROSIS FACTOR 
CORPUS LUTEUM HORMONES 
ESTROGENS 
INHIBINS 
ESTRADIOL 
ESTRIOL 
ESTRONE 
ESTROGEN RECEPTOR MODULATORS 
RECEPTORS ESTROGEN 
PROSTAGLANDIN ANTAGONISTS 
RECEPTORS PROSTAGLANDIN 
LEUKOTRIENES 
THROMBOXANES 
COLLAGENASES 
BODY CONSTITUTION 
BODY TEMPERATURE 
PALPATION 
SEXUALLY TRANSMITTED DISEASES BACTERIAL 
BACTEROIDACEAE INFECTIONS 
CHLAMYDIACEAE INFECTIONS 
GRANULOMA INGUINALE 
MYCOPLASMATALES INFECTIONS 
NEISSERIACEAE INFECTIONS 
TREPONEMAL INFECTIONS 
STAPHYLOCOCCAL INFECTIONS 
STREPTOCOCCAL INFECTIONS 
UREAPLASMA INFECTIONS 
LACTOBACILLUS 
HERPES GENITALIS 
URINARY TRACT INFECTIONS 
CHORIOAMNIONITIS 
AMNIOTIC FLUID 
LEUKOCYTES 
SALIVA 
BIOLOGICAL MARKERS 
CORTICOTROPINRELEASING HORMONE 
((older near women) or (elderly near women)) 
fibronectin* 
((premature near rupture) near membrane*) 
tocodynamo* 
((risk near factor*) or (socioeconomic near factor*)) 
((low near pregnancy) near weight) 
(high next parity) 
((early near bleeding) near pregnancy) 
(vaginal near bleeding) 
((uterine near hemorrhage) or (antepartum near hemorrhage)) 
((abdominal next pain) or (uterine next contraction*)) 
((pyrexia or febrile) or fever) 
((short near between) near pregnancies) 
(interpregnancy and interval*) 
(((((occupation* or socioeconomic) or ethnic) or ethnicity) or (manual next work)) or (long next hours)) 
((((((cocaine or heroin) or narcotics) or crack) or dope) or cannabis) or (substance next abuse)) 
(((((substance and disorder*) or smoking) or tobacco) or alcohol*) or lifestyle*) 
((estriol or (plasma near crf)) or (vaginal near infection*)) 
((biophysical or biochemical) and marker*) 
(bishop* and (score or scores)) 
((cervical near change*) or (cervical near length) or (cervical near measurement)) 
((endocervical near effacement) or (endocervical near assessment)) 
((cervical near effacement) or (cervical near assessment) or (cervical near state)) 
(((clinical near histor*) or (patient near histor*)) or (patient near record*)) 
(((obstetric near histor*) or (previous near preterm)) or (repeat near preterm)) 
((risk next scor*) or (physical next examination*)) 
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((((physical next exam) or (physical next exams)) or (cervical next dilation)) or (cervix near length)) 
(dilation near cervix) 
(((uterine near tocography) or (uterine near anomal*)) or tocometry) 
((cervical near abnormal*) or (cervical near incompetence) or (cervical near incompetent)) 
((cervix near abnormal*) or (cervix near incompetence) or (cervix near incompetent)) 
((cervical near ultrasound) or (cervical near ultrasonography)) 
((cervix near ultrasound) or (cervix near ultrasonography)) 
((vaginal near ultrasound) or (ultrasound near endovaginal) or (transvaginal near ultrasound) or (obstetric near ultrasound) or (vaginal near 
ultrasonography) or (ultrasonography near endovaginal) or (transvaginal near ultrasonography) or (obstetric near ultrasonography)) 
((uterine near activity) or (uterine near huam) or (uterine near excitability)) 
((myometrial near excitability) or (myometrium near excitability)) 
((oncofetal near protein*) or ((c next reactive) near protein*)  
((asymptomatic next bacteriuria) or (genital next tract next infection*)) 
((leucocyte next esterase*) or (leucocyte next cytokines)) 
((amniotic near culture*) or (blood near culture*) or (genital near culture*) or (vaginal near culture*) or (cervical near culture*)) 
(((timp or collagenase) or relaxin) or (tissue next inhibitor*)) 
(plasma next corticotropin next releasing next hormone*) 
((estrogen or oestrogen) or progestogen) 
((glucose next concentration*) near amniotic) 
(zinc near amniotic) 
(#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20) 
(#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40) 
(#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40) 
(#41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60) 
(#61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80) 
(#81 or #82 or #83 or #84 or #85 or #86 or #87 or #88 or #89 or #90 or #91 or #92 or #93 or #94 or #95 or #96 or #97 or #98 or #99 or #100) 
(#101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #112 or #113 or #114 or #115 or #116 or #117 
or #118 or #119 or #120) 
(#121 or #122 or #123 or #124 or #125 or #126 or #127 or #128 or #129 or #130 or #131 or #132 or #133 or #134 or #135 or #136 or #137 
or #138 or #139) 
(#141 or #142 or #143 or #144 or #145 or #146 or #147) 
(#7 and #148) 
 
 
MEDION. 2005. 27th September 2005. 
 
8 records were retrieved. Separate searches were performed using the abstract, title and ICPC code fields. 
 
ICPC code:  W Pregnancy, childbearing, family planning 
 
Abstract, Title:  ‘premature’, ‘preterm’, ‘pre term’, ‘pre-term’  
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Appendix III - Data extraction pro-forma 
Pro-forma for study inclusion and data extraction 
Reviewer Language 1st author Publication year 
 
Data extraction 
 
Country     
Population Asymptomatic Symptomatic   
Study design Cohort Case-control Can’t tell Others (state) 
Data collection Prospective Retrospective Can’t tell Others (state) 
Enrolment Consecutive Arbitrary Can’t tell Others (state) 
Blinding Yes No Can’t tell Others (state) 
Test description Yes No Can’t tell Others (state) 
Inclusion criteria     
Exclusion criteria     
Testing gestation(s)     
Threshold(s)     
Reference standard(s)     
Sample size     
 
2x2 data extraction here (reproduce table as many times as required) 
 
 Birth <48h/7d/34wks/37wks Birth >48h/7d/34wks/37wks Total 
Test positive    
Test negative    
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Appendix IV - Characteristics and results of individual included test accuracy studies 
 
Table 10 Characteristic of studies on accuracy of maternal history of previous spontaneous preterm birth in predicting subsequent spontaneous preterm birth 
 
Authors Year Country n Study designs Inclusion Exclusion Testing gestation Threshold 
Outcome 
(weeks’ 
gestation) 
          
Goldenberg61 1998 USA 1711 Cohort 
Prospective 
Test described 
Singleton pregnancies Placenta previa, 
congenital fetal 
anomaly 
First antenatal 
appointment 
Previous spontaneous preterm birth <35, <37 
Iams62 1998 USA 1282 Cohort 
Prospective 
Test described 
Singleton pregnancies  First antenatal 
appointment 
Previous spontaneous preterm birth 
before 26, 31 or 36 weeks’ gestation 
37 
Botsis57 2004 Greece 104 Cohort 
Prospective 
Test described 
Singleton pregnancies  First antenatal 
appointment 
Previous spontaneous preterm birth 36 
Kristensen63 1995 Denmark 13764 Cohort 
Retrospective 
Test described 
Singleton pregnancies  First antenatal 
appointment 
Previous spontaneous preterm birth 37 
Berkowitz56 1998 USA 13197 Cohort 
Retrospective 
Test described 
Singleton pregnancies  First antenatal 
appointment 
Previous spontaneous preterm birth 37 
Carr-Hill58 1985 UK 6072a 
1463b 
Cohort 
Retrospective 
Test described 
Singleton pregnancies  First antenatal 
appointment 
One, two previous spontaneous 
preterm birth 
37 
deCarvalho59 2005 Brazil 1958 Cohort 
Retrospective 
Test described 
Singleton pregnancies  First antenatal 
appointment 
Previous spontaneous preterm birth 34 
Ancel55 1999 France 13292 Case-control 
Retrospective 
Test described 
Singleton pregnancies  First antenatal 
appointment 
Previous spontaneous preterm birth 37 
Weidinger64 1974 Germany 911 Case-control 
Retrospective 
Test described 
Singleton pregnancies  First antenatal 
appointment 
One, two previous spontaneous 
preterm birth 
37 
deHaas60 1991 USA 420 Case-control 
Retrospective 
Test described 
Singleton pregnancies  First antenatal 
appointment 
Previous spontaneous preterm birth 37 
          
a. One previous spontaneous preterm birth, b. Two previous spontaneous preterm births 
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Table 11 Individual accuracy results of maternal history of previous spontaneous preterm birth in predicting subsequent spontaneous preterm birth 
 
Authors TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                 
Goldenberg61 85 278 119 1229 0.42 0.35 0.49 0.82 0.80 0.83 2.26 1.86 2.74 0.72 0.64 0.81 
Goldenberg$61 55 308 32 1316 0.63 0.52 0.73 0.81 0.79 0.83 3.33 2.76 4.03 0.45 0.34 0.60 
Iams+62 15 83 67 1117 0.18 0.11 0.28 0.93 0.91 0.94 2.64 1.60 4.37 0.88 0.79 0.97 
Iams++62 27 149 55 1051 0.33 0.23 0.44 0.88 0.86 0.89 2.65 1.88 3.74 0.77 0.66 0.89 
Iams+++62 55 323 27 877 0.67 0.56 0.77 0.73 0.70 0.76 2.49 2.09 2.98 0.45 0.33 0.61 
Botsis57 1 10 10 83 0.09 0.00 0.41 0.89 0.81 0.95 0.85 0.12 5.99 1.02 0.83 1.24 
Kristensen63 55 433 241 13035 0.19 0.14 0.23 0.97 0.96 0.97 5.78 4.47 7.46 0.84 0.80 0.89 
Berkowitz56 214 1049 465 11469 0.32 0.28 0.35 0.92 0.91 0.92 3.76 3.32 4.26 0.75 0.71 0.79 
Carr-Hillx58 76 418 261 537 0.23 0.18 0.27 0.56 0.53 0.59 0.52 0.42 0.64 1.38 1.27 1.49 
Carr-Hillxx58 8 17 57 1381 0.12 0.05 0.23 0.99 0.98 0.99 10.12 4.54 22.59 0.89 0.81 0.97 
deCarvalho59 25 155 41 1737 0.38 0.26 0.51 0.92 0.90 0.93 4.62 3.28 6.52 0.68 0.56 0.82 
Ancel55 850 526 4477 7439 0.16 0.15 0.17 0.93 0.93 0.94 2.42 2.18 2.68 0.90 0.89 0.91 
Weidingerx64 73 18 370 450 0.16 0.13 0.20 0.96 0.94 0.98 4.28 2.60 7.06 0.87 0.83 0.91 
Weidingerxx64 25 4 370 450 0.06 0.04 0.09 0.99 0.98 1.00 7.18 2.52 20.46 0.95 0.92 0.97 
deHaas60 21 14 119 266 0.15 0.10 0.22 0.95 0.92 0.97 3.00 1.57 5.72 0.89 0.83 0.96 
                 
$ Spontaneous preterm birth <35 weeks’ gestation 
+ Previous spontaneous preterm birth before 26 weeks’ gestation 
++ Previous spontaneous preterm birth before 31 weeks’ gestation 
+++ Previous spontaneous preterm birth before 36 weeks’ gestation 
x One previous spontaneous preterm birth 
xx Two previous spontaneous preterm birth 
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Table 12 Characteristics of test accuracy studies of digital examination in predicting spontaneous preterm birth stratified according to population of antenatal 
asymptomatic women and women symptomatic with threatened preterm labour 
 
Authors Year Country n Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks) 
Frequency 
of testing Threshold 
Outcome 
(weeks’ 
gestation) 
           
Asymptomatic           
Leveno70 1986 USA 185 Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Low risk pregnancy x 26 - 30 Single 2cm dilated <34 
Parikh72 1961 India 463 Cohort 
Prospective 
Consecutive 
Test described 
Singleton pregnancies Pre-eclampsia, infection, 
placenta previa, previous history 
of miscarriages 
24 - 36 Biweekly Admit digit 
at internal os 
<37 
Iams 2002 USA 270 Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancies Women who had received or 
were scheduled to receive an 
ambulatory monitor or tocolytic 
medication or to undergo 
cerclage were complicated by 
placenta previa or a major fetal 
anomaly detected by 
ultrasonography. Women who 
did not have telephones were not 
enrolled, because the 
transmission of data collected by 
the monitoring system required a 
telephone. 
<35 Quads Bishop score 
changes 
<35 
Stubbs74 1986 USA 108 Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancies Uterine or fetal anomaly, 
previous history of IUGR, 
spontaneous preterm birth, or 
cone biopsy, PPROM, history of 
second trimester miscarriage 
28, 32 and 
34 
Thrice 1cm internal 
os dilatation, 
30% 
effacement 
<37 
Chambers67 1991 France 5066 Cohort 
Prospective 
Test described 
Low risk pregnancy x 28 and 
<37 
Biweekly < 1cm long 
cervix at 28 
weeks, >1cm 
internal os 
dilatation 
before 37 
weeks 
<37 
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Blondel66 1990 France 3159 Cohort 
Prospective 
Test described 
Singleton pregnancies able to 
attend antenatal clinic at 25 - 28 
and 29 - 31 weeks' gestation, 
divided into nulliparous and 
multiparous groups 
Unknown gestation, iatrogenic 
preterm delivery 
25 – 28, 
29 - 31 
Twice 1cm internal 
os dilatation, 
1cm long 
cervix, mid-
position, soft 
cervix 
<37 
Newman71 1997 USA 2916 Cohort 
Prospective 
Test described 
Singleton pregnancies x 22 – 24, 
26 - 29 
Twice Bishop score 
≥4 or 
cervical 
score <1.5 
<35 
Schaffner73 1966 USA 83 Cohort 
Blinded 
Test described 
All pregnant women seen at 
routine antenatal clinic between 
28 - 32 weeks' gestation, divided 
into nulliparous and multiparous 
groups 
Operative cervical procedure, 
threatened or chronic 
miscarriage, hormone 
administration during pregnancy, 
PPROM, previous CS, uncertain 
dates 
28 - 32 Single 2-3cm 
dilated 
<37 
Chabra68 1991 India 75 Cohort 
Prospective 
Test described 
Singleton pregnancies Polyhydramnios, pre-eclampsia, 
vaginal bleeding, previous bad 
obstetrics history or history of 
preterm birth 
28 - 28 Single Central 
cervix 
position: 
≥2.6, ≥1.5 
cm long and 
posterior 
cervix 
position: 
≥2.6, ≥1.5 
cm long 
<37 
           
Symptomatic           
Onderoglu75 1997 Turkey 90 Cohort 
Prospective 
Blinded 
Test described 
Singletons, intact membrane, 
cervical dilatation <3cm, absence 
of fetal and maternal 
complication 
 25 - 36 Single >2cm 
dilated, 
>40% 
effacement 
<37 
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Table 13 Individual accuracy results of digital examination in predicting spontaneous preterm birth stratified according to population of asymptomatic antenatal 
women and symptomatic women with threatened preterm labour 
 
Authors 
Testing 
gestation 
(weeks) Threshold TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                   
Asymptomatic                   
Leveno70 26 - 30 2cm dilated 4 11 3 167 0.57 0.18 0.90 0.94 0.89 0.97 9.25 3.91 21.85 0.46 0.19 1.08 
Parikh72 24 - 36 admit finger 
at internal os 
28 174 29 232 0.49 0.36 0.63 0.57 0.52 0.62 1.15 0.86 1.53 0.89 0.68 1.16 
Stubbs74 34 30% 
effacement 
2 22 2 104 0.50 0.07 0.93 0.83 0.75 0.89 2.86 1.00 8.19 0.61 0.23 1.62 
Stubbs74 32 30% 
effacement 
5 23 5 103 0.50 0.19 0.81 0.82 0.74 0.88 2.74 1.33 5.64 0.61 0.33 1.14 
Stubbs74 28 1cm internal 
os 
2 15 6 85 0.25 0.03 0.65 0.85 0.76 0.91 1.67 0.46 6.04 0.88 0.59 1.33 
Stubbs74 32 1cm internal 
os 
4 28 6 98 0.40 0.12 0.74 0.78 0.70 0.85 1.80 0.79 4.11 0.77 0.46 1.29 
Stubbs74 28 30% 
effacement 
0 9 8 91 0.00 0.00 0.37 0.91 0.84 0.96 0.59 0.04 9.34 1.04 0.88 1.24 
Stubbs74 34 1cm internal 
os 
3 51 1 75 0.75 0.19 0.99 0.60 0.50 0.68 1.85 1.01 3.39 0.42 0.08 2.31 
Chambers67 <37 1cm internal 
os 
65 846 109 4046 0.37 0.30 0.45 0.83 0.82 0.84 2.16 1.77 2.64 0.76 0.67 0.85 
Chambers67 28 1cm long 
cervix 
29 487 109 4046 0.21 0.15 0.29 0.89 0.88 0.90 1.96 1.40 2.73 0.88 0.81 0.97 
Chambers67 <37 Combined 30 146 109 4046 0.22 0.15 0.29 0.97 0.96 0.97 6.20 4.35 8.84 0.81 0.74 0.89 
Blondela66 29 - 31 1cm long 
cervix 
26 228 92 2271 0.22 0.15 0.31 0.91 0.90 0.92 2.42 1.68 3.47 0.86 0.78 0.95 
Blondela66 25 - 28 1cm long 
cervix 
22 149 140 2848 0.14 0.09 0.20 0.95 0.94 0.96 2.73 1.80 4.15 0.91 0.86 0.97 
Blondela66 25 - 28 mid-position 
cervix 
45 520 117 2476 0.28 0.21 0.35 0.83 0.81 0.84 1.60 1.23 2.08 0.87 0.79 0.96 
Blondela66 29 - 31 mid-position 
cervix 
34 427 84 2072 0.29 0.21 0.38 0.83 0.81 0.84 1.69 1.25 2.27 0.86 0.76 0.96 
Blondela66 29 - 31 1cm internal 
os 
25 135 386 2071 0.06 0.04 0.09 0.94 0.93 0.95 0.99 0.66 1.50 1.00 0.97 1.03 
Blondela66 29 - 31 Soft cervix 103 1742 15 757 0.87 0.80 0.93 0.30 0.28 0.32 1.25 1.16 1.35 0.42 0.26 0.68 
Blondela66 25 - 28 1cm internal 
os 
21 48 139 2950 0.13 0.08 0.19 0.98 0.98 0.99 8.20 5.03 13.35 0.88 0.83 0.94 
Blondela66 25 - 28 Soft cervix 130 1870 30 1129 0.81 0.74 0.87 0.38 0.36 0.39 1.30 1.20 1.41 0.50 0.36 0.69 
Blondelb66 29 - 31 1cm long 
cervix 
14 130 56 1509 0.20 0.11 0.31 0.92 0.91 0.93 2.52 1.53 4.14 0.87 0.77 0.98 
Blondelb66 25 - 28 Soft 95 1434 21 616 0.82 0.74 0.88 0.30 0.28 0.32 1.17 1.07 1.28 0.60 0.41 0.89 
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Blondelb66 25 - 28 mid-position 
cervix 
30 384 88 1664 0.25 0.18 0.34 0.81 0.79 0.83 1.36 0.98 1.87 0.92 0.82 1.02 
Blondelb66 25 - 28 1cm long 
cervix 
12 96 103 1955 0.10 0.06 0.18 0.95 0.94 0.96 2.23 1.26 3.94 0.94 0.88 1.00 
Blondelb66 29 - 31 Soft cervix 59 1242 11 397 0.84 0.74 0.92 0.24 0.22 0.26 1.11 1.00 1.24 0.65 0.37 1.12 
Blondelb66 29 - 31 1cm internal 
os 
20 151 49 1489 0.29 0.19 0.41 0.91 0.89 0.92 3.15 2.11 4.69 0.78 0.67 0.91 
Blondelb66 25 - 28 1cm internal 
os 
17 59 98 1992 0.15 0.09 0.23 0.97 0.96 0.98 5.14 3.10 8.52 0.88 0.81 0.95 
Blondelb66 29 - 31 mid-position 
cervix 
16 292 50 1351 0.24 0.15 0.36 0.82 0.80 0.84 1.36 0.88 2.12 0.92 0.80 1.06 
Schaffnera73 28 - 32 2-3cm 
dilated 
0 12 5 56 0.00 0.00 0.52 0.82 0.71 0.91 0.46 0.03 6.85 1.12 0.86 1.46 
Schaffnerb73 28 - 32 2-3cm 
dilated 
5 60 10 141 0.33 0.12 0.62 0.70 0.63 0.76 1.12 0.53 2.36 0.95 0.66 1.37 
Chabra68 28 central 
1.5cm long 
cervix 
5 0 36 34 0.12 0.04 0.26 1.00 0.90 1.00 9.17 0.52 160.08 0.88 0.78 1.00 
Chabra68 28 posterior 2.6 
cm long 
cervix 
1 4 6 54 0.14 0.00 0.58 0.93 0.83 0.98 2.07 0.27 16.03 0.92 0.67 1.26 
Chabra68 28 central 
2.6cm long 
cervix 
24 5 17 29 0.59 0.42 0.74 0.85 0.69 0.95 3.98 1.70 9.31 0.49 0.33 0.72 
Chabra68 28 posterior 1.5 
cm long 
cervix 
7 57 0 1 1.00 0.59 1.00 0.02 0.00 0.09 0.96 0.80 1.16 2.46 0.11 55.35 
                   
Symptomatic                   
Onderoglu75 25 - 36 2cm dilated 
cervix 
21 16 11 42 0.66 0.47 0.81 0.72 0.59 0.83 2.38 1.46 3.87 0.47 0.29 0.79 
Onderoglu75 25 - 36 40% 
effacement 
20 18 12 40 0.63 0.44 0.79 0.69 0.55 0.80 2.01 1.26 3.22 0.54 0.34 0.88 
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Table 14 Characteristic of studies on the accuracy of bedside cervico-vaginal fetal fibronectin testing as a predictor of spontaneous preterm birth stratified 
according to study population of asymptomatic antenatal women and symptomatic women who presented with threatened preterm labour 
 
Authors Year n Study designs Inclusion criteria Exclusion criteria 
Testing gestation 
(weeks’ gestation) 
Reference 
standards 
(weeks’ 
gestation)* 
        
Asymptomatic        
        
Ruiz98 2001 78 Cohort 
Prospective 
Test described 
 
Asymptomatic women <18 or >40 years old, Rh iso-immunization, 
multiple gestation, cervical cerclage, use of 
tocolytics agents in the current pregnancy, maternal 
medical disorders, non-English speaking, >28 
weeks' gestation at enrolment, misses > 1 monthly 
antenatal check-up. 
23 – 26, 
27 – 30, 
and both times 
<37 
Arinami87 1999 438 Prospective 
Consecutive 
Test described 
Singleton pregnancies without medical or obstetrical 
complications. 
 
None stated 26-28 <34 weeks 
<37 weeks 
 
Goldenberg89 1996 2929 
 
Prospective 
Blind 
Test described 
Singletons pregnancies. 
 
Placenta previa. 
Fetal anomalies 
 
22, 24, 26, 28, 30 <34 weeks 
 
Goldenberg90 1997 1870 
 
Prospective 
Blind 
Test described 
 
Singleton pregnancies of women who are not 
randomised to treatment for Trichomonas vaginalis 
or Bacterial vaginosis. 
None stated 8-22 <35 weeks 
 
Goldenberg76 2000 6508 
 
Prospective 
Blind 
Test described 
 
Singletons pregnancies. 
 
None stated 8-22 <28 weeks 
<32 weeks 
<35 weeks 
<37 weeks 
 
Hux91 1995 54 
 
Prospective 
Blind 
Test described 
 
Intact membrane and undilated cervix. 
 
Candida infection, fetal anomalies, vaginal bleeding, 
placenta previa, and threatened preterm labour. 
 
26-29 <37 weeks 
 
Heath81 2000 5146 
 
Prospective 
Consecutive 
Blind 
Test described 
 
Singletons pregnancies of women attending an inner 
city ante-natal clinic 
 
Fetal abnormalities. 
 
22-24 <33 weeks 
 
Chang88 1997 234 
 
Prospective 
Blind 
Test described 
 
Singletons pregnancies without previous history of 
spontaneous preterm labour or birth  
Intact membrane. 
 
Vaginal bleeding. Pre-eclampsia. 
Placenta previa. 
Uncertain date. 
Fetal anomaly 
 
28 <34 weeks 
<37 weeks 
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Faron80 1997 
 
155 Prospective 
Consecutive 
Blind 
Test described 
 
All asymptomatic women in antenatal clinic with 
known gestation. 
Vaginal bleeding 24-33 <37 weeks 
 
Hellemans82 1995  
 
133 
 
Blind 
Consecutive 
Prospective 
Test described 
 
Low risk singletons pregnancies. 
Intact membrane. 
 
Placenta previa. 
Vaginal bleeding. 
Cervical dilatation >1cm or cervical cerclage. 
Threatened preterm labour <26 weeks, Unknown 
date. 
 
26-36 <37 weeks 
 
Garcia94 1999 
 
263 
 
Blind 
Prospective 
Test described 
 
Low risk singletons 
Intact membrane. 
 
Cerclage. 
 
24-37 <32 weeks 
<37 weeks 
 
Greenhagen95 1996 
 
108 
 
Blind 
Prospective 
Test described 
 
Low risk singletons pregnancies. 
Intact membrane. 
 
Previous history of spontaneous preterm labour or 
birth  
Vaginal bleeding. 
Fetal anomaly. 
 
24-34 <37 weeks 
 
DiStefano93 1999 
 
60 
 
Prospective 
Test described 
 
Singletons pregnancies 
Intact membrane. 
 
Previous history of spontaneous preterm labour or 
birth  
Vaginal bleeding. 
Fetal anomaly 
Cervical cerclage. 
Genital infection. 
Maternal or fetal complications during gestation 
&/or examination 
 
24-36 <37 weeks 
 
Crane92 1999 140 
 
Blind 
Consecutive 
Prospective 
Test described 
 
Singleton pregnancies. 
Intact membrane. 
 
Cerclage. 
Fetal anomalies or death. 
Vaginal bleeding. Recently treated bacterial 
vaginosis. 
 
20-24 <37 weeks 
 
Inglis96 1994 73 
 
Blind 
Prospective 
Test described 
 
 
Intact membrane Fetal anomalies, placenta previa, genital or urinary 
infection, use of antibiotics in the preceding 7 days 
 
<37 <37 weeks 
 
Lockwood97 1991 429 
 
Blind 
Prospective 
Test described 
 
Asymptomatic women from an inner city antenatal 
clinic. 
 
Uncertain date, placenta previa, iatrogenic preterm 
delivery 
24-37 <28 day 
<37 weeks 
 
Vercoustre99 1996 58 
 
Test described 
 
Asymptomatic women 
 
Coitus <24 hours and vaginal bleeding. 
 
27-37 <37 weeks 
 
Zamora77 2000 20 
 
Blind 
Test described 
 
Asymptomatic pregnant women 
Intact membrane. 
 
Coitus <24 hours. 
Recent usage of vaginal pessary 
 
28-36 <37 weeks 
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Symptomatic        
Luzzi110 2003 133 Cohort 
Consecutive 
Prospective 
Test described 
 
Preterm labour, intact membrane, < 3 cm cervical 
dilatation 
Scheduled caesarean section, induced delivery 
within 21 days of testing. 
24 - 35 <7, <14 and 
<21 days of 
testing 
 
Tekesin86 2005 170 Cohort 
Consecutive 
Prospective 
Blinded 
Test described 
 
Preterm labour, intact membrane, < 3 cm cervical 
dilatation 
Multiple gestations, cervical manipulations 
(examination, intercourse, ultrasound), vaginal 
bleeding, major fetal anomaly, PPROM, cervical 
cerclage, suspected fetal asphyxia 
24 - 35 <7, <14, <21 
days of testing 
and <34 and 
<37 
Musaad117 2005 27 Cohort 
Consecutive 
Prospective 
Test described 
 
Preterm labour, intact membrane, < 3 cm cervical 
dilatation 
Vaginal bleeding 24 - 33 <34, <37 
Dolinska126 2005 115 Cohort 
Retrospective 
Test described 
Singleton, preterm labour, intact membrane, < 3 cm 
cervical dilatation, no cerclage. 
 
x 24 - 34 <37 
Topete121 2004 74 Cohort 
Retrospective 
Test described 
 
Preterm labour, intact membrane, < 3 cm cervical 
dilatation 
x 24 - 34 <37 
Foxman104 2004 139 Cohort 
Prospective 
 
Preterm labour, intact membrane, < 3 cm cervical 
dilatation 
x x <7 
Hincz122 2002 82 Cohort 
Prospective 
Blinded 
Test described 
 
Preterm labour, intact membrane, < 3 cm cervical 
dilatation 
Cerclage, clinical criteria of intrauterine infection, 
vaginal bleeding, IUGR, pre-eclampsia 
24 - 34 <37 
Sakai113 2003 116 Cohort 
Test described 
Preterm labour, intact membrane, < 4 cm cervical 
dilatation 
PROM, multiple pregnancy, elective preterm 
delivery, pre-eclampsia, abruption, placenta previa, 
maternal medical conditions 
 
20 - 36 <7 days of 
testing, and <37 
 
Closset103 2001 61 Cohort 
Prospective 
Blinded 
Test described 
Preterm labour, intact membrane, < 3 cm cervical 
dilatation 
x 24 - 36 <7, <14, <21 
days of testing, 
and <37 
 
Gomez106 2005 215 Cohort 
Prospective 
Test described 
Preterm labour, intact membrane, < 3 cm cervical 
dilatation 
x 22 - 35 <48 hours, <7, 
<14 days of 
testing and <32, 
<35 
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Hansen109 2004 41 Cohort 
Prospective 
Test described 
>16 years of age, preterm labour, < 3cm dilatation 
for primigravida and < 4cm for multiparous. 
 
Multiple gestations, major fetal anomaly, vaginal 
bleeding, PPROM, cervical cerclage, suspected fetal 
asphyxia. 
23 - 34 <7, <14 days of 
testing, and <37 
Stevens129 2004 185 Cohort 
Prospective 
Test described 
 
Preterm labour, intact membrane, ≥ 2cm dilatation, 
≥ 50% effacement 
 24 - 34 <32, <37 
LaShay83 2000 118 
 
Cohort 
Consecutive 
Prospective 
Blind 
Test described 
 
Singleton pregnancies. 
Intact membrane. 
Cervical dilatation <3 cm. 
 
Coitus or digital vaginal examination within 24 
hours 
Vaginal bleeding 
Placenta previa 
Placental abruption 
Polyhydramnios 
Pre-eclampsia 
Known uterine or fetal abnormalities 
 
24-34 <48 hours 
<7 days 
<37 weeks 
 
Senden85 1996 49 Cohort 
Consecutive 
Prospective 
Blind 
Test described 
 
Singleton pregnancies. 
Intact membrane. 
Cervical dilatation <4 cm. 
 
Vaginal bleeding. 
Clinical chorioamnionitis. 
Diabetes mellitus. 
 
25-35 <7 days 
 
Bartnicki101 1996 112 Cohort 
Prospective 
Blind 
Test described 
 
Intact membrane, cervical dilatation <2 cm.  22-35 <7 days 
<14 days 
<21 days 
<28 days 
<34 weeks 
 
Benattar102 1997 124 
 
Cohort 
Prospective 
Blind 
Test described 
 
Singletons and twin pregnancies. Intact membrane, 
cervical dilatation <3 cm. 
 
Vaginal bleeding. 
Coitus < 24 hours. 
 
24-36 <7 days 
<14 days 
<21 days 
<32 weeks 
<34 weeks 
 
Malak111 1996 112 
 
Cohort 
Prospective 
Blind 
Test described 
 
Singletons pregnancies. 
Intact membrane. 
Cervical dilation < 2 cm. 
 
Placenta previa. 
Vaginal bleeding. 
Coitus < 24 hours. 
 
24-34 <7 days 
<14 days 
<21 days 
<37 weeks 
 
McKenna112 1999 50 
 
Cohort 
Consecutive 
Prospective 
Test described 
 
Cervical dilation < 3 cm. 
 
Coitus < 24 hours. 
Vaginal digital examination or transvaginal 
ultrasounds scan procedure. 
Cervical cerclage. 
Uterine anomalies. 
Placenta previa. 
Placental abruption. 
 
22-34 <7 days 
<14 days 
<37 weeks 
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Peaceman79 1997 725 
 
Cohort 
Prospective 
Blind 
Test described 
 
Singleton, twin pregnancies and 1 triplet. 
Intact membrane. 
Cervical dilatation <3 cm. 
 
Placenta previa. 
Cerclage. 
Trauma leading to preterm labour. 
 
24-34 <7 days 
<14 days 
<37 weeks 
 
Iams107 1995 192 Cohort 
Prospective 
Blind 
Test described 
 
Intact membrane. 
Cervical dilation < 3 cm. 
 
 
Placenta previa. 
Cerclage. 
Uterine anomalies. 
Vaginal bleeding. 
 
24-34 <7 days 
<37 weeks 
 
Giles105 2000 150 Cohort 
Prospective 
Test described 
 
Intact membrane. 
 
Vaginal bleeding. 
Coitus < 24 hours. 
Recent digital vaginal examination. 
 
24-34 <7 days 
<36 weeks 
 
Lopez108 2000 85 Cohort 
Retrospective 
 
Singletons pregnancies. 
Intact membrane. 
Cervical dilation < 3 cm. 
 
Uncertain date. 
Lost to follow up. 
Incomplete data. 
 
24-35 <7 days 
14 days 
<34 weeks 
<37 weeks 
 
Cox 
(Abstract)115  
1995 175 Test described 
 
Intact membrane. 
Cervical dilatation < 3 cm. 
 
None stated 24-34 <37 weeks 
 
Chuileannain118 1998 50 Cohort 
Retrospective 
Test described 
 
 
Singletons pregnancies. 
Intact membrane. 
Cervical dilation < 2 cm. 
 
Placenta previa. 
Placental abruption. 
Cerclage. 
Fetal anomalies. 
 
<34 <34 weeks 
 
Goffeng116 1997 63 Cohort 
Consecutive 
Prospective 
Test described 
 
Singletons pregnancies with intact membrane. 
 
Pre-eclampsia. 
Uterine or cervical abnormalities. 
Placenta previa, placental abruption. 
Fetal anomalies. 
Diabetes mellitus. 
 
23-34 <34 weeks 
<37 weeks 
 
Parker119 1995 36 Cohort 
Prospective 
Blind 
Test described 
 
Singletons pregnancies. 
Intact membrane. 
Cervical dilation < 2 cm. 
 
Placenta previa. 
Placental abruption. 
Cerclage. 
Fetal anomalies. 
Coitus < 24 hours. 
 
20-34 <34 
Burrus114 1995 37 Cohort 
Prospective 
Blind 
Test described 
 
Symptomatic women in their first pregnancy. 
Intact membrane 
Cervical dilatation <3 cm and changing, no contra-
indication to tocolytic 
 
Amnionitis. 
Placental abruption. 
 
<34 <37 weeks 
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Grandi78 1996 26 
 
Cohort 
Consecutive 
Prospective 
Blind 
Test described 
 
Singletons pregnancies. 
Intact membrane. 
Cervical dilation < 2cm 
 
Placenta previa. 
Placental abruption. 
Fetal anomalies. 
Coitus <24 hours, Iatrogenic preterm labour. 
 
24-36 <37 weeks 
 
Inglis96 1994 38 
 
Cohort 
Prospective 
Blind 
Test described 
 
Singletons pregnancies. 
Intact membrane. 
 
Fetal anomalies. 
Placenta previa. 
Genital or urinary infection. 
Use of antibiotics in the preceding 7 days 
 
<37 <37 weeks 
 
Irion123 1995 64 
 
Cohort 
Prospective 
Blind 
Test described 
 
Intact membrane. 
Cervical dilation < 2 cm. 
 
 
Fetal anomalies. 
Vaginal bleeding. 
Coitus < 24 hours. 
Iatrogenic preterm delivery. 
 
24-36 <37 weeks 
 
Langer124 1997 61 
 
Cohort 
Prospective 
Blind 
Test described 
 
Intact membrane. 
 
Vaginal bleeding. 
Coitus < 24 hours. 
Progressive cervical dilatation. 
Abnormal fetal heart rate monitoring. 
 
24-34 <37 weeks 
 
Lockwood97 1991 117 
 
Cohort 
Prospective 
Blind 
Test described 
 
Intact membrane Fetal anomalies. 
Placenta previa. 
Coitus < 24 hours. 
Intra-uterine growth restriction. 
Fetal distress. 
Previous pregnancy terminated due to severe pre-
eclampsia. 
 
25-35 <37 weeks 
 
Morrison84 1993 28 
 
Cohort 
Blind 
Consecutive 
Prospective 
Test described 
 
Singleton pregnancies. 
Intact membrane. 
 
Uterine or cervical abnormalities. 
Vaginal bleeding. 
Placenta previa. 
Suspected placental abruption. 
Coitus or douching <24 hours. 
Diabetes mellitus. 
Unknown date. 
Pre-eclampsia. 
<15 years old. 
 
24-34 <37 weeks 
Rizzo127 1997 106 
 
Cohort 
Prospective 
Blind 
Test described 
 
Singleton pregnancies. 
Intact membrane. 
Cervical dilatation <3 cm. 
 
Fetal or maternal complications. 
Urinary or genital infection. 
Use of antibiotic in the preceding 14 days 
 
24-36 <37 weeks 
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Rozenberg128 1997 76 
 
Cohort 
Prospective 
Blind 
Test described 
 
Singleton pregnancies. 
Intact membrane. 
Cervical dilatation <2 cm. 
 
Gestation <24 or >34 weeks. 
Cerclage. 
Placenta previa. 
Placental abruption. 
Iatrogenic preterm delivery. 
 
24-34 <37 weeks 
 
Calda120 1995 84 
 
Cohort 
Prospective 
Test described 
 
Intact membrane. 
 
 24-34 <36 weeks 
 
Mansouri125 1996 90 Cohort 
Retrospective 
Test described 
 
Intact membrane. 
 
Vaginal bleeding 
Coitus < 24 hours 
 
24-34 <37 weeks 
 
Vercoustre99 1996 86 Test described 
 
Singleton pregnancies with threatened preterm 
labour 
 
Coitus < 24 hours 
Vaginal bleeding 
 
<37 <37 weeks 
 
Vetr130 1996 46 
 
Cohort 
Prospective 
Test described 
 
Intact membrane. 
 
Fetal anomalies 
Placenta previa 
Vaginal bleeding 
Intra-uterine growth restriction 
Fetal distress 
Diabetes mellitus 
Pre-eclampsia 
 
25-36 <37 weeks 
 
        
 
*unless otherwise state 
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Table 15 Individual accuracy results of cervico-vaginal fetal fibronectin (fFN) in predicting spontaneous preterm birth among symptomatic women with threatened 
preterm labour 
 
Authors TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                 
<7 – 10 days                 
Tekesin86 9 37 2 122 0.82 0.48 0.98 0.77 0.69 0.83 3.52 2.36 5.23 0.24 0.07 0.83 
Closset103 5 11 1 44 0.83 0.36 1.00 0.80 0.67 0.90 4.17 2.20 7.89 0.21 0.03 1.25 
LaShay83 3 10 2 103 0.60 0.15 0.95 0.91 0.84 0.96 6.78 2.68 17.16 0.44 0.15 1.29 
Luzzi110 4 34 3 92 0.57 0.18 0.90 0.73 0.64 0.81 2.12 1.05 4.28 0.59 0.25 1.39 
Senden85 4 4 1 20 0.80 0.28 0.99 0.83 0.63 0.95 4.80 1.77 13.00 0.24 0.04 1.40 
Bartnicki101 3 33 1 79 0.75 0.19 0.99 0.71 0.61 0.79 2.55 1.35 4.80 0.35 0.06 1.94 
Benattar102 8 11 1 104 0.89 0.52 1.00 0.90 0.84 0.95 9.29 5.06 17.06 0.12 0.02 0.78 
Gomez106 18 34 10 153 0.64 0.44 0.81 0.82 0.76 0.87 3.54 2.34 5.33 0.44 0.26 0.72 
Hansen109 2 7 1 31 0.67 0.09 0.99 0.82 0.66 0.92 3.62 1.28 10.27 0.41 0.08 2.04 
Iams107 13 32 1 146 0.93 0.66 1.00 0.82 0.76 0.87 5.17 3.66 7.30 0.09 0.01 0.58 
Malak111 8 10 2 92 0.80 0.44 0.97 0.90 0.83 0.95 8.16 4.20 15.87 0.22 0.06 0.77 
McKenna112 5 13 1 35 0.83 0.36 1.00 0.73 0.58 0.85 3.08 1.71 5.53 0.23 0.04 1.38 
Peaceman79 19 123 2 581 0.90 0.70 0.99 0.83 0.80 0.85 5.18 4.19 6.40 0.12 0.03 0.43 
Plaut100 1 8 1 86 0.50 0.01 0.99 0.91 0.84 0.96 5.88 1.26 27.30 0.55 0.14 2.19 
Giles105 11 34 5 100 0.69 0.41 0.89 0.75 0.66 0.82 2.71 1.75 4.21 0.42 0.20 0.87 
Sakai113 11 27 7 71 0.61 0.36 0.83 0.72 0.63 0.81 2.22 1.36 3.62 0.54 0.30 0.97 
Foxman104 6 25 1 107 0.86 0.42 1.00 0.81 0.73 0.87 4.53 2.84 7.20 0.18 0.03 1.08 
Lopez108 8 12 1 64 0.89 0.52 1.00 0.84 0.74 0.92 5.63 3.19 9.94 0.13 0.02 0.84 
                 
<34 weeks                 
Musaad117 5 5 1 21 0.83 0.36 1.00 0.81 0.61 0.93 4.33 1.82 10.29 0.21 0.03 1.25 
Tekesin86 20 26 8 116 0.71 0.51 0.87 0.82 0.74 0.88 3.90 2.57 5.93 0.35 0.19 0.63 
Burrus114 23 6 3 5 0.88 0.70 0.98 0.45 0.17 0.77 1.62 0.93 2.83 0.25 0.07 0.88 
Goffeng116 7 7 4 45 0.64 0.31 0.89 0.87 0.74 0.94 4.73 2.08 10.75 0.42 0.19 0.93 
Parker119 6 7 1 25 0.86 0.42 1.00 0.78 0.60 0.91 3.92 1.90 8.06 0.18 0.03 1.13 
Chuileannain118 9 11 1 49 0.90 0.55 1.00 0.82 0.70 0.90 4.91 2.77 8.70 0.12 0.02 0.79 
Cox115 3 22 11 139 0.21 0.05 0.51 0.86 0.80 0.91 1.57 0.53 4.60 0.91 0.69 1.20 
Lopez108 11 9 4 61 0.73 0.45 0.92 0.87 0.77 0.94 5.70 2.88 11.28 0.31 0.13 0.71 
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<37 weeks                 
Tekesin86 31 15 4 120 0.89 0.73 0.97 0.89 0.82 0.94 7.97 4.88 13.03 0.13 0.05 0.32 
Closset103 12 4 11 34 0.52 0.31 0.73 0.89 0.75 0.97 4.96 1.81 13.56 0.53 0.34 0.83 
Grandi78 4 9 4 9 0.50 0.16 0.84 0.50 0.26 0.74 1.00 0.43 2.30 1.00 0.43 2.30 
Hincz122 10 5 4 63 0.71 0.42 0.92 0.93 0.84 0.98 9.71 3.92 24.05 0.31 0.13 0.71 
LaShay83 10 8 24 76 0.29 0.15 0.47 0.90 0.82 0.96 3.09 1.33 7.15 0.78 0.62 0.98 
Morrison84 9 5 1 13 0.90 0.55 1.00 0.72 0.47 0.90 3.24 1.50 7.02 0.14 0.02 0.91 
Musaad117 5 3 5 15 0.50 0.19 0.81 0.83 0.59 0.96 3.00 0.90 10.01 0.60 0.31 1.15 
Bartnicki101 27 7 13 65 0.68 0.51 0.81 0.90 0.81 0.96 6.94 3.33 14.49 0.36 0.23 0.57 
Benattar102 9 9 16 90 0.36 0.18 0.57 0.91 0.83 0.96 3.96 1.76 8.93 0.70 0.52 0.95 
Goffeng116 10 4 18 31 0.36 0.19 0.56 0.89 0.73 0.97 3.13 1.10 8.91 0.73 0.54 0.98 
Hansen109 3 6 6 26 0.33 0.07 0.70 0.81 0.64 0.93 1.78 0.55 5.74 0.82 0.50 1.34 
Iams107 27 18 35 112 0.44 0.31 0.57 0.86 0.79 0.92 3.15 1.88 5.26 0.66 0.52 0.82 
Inglis96 7 2 9 20 0.44 0.20 0.70 0.91 0.71 0.99 4.81 1.15 20.18 0.62 0.39 0.97 
Irion123 15 11 7 31 0.68 0.45 0.86 0.74 0.58 0.86 2.60 1.45 4.66 0.43 0.23 0.82 
Langer124 10 8 8 35 0.56 0.31 0.78 0.81 0.67 0.92 2.99 1.41 6.32 0.55 0.32 0.93 
Lockwood97 49 10 11 47 0.82 0.70 0.90 0.82 0.70 0.91 4.66 2.62 8.28 0.22 0.13 0.38 
Malak111 17 5 10 109 0.63 0.42 0.81 0.96 0.90 0.99 14.36 5.81 35.47 0.39 0.24 0.63 
Peaceman79 61 81 78 505 0.44 0.35 0.53 0.86 0.83 0.89 3.17 2.41 4.18 0.65 0.56 0.76 
Rizzo127 40 12 9 45 0.82 0.68 0.91 0.79 0.66 0.89 3.88 2.31 6.52 0.23 0.13 0.43 
Rozenberg128 14 17 6 39 0.70 0.46 0.88 0.70 0.56 0.81 2.31 1.41 3.76 0.43 0.22 0.86 
Stevens129 32 20 37 86 0.46 0.34 0.59 0.81 0.72 0.88 2.46 1.54 3.93 0.66 0.52 0.84 
Calda120 19 13 2 50 0.90 0.70 0.99 0.79 0.67 0.89 4.38 2.65 7.26 0.12 0.03 0.45 
Giles105 12 33 7 99 0.63 0.38 0.84 0.75 0.67 0.82 2.53 1.61 3.97 0.49 0.27 0.89 
Sakai113 26 12 36 42 0.42 0.30 0.55 0.78 0.64 0.88 1.89 1.06 3.37 0.75 0.58 0.96 
Vetr130 5 11 4 26 0.56 0.21 0.86 0.70 0.53 0.84 1.87 0.87 4.02 0.63 0.30 1.35 
Chuileannain118 13 7 1 49 0.93 0.66 1.00 0.88 0.76 0.95 7.43 3.66 15.08 0.08 0.01 0.54 
Dolinska126 28 8 10 69 0.74 0.57 0.87 0.90 0.81 0.95 7.09 3.58 14.04 0.29 0.17 0.50 
Mansouri125 13 12 12 53 0.52 0.31 0.72 0.82 0.70 0.90 2.82 1.49 5.31 0.59 0.39 0.90 
Topete121 24 4 10 36 0.71 0.53 0.85 0.90 0.76 0.97 7.06 2.72 18.34 0.33 0.19 0.56 
Vercoustre99 12 21 1 44 0.92 0.64 1.00 0.68 0.55 0.79 2.86 1.94 4.20 0.11 0.02 0.75 
Lopez108 17 3 31 34 0.35 0.22 0.51 0.92 0.78 0.98 4.37 1.38 13.80 0.70 0.56 0.88 
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Table 16 Individual accuracy results of cervico-vaginal fetal fibronectin (fFN) in predicting spontaneous preterm birth among asymptomatic antenatal women 
 
Authors TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                 
<34 weeks                 
Arinami 1 1 4 432 0.20 0.01 0.72 1.00 0.99 1.00 86.60 6.26 1198.92 0.80 0.52 1.24 
Heath 15 167 30 4934 0.33 0.20 0.49 0.97 0.96 0.97 10.18 6.56 15.80 0.69 0.56 0.85 
Chang 3 2 3 226 0.50 0.12 0.88 0.99 0.97 1.00 57.00 11.57 280.92 0.50 0.23 1.12 
Goldenberg 13 144 33 1680 0.28 0.16 0.43 0.92 0.91 0.93 3.58 2.20 5.82 0.78 0.65 0.93 
Goldenberg 29 88 98 2714 0.23 0.16 0.31 0.97 0.96 0.97 7.27 4.97 10.63 0.80 0.72 0.88 
Goldenberg 79 457 331 5641 0.19 0.16 0.23 0.93 0.92 0.93 2.57 2.07 3.19 0.87 0.83 0.92 
Hux 3 5 1 45 0.75 0.19 0.99 0.90 0.78 0.97 7.50 2.74 20.51 0.28 0.05 1.52 
                 
<37 weeks                 
Arinami 1 1 15 421 0.06 0.00 0.30 1.00 0.99 1.00 26.38 1.73 402.99 0.94 0.83 1.07 
Crane 1 34 8 97 0.11 0.00 0.48 0.74 0.66 0.81 0.43 0.07 2.78 1.20 0.93 1.54 
Faron 4 6 11 134 0.27 0.08 0.55 0.96 0.91 0.98 6.22 1.97 19.60 0.77 0.56 1.04 
Hellemans 6 18 4 105 0.60 0.26 0.88 0.85 0.78 0.91 4.10 2.11 7.95 0.47 0.22 1.00 
Chang 3 2 15 214 0.17 0.04 0.41 0.99 0.97 1.00 18.00 3.21 100.86 0.84 0.68 1.03 
Garcia 22 9 5 227 0.81 0.62 0.94 0.96 0.93 0.98 21.37 10.98 41.57 0.19 0.09 0.42 
Goldenberg 118 418 675 5297 0.15 0.12 0.18 0.93 0.92 0.93 2.03 1.68 2.46 0.92 0.89 0.95 
Goldenberg 24 133 144 1569 0.14 0.09 0.21 0.92 0.91 0.93 1.83 1.22 2.74 0.93 0.87 0.99 
Greenhagen 5 16 3 84 0.63 0.24 0.91 0.84 0.75 0.91 3.91 1.94 7.87 0.45 0.18 1.10 
Inglis 2 11 9 51 0.18 0.02 0.52 0.82 0.70 0.91 1.02 0.26 4.01 0.99 0.74 1.34 
Lockwood 30 108 19 272 0.61 0.46 0.75 0.72 0.67 0.76 2.15 1.64 2.83 0.54 0.38 0.77 
Ruiz 0 8 6 62 0.00 0.00 0.46 0.89 0.79 0.95 0.60 0.04 9.28 1.05 0.84 1.32 
DiStefano 4 8 2 46 0.67 0.22 0.96 0.85 0.73 0.93 4.50 1.92 10.57 0.39 0.13 1.22 
Zamora 4 13 1 15 0.80 0.28 0.99 0.54 0.34 0.72 1.72 0.95 3.11 0.37 0.06 2.23 
Vercoustre 1 6 0 58 1.00 0.03 1.00 0.91 0.81 0.96 7.50 2.54 22.14 0.28 0.03 3.07 
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Table 17 Characteristics of studies on test accuracy of cervico-vaginal prolactin in predicting spontaneous preterm birth stratified according to population of 
antenatal asymptomatic women and symptomatic women with threatened preterm labour 
 
Authors Year Country n Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks) 
Frequency 
of testing Thresholds 
Outcome 
(weeks’ 
gestation)* 
           
Asymptomatic           
O'Brien131 1994 USA 40 
Cohort 
Prospective 
Blinded 
Test described 
Asymptomatic antenatal 
women 
Rupture of membrane, fetal anomalies, 
vaginal bleeding, contra-indication to 
tocolysis 24-32 Single 2.0 ng/ml <34 
Koca132 1999 Turkey 40 
Cohort 
Prospective 
Test described 
Singleton pregnancies, 
asymptomatic antenatal 
women 
Rupture of membrane, fetal anomalies, 
contra-indication to tocolysis 24-32 Single 1.5 ng/ml <37 
           
Symptomatic           
Jotterand134 1997 France 64 
Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancies, 
threatened preterm labour 
Rupture of membrane, fetal anomalies, 
vaginal bleeding, fetal distress, placenta 
previa, contra-indication to tocolysis 21-34 Single 2.0 ng/ml <34, <37 
O'Brien131 1994 USA 40 
Cohort 
Prospective 
Blinded 
Test described Threatened preterm labour 
Rupture of membrane, fetal anomalies, 
vaginal bleeding, contra-indication to 
tocolysis 24-32 Single 2.0 ng/ml 
Within 7 
and 14 
days of 
testing, 
<34, <37 
Leylek135 1997 Turkey 66 
Cohort 
Prospective 
Test described 
Singleton pregnancies, 
threatened preterm labour  29-36 Single 50 ng/ml 
Within 12 
days of 
testing and 
<37 
Koca132 1999 Turkey 35 
Cohort 
Prospective 
Test described 
Singleton pregnancies, 
threatened preterm labour 
Rupture of membrane, fetal anomalies, 
contra-indication to tocolysis 24-32 Single 1.5 ng/ml <34, <37 
Guvenal133 2001 Turkey 60 
Case-control 
Retrospective 
Test described 
Singleton pregnancies, 
threatened preterm labour 
Rupture of membrane, fetal anomalies, 
contra-indication to tocolysis, maternal 
hypertension, IUGR, fetal distress, placenta 
previa 24-36 Single 1.8 ng/ml 37 
           
 
*Unless otherwise stated 
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Table 18 Individual accuracy results of cervico-vaginal prolactin measurement in predicting spontaneous preterm birth among asymptomatic antenatal women and 
symptomatic women with threatened preterm labour 
 
Authors Outcome TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                  
Asymptomatic                  
O'Brien131 34 1 1 1 37 0.50 0.01 0.99 0.97 0.86 1.00 19.00 1.76 205.15 0.51 0.13 2.06 
Koca132 37 5 9 1 25 0.83 0.36 1.00 0.74 0.56 0.87 3.15 1.62 6.12 0.23 0.04 1.37 
                  
Symptomatic                  
O'Brien131 7 6 14 3 17 0.67 0.30 0.93 0.55 0.36 0.73 1.48 0.81 2.70 0.61 0.23 1.62 
O'Brien131 34 16 4 7 13 0.70 0.47 0.87 0.76 0.50 0.93 2.96 1.20 7.26 0.40 0.20 0.78 
Koca132 34 10 7 3 15 0.77 0.46 0.95 0.68 0.45 0.86 2.42 1.22 4.77 0.34 0.12 0.95 
Jotterand134 34 4 7 3 50 0.57 0.18 0.90 0.88 0.76 0.95 4.65 1.81 11.97 0.49 0.21 1.16 
O'Brien131 37 17 3 11 9 0.61 0.41 0.78 0.75 0.43 0.95 2.43 0.87 6.76 0.52 0.30 0.92 
Leylek135 37 19 0 15 32 0.56 0.38 0.73 1.00 0.89 1.00 36.77 2.31 584.80 0.45 0.31 0.65 
Koca132 37 14 3 6 12 0.70 0.46 0.88 0.80 0.52 0.96 3.50 1.22 10.02 0.38 0.18 0.77 
Guvenal133 37 4 2 4 50 0.50 0.16 0.84 0.96 0.87 1.00 13.00 2.83 59.76 0.52 0.26 1.04 
Jotterand134 37 5 6 11 42 0.31 0.11 0.59 0.88 0.75 0.95 2.50 0.88 7.10 0.79 0.56 1.11 
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Table 19 Characteristic of studies on the accuracy of rapid test for phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) in cervical secretion as 
a predictor of spontaneous preterm birth stratified according to study population of asymptomatic antenatal women and symptomatic women who presented with 
threatened preterm labour 
 
Authors Year n Study design Inclusion criteria Exclusion criteria 
Testing gestation 
(weeks’ gestation) 
Reference 
standards 
(weeks’ 
gestation)* 
        
Asymptomatic        
Bittar138 2001 53 Cohort 
Prospective 
Test described 
 
Previous premature delivery, intact membrane, 
no vaginal bleeding, screened and treated for 
Trichomonas, Candida, N. gonorrhoea, C. 
trachomatis, Group B Streptococcus 
 
Lost to follow-up 
 
24 - 34, 3 weekly <37 
        
Symptomatic        
Shine136 2001 32 Cohort 
Prospective 
Test described 
 
Threatened preterm labour, cervix < 2 cm 
dilated, intact membrane 
 
 24 - 36 <34 and <37 
Lembet140 2002 36 Cohort 
Prospective 
Blinded 
Test described 
 
Threatened preterm labour 
 
Uterine anomaly, congenital fetal abnormality, 
intra-uterine growth restriction, pre-eclampsia, 
vaginal bleeding 
 
20 - 36 <48 hours, <7 
days, and <37 
Choi142 2003 42 Cohort 
Prospective 
Test described 
 
Threatened preterm labour 
 
 20 - 36 <37 
Park143 2003 50 Cohort 
Prospective 
Test described 
 
Threatened preterm labour, cervix < 3 cm 
dilated, intact membrane 
 
 24 - 34 <7 days, <34, and 
<37 
Akercan141;143 2004 45 Cohort 
Prospective 
Test described 
 
Threatened preterm labour 
 
Pre-eclampsia, ruptured membrane, vaginal 
bleeding, intra-uterine growth restriction, 
congenital fetal abnormality, and uterine 
anomaly 
 
24 - 36 <37 
Kwek139 2004 47 Cohort 
Consecutive 
Prospective 
Test described 
 
Threatened preterm labour 
 
Antepartum haemorrhage, cervix >3 cm dilated, 
contra-indication to tocolysis, insertion of 
cervical cerclage 
 
24 - 34 <48 hours, <7 
days, and <36 
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Elizur144 2005 35 Cohort 
Prospective 
Blinded 
Test described 
 
Threatened preterm labour 
 
 24 - 35 <48 hours, <7 
days, <34, and 
<37 
Halle146 1999 93 Cohort 
Test described 
 
Threatened preterm labour 
 
 23 - 32 <37 
Paternoster145 2005 135 Cohort 
 
Threatened preterm labour 
 
Pre-eclampsia, ruptured membrane, vaginal 
bleeding, intra-uterine growth restriction, 
congenital fetal abnormality, and uterine 
anomaly 
 
Not stated <37 
Turnell137 2005 100 Cohort 
Consecutive 
 
Threatened preterm labour  Not stated <37 
        
*Unless otherwise stated 
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Table 20 Individual accuracy results of bedside rapid test cervico-vaginal phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) in predicting 
spontaneous preterm birth among symptomatic women with threatened preterm labour 
 
Authors Year TP FP FN TN Sensitivity (95% CI) Specificity (95% CI) LR+ (95% CI) LR- (95% CI) 
                  
48 hours                  
Lembet140 2002 14 4 1 17 0.88 (0.62 - 0.98) 0.81 (0.58 - 0.95) 4.59 (1.87 - 11.31) 0.15 (0.04 - 0.57) 
Kwek139 2004 4 14 2 20 0.67 (0.22 - 0.96) 0.59 (0.41 - 0.75) 1.62 (0.81 - 3.24) 0.57 (0.18 - 1.82) 
Elizur144 2005 0 7 0 29 0.50 (0.01 - 0.99) 0.79 (0.63 - 0.90) 2.38 (1.52 - 10.82) 0.63 (0.16 - 2.56) 
         Summary LR’s 2.53 (1.17 – 5.48) 0.32 (0.15 – 0.66) 
7 days                  
Lembet140 2002 15 3 1 17 0.94 (0.70 - 1.00) 0.85 (0.62 - 0.97) 6.25 (2.19 - 17.88) 0.07 (0.01 - 0.49) 
Park143 2003 11 10 2 27 0.85 (0.55 - 0.98) 0.73 (0.56 - 0.86) 3.13 (1.76 - 5.58) 0.21 (0.06 - 0.77) 
Kwek139 2004 10 8 2 20 0.83 (0.52 - 0.98) 0.71 (0.51 - 0.87) 2.92 (1.54 - 5.52) 0.23 (0.06 - 0.84) 
Elizur144 2005 0 7 0 29 0.50 (0.01 - 0.99) 0.79 (0.63 - 0.90) 2.38 (0.52 - 10.82) 0.63 (0.16 - 2.56) 
         Summary LR’s 3.29 (2.24 – 4.83) 0.20 (0.10 – 0.41) 
34 weeks                  
Shine136 2001 5 8 0 19 1.00 (0.48 - 1.00) 0.70 (0.50 - 0.86) 3.02 (1.64 - 5.56) 0.12 (0.01 - 1.72) 
Park143 2003 9 12 2 27 0.82 (0.48 - 0.98) 0.69 (0.52 - 0.83) 2.66 (1.54 - 4.60) 0.26 (0.07 - 0.94) 
Elizur144 2005 1 6 0 29 1.00 (0.03 - 1.00) 0.83 (0.66 - 0.93) 4.15 (1.44 - 11.99) 0.31 (0.03 - 3.38) 
         Summary LR’s 2.96 (2.02 – 4.33) 0.22 (0.08 – 0.64) 
37 weeks                  
Halle146 1999 22 11 6 54 0.79 (0.59 - 0.92) 0.83 (0.72 - 0.91) 4.64 (2.62 - 8.23) 0.26 (0.13 - 0.53) 
Shine136 2001 8 5 2 17 0.80 (0.44 - 0.97) 0.77 (0.55 - 0.92) 3.52 (1.53 - 8.08) 0.26 (0.07 - 0.91) 
Lembet140 2002 17 1 2 16 0.89 (0.67 - 0.99) 0.94 (0.71 - 1.00) 15.21 (2.26 - 102.48) 0.11 (0.03 - 0.42) 
Choi142 2003 5 17 2 18 0.71 (0.29 - 0.96) 0.51 (0.34 - 0.69) 1.47 (0.82 - 2.62) 0.56 (0.16 - 1.87) 
Park143 2003 17 1 5 24 0.77 (0.55 - 0.92) 0.96 (0.80 - 1.00) 19.32 (2.79 - 133.58) 0.24 (0.11 - 0.51) 
Akercan141;143 2004 11 4 3 27 0.79 (0.49 - 0.95) 0.87 (0.70 - 0.96) 6.09 (2.34 - 15.82) 0.25 (0.09 - 0.68) 
Kwek139 2004 14 4 5 17 0.74 (0.49 - 0.91) 0.81 (0.58 - 0.95) 3.87 (1.54 - 9.72) 0.33 (0.15 - 0.71) 
Elizur144 2005 4 3 2 6 0.67 (0.22 - 0.96) 0.67 (0.30 - 0.93) 2.00 (0.68 - 5.91) 0.50 (0.15 - 1.70) 
Paternoster145 2005 9 9 4 86 0.69 (0.39 - 0.91) 0.91 (0.83 - 0.96) 7.31 (3.56 - 15.0)1 0.34 (0.15 - 0.77) 
       Summary LR’s 4.26 (2.54 – 7.17) 0.28 (0.20 – 0.38) 
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Table 21 Characteristics of the included studies on accuracy of maternal serum α-fetoprotein (MSAFP) testing in predicting spontaneous preterm birth for 
asymptomatic pregnant women 
 
Authors Year Country n Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks’) 
Frequency 
of testing Thresholds 
Outcome 
(weeks’ 
gestation) 
           
Goldenberg1
53 
2001 USA 2929 Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancies Pregnant women with cervical 
dilatation >2 cm (nulliparous) and 
>3 cm (multiparous), Placenta 
previa, Fetal anomaly 
23-24 Single 90th centile <32, <35 
Tanaka160 1994 Japan 1097 Cohort 
Consecutive 
Prospective 
Test described 
Singleton pregnancies Fetal and chromosomal 
abnormalities 
18-20 Single 2.0 MoM <37 
Simpson158 1995 USA 650 Cohort 
Prospective 
Blinded 
Test described 
Singletons pregnant women who 
provided specimen on the two 
specified occasions 
Congenital anomaly 15-20,  
24-36 
Single 2.0 MoM <37 
Dugoff151 2005 USA 33145 Cohort 
Prospective 
Test described 
Singleton gestation, women >16 
years 
Fetal chromosomal or structural 
abnormalities 
15-19 Single 2.0 MoM <32 
Morssink156 1995 Netherlands 7992 Cohort 
Prospective 
Test described 
Singletons who underwent neural 
tube or Down’s syndrome 
screening 
Congenital anomaly, Delivery 
before 25 weeks’ gestation, Insulin 
dependent diabetes mellitus 
15-20 Single 2.5 MoM <37 
Davis* 150 1992 USA 843 Cohort 
Prospective 
Test described 
Singleton pregnancies Non-viable pregnancy, Stillbirths, 
Fetal anomaly 
14-22 Single 2.5 MoM <37 
Waller162 1996 USA 51008 Cohort 
Retrospective 
Test described 
Singleton pregnancies Fetal anomaly, Fetal death, 
Multiple gestations, (Non-lethal 
chromosomal abnormalities might 
have been included) 
15-19 Single 2.0, 2.5 MoM <28, <32, <34, 
<37 
Spencer159 2000 UK 27129 Case-control 
Prospective 
Test described 
Singleton pregnancies Fetal anomaly, Chromosomal 
abnormality, Pregnancy 
termination, Loss before 24 
weeks’ gestation 
14-18 Single 2.0 MoM <35, <37 
Yaron165 1999 USA 20982 Cohort 
Retrospective 
Test described 
Singleton pregnancies Fetal anomaly, Chromosomal 
abnormality 
14-22 Single 2.5 MoM <37 
Hsieh155 1997 Taiwan 5885 Cohort 
Retrospective 
Test described 
Singleton pregnancies Multiple gestation, diabetes 
mellitus, fetal and chromosomal 
abnormalities 
14-22 Single 2.0 MoM <37 
Davis*150 1992 USA 5555 Cohort 
Retrospective 
Test described 
Singleton pregnancies Non-viable pregnancy, Stillbirths, 
Fetal anomaly 
14-22 Single 2.5 MoM <37 
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Wenstorm163 1996 USA 4574 Cohort 
Retrospective 
Test described 
Singleton pregnancies Fetal and Chromosomal 
abnormality 
14-20 Single 2.5 MoM <37 
Brazerol148 1994 USA 776 Cohort 
Retrospective 
Test described 
Singleton pregnancies Fetal anomaly, Oligohydramnios, 
Fetal death 
15-20 Single 2.0 MoM <28, <37 
Duric152 2002 Croatia 672 Cohort 
Retrospective 
Test described 
Singleton pregnancies Fetal chromosomal or structural 
abnormalities 
15-22 Single 2.02 MoM 37 
Sharara157 1995 Qatar 360 Case-control 
Prospective 
Test described 
Singleton pregnancies Fetal anomaly, Chromosomal 
abnormality, Diabetes mellitus, 
Pre-existing hypertension, 
Threatened miscarriage, Molar 
pregnancy 
16-18 Single 2.5 MoM 37 
Akinbiyi147 1996 UK 300 Case-control 
Retrospective 
Test described 
Singleton pregnancies Fetal and chromosomal 
abnormality 
16-18 Single 2.0 MoM 37 
Cho149 1997 USA 255 Case-control 
Prospective 
Test described 
Singleton pregnancies Non-viable pregnancies, Fetal 
anomaly, Chromosomal 
abnormality 
14-20 Single 2.5 MoM 37 
Williams164 1992 USA 412 Case-control 
Retrospective 
Test described 
Singleton pregnancies Fetal anomaly, Chromosomal 
abnormality, Fetal death 
14-20 Single 2.0 MoM 37 
Hamilton154 1985 USA 286 Case-control 
Retrospective 
Test described 
Singleton pregnancies Congenital anomaly 16-20 Single, 
twice 
2.5 MoM <34, <37 
Wald161 1977 UK 188 Case-control 
Retrospective 
Test described 
Singleton pregnancies Congenital abnormalities 14-22 Single 3.0 MoM 37 
           
*Initial retrospective study consisted of 5555 pregnant women, followed by a prospective study on 843 women 
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Table 22 Individual accuracy results of maternal serum α-fetoprotein (MSAFP) testing in predicting spontaneous preterm birth among antenatal asymptomatic 
women 
 
Authors 
Threshold 
(MoM)* 
Outcome 
(weeks’ 
gestation) TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                   
Goldenberg153 
90th 
centile 32 18 184 32 2695 0.36 0.23 0.51 0.94 0.93 0.94 5.63 3.79 8.36 0.68 0.56 0.84 
Goldenberg153 
90th 
centile 35 45 389 82 2490 0.35 0.27 0.44 0.86 0.85 0.88 2.62 2.04 3.38 0.75 0.66 0.85 
Tanaka160 2.0 37 8 65 69 955 0.10 0.05 0.19 0.94 0.92 0.95 1.63 0.81 3.27 0.96 0.89 1.03 
Simpson+158 2.0 37 8 119 34 489 0.19 0.09 0.34 0.80 0.77 0.84 0.97 0.51 1.85 1.01 0.86 1.17 
Simpson++158 2.0 37 4 62 38 546 0.10 0.03 0.23 0.90 0.87 0.92 0.93 0.36 2.44 1.01 0.91 1.12 
Dugoff151 2.0 32 28 531 229 32357 0.11 0.07 0.15 0.98 0.98 0.99 6.75 4.71 9.67 0.91 0.87 0.95 
Morssink156 2.5 37 10 60 467 7455 0.02 0.01 0.04 0.99 0.99 0.99 2.63 1.35 5.10 0.99 0.97 1.00 
Davis150 2.5 37 29 3 73 738 0.28 0.20 0.38 1.00 0.99 1.00 70.23 21.78 226.38 0.72 0.64 0.81 
Waller162 2.0 28 48 2418 237 48305 0.17 0.13 0.22 0.95 0.95 0.95 3.53 2.72 4.59 0.87 0.83 0.92 
Waller162 2.5 28 21 629 264 50094 0.07 0.05 0.11 0.99 0.99 0.99 5.94 3.91 9.03 0.94 0.91 0.97 
Waller162 2.0 32 118 2348 576 47966 0.17 0.14 0.20 0.95 0.95 0.96 3.64 3.08 4.31 0.87 0.84 0.90 
Waller162 2.5 32 47 603 647 49711 0.07 0.05 0.09 0.99 0.99 0.99 5.65 4.24 7.53 0.94 0.92 0.96 
Waller162 2.0 34 227 2239 1149 47393 0.16 0.15 0.19 0.95 0.95 0.96 3.66 3.23 4.15 0.87 0.85 0.90 
Waller162 2.5 34 79 571 1297 49061 0.06 0.05 0.07 0.99 0.99 0.99 4.99 3.97 6.28 0.95 0.94 0.97 
Waller162 2.0 37 499 1967 3212 45330 0.13 0.12 0.15 0.96 0.96 0.96 3.23 2.95 3.55 0.90 0.89 0.91 
Waller162 2.5 37 158 492 3553 46805 0.04 0.04 0.05 0.99 0.99 0.99 4.09 3.43 4.88 0.97 0.96 0.97 
Spencer159 2.0 35 57 548 607 25917 0.09 0.07 0.11 0.98 0.98 0.98 4.15 3.19 5.39 0.93 0.91 0.96 
Spencer159 2.0 37 123 482 1429 25095 0.08 0.07 0.09 0.98 0.98 0.98 4.21 3.47 5.09 0.94 0.92 0.95 
Yaron165 2.5 37 9 75 757 20141 0.01 0.01 0.02 1.00 1.00 1.00 3.17 1.59 6.30 0.99 0.98 1.00 
Hsieh155 2.0 37 23 153 329 5380 0.07 0.04 0.10 0.97 0.97 0.98 2.36 1.55 3.61 0.96 0.93 0.99 
Davis150 2.5 37 87 19 393 5056 0.18 0.15 0.22 1.00 0.99 1.00 48.41 29.74 78.82 0.82 0.79 0.86 
Wenstorm163 2.5 37 62 99 609 3804 0.09 0.07 0.12 0.97 0.97 0.98 3.64 2.68 4.95 0.93 0.91 0.95 
Brazerol148 2.0 28 6 51 9 710 0.40 0.16 0.68 0.93 0.91 0.95 5.97 3.04 11.71 0.64 0.43 0.97 
Brazerol148;148 2.0 37 4 53 37 682 0.10 0.03 0.23 0.93 0.91 0.95 1.35 0.51 3.56 0.97 0.88 1.08 
Duric152 2.0 37 1 39 32 601 0.03 0.00 0.16 0.94 0.92 0.96 0.50 0.07 3.51 1.03 0.97 1.10 
Sharara157 2.5 37 18 102 20 220 0.47 0.31 0.64 0.68 0.63 0.73 1.50 1.03 2.17 0.77 0.56 1.05 
Akinbiyi147 2.0 37 9 91 4 196 0.69 0.39 0.91 0.68 0.63 0.74 2.18 1.46 3.26 0.45 0.20 1.02 
Cho149 2.5 37 37 80 16 122 0.70 0.56 0.82 0.60 0.53 0.67 1.76 1.38 2.25 0.50 0.33 0.76 
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Williams164 2.0 37 43 158 23 188 0.65 0.52 0.76 0.54 0.49 0.60 1.43 1.16 1.76 0.64 0.45 0.90 
Hamilton**154 2.5 34 19 81 1 185 0.95 0.75 1.00 0.70 0.64 0.75 3.12 2.53 3.84 0.07 0.01 0.49 
Hamilton**154 2.5 37 26 74 6 180 0.81 0.64 0.93 0.71 0.65 0.76 2.79 2.16 3.60 0.26 0.13 0.55 
Hamilton154 2.5 34 9 78 1 185 0.90 0.55 1.00 0.70 0.64 0.76 3.03 2.30 4.01 0.14 0.02 0.91 
Hamilton154 2.5 37 18 68 6 180 0.75 0.53 0.90 0.73 0.67 0.78 2.74 2.01 3.72 0.34 0.17 0.69 
Wald161 3.0 37 23 4 71 90 0.24 0.16 0.34 0.96 0.89 0.99 5.75 2.07 15.99 0.79 0.70 0.89 
                   
+ Tested at 15-20 weeks’ gestation ++ Tested at 24-36 weeks’ gestation * Unless otherwise stated ** Tested twice 
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Table 23 Characteristics of studies on test accuracy of maternal serum relaxin in predicting spontaneous preterm birth stratified according to population of 
antenatal asymptomatic women and symptomatic women with threatened preterm labour 
 
Authors Year Country n Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks) 
Frequenc
y of 
testing Threshold 
Outcome 
(weeks’ 
gestation) 
           
Asymptomatic           
Weiss166 1993 USA 76 Cohort 
Prospective 
Consecutive 
Test described 
All 18 - 42 years old women who 
achieved singleton pregnancies from 
either ovulatory induction with or 
without IVF/ET 
No previous history of preterm birth, 
uterine or fetal abnormalities, more 
than one major cervical surgery, no 
previous DES exposure, placenta 
previa, pre-eclampsia 
6 - 12 Serial +3SD* <37 
Vogel168 2006 USA 61 Cohort 
Prospective 
Consecutive 
Test described 
Asymptomatic women with at least 1 
previous late spontaneous 
miscarriage or early spontaneous 
preterm delivery between 16 - 30 
weeks' gestation 
Multiple gestation, PPROM, uterine 
or fetal abnormalities, threatened 
preterm labour 
12 - 25 Single 406 mg/L <37 
Goldenberg153 2001 USA 2929 Case-control 
Retrospective 
Blinded 
Test described 
Singleton pregnancy Cervical dilatation >3cm in 
multiparous, >2cm in nulliparous, 
PPROM, bulging membrane at 
cervical os, placenta previa 
24 Single 90th centile <32, <35 
Vogel167 2005 Denmark 483 Case-control 
Retrospective 
Test described 
Singleton asymptomatic pregnancies Multiple gestation, PPROM, fetal 
abnormalities, diabetes 
18 - 24 Single 932 pg/ml  <37 
           
Symptomatic           
Vogel169 2002 Denmark 34 Cohort 
Prospective 
Test described 
Singleton pregnancy presenting with 
threatened preterm labour and intact 
membrane and without evidence of 
ripening cervix 
Elevated blood pressure, women with 
major medical disease, vaginal 
bleeding 
24 - 34 Single 300 pg/ml <34, <37 
           
*Standard deviation 
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Table 24 Individual accuracy results of maternal serum relaxin measurement in predicting spontaneous preterm birth among asymptomatic antenatal women and 
symptomatic women with threatened preterm labour 
 
Authors 
Outcome 
(weeks’ 
gestation) TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                  
Asymptomatic                  
Weiss166 37 6 37 3 30 0.67 0.30 0.93 0.45 0.33 0.57 1.21 0.73 2.01 0.74 0.28 1.95 
Vogel168 37 9 33 11 8 0.45 0.23 0.68 0.20 0.09 0.35 0.56 0.34 0.93 2.82 1.35 5.89 
Vogel167 37 18 50 66 350 0.21 0.13 0.32 0.88 0.84 0.91 1.71 1.06 2.78 0.90 0.80 1.01 
Goldenberg153 32 11 628 39 2251 0.22 0.12 0.36 0.78 0.77 0.80 1.01 0.60 1.71 1.00 0.86 1.16 
Goldenberg153 35 43 595 84 2214 0.34 0.26 0.43 0.79 0.77 0.80 1.60 1.24 2.06 0.84 0.74 0.95 
                  
Symptomatic                  
Vogel169 34 1 7 2 24 0.33 0.01 0.91 0.77 0.59 0.90 1.48 0.26 8.31 0.86 0.38 1.96 
Vogel167 37 2 6 8 18 0.20 0.03 0.56 0.75 0.53 0.90 0.80 0.19 3.31 1.07 0.72 1.57 
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Table 25 Characteristics of studies on test accuracy of corticotrophin releasing hormone (CRH) in predicting spontaneous preterm birth stratified according to 
population of antenatal asymptomatic women and symptomatic women with threatened preterm labour 
 
Authors Year Country Population Quality of studies Inclusion criteria Exclusion criteria 
Testing 
gestation 
(weeks’ 
gestation) 
Frequency of 
testing Thresholds 
Outcome 
(weeks’ 
gestation) 
           
Asymptomatic           
Leung173 1999 Hong Kong 1014 Blinded 
Cohort 
Prospective 
Test described 
Singleton pregnancies Mid-trimester miscarriage 15-20 Single 1.9 MoM <34 
Berkowitz170 1996 USA 396 Cohort 
Prospective 
Test described 
Asymptomatic Hispanic women Multiple gestations, stillbirths, 
congenital malformation, 
iatrogenic preterm birth, women 
with chronic hypertension, pre-
eclampsia 
 
20-24 
24-28 
29-33 
33-37 
 
Serial 3.1, 41.3, 234, 
665.7 pg/ml 
 
<37 
Inder172 2001 USA 297 Cohort 
Prospective 
Test described 
Antenatal women from a local 
area medical practice 
 
None stated 26 Single** 
 
 
50, 70, 90, 110, 
130, 150 pmol/l 
<37 
Goldenberg153 2001 USA 2929 Blinded 
Case-control 
Retrospective 
Test described 
Singleton pregnancies 
 
Fetal anomalies, chromosomal 
abnormalities, placenta previa, 
cervical dilatation >3 cm, or 
bulging membrane 
 
23-24 Single 90th centile <32 and <35 
Holzman171 2001 USA 304 (White), 
181(Black) 
Blinded 
Case-control 
Retrospective 
Test described 
Antenatal patients at tertiary 
referral centre 
Other ethnic groups beside black or 
white, multiple gestations, diabetes 
before pregnancy, chromosomal 
abnormalities 
 
15-19 Single 1.0, 1.5 MoM <35 
           
Symptomatic           
Coleman174 2000 New Zealand 94 Blinded 
Cohort 
Prospective 
Test described 
Non-diabetic singleton 
pregnancies presenting with 
preterm labour, intact membrane, 
and cervical dilatation <3 cm 
Fetal anomaly and chromosomal 
abnormality 
24-36 Single 90th centile <10 days of 
testing and 
<37 
           
*(Sample was collected weekly from 17-30 weeks’ gestation) but only the sample closest to 22nd weeks’ gestation was used in the analysis) 
**(Sample was collected weekly from 16-20 weeks’ gestation) but only the sample closest to 26th weeks’ gestation was used in the analysis) 
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Table 26 Individual accuracy results of maternal serum corticotrophin releasing hormone (CRH) measurement in predicting spontaneous preterm birth among 
asymptomatic antenatal women and symptomatic women with threatened preterm labour 
 
Authors Thresholds Outcome TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                   
Asymptomatic                   
Leung173 1.9 MoM 34 8 217 3 786 0.73 0.39 0.94 0.78 0.76 0.81 3.36 2.30 4.92 0.35 0.13 0.91 
Berkowitz170 3.1 pg/ml 37 4 25 41 326 0.09 0.02 0.21 0.93 0.90 0.95 1.25 0.46 3.42 0.98 0.89 1.08 
Berkowitz170 41.3 pg/ml 37 11 71 34 280 0.24 0.13 0.40 0.80 0.75 0.84 1.21 0.69 2.10 0.95 0.80 1.13 
Berkowitz170 234 pg/ml 37 13 71 32 280 0.29 0.16 0.44 0.80 0.75 0.84 1.43 0.86 2.36 0.89 0.73 1.08 
Berkowitz170 665.7 pg/ml 37 9 74 36 277 0.20 0.10 0.35 0.79 0.74 0.83 0.95 0.51 1.76 1.01 0.87 1.18 
Inder172 90 pmol/l 37 14 16 17 250 0.45 0.27 0.64 0.94 0.90 0.97 7.51 4.07 13.86 0.58 0.42 0.80 
Inder172 70 pmol/l 37 17 29 14 237 0.55 0.36 0.73 0.89 0.85 0.93 5.03 3.15 8.04 0.51 0.34 0.75 
Inder172 110 pmol/l 37 11 9 20 257 0.35 0.19 0.55 0.97 0.94 0.98 10.49 4.72 23.31 0.67 0.51 0.87 
Inder172 130 pmol/l 37 8 6 23 260 0.26 0.12 0.45 0.98 0.95 0.99 11.44 4.25 30.82 0.76 0.62 0.93 
Inder172 150 pmol/l 37 6 2 25 264 0.19 0.07 0.37 0.99 0.97 1.00 25.74 5.43 122.07 0.81 0.68 0.97 
Inder172 50 pmol/l 37 21 60 10 206 0.68 0.49 0.83 0.77 0.72 0.82 3.00 2.16 4.18 0.42 0.25 0.70 
Goldenberg153 90th centile 32 6 242 44 2637 0.12 0.05 0.24 0.92 0.91 0.93 1.43 0.67 3.05 0.96 0.87 1.06 
Goldenberg153 90th centile 35 15 233 112 2569 0.12 0.07 0.19 0.92 0.91 0.93 1.42 0.87 2.32 0.96 0.90 1.03 
Holzman171 
1.0 MoM 
(Black) 35 33 78 8 62 0.80 0.65 0.91 0.44 0.36 0.53 1.44 1.17 1.78 0.44 0.23 0.84 
Holzman171 
1.0 MoM 
(White) 35 34 120 22 128 0.61 0.47 0.74 0.52 0.45 0.58 1.25 0.98 1.61 0.76 0.54 1.08 
Holzman171 
1.5 MoM 
(Black) 35 17 32 24 108 0.41 0.26 0.58 0.77 0.69 0.84 1.81 1.13 2.91 0.76 0.58 1.00 
Holzman171 
1.5 MoM 
(White) 35 16 48 40 200 0.29 0.17 0.42 0.81 0.75 0.85 1.48 0.91 2.40 0.89 0.74 1.06 
                   
Symptomatic                   
Coleman174 90th centile 10 6 12 7 69 0.46 0.19 0.75 0.85 0.76 0.92 3.12 1.42 6.84 0.63 0.38 1.05 
Coleman174 90th centile 37 12 6 19 57 0.39 0.22 0.58 0.90 0.80 0.96 4.06 1.68 9.81 0.68 0.51 0.91 
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Table 27 Characteristics of the included studies on accuracy of β-human chorionic gonadotrophin (β-hcg) testing in predicting spontaneous preterm birth for 
asymptomatic pregnant women and women who presented with threatened preterm labour 
 
Authors Year Country N Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks) 
Frequency 
of testing 
Threshold 
(MoM)+* 
Outcome 
(weeks’ 
gestation)* 
           
Yaron165 2002 Israel 1,622 Cohort 
Consecutive 
Prospective 
Test described 
 
Singleton pregnancies without 
fetal and chromosomal 
abnormalities 
x 10 - 13 Single ≥1.0, ≥2.0, 
≥3.0, ≥4.0, 
≥5.0  
<37 
Dugoff151 2005 USA 33,145 Cohort 
Consecutive 
Prospective 
Test described 
 
Singleton pregnancies without 
fetal and chromosomal 
abnormalities 
x 15 - 19 Single >2.0 <32 
Ong185 2000 UK 5,297 Cohort 
Consecutive 
Prospective 
Test described 
 
Singleton pregnancies without 
fetal and chromosomal 
abnormalities 
x 10 - 14 Single 5th, 10th 
centile 
<34, <37 
Dugoff179 2004 USA 34,271 Cohort 
Prospective 
Test described 
 
Singleton pregnancies without 
fetal and chromosomal 
abnormalities 
x 10 - 14 Single 1st, 5th , and 
10th centile 
<32, <37 
Morssink156 1995 Netherland 7,992 Cohort 
Prospective 
Test described 
Singleton pregnancies Unknown pregnancy outcome, a 
congenital anomaly, delivery 
before 25 weeks of amenorrhea, 
or known insulin-dependent 
diabetes 
15 - 20 Single ≥2.5 <37 
Chandra178 2003 Canada 8,585 Cohort 
Prospective 
Test described 
< 35 years, low risk singleton 
pregnancies without fetal or 
chromosomal abnormalities 
 
x 15 - 20 Single ≥2.0 <37 
Tanaka160 1994 Japan 1,097 Cohort 
Consecutive 
Prospective 
Test described 
Consecutive pregnant women in 
whom gestation was dated by 
ultrasonography, with singleton 
pregnancies 
 
x 18 - 20 Single ≥2.0 <37 
Haddad188 1999 France 169 Cohort 
Retrospective 
Test described 
 
IVF singleton pregnancies No fetal or chromosomal 
abnormalities 
6 - 7 Serial 90th centile <37 
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Duric152 2002 Croatia 672 Cohort 
Retrospective 
Test described 
< 35 years women with singleton 
pregnancies without fetal or 
chromosomal abnormalities 
 
x 15 - 22 Single ≥2.02 <37 
Spencer159 2000 UK 26,918 Case-control 
Retrospective 
Test described 
Control of singleton 
uncomplicated pregnancies 
outcome. Cases were those with 
spontaneous preterm delivery 
 
x 14 - 18 Single ≥2.0 <35, <37 
Lieppman18
2 
1993 USA 460 Case-control 
Retrospective 
Test described 
 
Non-diabetic women with 
singleton pregnancies between 15 
and 18 weeks’ gestation 
Multiple gestations, diabetic 
pregnancies, fetal and 
chromosomal abnormalities 
 
15 - 18 Single ≥2.0 <37 
Onderoglu1
84 
1997 Turkey 562 Case-control 
Retrospective 
Test described 
Singleton non-diabetic 
pregnancies with know outcomes 
Fetal and chromosomal 
abnormalities or maternal serum 
alpha feto-protein > 2.0 MoM 
 
15 - 20 Single ≥2.0 <37 
Hsieh155 1997 Taiwan 5,885 Cohort 
Retrospective 
Test described 
 
Taiwanese women under 35 years 
of age with singleton pregnancies 
without fetal or chromosomal 
abnormalities 
 
x 14 - 22 Single ≥2.0 <37 
Wenstorm1
86 
1994 USA 252 Case-control 
Retrospective 
Test described 
Cases were singleton pregnancies 
without fetal or chromosomal 
abnormalities who underwent 
amniocentesis with matched 
control who did not have 
amniocentesis 
 
x 15 - 20 Single ≥2.0 <37 
Gonen180 1992 Israel 493 Case-control 
Retrospective 
Test described 
Cases were singleton pregnancies 
with confirmed gestational age 
Fetal or chromosomal 
abnormalities and maternal serum 
alpha feto-protein > 2.5 MoM 
 
16 - 20 Single ≥2.5 <37 
Yaron165 1999 Israel 45,565 Cohort 
Retrospective 
Test described 
All singleton pregnancies 
screened for Down’ syndrome 
risks 
 
Fetal or chromosomal 
abnormalities 
14 - 22 Single >2.5 <37 
Benn176 1996 USA 1,079 Case-control 
Retrospective 
Test described 
<35 years, singleton pregnancies 
without diabetes mellitus, fetal 
and chromosomal abnormalities 
 
x 15 - 22 Single ≥3.0 <37 
Brajenovic1
77 
2004 Croatia 1,507 Case-control 
Retrospective 
Test described 
 
Singleton pregnancies without 
fetal or chromosomal 
abnormalities 
 15 - 20 Single ≥2.0 <37 
Lepage181 2003 Canada 2,256 Case-control 
Retrospective 
Test described 
 
Singleton pregnancies without 
fetal anomalies 
x 15 - 20 Single ≥4.0 <37 
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Liu183 1999 USA 72 Case-control 
Retrospective 
Test described 
Unexplained elevated maternal 
serum hcg levels compared with 
controls with normal ms-hcg 
levels delivering during the same 
period 
 
x 15 - 20 Not stated ≥2.0 <36 
           
Ramos190 2003 USA 86 Cohort 
Prospective 
Blinded 
Test described 
 
Preterm labour, < 4cm cervical 
dilatation, intact membrane  
PPROM, presence of gross blood 
in vagina, cervical cerclage, fetal 
anomaly, IUGR, pre-eclampsia 
24 - 34 Single 25 mIU/ml <37 
Gurbuz189 2004 Turkey 102 Cohort 
Prospective 
Test described 
Preterm labour, < 3cm cervical 
dilatation, intact membrane  
Fetal compromise, placenta 
previa, abruption, fetal anomaly, 
PPROM, pre-eclampsia. 
25 - 35 Single 32 mIU/ml 
42 mIU/ml 
30 mIU/ml 
33 mIU/ml 
 
27 mIU/ml 
 
<100 hours 
<100 hours 
< 7 days 
<14 days of 
testing, 
<35 and <37 
 
Guvenal133 2001 Turkey 60 Case-control 
Prospective 
Test described 
Singleton pregnancies without 
fetal or chromosomal 
abnormalities, cervical dilatation 
<3cm 
Placenta previa, vaginal bleeding, 
pre-eclampsia, hypertension, 
IUGR, fetal distress, rupture of 
membrane at presentation 
24 - 36 Single 27.1 mIU/ml <37 
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Table 28 Individual accuracy results of β-human chorionic gonadotrophin (β-hcg) testing in predicting spontaneous preterm birth among asymptomatic and 
symptomatic women with threatened preterm labour 
 
Authors TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
           
Asymptomatic women, threshold 2.0 MoM, <37 weeks gestation           
Yaron165 32 1246 12 332 0.73 0.57 0.85 0.21 0.19 0.23 0.92 0.77 1.11 1.30 0.79 2.12 
Chandra178 203 637 1352 6393 0.13 0.11 0.15 0.91 0.90 0.92 1.44 1.24 1.67 0.96 0.94 0.98 
Duric152 11 97 23 541 0.32 0.17 0.51 0.85 0.82 0.87 2.13 1.27 3.58 0.80 0.63 1.01 
Tanaka160 8 65 69 955 0.10 0.05 0.19 0.94 0.92 0.95 1.63 0.81 3.27 0.96 0.89 1.03 
Brajenovic177 5 116 44 1342 0.10 0.03 0.22 0.92 0.91 0.93 1.28 0.55 3.00 0.98 0.89 1.07 
Lieppman182 25 200 9 226 0.74 0.56 0.87 0.53 0.48 0.58 1.57 1.25 1.96 0.50 0.28 0.88 
Onderoglu184 27 54 39 442 0.41 0.29 0.54 0.89 0.86 0.92 3.76 2.56 5.52 0.66 0.54 0.81 
Shieh155 33 383 329 5140 0.09 0.06 0.13 0.93 0.92 0.94 1.31 0.94 1.85 0.98 0.94 1.01 
Spencer159 250 3713 1302 22541 0.16 0.14 0.18 0.86 0.85 0.86 1.14 1.01 1.28 0.98 0.96 1.00 
Wenstorm186 4 18 37 193 0.10 0.03 0.23 0.91 0.87 0.95 1.14 0.41 3.20 0.99 0.88 1.10 
Dugoff1 179 54 278 2137 30926 0.02 0.02 0.03 0.99 0.99 0.99 2.77 2.07 3.69 0.98 0.98 0.99 
Dugoff2 151 187 1485 2004 29719 0.09 0.07 0.10 0.95 0.95 0.95 1.79 1.55 2.07 0.96 0.95 0.97 
Dugoff3 151 329 2945 1862 28259 0.15 0.14 0.17 0.91 0.90 0.91 1.59 1.43 1.77 0.94 0.92 0.96 
                 
Symptomatic women, threshold 30 mIU/mL, within 7 days of testing           
Gurbuz189 56 7 2 37 0.97 0.88 1.00 0.84 0.70 0.93 6.07 3.07 11.99 0.04 0.01 0.16 
                 
Symptomatic women, threshold 30 mIU/mL, <37 weeks ‘ gestation           
Ramos190 18 17 10 41 0.64 0.44 0.81 0.71 0.57 0.82 2.19 1.35 3.56 0.51 0.30 0.85 
Gurbuz189 61 10 19 12 0.76 0.65 0.85 0.55 0.32 0.76 1.68 1.04 2.69 0.44 0.25 0.75 
Guvenal133 7 18 1 34 0.88 0.47 1.00 0.65 0.51 0.78 2.53 1.60 3.99 0.19 0.03 1.21 
                 
1. Threshold = 0.28 MoM (i.e. 1st centile), 2. Threshold = 0.42 MoM (5th centile) and 3. Threshold = 0.52 MoM (10th centile) 
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Table 29 Characteristics of studies on test accuracy of estriol in predicting spontaneous preterm birth stratified according to population of antenatal asymptomatic 
women and symptomatic women with threatened preterm labour 
 
Authors Year Country n Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks’) 
Frequency 
of testing Threshold 
Outcome 
(weeks’ 
gestation)* 
           
Asymptomatic           
Heine192 2000 USA 601 Cohort 
Prospective 
Blinded 
Test described 
Singleton gestation, 
women >18 years 
Placenta previa, cerclage, PPROM, pre-eclampsia, 
medications known to affect hormone levels, planned 
caesarean section, major congenital abnormalities, intra-
uterine growth restriction, fetal chromosomal and 
structural abnormalities, erythroblastosis fetalis, oral 
conditions that interfere with saliva collections, maternal 
medical complications 
21-25 Single and 
twice (7 days 
apart) 
2.1 ng/ml 37 
Dugoff151 2005 USA 33145 Cohort 
Prospective 
Test described 
Singleton gestation, 
women >16 years 
Fetal chromosomal or structural abnormalities 15-19 Single 0.5 MoM 32 
Yaron165 1999 USA 24504 Cohort 
Retrospective 
Test described 
All singleton 
pregnancies 
Fetal chromosomal or structural abnormalities 14-22 Single 0.5 MoM 37 
Kim193 2000 Korea 1096 Cohort 
Test described 
All singletons <35 
years old 
Multiple pregnancies, diabetes mellitus, smoking 
abnormal alpha feto-protein and or human chorionic 
gonadotrophin 
15-20 Single 0.75 MoM 37 
Duric152 2003 Croatia 672 Cohort 
Retrospective 
Test described 
Singleton 
pregnancies 
Fetal chromosomal or structural abnormalities 15-22 Single 0.74 MoM 37 
Kowalczyk194 1998 USA 399 Cohort 
Retrospective 
Test described 
Singleton 
pregnancies, <35 
years old  
Elevated hcg and/or AFP 15-21 Single 0.75 MoM 37 
           
Symptomatic           
Heine192 2000 USA 115 Cohort 
Prospective 
Blinded 
Test described 
Symptomatic with 
threatened preterm 
labour 
Placenta previa, tocolytics therapy, cerclage, PPROM, 
pre-eclampsia, medications known to affect hormone 
levels, planned caesarean section, major congenital 
abnormalities, intra-uterine growth restriction, fetal 
chromosomal and structural abnormalities, 
erythroblastosis fetalis, oral conditions that interfere with 
saliva collections, maternal medical complications 
21-25 Single 1.4 ng/ml 
and 2.1 
ng/ml 
Within 14 
days of 
testing 
McGregor191 1995 USA 190 Cohort 
Prospective 
Test described 
Singleton 
pregnancies 
presenting with 
threatened preterm 
labour 
Fetal anomalies, IUGR,  22-26 Single 2.1 ng/ml 37 
           
*Unless otherwise stated 
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Table 30 Individual accuracy results of maternal estriol measurement in predicting spontaneous preterm birth among asymptomatic antenatal women and 
symptomatic women with threatened preterm labour+ 
 
Authors Thresholds 
Outcome 
(weeks)* TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                   
Asymptomatic                   
Heine192 2.1 ng/ml 37 10 46 13 532 0.43 0.23 0.66 0.92 0.90 0.94 5.46 3.18 9.40 0.61 0.43 0.88 
Heine**192 2.1 ng/ml 37 13 128 10 450 0.57 0.34 0.77 0.78 0.74 0.81 2.55 1.73 3.77 0.56 0.35 0.89 
Dugoff 0.5 MoM 32 5 369 252 32519 0.02 0.01 0.04 0.99 0.99 0.99 1.73 0.72 4.15 0.99 0.97 1.01 
Yaron165 0.5 MoM 37 50 1688 865 21901 0.05 0.04 0.07 0.93 0.93 0.93 0.76 0.58 1.00 1.02 1.00 1.03 
Kim193 0.75 MoM 37 7 100 54 935 0.11 0.05 0.22 0.90 0.88 0.92 1.19 0.58 2.44 0.98 0.89 1.07 
Duric152 0.74 MoM 37 12 104 22 534 0.35 0.20 0.54 0.84 0.81 0.86 2.17 1.33 3.53 0.77 0.60 0.99 
Kowalczyk194 0.75 MoM 37 12 69 38 190 0.24 0.13 0.38 0.73 0.68 0.79 0.90 0.53 1.54 1.04 0.87 1.23 
                   
Symptomatic                   
Heine192 1.4 ng/ml 
<14 days 
of testing 14 22 9 70 0.61 0.39 0.80 0.76 0.66 0.84 2.55 1.56 4.16 0.51 0.31 0.87 
Heine192 2.1 ng/ml 
<14 days 
of testing 7 1 16 91 0.30 0.13 0.53 0.99 0.94 1.00 28.00 3.62 216.39 0.70 0.54 0.92 
McGregor191 2.1 ng/ml 37 16 53 6 115 0.73 0.50 0.89 0.68 0.61 0.75 2.31 1.64 3.24 0.40 0.20 0.79 
                   
+Single testing unless otherwise stated 
*Unless otherwise stated 
**Serial testing 7 days apart 
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Table 31 Characteristic of studies on accuracy of maternal C-reactive protein (CRP) measurement in predicting spontaneous preterm birth 
 
Author Year n Study quality Gestation at testing (weeks) Cut-off [ng/mL]* Reference Standard* 
       
Amniotic fluid CRP in asymptomatic women    
Ghezzi200 2002 306 Cohort, blinding, test described 14-20 110 34 weeks’ gestation 
Ozer205 2005 141 Cohort, consecutive, prospective, test described 15-20 6.5 37 weeks’ gestation 
       
Blood serum CRP In asymptomatic women    
Hvilsom202 2002 484 Case-control, test described 14-18 7.6 37 weeks’ gestation 
Karinen203 2005 506 Case-control, test described 12-16 4.3 37 weeks’ gestation 
Rückhäberle206 1991 216 Cohort Not reported pos/neg 37 weeks’ gestation 
       
Blood serum CRP In symptomatic women    
Cammu196 1989 87 Cohort, consecutive, blinding, test described 22-35 12,5 7 days after testing, 
37 weeks’ gestation 
Cylwik197 1997 35 Cohort, retrospective, test described >24 10 37 weeks’ gestation 
Dodds198 1987 34 Cohort, retrospective, test described 24-35 8 7 days after testing 
Foulon199 1995 44 Cohort, consecutive, retrospective, test described 20-34 15 34 weeks’ gestation 
Handwerker201 1984 50 Cohort, consecutive, blinding, test described 24-34 0,8-1,0 7 days after testing 
Mazor204 1993 48 Cohort, consecutive, test described 24-36 8 37 weeks’ gestation 
Potkul195 1985 40 Cohort, consecutive, blinding, test described 24-36 7 37 weeks’ gestation 
Winkler207 1987 98 Cohort, consecutive Not reported 10 7 days after testing 
       
*unless otherwise stated 
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Table 32 Sensitivity and specificity (with corresponding 95% Confidence Intervals (CI)) of C-reactive protein (CRP) among individual studies in predicting 
spontaneous preterm birth according to type of tests, reference standards, and populations 
 
Author  Year 
 Cut-off 
[ng/ml] 
 TP*  FP*  FN*  TN*  Sensitivity  
95% CI 
lower limit 
 
95% CI 
upper limit 
 Specificity  
95% CI 
lower limit 
 
95% CI 
upper limit 
                         
Amniotic fluid CRP for predicting birth before 34 weeks’ gestation 
Asymptomatic women                        
Ghezzi200  2002  110  8  90  2  206  0.80  0.44  0.97  0.70  0.64  0.75 
                         
Amniotic fluid CRP for predicting birth before 37 weeks’ gestation                 
Asymptomatic women                        
Ozer205  2005  6.5  13  27  1  100  0.93  0.66  0.99  0.79  0.72  0.85 
                         
Blood Serum CRP for predicting birth within 7 days of testing 
Symptomatic women                        
Cammu196  1989  12,5  9  1  2  41  0.82  0.48  0.98  0.98  0.87  1.00 
Dodds198  1987  8  17  4  3  10  0.85  0.62  0.97  0.71  0.42  0.92 
Handwerker201  1984  0,8-1,0  11  4  2  33  0.85  0.55  0.98  0.89  0.75  0.97 
Winkler207  1987  10  13  14  27  44  0.33  0.19  0.49  0.76  0.63  0.86 
                         
Blood Serum CRP for predicting birth before 37 weeks’ gestation 
Asymptomatic women                        
Hvilsom202  2002  7.6  22  58  62  342  0.26  0.17  0.37  0.86  0.82  0.89 
Karinen203  2005  4.3  36  90  68  312  0.35  0.26  0.46  0.78  0.73  0.82 
Rückhäberle206  1991  pos/neg  39  20  66  91  0.37  0.28  0.47  0.82  0.74  0.89 
                        
Symptomatic women                        
Cammu196  1989  12,5  14  19  7  47  0.67  0.43  0.85  0.71  0.59  0.82 
Cylwik197  1997  10  2  4  3  26  0.40  0.05  0.85  0.87  0.69  0.96 
Foulon**199  1995  15  3  2  5  34  0.38  0.09  0.76  0.94  0.81  0.99 
Mazor204  1993  8  8  8  10  22  0.44  0.22  0.69  0.73  0.54  0.88 
Potkul195  1985  7  14  2  11  13  0.56  0.35  0.76  0.87  0.60  0.98 
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*TP = true positive, FP = false positive, FN = false negative, TN = true negative. 
**Reference standard births < 34 weeks’ gestation 
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Table 33 Likelihood Ratios for positive (LR+) and negative (LR-) test results (with corresponding 95% Confidence Intervals (CI)) of C-reactive protein (CRP) in 
predicting spontaneous preterm birth among individual studies according to type of tests, reference standard and populations 
 
Author Year  Cut-off [ng/ml]  LR+  95% CI lower limit  95% CI upper limit  LR-  95% CI lower limit  95% CI upper limit 
                
Amniotic fluid CRP for predicting birth before 34 weeks’ gestation 
Asymptomatic women               
Ghezzi200 2002  110  2.63  1.85  3.75  0.29  0.08  0.99 
Ozer205 2005  6.5  4.37  3.03  6.29  0.09  0.014  0.60 
                
Blood Serum CRP for predicting birth within 7 days of testing 
Symptomatic women               
Cammu196 1989  12,5  34.36  4.86  243.09  0.19  0.05  0.65 
Dodds198 1987  8  2.98  1.27  6.95  0.21  0.07  0.63 
Handwerker201 1984  0,8-1,0  7.83  3.01  20.32  0.17  0.05  0.62 
Winkler207 1987  10  1.35  0.71  2.55  0.89  0.69  1.15 
   Summary  4.54  1.48  13.91  0.30  0.08  1.15 
                
Blood Serum CRP for predicting birth before 37 weeks’ gestation 
Asymptomatic women               
Hvilsom202 2002  7.6  1.81  1.17  2.78  0.86  0.76  0.98 
Karinen203 2005  4.3  1.55  1.22  2.13  0.84  0.73  0.98 
Rückhäberle206 1991  pos/neg  2.06  1.29  3.29  0.77  0.65  0.91 
   Summary  1.72  1.38  2.16  0.83  0.76  0.91 
                
Symptomatic women               
Cammu196 1989  12,5  2.32  1.43  3.76  0.47  0.25  0.87 
Cylwik197 1997  10  3.00  0.73  12.27  0.69  0.33  1.44 
Foulon199 1995  15  6.75  1.34  34.00  0.66  0.38  1.14 
Mazor204 1993  8  1.67  0.76  3.66  0.76  0.48  1.21 
Potkul195 1985  7  4.20  1.10  15.98  0.51  0.31  0.82 
   Summary  2.29  1.57  3.35  0.60  0.46  0.79 
                
**Reference standard births < 34 weeks’ gestation 
+ See table 1 for patient characteristics 
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Table 34 Characteristics of the included studies on accuracy of interleukin-6 (IL6) testing in predicting spontaneous preterm birth for asymptomatic pregnant 
women and symptomatic women who presented with threatened preterm labour, stratified according to specimen source 
 
Authors Year Country n Study designs Inclusion criteria Exclusion criteria 
Testing 
gestations 
Frequency 
of testing Thresholds 
Outcome 
(weeks’ 
gestation)* 
           
Asymptomatic           
Amniotic fluid           
Wenstorm210 1998 USA 482 Case-control 
Retrospective 
Test described 
Singleton pregnancies that 
underwent amniocentesis 
for various reasons (e.g. 
prenatal diagnosis) 
 
Aneuploidies, anomalies, 
pregnancy loss within 30 
days of amniocentesis 
14 - 18 Single 2.9 ng/ml 34, 37 
Ghidini212 1997 USA 179 Case-control 
Retrospective 
Test described 
Singleton uncomplicated 
pregnancy 
Multiple gestations, 
uterine, fetal or neonatal 
abnormalities, cytogenetic 
evidence of karyotypical 
abnormalities. 
 
15 - 20 Single 1740 pg/ml 34 
           
Cervico-vaginal           
Lockwood211 1994 USA 161 Cohort 
Prospective 
Consecutive 
Blinding 
Test described 
 
Singleton pregnancies. 
Intact membrane. Cervical 
dilatation <3 cm 
Unknown dates, placenta 
previa, hydatidiform mole, 
major congenital anomaly, 
serious maternal medical 
complications. 
24 - 36 Serial 3 - 4 
weekly 
125 & 250 
pg/ml 
37 
Inglis96 1994 USA 73 Cohort 
Prospective 
Consecutive 
Blinding 
Test described 
 
All patients between 15 
and 40 years old with 
singleton pregnancies. 
Congenital anomalies, 
placenta previa, kwon 
genital or urinary tract 
infection, use of antibiotics 
within the past 7 days. 
20 - 36 Single 50 pg/ml 37 
Goepfert221 2001 USA 250 Case-control 
Retrospective 
Blinding 
Test described 
 
Singleton pregnancies. 
Intact membrane. Cervical 
dilatation <3 cm 
Placenta previa, fetal 
abnormalities, maternal 
medical complications, 
uterine abnormalities. 
22 - 24 Single 305 pg/ml 35, 37 
           
Symptomatic           
Amniotic fluid           
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Rizzo217 1996 Italy 92 Cohort 
Prospective 
Consecutive 
Blinding 
Test described 
 
Singleton gestation in 
premature labour with 
intact membrane, cervical 
dilatation 
Presence of other fetal or 
maternal complications, 
known genital or urinary 
infection, antibiotics use 
within the last 14 days. 
24 - 36 Single 50 pg/ml 37 
Romero208 1993 USA 146 Cohort 
Prospective 
Consecutive 
Test described 
 
Singleton pregnant women 
with threatened preterm 
labour 
x 20 - 34 Single 0.5, 2.0 & 
11.30 ng/ml 
36 
Coultrip214 1994 USA 89 Cohort 
Prospective 
Blinding 
Test described 
Symptomatic women 
singleton pregnancies with 
intact membrane. 
x 20 - 36 Single 0.38, 0.617 
& 1.13 ng/ml 
Within 3 
days of 
testing (0.38 
ng/ml only), 
37 
Greig229 1993 USA 57 Cohort 
Prospective 
Blinding 
Test described 
Singleton gestation in 
premature labour with 
intact membrane 
Cervical dilatation >4 cm, 
antibiotic treatment in the 
past 7 days, any medical 
condition requiring 
antibiotic treatment. 
 
24 - 34 Single 600 pg/ml 3 
Greci215 1998 USA 53 Cohort 
Prospective 
Blinding 
Test described 
Women who presented 
with threatened preterm 
labour and intact 
membrane 
Vaginal bleeding, placenta 
previa, abruption, multiple 
gestations, 
polyhydramnios, pre-
eclampsia, cervical 
cerclage, known uterine or 
fetal anomalies. 
 
24 - 34 Single 7586 pg/ml Within 2 & 7 
days of 
testing 
Burrus114 1995 USA 18 Cohort 
Prospective 
Blinding 
Test described 
Symptomatic women in 
first pregnancy. Intact 
membrane. Cervical 
dilatation <3 cm 
Chorioamnionitis, 
placental abruption. 
24 - 34 Single 1500 pg/ml 48 
Hillier216 1993 USA 50 Cohort 
Prospective 
Test described 
Afebrile women who 
presented with threatened 
preterm labour with intact 
membrane 
<16 or >40 years old, 
uterine or fetal 
abnormalities, multiple 
pregnancies, 
polyhydramnios, cervical 
cerclage, placenta previa, 
abruption, hypertension, 
diabetes or had received 
antibiotics the previous 
week. 
 
23 - 34 Single 1500 pg/ml Within 7 
days of 
testing, 34 
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Silver219 1993 USA 29 Cohort 
Prospective 
Test described 
Symptomatic women 
singleton pregnancies with 
intact membrane. 
Additional medical or 
obstetrics problems e.g. 
diabetes, chronic 
hypertension, placental 
abruption  
24 - 37 Single 400 & 500 
ng/ml 
37 
Allbert213 1994 USA 23 Cohort 
Prospective 
Test described 
Singleton gestation in 
premature labour with 
intact membrane 
Fetal distress, IUGR, 
abruption, clinical 
amnionitis, substantial 
haemorrhage, fetal 
anomalies, or stillbirth. 
 
20 - 32 Single 20 ng/ml Within 2 & 7 
days of 
testing 
Romero220 1993 USA 120 Cohort 
Test described 
Singleton pregnant women 
with threatened preterm 
labour 
Patients who received 
antibiotics before 
amniocentesis, abnormal 
GTT or diabetes mellitus. 
 
22 - 36 Single 11.30 ng/ml 37 
Dudley227 1994 USA 75 Cohort 
Retrospective 
Test described 
Women who presented 
with threatened preterm 
labour, intact membrane 
who delivered 
 x Single 200 pg/ml 7 
Romero218 1990 USA 56 Cohort 
Test described 
Women admitted with 
threatened preterm labour 
and intact membrane 
 x Single 46 ng/ml 35 
           
Cervico-vaginal           
Inglis96 1994 USA 38 Cohort 
Prospective 
Consecutive 
Blinding 
Test described 
All pregnant women 
between 15 and 40 years, 
singleton, less than 37 
weeks and in 
Fetal congenital 
anomalies, placenta previa, 
known genital or UTI, use 
of antibiotics within 7 days 
of testing. 
 
24 - 37 Single 50 pg/ml 37 
LaShay83 2000 USA 118 Cohort 
Prospective 
Blinding 
Test described 
Singleton pregnancies. 
Intact membrane. Cervical 
dilatation <3 cm 
Coitus or digital vaginal 
examination within 24 
hours. Vaginal bleeding. 
Placenta previa. Placental 
abruption. 
Polyhydramnios. Pre-
eclampsia. Known uterine 
or fetal abnormalities. 
 
24 - 34 Single 100 pg/ml 37 
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Kurkinen-Raty223 2001 Finland 77 Cohort 
Prospective 
Consecutive 
Test described 
Consecutive singleton 
pregnant women between 
22 - 32 weeks' gestation 
who present 
Coitus or digital vaginal 
examination within 24 
hours. Vaginal bleeding. 
Placenta previa. Placental 
abruption. 
Polyhydramnios. Pre-
eclampsia. Known uterine 
or fetal abnormalities. 
 
22 - 32 Single 61 ng/L 37 
Trebeden226 2001 France 142 Cohort 
Prospective 
Test described 
Pregnant women with 
threatened preterm labour 
and intact membrane. 
x 22 - 34 Single 20 pg/ml Within 7 
days of 
testing, 34 
Holst222 2005 Sweden 91 Cohort 
Prospective 
Test described 
Women with singleton 
pregnancy presenting with 
threatened preterm labour 
and intact membrane. 
Uterine and fetal 
abnormalities, vaginal 
bleeding, imminent 
delivery and fetal distress. 
 
22 - 34 Single 1.3 ng/ml 7 
Sozmen225 2005 Turkey 40 Cohort 
Prospective 
Test described 
Singleton pregnancies. 
Intact membrane. Cervical 
dilatation <3 cm 
Vaginal bleeding, placenta 
previa, abruption, 
intercourse within last 24 
hours, signs of intra-
uterine infection, 
polyhydramnios, IUGR, 
hypertension, diabetes, 
cervical cerclage, known 
uterine or fetal anomalies. 
 
28 - 36 Single 172 pg/ml 37 
Lange224 2003 Germany 27 Cohort 
Prospective 
Test described 
Singleton pregnancies. 
Intact membrane. Cervical 
dilatation <3 cm 
Multiple gestations. 24 - 34 Single 20 pg/ml Within 2 & 7 
days of 
testing, 34 
           
Serum           
Greig229 1997 USA 56 Cohort 
Prospective 
Blinded 
Test described 
Pregnant women who 
presented to the clinic or 
hospital in suspected 
preterm labour 
Refusal to participate, 
premature pre-labour 
rupture of membrane, 
multiple pregnancy, HIV 
infection, evidence of 
chorioamnionitis, UTI, 
pre-eclampsia, maternal 
age <17 or >40. 
 
22 - 34 Single 6 pg/ml Within 5 
days of 
testing 
Alvarez-de-la-
Rosa228 
2000 Spain 49 Cohort 
Prospective 
Blinded 
Test described 
Pregnant women who 
presented to the clinic or 
hospital in suspected 
preterm labour 
Refusal to participate, 
multiple pregnancies, HIV 
infection, evidence of 
chorioamnionitis or fetal 
distress. 
 
26 - 37 Single 10 pg/ml Within 2 
days of 
testing, 34 
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Turhan230 2000 Turkey 82 Cohort 
Prospective 
Test described 
Singleton pregnancies with 
threatened preterm labour. 
Intact membrane. 
Fetal or uterine 
abnormalities, diabetes 
mellitus, placenta previa, 
bleeding consistent with 
placental abruption, 
cervical cerclage, pre-
eclampsia, known or 
suspected maternal 
infectious disease, positive 
urine culture or known 
maternal medical 
condition leading to 
preterm delivery. 
 
24 - 36 Single 8.3 pg/ml Within 2 & 7 
days of 
testing 
vonMinckwitz231 2000 Germany 72 Cohort 
Prospective 
Test described 
Singleton pregnancies with 
threatened preterm labour. 
Intact membrane. 
Multiple gestation, 
diabetes mellitus, 
polyhydramnios, severe 
concomitant disease, 
clotting disorders, drug 
addictions. 
 
25 - 37 Single 4 pg/ml 24 
Sozmen225 2005 Turkey 40 Cohort 
Prospective 
Test described 
Singleton pregnancies. 
Intact membrane. Cervical 
dilatation <3 cm 
Vaginal bleeding, placenta 
previa, abruption, 
intercourse within last 24 
hours, signs of intra-
uterine infection, 
polyhydramnios, IUGR, 
hypertension, diabetes, 
cervical cerclage, known 
uterine or fetal anomalies. 
 
28 - 36 Single 5 pg/ml 37 
           
 
*Unless otherwise stated 
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Table 35 Individual accuracy results of interleukin-6 (IL6) testing in predicting spontaneous preterm birth among asymptomatic and symptomatic women with 
threatened preterm labour, stratified according to outcome (weeks’ gestation) and specimen source 
 
Authors TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                 
Asymptomatic                 
34 weeks                 
Wenstorm1 210 17 15 107 275 0.14 0.08 0.21 0.95 0.92 0.97 2.65 1.37 5.14 0.91 0.84 0.98 
Ghidini1 212 3 13 10 153 0.23 0.05 0.54 0.92 0.87 0.96 2.95 0.96 9.04 0.83 0.62 1.13 
Goepfert2 221 10 3 39 46 0.20 0.10 0.34 0.94 0.83 0.99 3.33 0.98 11.38 0.85 0.72 0.99 
                 
37 weeks x x x x x x x x x x x x x x x x 
Wenstorm1 210 19 15 173 275 0.10 0.06 0.15 0.95 0.92 0.97 1.91 1.00 3.67 0.95 0.90 1.00 
Lockwood2 211 17 19 17 108 0.50 0.32 0.68 0.85 0.78 0.91 3.34 1.96 5.70 0.59 0.42 0.83 
Lockwood2 211 15 17 19 110 0.44 0.27 0.62 0.87 0.79 0.92 3.30 1.84 5.90 0.65 0.47 0.88 
Inglis2 96 1 10 10 52 0.09 0.00 0.41 0.84 0.72 0.92 0.56 0.08 3.97 1.08 0.87 1.35 
Goepfert2 221 25 12 100 113 0.20 0.13 0.28 0.90 0.84 0.95 2.08 1.10 3.96 0.88 0.80 0.98 
                 
Symptomatic                 
7 - 10 days                 
Greci1 215 17 4 3 29 0.85 0.62 0.97 0.88 0.72 0.97 7.01 2.75 17.90 0.17 0.06 0.49 
Hillier1 216 22 8 4 15 0.85 0.65 0.96 0.65 0.43 0.84 2.43 1.36 4.36 0.24 0.09 0.61 
Allbert1 213 4 0 1 18 0.80 0.28 0.99 1.00 0.81 1.00 28.50 1.78 456.57 0.26 0.06 1.03 
Dudley1 227 26 9 14 26 0.65 0.48 0.79 0.74 0.57 0.88 2.53 1.38 4.64 0.47 0.30 0.75 
Trebeden2 226 18 10 26 88 0.41 0.26 0.57 0.90 0.82 0.95 4.01 2.02 7.96 0.66 0.51 0.85 
Holst2 222 22 13 7 51 0.76 0.56 0.90 0.80 0.68 0.89 3.73 2.21 6.33 0.30 0.16 0.58 
Lange2 224 6 8 0 13 1.00 0.54 1.00 0.62 0.38 0.82 2.40 1.37 4.23 0.12 0.01 1.72 
Turhan3 230 36 5 20 21 0.64 0.50 0.77 0.81 0.61 0.93 3.34 1.48 7.53 0.44 0.30 0.66 
                 
34 weeks                 
Hillier1 216 28 2 4 15 0.88 0.71 0.96 0.88 0.64 0.99 7.44 2.01 27.52 0.14 0.06 0.36 
Trebeden2 226 24 4 54 60 0.31 0.21 0.42 0.94 0.85 0.98 4.92 1.80 13.46 0.74 0.63 0.87 
Lange1 224 7 7 0 13 1.00 0.59 1.00 0.65 0.41 0.85 2.63 1.44 4.79 0.10 0.01 1.45 
Alvarez-de-la-Rosa3 
228 7 19 3 20 0.70 0.35 0.93 0.51 0.35 0.68 1.44 0.86 2.41 0.59 0.22 1.58 
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34 weeks                 
Rizzo1 217 18 0 34 40 0.35 0.22 0.49 1.00 0.91 1.00 28.62 1.78 461.04 0.66 0.54 0.80 
Coultrip1 214 38 5 9 37 0.81 0.67 0.91 0.88 0.74 0.96 6.79 2.95 15.64 0.22 0.12 0.40 
Silver1 219 8 2 5 14 0.62 0.32 0.86 0.88 0.62 0.98 4.92 1.26 19.29 0.44 0.22 0.90 
Romero1 208 11 19 0 90 1.00 0.72 1.00 0.83 0.74 0.89 5.41 3.55 8.22 0.05 0.00 0.76 
Inglis2 96 1 10 10 52 0.09 0.00 0.41 0.84 0.72 0.92 0.56 0.08 3.97 1.08 0.87 1.35 
LaShay2 83 21 59 13 25 0.62 0.44 0.78 0.30 0.20 0.41 0.88 0.65 1.19 1.28 0.75 2.20 
Kurkinen-Raty2 223 8 26 3 40 0.73 0.39 0.94 0.61 0.48 0.72 1.85 1.15 2.95 0.45 0.17 1.20 
Sozmen2 225 14 1 6 19 0.70 0.46 0.88 0.95 0.75 1.00 14.00 2.03 96.62 0.32 0.16 0.62 
Sozmen3 225 9 8 11 12 0.45 0.23 0.68 0.60 0.36 0.81 1.13 0.55 2.32 0.92 0.54 1.56 
                 
1. Amniotic fluid specimen, 2. Cervico-vaginal specimen, 3. Maternal serum specimen 
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Table 36 Characteristics of the included studies on accuracy of interleukin-8 (IL8) testing in predicting spontaneous preterm birth for asymptomatic pregnant 
women and symptomatic women who presented with threatened preterm labour 
 
Authors Year Country n Study designs Inclusion criteria Exclusion criteria 
Testing 
gestation 
(weeks) 
Frequency of 
testing Thresholds 
Outcomes 
(weeks’ 
gestation)* 
           
Asymptomatic           
Sakai235 2004 Japan 4203 Cohort 
Prospective 
Blinding 
Test described 
Asymptomatic women with 
singleton pregnancy and 
intact membrane 
Preterm pre-labour rupture of 
membrane, threatened or 
impending miscarriage or 
preterm delivery, genital 
bleeding 
20 - 28 Serial 
(2weekly) 
360 ng/ml 32, 34, 37 
           
Sakai234 2004 Japan 501 Cohort 
Prospective 
Test described 
Asymptomatic women with 
singleton pregnancy 
Iatrogenic prematurity, fetal 
asphyxia, abruption, placenta 
previa, pre-eclampsia 
20 - 24 Single 377 ng/ml 37 
           
Symptomatic           
Kurkinen223 2001 Finland 77 Cohort 
Prospective 
Consecutive 
Test described 
Consecutive singleton 
pregnant women between 22 
- 32 weeks' gestation who 
presented with threatened 
preterm labour. 
Preterm pre-labour rupture of 
membrane, impending 
preterm delivery 
22 - 32 Single 3739 ng/L 37 
           
Holst222 2005 Sweden 91 Cohort 
Prospective 
Test described 
Women with singleton 
pregnancy presenting with 
threatened preterm labour 
and intact membrane 
Uterine and fetal 
abnormalities, vaginal 
bleeding, imminent delivery 
and fetal distress 
22 - 34 Single 7.7 ng/ml Within 7 
days of 
testing 
           
Allbert** 213 1994 USA 23 Cohort 
Prospective 
Test described 
Singleton gestation in 
premature labour with intact 
membrane 
Fetal distress, IUGR, 
abruption, clinical 
amnionitis, substantial 
haemorrhage, fetal 
anomalies, or stillbirth 
20 - 32 Single 15 ng/ml Within 2 & 7 
days of 
testing 
           
*Unless otherwise stated 
**Amniotic fluid specimen 
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Table 37 Individual accuracy results of interleukin-8 (IL8) testing in predicting spontaneous preterm birth among asymptomatic and symptomatic women with 
threatened preterm labour and stratified according to outcome (weeks’ gestation)* 
 
Authors 
Outcome 
(weeks’ 
gestation) TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                  
Asymptomatic                  
Sakai1 235 32 7 838 11 3347 0.39 0.17 0.64 0.80 0.79 0.81 1.94 1.08 3.48 0.76 0.53 1.10 
Sakai1 235 34 12 833 15 3343 0.44 0.25 0.65 0.80 0.79 0.81 2.23 1.46 3.41 0.69 0.50 0.97 
Sakai1 235 37 38 807 101 3257 0.27 0.20 0.36 0.80 0.79 0.81 1.38 1.04 1.82 0.91 0.82 1.01 
Sakai234 37 11 73 15 402 0.42 0.23 0.63 0.85 0.81 0.88 2.75 1.68 4.52 0.68 0.49 0.95 
                  
Symptomatic                  
Allbert2 213 23 4 0 0 19 1.00 0.40 1.00 1.00 0.82 1.00 36.00 2.30 564.54 0.10 0.01 1.42 
Holst222 73 18 17 11 47 0.62 0.42 0.79 0.73 0.61 0.84 2.34 1.42 3.84 0.52 0.32 0.84 
Allbert2 213 73 4 0 1 18 0.80 0.28 0.99 1.00 0.81 1.00 28.50 1.78 456.57 0.26 0.06 1.03 
Kurkinen223 37 7 30 4 36 0.64 0.31 0.89 0.55 0.42 0.67 1.40 0.83 2.35 0.67 0.30 1.50 
                  
*Unless otherwise stated, testing were done on a single occasion and cervico-vaginal samples of IL8 were used 
1. Serial testing 2. Amniotic fluid 3. Birth within the stated number of days of testing 
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Table 38 Characteristics of the included studies on accuracy of matrix metalloprotease 9 (MMP-9) testing in predicting spontaneous preterm birth in symptomatic 
women who presented with threatened preterm labour 
 
Authors Year Country n sample Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks) 
Frequency 
of testing Threshold 
Outcome 
(weeks’ 
gestation) 
            
Makrakis237 2003 Greece 20 Urine, 
plasma 
Cohort 
Prospective 
Test described 
Symptomatic women who 
presented with threatened 
preterm labour, 20 - 35 years, no 
other pregnancy complication 
Absence of cervical 
dilatation, no evidence of 
rupture membrane or 
chorioamnionitis 
24 - 36 Single 7.71 ng/ml 
(urine), 
68.43 ng/ml 
(plasma) 
<37 
Agrez236 1999 Australia 15 urine Cohort 
Prospective 
Test described 
Symptomatic women who 
presented with threatened 
preterm labour 
x 27 - 34 Single 5 ng/ml <37 
            
 
 
Table 39 Individual accuracy results of matrix metalloprotease 9 (MMP-9) testing in predicting spontaneous preterm birth among asymptomatic and symptomatic 
women with threatened preterm labour 
 
Authors Thresholds TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                  
Agrez236 5 ng/ml 4 1 2 8 0.67 0.22 0.96 0.89 0.52 1.00 6.00 0.87 41.44 0.38 0.12 1.19 
Makrakis237 7.71 ng/ml 6 1 3 10 0.67 0.30 0.93 0.91 0.59 1.00 7.33 1.07 50.27 0.37 0.14 0.94 
Makrakis237 68.43 ng/ml 6 1 3 10 0.67 0.30 0.93 0.91 0.59 1.00 7.33 1.07 50.27 0.37 0.14 0.94 
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Table 40 Characteristics of the included studies on accuracy of periodontal health assessment in predicting spontaneous preterm birth among asymptomatic 
pregnant women 
 
Authors 
 
Year Country N Study designs Inclusion Exclusion Testing gestation Threshold Outcome 
          
Jeffcoat244 2001 USA 1313 Cohort 
Prospective 
Blinded 
Test described 
 
All pregnant women being studied 
by the Perinatal Emphasis 
Research Center at UAB 
Women who required antibiotic 
prophylaxis for dental examination 
or who is taking antibiotics 
21 - 24 Periodontitis ≥3 sites with 
≥3mm attachment loss (AL), 
severe periodontitis ≥90 sites, 
and healthy <3 sites <3mm AL 
37 
Offenbacher2
38 
2001 USA 812 Cohort 
Prospective 
Blinded 
Test described 
Pregnant women enrolled before 
26 weeks’ gestation 
 Before 26 weeks’ 
gestation and within 
48 hours of deliveries 
Periodontitis: Periodontal health 
(absence of any probe depth 
(PD) >3mm and no sites with 
attachment loss (AL) >2mm), 
moderate severe disease (≥4 
sites with PD ≥5mm & ≥2mm 
AL at ≥4 sites), and mild 
periodontitis i.e. less than the 
moderate to severe group but 
had more than the healthy group. 
 
Progression of periodontitis 
 
37 
Moore246 2004 UK 539 Cohort 
Prospective 
Blinded 
Test described 
Women who attended for NT 
Down syndrome screening at 12 
weeks' gestation 
Pregnancy less than 10 or more 
than 15 weeks' gestation, multiple 
pregnancy and need for antibiotics 
before dental treatment 
10 -15 Healthy: <10% sites with probe 
depth (PD) ≥3mm & <5% sites 
with loss of attachment (LA) 
≥2mm, Severe: >5 sites with PD 
≥5mm & >3 sites with LA 
≥3mm 
 
32, 37 
Offenbacher2
48 
1996 USA 124 Cohort 
Prospective 
Blinded 
Test described 
 
Pregnant women under routine 
antenatal care in a University 
Hospital Prenatal Clinic 
Concurrent genito-urinary tract 
infection, use of antibiotics and if 
at risk for bacterial endocarditis 
Day 3 postnatal Probe depth and loss of 
attachment ≥3mm affecting 
>60% (Extent 3:60) in all 
women and in primiparous 
37 
Holbrook242 2004 Iceland 96 Cohort 
Consecutive 
Prospective 
Test described 
Healthy otherwise unselected 
pregnant women. Bacterial 
vaginosis testing using Amsel’s 
criteria was also performed on 
enrolled women 
 
 28 - 30 >4 pockets >4mm probe depth 37 
Rajapakse250 2005 Sri Lanka 227 Cohort 
Prospective 
Test described 
Nulliparous, 18 - 34 years, 
singleton pregnancy 
Hypertension, diabetes, smoking, 
betel chewing, alcohol and drug 
abuse 
24 - 37 Mean pocket depth, plaque 
scores, and bleeding scores 
composite that are greater than 
the median value in the total 
cohort. 
37 
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Moore247 2005 UK 154 Case-control 
Prospective 
Blinded 
Test described 
Cases were women who had 
spontaneous preterm birth before 
37 weeks' gestation. Controls were 
uncomplicated term vaginal or 
elective caesarean section delivery. 
 
Multiple pregnancy, medical 
history that require antibiotic 
cover, iatrogenic preterm delivery, 
hypertension, pre-eclampsia, 
diabetes mellitus. 
Day 5 postnatal Probe depth (≥4mm, ≥5mm) and 
loss of attachment (≥2mm, 
≥3mm) 
 
37 
Goepfert241 2004 USA 103 Case-control 
Prospective 
Blinded 
Test described 
 
Cases were women who delivered 
between 24 and 32 weeks' 
gestation. 
 Day 3 postnatal >3mm and >5mm loss of 
attachment 
32 
Dasanayake2
39 
2001 USA 80 Case-control 
Prospective 
Blinded 
Test described 
Cases were women who had 
spontaneous preterm birth before 
37 weeks' gestation. Controls were 
term delivery. 
 
Missing second trimester samples 
and elective preterm deliveries 
14 - 24 Median and >75% Ig 
Prophyromonas gingivalis 
presence in serology. 
37 
Dortbudak240 2005 Austria 36 Cohort 
Prospective 
Test described 
 
Pregnant women undergoing 
amniocentesis for medical 
conditions 
x 15 - 20 Probe depth ≥5mm 37 
Radnai249 2004 Hungary 85 Case-control 
Retrospective 
Blinded 
Test described 
Systematically healthy women, 
cases were spontaneous premature 
birth before 37 weeks' gestation. 
Diabetes, asthma, cardiac or renal 
problems, thyroid problems, 
chronic infectious disease or 
multiple pregnancies, patients who 
needed prophylaxis antibiotics. 
 
Day 3 postnatal Probe depth ≥4mm, bleeding on 
probing, and combination of 
probe depth, bleeding on 
probing 
37 
Jarjoura243 2005 USA 203 Case-control 
Retrospective 
Test described 
Singleton pregnancies Fetal or uterine anomalies, cervical 
incompetence, iatrogenic 
premature delivery, women who 
required antibiotics prophylaxis 
before dental assessment 
 
Day 3 postnatal Clinical attachment loss (CAL) 
≥3mm in ≥5 sites 
37 
Konopka245 2003 Poland 128 Case-control 
Retrospective 
Test described 
Cases were women who had 
spontaneous preterm birth before 
37 weeks' gestation of infant who 
weighed <2500g 
Multiple pregnancy, 
developmental defects, treated 
infertility patients, IVF, iatrogenic 
preterm births and systemic 
infection (apart from UTI) 
 
Day 3 postnatal Periodontal index >4 37 
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Table 41 Individual accuracy results of periodontal health assessment in predicting spontaneous preterm birth among asymptomatic women 
 
Authors Thresholds TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                  
Offenbacher238 
Mild 
periodontitis 132 434 38 163 0.78 0.71 0.84 0.27 0.24 0.31 1.07 0.97 1.17 0.82 0.60 1.12 
Offenbacher238 
Moderate-
severe 
periodontitis 18 27 38 163 0.32 0.20 0.46 0.86 0.80 0.90 2.26 1.35 3.79 0.79 0.65 0.96 
Offenbacher238 
Progressive 
periodontitis 75 180 113 444 0.40 0.33 0.47 0.71 0.67 0.75 1.38 1.12 1.71 0.84 0.74 0.96 
Moore* 246 
Severe 
periodontitis 9 254 4 272 0.69 0.39 0.91 0.52 0.47 0.56 1.43 0.99 2.08 0.60 0.26 1.35 
Moore246 
Severe 
periodontitis 24 239 20 256 0.55 0.39 0.70 0.52 0.47 0.56 1.13 0.85 1.50 0.88 0.63 1.23 
Offenbacher248 
All women 
with 
periodontitis 87 22 6 9 0.94 0.86 0.98 0.29 0.14 0.48 1.32 1.05 1.66 0.22 0.09 0.57 
Offenbacher248 
Primiparous 
with 
periodontitis 41 11 5 9 0.89 0.76 0.96 0.45 0.23 0.68 1.62 1.08 2.44 0.24 0.09 0.63 
Holbrook242 
PD≥4mm in > 
pockets 0 16 6 74 0.00 0.00 0.46 0.82 0.73 0.89 0.39 0.03 5.90 1.13 0.90 1.42 
Rajapakse250 
PD≥ cohort 
median value 27 39 12 149 0.69 0.52 0.83 0.79 0.73 0.85 3.34 2.35 4.73 0.39 0.24 0.63 
Moore247 PD≥4mm 5 10 56 83 0.08 0.03 0.18 0.89 0.81 0.95 0.76 0.27 2.12 1.03 0.93 1.14 
Moore247 LA≥3mm 1 2 60 91 0.02 0.00 0.09 0.98 0.92 1.00 0.76 0.07 8.23 1.01 0.96 1.05 
Moore247 LA≥2mm 3 7 58 86 0.05 0.01 0.14 0.92 0.85 0.97 0.65 0.18 2.43 1.03 0.95 1.12 
Moore247 PD≥5mm 1 4 60 89 0.02 0.00 0.09 0.96 0.89 0.99 0.38 0.04 3.33 1.03 0.97 1.08 
Goepfert*241 Extent 5 11 4 48 40 0.19 0.10 0.31 0.91 0.78 0.97 2.05 0.70 6.01 0.89 0.77 1.04 
Goepfert* 241 Extent 3 28 13 31 31 0.47 0.34 0.61 0.70 0.55 0.83 1.61 0.95 2.73 0.75 0.55 1.02 
Dortbudak240 PD≥5mm 5 6 1 30 0.83 0.36 1.00 0.83 0.67 0.94 5.00 2.22 11.28 0.20 0.03 1.20 
Radnai249 PD≥4mm 22 18 19 26 0.54 0.37 0.69 0.59 0.43 0.74 1.31 0.83 2.07 0.78 0.52 1.18 
Radnai249 
Bleeding on 
probing (BOP) 20 9 21 35 0.49 0.33 0.65 0.80 0.65 0.90 2.38 1.23 4.62 0.64 0.46 0.90 
Radnai249 
PD≥4mm + 
BOP 19 5 22 39 0.46 0.31 0.63 0.89 0.75 0.96 4.08 1.68 9.92 0.61 0.45 0.82 
Jarjoura243 Periodontitis 21 25 62 95 0.25 0.16 0.36 0.79 0.71 0.86 1.21 0.73 2.02 0.94 0.81 1.10 
Konopka245 
Periodontal 
index greater 
than 4 27 12 57 32 0.32 0.22 0.43 0.73 0.57 0.85 1.18 0.66 2.09 0.93 0.74 1.18 
                  
Spontaneous preterm birth before 32 weeks’ gestation 
 
 
 
256
Table 42 Characteristics of the included studies on accuracy of asymptomatic bacteriuria assessment in predicting spontaneous preterm birth before 37 weeks’ 
gestation for asymptomatic pregnant women 
 
Authors Year Country n Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks) 
Frequency 
of testing 
Outcome 
(weeks’ 
gestation) 
          
MSU          
Wren278 1969 Australia 3099 Cohort 
Consecutive 
Prospective 
Test described 
All pregnant patient booking at their first 
antenatal visit 
Twin pregnancies and women who moved 
hospital 
Antenatal Repeat if 
positive 
<37 
Robertson269 1968 UK 2184 Cohort 
Consecutive 
Prospective 
Test described 
Singleton pregnancies Miscarriages, treated women, delivered 
elsewhere 
Booking Single <37 
Uncu274 2002 Turkey 186 Cohort 
Consecutive 
Prospective 
Test described 
Singleton pregnancies Patient with renal disease, recent or current 
antibiotic treatment, current or recent 
asymptomatic bacteriuria 
<32 Repeat if 
positive 
<37 
Layton262 1964 UK 176 Cohort 
Consecutive 
Prospective 
Test described 
Antenatal asymptomatic women  <32 Single <37 
Versi275 1997 UK 6864 Cohort 
Prospective 
Test described 
Singleton pregnancies (Caucasian & 
Bangladeshi populations only) 
 11 - 14 Single <37 
Patrick268 1967 UK 575 Cohort 
Prospective 
Test described 
Antenatal asymptomatic women  Booking Single <37 
Schieve271 1994 USA 25663 Cohort 
Retrospective 
Test described 
Singleton pregnancies  Antenatal Single <37 
LeBlanc263 1964 USA 1248 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Gold256 1966 USA 1246 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Kass259 1962 USA 1095 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Hoja258 1964 USA 879 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
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Stuart273 1965 UK 817 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Henderson257 1965 USA 808 Case-control 
Retrospective 
Test described 
Singleton pregnancies Placenta previa, pre-eclampsia, abruption, 
induced labour, erythroblastosis fetalis 
<22 Single <36 
Low264 1964 USA 771 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Forkman255 1964 Sweden 595 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Schamadan270 1965 USA 556 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Kincaid260 1964 USA 556 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Whalley276 1965 USA 283 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Sleigh272 1964 UK 200 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Norden267 1965 USA 197 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Kubicki261 1976 Poland 192 Case-control 
Retrospective 
Test described 
Singleton pregnancies  18 - 23 Single <37 
Bryant254 1964 USA 66 Case-control 
Retrospective 
Test described 
Singleton pregnancies  <20 Single <37 
Abdul-
Jabbar253 
1991 Saudi  Case-control 
Retrospective 
Test described 
Pregnant women without apparent ailments  Booking Single <37 
          
GBS          
Moller266 1984 Denmark 2745 Cohort 
Consecutive 
Prospective 
Test described 
Singleton pregnancies  Antenatal Single <37 
McDonald265 1989 Australia 692 Cohort 
Consecutive 
Prospective 
Test described 
Singleton pregnancies  20 - 24 Single <37 
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White277 1984 UK 8083 Cohort 
Retrospective 
Test described 
Singleton pregnancies  Antenatal Single <37 
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Table 43 Individual accuracy results of asymptomatic bacteriuria assessment in predicting spontaneous preterm birth before 37 weeks’ gestation among 
asymptomatic antenatal women 
 
Authors TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                 
MSU                 
Wren278 15 75 204 2805 0.07 0.04 0.11 0.97 0.97 0.98 2.63 1.54 4.50 0.96 0.92 0.99 
Robertson269 13 191 62 1918 0.17 0.10 0.28 0.91 0.90 0.92 1.91 1.15 3.19 0.91 0.82 1.01 
Uncu274 6 17 16 147 0.27 0.11 0.50 0.90 0.84 0.94 2.63 1.16 5.96 0.81 0.62 1.05 
Layton262 4 59 9 104 0.31 0.09 0.61 0.64 0.56 0.71 0.85 0.37 1.97 1.09 0.74 1.59 
Versia 275 13 139 624 6694 0.02 0.01 0.03 0.98 0.98 0.98 1.00 0.57 1.76 1.00 0.99 1.01 
Versib 275 39 393 512 5920 0.07 0.05 0.10 0.94 0.93 0.94 1.14 0.83 1.56 0.99 0.97 1.01 
Patrick268 7 68 21 479 0.25 0.11 0.45 0.88 0.85 0.90 2.01 1.02 3.97 0.86 0.69 1.06 
Schieve271 293 1687 2546 21137 0.10 0.09 0.11 0.93 0.92 0.93 1.40 1.24 1.57 0.97 0.96 0.98 
LeBlanc263 6 21 133 1088 0.04 0.02 0.09 0.98 0.97 0.99 2.28 0.94 5.55 0.98 0.94 1.01 
Gold256 0 30 168 1048 0.00 0.00 0.02 0.97 0.96 0.98 0.10 0.01 1.70 1.03 1.01 1.04 
Kass259 26 69 88 912 0.23 0.15 0.32 0.93 0.91 0.94 3.24 2.16 4.87 0.83 0.75 0.92 
Hoja258 1 21 54 803 0.02 0.00 0.10 0.97 0.96 0.98 0.71 0.10 5.21 1.01 0.97 1.05 
Stuart273 20 68 83 646 0.19 0.12 0.28 0.90 0.88 0.93 2.04 1.30 3.21 0.89 0.81 0.98 
Henderson257 33 15 371 389 0.08 0.06 0.11 0.96 0.94 0.98 2.20 1.21 3.99 0.95 0.92 0.99 
Low264 5 75 49 642 0.09 0.03 0.20 0.90 0.87 0.92 0.89 0.37 2.10 1.01 0.93 1.11 
Forkman255 1 33 19 542 0.05 0.00 0.25 0.94 0.92 0.96 0.87 0.13 6.06 1.01 0.91 1.12 
Schamadan270 8 48 25 475 0.24 0.11 0.42 0.91 0.88 0.93 2.64 1.36 5.11 0.83 0.69 1.01 
Kincaid260 12 44 25 475 0.32 0.18 0.50 0.92 0.89 0.94 3.83 2.22 6.59 0.74 0.59 0.92 
Whalley276 11 96 21 155 0.34 0.19 0.53 0.62 0.55 0.68 0.90 0.54 1.49 1.06 0.81 1.39 
Sleigh272 7 93 7 93 0.50 0.23 0.77 0.50 0.43 0.57 1.00 0.58 1.72 1.00 0.58 1.72 
Norden267 11 77 14 95 0.44 0.24 0.65 0.55 0.47 0.63 0.98 0.61 1.58 1.01 0.70 1.47 
Kubicki261 18 83 5 86 0.78 0.56 0.93 0.51 0.43 0.59 1.59 1.22 2.08 0.43 0.19 0.94 
Bryant254 2 30 4 40 0.33 0.04 0.78 0.57 0.45 0.69 0.78 0.24 2.49 1.17 0.64 2.13 
Abdul-
Jabbar253 18 180 16 184 0.53 0.35 0.70 0.51 0.45 0.56 1.07 0.77 1.49 0.93 0.64 1.35 
                 
GBS                 
Moller266 14 54 228 2449 0.06 0.03 0.10 0.98 0.97 0.98 2.68 1.51 4.76 0.96 0.93 0.99 
McDonald265 4 24 46 618 0.08 0.02 0.19 0.96 0.94 0.98 2.14 0.77 5.93 0.96 0.88 1.04 
White277 10 127 389 7557 0.03 0.01 0.05 0.98 0.98 0.99 1.52 0.80 2.86 0.99 0.98 1.01 
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a. Caucasian population, b. Bangladeshi population 
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Table 44 Characteristics of the included studies on accuracy of bacterial vaginosis (BV) testing in predicting spontaneous preterm birth for asymptomatic pregnant 
women and women who presented with threatened preterm labour 
 
Study Population Test Reference 
standards 
          
Population 
Author, 
publication year 
Country Study quality* n Inclusion criteria 
 
Exclusion criteria 
 
Gestational 
age at 
testing 
 
Site and 
frequency of 
testing 
 
Criteria for 
diagnosis of BV 
Gestational 
age at birth 
(weeks’ 
gestation) 
 
          
Asymptomatic pregnant women        
          
Oakeshott, 
2004285 
USA Cohort 
Consecutive 
Prospective 
Test described 
 
887 All consecutive <10 weeks' 
gestation. 
Miscarriages, terminations, multiple 
gestations, antibiotics treatment, missing 
specimen slides. 
<10 Vaginal swab 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
<37 
Klebanoff, 
2005284 
USA Cohort 
Prospective 
Blinded 
Test described 
 
12937 Did not report genital 
itching, burning, malodour 
to questioning, no major 
medical or obstetrics 
complications in current 
pregnancy, not received or 
expected to receive 
antibiotics, could be 
followed after delivery. 
 
 <13, 13-14, 
15-16, 17-
18, 19-20, 
21-22 
 
Vaginal swab 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
<37 (data 
was 
collected for 
23-26 
weeks’ 
gestation 
births but 
this was not 
published) 
DeSeta, 2005286 Italy Cohort 
Consecutive 
Prospective 
Test described 
 
598 
 
Singleton, negative urine 
culture the past two weeks, 
no other genito-urinary 
tract infection 
 
Diabetes, hypertension, cardiac or chronic 
renal disease, Rh iso-immunization, cervical 
cerclage, antibiotics treatment, un-protected 
intercourse or vaginal washing in the last 48 
hours. 
 
13-18 Vaginal swab 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
<37 
Purwar, 2001295 India Cohort 
Blind 
Prospective 
Test described 
938 
 
Arbitrary selection of 
singleton pregnancies 
Multiple pregnancy 
Placenta previa 
Symptomatic vaginal discharge 
History suggestive of cervical incompetence 
Vaginal bleeding 
Leaking membrane 
Antibiotic use in the preceding 15 days 
Suspected uterine malformation 
 
16-28 
 
Vaginal swab 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
 
<37 
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Hillier, 1995294 USA Cohort 
Blind 
Prospective 
Test described 
 
8197 
 
Women with singleton 
pregnancies who has 
completed 23-26 weeks’ 
gestation and attending 
routine antenatal clinic 
<16 years old 
Rhesus iso-immunisation disease 
Preceding 2 weeks or current use of 
antibiotics 
Chronic renal disease 
Organic heart disease 
Insulin dependent diabetes mellitus 
Multiple gestation 
Cervical cerclage 
Hypertension requiring treatment 
 
23-26 
 
Posterior 
fornix 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
Or 
 
Vaginal pH 
>4.5 
 
 
<37 
 
Govender, 
1996293 
S Africa Cohort 
Blind 
Prospective 
Test described 
 
168 
 
Singleton pregnancies less 
than 30 weeks’ gestation 
 
Previous spontaneous premature birth 
Antibiotics in the current pregnancy 
Symptomatic discharge 
Urinary tract infection 
Multiple pregnancy 
 
<30 weeks Vaginal swab 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
<37 
Kurki, 1992296 Finland Cohort 
Blind 
Prospective 
Test described 
 
733 
 
Singletons 
First pregnancy 
 
Antibiotics in current pregnancy 
Multiple pregnancy 
Induction prior to 37 weeks 
 
8-17 
 
Posterior 
fornix 
 
Single 
 
Gram’s staining 
 
(Spiegel’s 
criteria) 
 
<37 
Crane, 199992 Canada Cohort 
Blind 
Prospective 
Test described 
 
140 
 
Singletons 
 
Multiple pregnancy 
Pre-labour rupture of membranes 
Placenta previa 
Previously treated for BV in current 
pregnancy 
Cerclage 
Major fetal anomalies 
 
20-24 Posterior 
fornix 
 
Single 
 
Gram staining 
(Nugent’s 
criteria) 
 
Or 
 
Clinical criteria 
 
<37 
Hay, 1994297 England 
 
Cohort 
Blind 
Prospective 
Test described 
 
706 
 
Singletons 
First antenatal visit 
between 9-24 weeks’ 
gestation 
 
Multiple pregnancy 
Lethal congenital malformations 
Antibiotics in the current pregnancy 
 
9-24 
 
Posterior 
fornix 
 
Single 
Gram’s staining 
(Spiegel’s 
criteria) 
 
<37 
McGregor, 
1990298 
USA Cohort 
Blind 
Prospective 
Test described 
 
194 
 
Singletons 
Women receiving care at 2 
prenatal clinics  
Multiple pregnancy 
Cerclage 
Placenta previa 
Vaginal bleeding 
Preterm labour. 
Preceding 2 weeks antibiotics course 
Douching within 24 hours of examination 
 
24 Mid-vaginal 
swab 
 
Single 
 
Gram’s staining 
(Spiegel’s 
criteria) 
 
 
<37 
Gratacos, 1998291 Spain 
 
Cohort 
Blind 
Prospective 
Test described 
 
635 
 
Singletons 
 
Multiple pregnancy 
Abortion or termination 
Congenital malformation 
Lost to follow-up 
 
<24 and 
<35 
 
Posterior 
fornix 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
<37 
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Helou, 1996292 Israel 
 
Cohort 
Blind 
Prospective 
Test described 
 
400 
 
Singletons 
 
Iatrogenic preterm delivery 
 
15-20 and 
27-32 
 
Vaginal swab 
 
Serial (twice) 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
<37 
 
Balu, 2003287 USA Cohort 
Prospective 
Test described 
 
646 Singleton pregnancy, 
access to telephone, >16 
years old, planned to 
continue care in the same 
hospital 
 
 24-29  Gram’s staining 
(Nugent’s 
criteria) 
 
<32, <34, 
and <37 
 
Riduan, 1993289 Indonesia 
 
Cohort 
Prospective 
Test described 
 
490 
 
Singletons 
 
Medical conditions associated with preterm 
delivery 
Previous tocolysis or steroids treatment 
Antibiotics within 2 weeks of enrolment 
Incompetent cervix 
 
16-20 and 
28-32 
 
Vaginal swab 
 
Serial (twice) 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
<37 
Meis, 1995288 USA 
 
Cohort 
Prospective 
Test described 
 
2929 
 
Singletons 
 
Cerclage 
Major congenital anomaly 
Placenta previa, Polyhydramnios 
Oligohydramnios 
Cervix >2cm dilated in nulliparous and 
>3cm multiparous women 
 
24 and 28 
 
Posterior 
fornix 
 
Serial (twice) 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
<35 
Cauci, 2003283 USA Cohort 
Retrospective 
Test described 
 
417 Singletons Major congenital anomaly 8-24 Posterior 
fornix 
(Single) 
Clinical criteria <37 
Thorsen, 1996290 USA 
 
Cohort 
Test described 
 
2927 
 
Singletons 
 
Congenital malformations 
Placenta previa, pre-eclampsia 
Cerclage, placental abruption 
Serious medical disease 
Rhesus iso-immunisation 
 
7-24 Posterior 
fornix 
 
Single 
 
Clinical criteria 
 
<37 
Mascagni, 
2004282 
USA Retrospective 
Case-control 
 
103 Singleton pregnancy, 18 - 
34 years old, asymptomatic 
from vaginal infection 
 
Medical or obstetrics problem requiring 
elective preterm delivery, cigarette smoking, 
diabetes, hypertension, STD. 
15-16 Vaginal swab 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
<37 
 
          
Women with threatened preterm labour       
          
Goffinet, 2003300 France Cohort 
Prospective 
Blind 
Test described 
 
212 Singleton with threatened 
preterm labour and intact 
membrane. 
Rupture of membrane, chorioamnionitis, 
suspected fetal distress, fetal malformation, 
maternal disorder requiring delivery, > 3cm 
dilatation. 
24 - 34 Vaginal swab 
 
Single 
Gram staining 
(Nugent’s 
criteria) 
<7 days of 
testing, <33, 
and <35 
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Martius, 1988305 USA Blind 
Prospective 
Case-control 
Test described 
 
212 
 
Singletons 
 
<16 years 
Antibiotics within 2 weeks 
Insulin dependent diabetes mellitus 
Congenital heart disease 
Pre-eclampsia 
Renal disease 
Essential hypertension 
Placental abruption 
Placenta previa 
Multiple gestation 
Congenital malformation 
 
20-36 
 
Vaginal swab 
 
Single 
Gram’s staining 
(Spiegel’s 
criteria) 
 
 
<37 
Holst, 1994232 Sweden 
 
Prospective 
Case-control 
Consecutive 
Test described 
 
87 
 
Women with singleton 
pregnancies admitted for 
preterm labour 
Control were women 
admitted in labour at term 
Diabetics 
Pre-eclampsia 
Placental abruption 
Placenta previa 
Multiple gestation 
Cervical cerclage 
Pre-labour preterm rupture of membrane 
 
24-36 
 
Vaginal swab 
 
Single 
 
Gram’s staining 
(Spiegel’s 
criteria) 
 
< 34 and <37 
 
Eschenbach, 
1984304 
USA Blind 
Prospective 
Case-control 
Test described 
 
171 
 
Women admitted in labour 
and had vaginal exam 
2 controls, women who 
delivered at term, were 
selected for each case 
enrolled 
 
Vaginal swab was not obtained 
Iatrogenic preterm birth 
Congenital malformation 
Placental abruption 
Placenta previa 
Vaginal bleeding of indeterminate origin 
 
24-36 
 
Vaginal swab 
 
Single 
 
Gas liquid 
chromatography 
 
<37 
 
Elliott, 1990301 Kenya 
 
Retrospective 
Case-control 
Test described 
 
 
276 
 
Preterm singleton 
pregnancies who presented 
with preterm labour 
Control were women who 
delivered >36 weeks’ 
gestation 
 
None stated 
 
24-36 
 
Vaginal swab 
 
Single 
 
Gram’s staining 
(Spiegel’s 
criteria) 
 
<36 
 
 
Subtil, 2002303  France 
 
Prospective 
Case-control 
Test described 
 
102 
 
Women presented with 
preterm labour with either 
cervical dilatation >2 cm 
or history of previous 
preterm labour. 
Control matched for 
gestation and admitted 
preterm for reasons 
unrelated to preterm labour 
(e.g. pre-eclampsia, 
diabetes, intra-uterine 
growth restriction, and 
cholestasis). 
 
Gestational age less than 20 or more than 34 
weeks’ gestation, local or general antibiotic 
therapy within the past 8 days, premature 
rupture of membrane, bleeding, or presence 
of a clear cause for preterm labour (e.g. 
multiple pregnancy, hydramnios). 
 
20-34 
 
Vaginal swab 
 
Single 
 
Clinical criteria 
 
<37 
 
 
 
265
Krohn, 1991302 USA 
 
Prospective 
Test described 
 
211 
 
Women who presented 
with preterm labour 
 
Less than 16 or more than 40 years old 
Uterine or fetal anomaly 
Hypertension 
Diabetics 
Cervical cerclage 
Placenta previa 
Placenta abruption 
 
22-34 
 
Vaginal swab 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
 
<35 
 
Carlini, 2003299 USA Case-control 
Prospective 
Test described 
 
753 Singleton with threatened 
preterm labour and intact 
membrane 
Elective preterm delivery 20 – 37 Vaginal swab 
 
Single 
 
Gram’s staining 
(Nugent’s 
criteria) 
 
 
<37 
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Table 45 Individual accuracy results of bacterial vaginosis (BV) testing in predicting spontaneous preterm birth among symptomatic women with threatened 
preterm labour 
 
Authors TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                 
Asymptomatic                 
Single testing (Nugent)                 
Oakeshott285 6 143 38 700 0.14 0.05 0.27 0.83 0.80 0.86 0.80 0.38 1.72 1.04 0.92 1.17 
Crane92 1 30 8 101 0.11 0.00 0.48 0.77 0.69 0.84 0.49 0.07 3.16 1.15 0.90 1.48 
DeSeta286 14 90 35 459 0.29 0.17 0.43 0.84 0.80 0.87 1.74 1.08 2.82 0.85 0.71 1.02 
Govender293 24 64 11 69 0.69 0.51 0.83 0.52 0.43 0.61 1.43 1.07 1.90 0.61 0.36 1.01 
Gratacos291 20 105 26 484 0.43 0.29 0.59 0.82 0.79 0.85 2.44 1.68 3.54 0.69 0.53 0.89 
Helou292 7 53 31 309 0.18 0.08 0.34 0.85 0.81 0.89 1.26 0.62 2.57 0.96 0.82 1.12 
Hillier294 77 1141 29 6949 0.73 0.63 0.81 0.86 0.85 0.87 5.15 4.53 5.86 0.32 0.23 0.43 
Klebanoff284 74 121 423 1156 0.15 0.12 0.18 0.91 0.89 0.92 1.57 1.20 2.06 0.94 0.90 0.98 
Purwar295 30 83 29 783 0.51 0.37 0.64 0.90 0.88 0.92 5.31 3.84 7.33 0.54 0.42 0.71 
Balu287 71 157 171 350 0.29 0.24 0.36 0.69 0.65 0.73 0.95 0.75 1.20 1.02 0.93 1.13 
Riduan289 17 67 48 358 0.26 0.16 0.39 0.84 0.80 0.88 1.66 1.04 2.64 0.88 0.75 1.02 
Mascagni282 6 22 6 69 0.50 0.21 0.79 0.76 0.66 0.84 2.07 1.06 4.05 0.66 0.37 1.17 
                 
Single testing (Amsel)                 
Crane92 2 18 7 113 0.22 0.03 0.60 0.86 0.79 0.92 1.62 0.44 5.91 0.90 0.63 1.29 
Thorsen290 14 438 91 2434 0.13 0.07 0.21 0.85 0.83 0.86 0.87 0.53 1.43 1.02 0.95 1.10 
Cauci283 11 61 75 356 0.13 0.07 0.22 0.85 0.82 0.89 0.87 0.48 1.59 1.02 0.93 1.12 
                 
Serial testing (Nugent)                 
Gratacos291 8 33 7 38 0.53 0.27 0.79 0.54 0.41 0.65 1.15 0.67 1.96 0.87 0.49 1.56 
Helou292 3 24 20 330 0.13 0.03 0.34 0.93 0.90 0.96 1.92 0.63 5.92 0.93 0.79 1.10 
Riduan289 8 31 53 370 0.13 0.06 0.24 0.92 0.89 0.95 1.70 0.82 3.52 0.94 0.85 1.04 
                 
Symptomatic                 
Subtil303 Amsel 6 8 38 50 0.14 0.05 0.27 0.86 0.75 0.94 0.99 0.37 2.64 1.00 0.86 1.17 
Goffinet300 Nugent 4 19 33 156 0.11 0.03 0.25 0.89 0.84 0.93 1.00 0.36 2.76 1.00 0.88 1.13 
Carlini299 Nugent 85 39 321 308 0.21 0.17 0.25 0.89 0.85 0.92 1.86 1.31 2.65 0.89 0.84 0.95 
Krohn302 Nugent 35 20 104 52 0.25 0.18 0.33 0.72 0.60 0.82 0.91 0.57 1.45 1.04 0.87 1.23 
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Holst232 Spiegel 9 3 13 24 0.41 0.21 0.64 0.89 0.71 0.98 3.68 1.13 11.97 0.66 0.46 0.96 
Martius305 Spiegel 21 34 40 117 0.34 0.23 0.48 0.77 0.70 0.84 1.53 0.97 2.41 0.85 0.69 1.03 
Elliot301 Spiegel 30 115 27 104 0.53 0.39 0.66 0.47 0.41 0.54 1.00 0.76 1.32 1.00 0.73 1.36 
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Table 46 Characteristic of studies on test accuracy of mammary stimulation test in predicting spontaneous preterm birth among asymptomatic women 
 
Authors Year Country Population Quality of studies Inclusion criteria Exclusion criteria 
Testing 
gestation 
(weeks’ 
gestation) 
 
Frequency of 
testing 
Outcome 
(weeks’ 
gestation) 
        
Eden306 1991 USA 94 Cohort 
Blinded 
Prospective 
Test described 
 
Inner city pregnant women None stated 24-32 Single <5 days of 
testing, <34 
<37 
Guinn307 1994 USA 247 Cohort 
Blinded 
Prospective 
Test described 
 
Nulliparous women receiving 
private ante-natal care with 
singleton pregnancies 
Placenta previa 
Multiple gestations 
Preterm pre-labour rupture of 
membrane 
 
26-28 Single <34 and <37 
        
 
Table 47 Individual accuracy results of mammary stimulation test in predicting spontaneous preterm birth among asymptomatic women stratified according testing 
gestation and outcome gestations 
 
Authors 
Outcome 
(weeks’ 
gestation) TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                  
Guinn307 34 7 40 2 198 0.78 0.40 0.97 0.83 0.78 0.88 4.63 2.95 7.25 0.27 0.08 0.91 
Guinn307 37 3 44 2 198 0.60 0.15 0.95 0.82 0.76 0.86 3.30 1.54 7.08 0.49 0.17 1.43 
Eden306 37 16 31 3 44 0.84 0.60 0.97 0.59 0.47 0.70 2.04 1.46 2.84 0.27 0.09 0.77 
Eden* 306 37 11 8 2 16 0.85 0.55 0.98 0.67 0.45 0.84 2.54 1.38 4.68 0.23 0.06 0.85 
Eden306 5** 12 35 0 47 1.00 0.74 1.00 0.57 0.46 0.68 2.25 1.71 2.95 0.07 0.00 1.02 
                  
 
*High risk women according to Creasy risk scoring system **Within 5 days of testing 
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Table 48 Characteristics of test accuracy studies of uterine activities monitoring in predicting spontaneous preterm birth stratified according to population of 
antenatal asymptomatic women and women symptomatic with threatened preterm labour 
 
Authors Year Country n Test Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks) 
Frequency 
of testing Threshold 
Outcome 
(weeks’ 
gestation) 
            
Asymptomatic            
Iams69 2002 USA 270 Tocograph Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancies Women who had received 
or were scheduled to 
receive an ambulatory 
monitor or tocolytic 
medication or to undergo 
cerclage were complicated 
by placenta previa or a 
major fetal anomaly 
detected by 
ultrasonography. Women 
who did not have 
telephones were not 
enrolled, because the 
transmission of data 
collected by the 
monitoring system 
required a telephone. 
22 - 30 Four times – 
two sessions 
of at least 
two hours 
apart (one at 
night, one at 
day time) 
before 28 
week and 
two more 
sessions 
between 28 – 
30 weeks 
Max night-
time and day 
time 
contraction 
of ≥4/h 
<35 
Iams309 1988 USA 100 Tocograph Cohort 
Prospective 
Test described 
Asymptomatic singleton 
pregnancies data only 
x 20 - 34 Single ≥4contractio
ns/hour 
<37 
            
Symptomatic            
Bell308 1983 UK 15 Tocograph Cohort 
Test described 
Singleton pregnancy 
presenting with threatened 
preterm labour 
 
 20 - 28 Single Pmax 
≥15mmHg 
<37 
Maner310 2003 USA 99 Electromyography Case-control 
Retrospective 
Test described 
Singleton pregnancies 
presenting with threatened 
preterm labour leading to 
vaginal deliveries, intact 
membrane, dilatation 
<2cm, no evidence of 
systemic infection or fetal 
distress 
To ensure optimal 
recording, patient over 230 
lb was excluded 
24 - 42 Single 0.463 <37 
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Table 49 Individual accuracy results of uterine activities monitoring in predicting spontaneous preterm birth stratified according to population of asymptomatic 
antenatal women and symptomatic women with threatened preterm labour 
 
Authors TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                 
Asymptomatic                 
Iamsa 69 4 8 42 214 0.09 0.02 0.21 0.96 0.93 0.98 2.41 0.76 7.68 0.95 0.86 1.04 
Iamsb 69 0 4 48 218 0.00 0.00 0.07 0.98 0.95 1.00 0.51 0.03 9.24 1.01 0.98 1.05 
Iams309 14 15 2 69 0.88 0.62 0.98 0.82 0.72 0.90 4.90 2.99 8.04 0.15 0.04 0.56 
                 
Symptomatic                 
Bell308 3 2 1 9 0.75 0.19 0.99 0.82 0.48 0.98 4.13 1.04 16.32 0.31 0.05 1.71 
Maner310 23 3 19 54 0.55 0.39 0.70 0.95 0.85 0.99 10.40 3.34 32.38 0.48 0.34 0.67 
                 
a. night-time contraction, b. day time contraction 
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Table 50 Characteristic of studies on test accuracy of rheobase measurement in predicting spontaneous preterm birth among symptomatic women 
 
Authors Year Country n 
Quality of 
studies Inclusion criteria Exclusion criteria 
Testing gestation 
(weeks’ gestation) 
Frequency 
of testing Thresholds 
Outcome 
(weeks’ 
gestation) 
           
Arabin311 1985 Germany 176 Cohort 
Prospective 
Test described 
Singleton pregnancies 
presenting with threatened 
preterm labour from 20 
weeks' gestation onwards 
Iatrogenic preterm 
delivery, suspected 
chorioamnionitis, fetal 
distress, placental 
bleeding, polyhydramnios 
20 - 36 Serial >2.8, >3.4 mA 37 
           
 
Table 51 Individual accuracy results of rheobase measurement in predicting spontaneous preterm birth among asymptomatic women stratified according testing 
gestation and outcome gestations 
 
Authors 
Threshold 
(mA) TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                  
Arabin311 2.8 18 34 15 109 0.55 0.36 0.72 0.76 0.68 0.83 2.29 1.50 3.52 0.60 0.41 0.88 
Arabin311 3.4 25 46 8 97 0.76 0.58 0.89 0.68 0.60 0.75 2.36 1.73 3.20 0.36 0.19 0.66 
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Table 52 Characteristic of studies on test accuracy of absence of fetal breathing movement (FBM) in predicting spontaneous preterm birth in symptomatic women 
 
Study Year Language Study quality Population Inclusion criteria Exclusion criteria 
Frequency of 
testing 
Testing 
gestation 
(weeks’ 
gestation)
Definitions of thresholds for 
abnormality Outcome 
          
Senden85 1996 English Cohort 
Prospective 
Consecutive 
Blinding 
Test described 
25 Singletons presenting with 
threatened preterm labour 
 
PPROM 
Vaginal bleeding 
Chorioamnionitis 
Diabetes mellitus 
Cervical dilatation >4cm 
History suggestive of cervical 
incompetence 
 
Single 25-35 Absence of sustained FBM in a 
30s period during a 30 minutes 
observations 
 
<7 days 
Schreyer318 1988 English Cohort 
Prospective 
Consecutive 
Test described 
70 Uncomplicated singleton 
pregnancies presenting with 
threatened preterm labour 
 
Multiple pregnancies 
PPROM 
Vaginal bleeding 
Pyrexia 
Non-recordable uterine 
contractions on tocodynamometer 
Non-reassuring fetal heart rate 
recording 
 
Single 
 
32-36 No sustained FBM (lasting >20s) 
in a 45 minutes observation 
period 
 
<24 hours 
<48 hours 
<7 days 
 
Agustsson313 1987 English Cohort 
Retrospective 
Test described 
 
64 Women suspected of preterm 
labour 
Advanced cervical dilatation 
Regular contraction not detectable 
 
Single 26-36 No sustained FBM (lasting >20s) 
in a 45 minutes observation 
period 
 
<56 hours 
<7 days 
 
Besinger314 1987 English Cohort 
Prospective 
Test described 
 
50 Women suspected of threatened 
preterm labour 
 
None stated Single 26-34 No sustained FBM (lasting >20s) 
in a 20 minutes observation 
period 
 
<48 hours 
Kanaan316 1991 English Cohort 
Prospective 
Test described 
34 Singletons 
Healthy volunteers 
Regular preterm uterine 
contractions 
 
Vaginal bleeding 
PPROM 
 
Single 
 
24-36 Absence of FBM in a 20s period 
or decreased FBM in a 15 minutes 
observation 
<48 hours 
Markwitz317 2001 Polish Cohort 
Retrospective 
Test described 
 
36 Singleton pregnancies with 
suspected preterm labour 
 
None stated 
 
Single 28-36 No sustained FBM (lasting >20s) 
in a 30 minutes observation 
period 
<7 days 
Devoe315 1994 English Cohort 
Prospective 
Test described 
25 Regular uterine contractions 
No clinical signs of 
chorioamnionitis 
No significant vaginal bleeding 
Singletons 
 
Congenital abnormalities 
Maternal medical or obstetrical 
complications 
 
Single 28-36 Absence of FBM within 6s period 
in a 45 minutes observation 
 
<7 days 
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Castle312 1983 English Cohort 
Prospective 
Test described 
 
24 Women suspected of preterm 
labour 
None stated Single 25-34 No sustained FBM (lasting >20s) 
in a 45 minutes observation 
period 
<7 days 
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Table 53 Individual accuracy results of absence of fetal breathing movement in predicting spontaneous preterm birth among symptomatic women with threatened 
preterm labour 
 
Study 
Intact membrane (Intact) or 
Pre-labour premature 
rupture of membrane 
(PPROM) 
 
Reference standards
(hours to delivery or 
within days of 
testing) FP FP FN TN 
Likelihood ratios for positive test 
(LR+) 
(95% confidence interval) 
 
Likelihood ratios for negative test 
(LR-) 
(95% confidence interval) 
 
         
Agustsson313 Intact <56 hours 17 0 5 42 65.43 (4.12 - 1039.20) 0.23 (0.11 - 0.49) 
Agustsson313 Intact <7 days 17 0 14 33 37.19 (2.33 - 93.09) 0.45 (0.31 - 0.67) 
Besinger314 Intact <48 hours 9 1 4 26 18.69 (2.64 - 132.33) 0.32 (0.14 - 0.72) 
Besinger314 PPROM <48 hours 7 0 0 3 7.50 (0.56 - 100.87) 0.07 (0.00 - 1.07) 
Castle312 Intact <7 days 5 0 2 17 24.75 (1.55 - 396.04) 0.29 (0.09 - 0.92) 
Castle312 PPROM <7 days 10 0 6 1 2.47 (0.22 - 28.05) 0.38 (0.20 - 0.71) 
Devoe315 Intact <7 days 2 0 10 38 15.00 (0.77 - 292.61) 0.83 (0.65 - 1.07) 
Devoe315 Intact <72 hours 2 0 8 40 18.64 (0.96 - 360.56) 0.80 (0.59 - 1.09) 
Devoe315 PPROM <7 days 9 0 14 2 2.38 (0.18 - 31.28) 0.61 (0.44 - 0.84) 
Devoe315 PPROM <72 hours 11 0 9 5 6.57 (0.45 - 96.05) 0.45 (0.28 - 0.73) 
Kanaan316 Intact <48 hours 4 11 1 18 2.11 (1.11 - 4.00) 0.32 (0.05 - 1.90) 
Markwitz317 Intact <7 days 8 0 4 24 32.69 (2.04 - 522.93) 0.33 (0.15 - 0.74) 
Markwitz317 PPROM <7 days 16 0 6 2 4.30 (0.34 - 54.76) 0.27 (0.14 - 0.54) 
Schreyer318 Intact <24 hours 7 7 1 55 7.75 (3.68 - 16.33) 0.14 (0.02 - 0.88) 
Schreyer318 Intact <48 hours 11 3 2 54 16.08 (5.22 - 49.55) 0.16 (0.05 - 0.58) 
Schreyer318 Intact <7 days 12 2 4 52 20.25 (5.05 - 81.23) 0.26 (0.11 - 0.61) 
Senden85 Intact <7 days 2 2 3 18 4.00 (0.73 - 21.84) 0.67 (0.32 - 1.38) 
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Table 54 Characteristics of test accuracy studies of cervical length measurement in predicting spontaneous preterm birth in antenatal asymptomatic women 
 
Authors Year Country n Study designs Inclusion Exclusion 
Test 
gestation 
Frequency 
of testing 
Threshold 
(mm)  
Outcome 
(weeks’ 
gestation) 
           
Leung326 2005 HK 2952 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Singleton pregnancy of ethnic Chinese 
women only 
Fetal abnormalities, non-viable 
pregnancies, lack of outcome 
information, outside test gestation 18 - 22 Single 
<15, <20, 
<25, <27, 
<30, <35 <34 
Yazici332 2004 Turkey 357 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Singleton pregnancies in the absence 
of history of cervical incompetence, 
PPROM or previous preterm delivery 
Uterine or fetal anomalies, pregnancy 
related complications, maternal 
systemic disease 24 Single <32.5 <36 
Owen328 2001 USA 183 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Singletons with at least one previous 
spontaneous preterm birth. 
Cervical cerclage, uterine anomaly, 
chronic medical problem which may 
cause iatrogenic preterm delivery. 16 - 18 Single 
<15, <20, 
<25, <30 <35 
Berghella323 1997 USA 96 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Singletons, previous spontaneous 
preterm birth, >2 previous abortions, 
previous cone biopsy, Ehler-Danlos 
syndrome. 
Cervical cerclage, placenta previa, 
major fetal anomaly. 14 - 22 Single <16, <25 <35 
Andrews322 2000 USA 69 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Singleton pregnancies with previous 
history of spontaneous preterm birth 
between 16 - 30 weeks' gestation 
Medical or obstetrics complication. 
History of incompetent cervix that 
required cerclage. Presented for 
antenatal care after 28 weeks <20 Thrice <22, <25 <35 
To331 2001 UK 6334 
Cohort 
Prospective 
Consecutive 
Test described Singleton pregnancies x 22 - 24 Single <15 33 
Sakai235 2004 Japan 4203 
Cohort 
Prospective 
Blinding 
Test described 
Asymptomatic women with singleton 
pregnancy and intact membrane 
Preterm pre-labour rupture of 
membrane, threatened or impending 
miscarriage or preterm delivery, 
genital bleeding 20 - 28 Single 25 
<32, <34, 
<37 
Taipale330 1998 Finland 3694 
Cohort 
Prospective 
Consecutive 
Test described Singleton pregnancies 
Inadequate imaging, iatrogenic 
preterm delivery, fetal death or 
malformation 18 - 22 Single 
<25, <29, 
<35, <40, 
<45, <50 <35, <37 
Hibbard325 2000 USA 760 
Cohort 
Prospective 
Consecutive 
Test described Singleton pregnancies x 16 - 22 Single 
<22, <27, 
<30 <35 
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Dilek324 2006 Turkey 250 
Cohort 
Prospective 
Consecutive 
Test described 
Singleton pregnancies in the absence 
of history of cervical incompetence, 
PPROM or previous preterm delivery 
Uterine or fetal anomalies, pregnancy 
related complications, maternal 
systemic disease 22 Single <33.15 <37 
Andersen321 1990 USA 113 
Cohort 
Prospective 
Blinded 
Test described Singletons 
Placenta previa, patient thought to be 
at risk from cervical incompetence. 7 - 30 Single <39 <37 
deCarvalho59 2005 Brazil 1958 
Cohort 
Retrospective 
Test described 
Singleton pregnancy attending routine 
antenatal care at 21 - 24 weeks' 
gestation 
Iatrogenic preterm delivery, missing 
outcomes 21 - 24 Single 
<10, <15, 
<20, <25, 
<30 <34 
Pires329 2005 Brazil 338 
Cohort 
Prospective 
Test described Singleton uncomplicated pregnancy 
Previous history of preterm delivery, 
uterine or fetal abnormalities, 
miscarriage, fetal death, alteration in 
amniotic fluid, placenta previa, 
previous uterine or cervical surgery, 
surgical procedures during gestation 
and conditions requiring iatrogenic 
preterm delivery 21 - 24 Single <20 <35, <37 
Mara327 2002 Czech 247 
Case-control 
Prospective 
Test described 
Singleton viable pregnancy, delivering 
at investigating institution 
Congenital or chromosomal 
abnormalities, history of uterine or 
cervix surgery, greater than 3 previous 
vaginal deliveries 18 - 20 Single <20 <34 
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Table 55 Characteristics of test accuracy studies of cervical length measurement in predicting spontaneous preterm birth in women symptomatic with threatened 
preterm labour 
 
Authors Year Country n Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks) 
Frequency 
of Testing 
Threshold 
(mm) 
Outcome 
(weeks’ 
gestation)* 
           
Crane333 1997 USA 136 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Singleton pregnancies whose 
contraction has been arrested by 
tocolysis 
Cervical dilatation > 3cm, placenta 
previa, PPROM 24 - 34 Single <30 <34 
Gomez337 1994 USA 59 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described Singleton pregnancies PPROM, cervix dilatation >3 cm 21 - 35 Single <18 <37 
Tsoi346 2005 UK 510 
Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancy presenting with 
threatened preterm labour, intact 
membrane, cervical dilatation <3cm x 24 - 34 Single 
<5, <10, 
<15, <20 
<48 hours, 
<7 days of 
testing, <37 
Schmitz342 2006 France 359 
Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancy presenting with 
threatened preterm labour, intact 
membrane, cervical dilatation <3cm 
Cervical manipulation, PPROM, 
fetal or uterine anomalies, vaginal 
bleeding, placenta previa, abruption, 
IUGR, pre-eclampsia, iatrogenic 
preterm delivery 18 - 34 Single 
<15, <25, 
<30 
<7 days of 
testing, <35 
Fuchs335 2004 Germany 253 
Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancy presenting with 
threatened preterm labour, intact 
membrane, cervical dilatation <3cm 
PPROM, cervical cerclage, 
requirement for iatrogenic preterm 
delivery, abruption, placenta previa, 
suspected fetal distress 24 - 36 Single <15 
<7 days of 
testing 
Tsoi344 2003 UK 216 
Cohort 
Prospective 
Blinded 
Test described 
Singleton viable pregnancies 
presenting with threatened preterm 
labour 
Cervical dilatation >3 cm or 
PPROM 24 - 36 Single <15 
<7 days of 
testing 
Onderoglu7
5 1997 Turkey 90 
Cohort 
Prospective 
Blinded 
Test described 
Singletons, intact membrane, 
cervical dilatation <3cm, absence of 
fetal and maternal complication x 25 - 36 Single <28 <37 
Tekesin343 2005 Germany 85 
Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancy presenting with 
threatened preterm labour, intact 
membrane, cervical dilatation <3cm 
Fetal abnormalities, PPROM, 
cervical cerclage, requirement for 
iatrogenic preterm delivery, 
abruption, placenta previa, suspected 
fetal distress 24 - 36 Single <25 <37 
Kurkinen223 2001 Finland 76 
Cohort 
Prospective 
Consecutive 
Test described 
Consecutive singleton pregnant 
women between 22 - 32 weeks' 
gestation who presented with 
threatened preterm labour. 
Preterm pre-labour rupture of 
membrane, impending preterm 
delivery 22 - 32 Single <29.3 <37 
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Tsoi345 2004 UK 63 
Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancy presenting with 
threatened preterm labour, intact 
membrane, cervical dilatation <3cm PPROM 24 - 36 Single <15 
<7 days of 
testing 
Rozenberg3
41 2003 France 28 
Cohort 
Prospective 
Blinded 
Test described 
Singleton pregnancy presenting with 
threatened preterm labour, intact 
membrane, cervical dilatation <3cm 
History of cervical incompetence 
with cerclage, suspected 
chorioamnionitis, PPROM, 
polyhydramnios, placenta previa, 
abruption, IUGR, pre-eclampsia, 
feta distress, other maternal or fetal 
distress requiring preterm delivery 24 - 34 Single <26 <37 
Gomez106 2005 Chile 215 
Cohort 
Prospective 
Test described 
Singleton pregnancy presenting with 
threatened preterm labour, intact 
membrane, cervical dilatation <3cm x 22 - 35 Single <15, <30 
<48 hours, 
<7, <14 
days of 
testing, <32, 
<35 
Venditelli34
7 2001 France 174 
Cohort 
Prospective 
Test described Singleton pregnancies 
Cervical dilatation >3 cm, PPROM, 
cervical cerclage, active vaginal 
bleeding, known fetal malformation 
or death, placenta previa 18 - 36 Single <30 <37 
Daskalakis3
34 2005 Greece 172 
Cohort 
Prospective 
Test described 
Singleton pregnancy presenting with 
threatened preterm labour, intact 
membrane, cervical dilatation <3cm 
PPROM, cervical cerclage, 
requirement for iatrogenic preterm 
delivery, abruption, placenta previa, 
suspected fetal distress 24 - 34 Single 
<20, <25, 
<30, <35 <34 
Goffinet336 1997 France 108 
Cohort 
Prospective 
Test described Singleton pregnancies 
Cervical cerclage, PPROM, cervical 
dilatation >2cm, iatrogenic preterm 
delivery 24 - 34 Single <26 <37 
Rizzo340 1996 Italy 108 
Cohort 
Prospective 
Test described 
Singletons pregnancies, intact 
membrane, cervical dilatation <3cm, 
absence of maternal or fetal 
complication  24 - 36 Single <20 <37 
Botsis57 2005 Greece 104 
Cohort 
Prospective 
Test described 
Singleton viable pregnancy 
presenting with threatened preterm 
labour between 24 - 36 weeks' 
gestation with intact fetal membrane 
and cervical dilatation <2cm  24 - 36 Single <15 
<7 days of 
testing 
Murakawa3
38 1993 Japan 32 
Cohort 
Prospective 
Test described Singleton pregnancies Suspicion of cervical incompetence 25 - 35 Single <30, <35 <37 
Rageth339 1997 Switzerland 61 
Cohort 
Retrospective 
Test described 
Singleton pregnancies whose 
contraction has been arrested by 
tocolysis IUGR, pre-eclampsia, diabetes 25 - 35 Single <30 <34 
           
*Unless otherwise stated 
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Table 56 Characteristics of test accuracy studies of cervical funnelling assessment in predicting spontaneous preterm birth stratified according to population of 
antenatal asymptomatic women and women symptomatic with threatened preterm labour 
 
Authors Year Country n Study designs Inclusion Exclusion 
Testing 
gestation 
(weeks) 
Frequency 
of Testing Threshold 
Outcome 
(weeks’ 
gestation)* 
           
Asymptomatic           
Leung326 2005 HK 2952 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Singleton pregnancy of ethnic 
Chinese women only 
Fetal abnormalities, non-viable 
pregnancies, lack of outcome 
information, outside test gestation 18 - 22 Single 5mm length 34 
Iams319 1996 USA 2915 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described Singleton pregnancies 
Multiple gestations, cervical 
cerclage, placenta previa, fetal 
anomaly at 28 Twice 3mm length 35 
Andrews322 2000 USA 69 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Singleton pregnancies with 
previous history of spontaneous 
preterm birth between 16 - 30 
weeks' gestation 
Medical or obstetrics complication. 
History of incompetent cervix that 
required cerclage. Presented for 
antenatal care after 28 weeks 25 - 29 Twice any 35 
To331 2001 UK 6334 
Cohort 
Prospective 
Consecutive 
Test described Singleton pregnancies x 22 - 24 Single 5mm width 33 
Pires329 2005 Brazil 338 
Cohort 
Prospective 
Test described Singleton uncomplicated pregnancy 
Previous history of preterm delivery, 
uterine or fetal abnormalities, 
miscarriage, fetal death, alteration in 
amniotic fluid, placenta previa, 
previous uterine or cervical surgery, 
surgical procedures during gestation 
and conditions requiring iatrogenic 
preterm delivery 21 - 24 Single any 35 
Mara327 2002 Czech 247 
Case-control 
Prospective 
Singleton viable pregnancy, 
delivery at investigating institutions 
Congenital or chromosomal 
abnormalities, history of uterine or 
cervix surgery, greater than 3 
previous vaginal deliveries 18 - 20 Single any 34 
           
Symptomatic           
Crane333 1997 USA 136 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described 
Singleton pregnancies whose 
contraction has been arrested by 
tocolysis 
Cervical dilatation > 3cm, placenta 
previa, PPROM 24 - 34 Single V-shaped 37 
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Gomez337 1994 USA 59 
Cohort 
Prospective 
Consecutive 
Blinded 
Test described Singleton pregnancies PPROM, cervix dilatation >3 cm 21 - 35 Single 6mm width 36 
Kurkinen223 2001 Finland 76 
Cohort 
Prospective 
Consecutive 
Test described 
Consecutive singleton pregnant 
women between 22 - 32 weeks' 
gestation who presented with 
threatened preterm labour. 
Preterm pre-labour rupture of 
membrane, impending preterm 
delivery 22 - 32 Single 5mm width 37 
Okitsu320 1992 Japan 130 
Cohort 
Prospective 
Test described Singleton pregnancies Placenta previa 25 - 36 Single 5mm width 36 
Rizzo340 1996 Italy 108 
Cohort 
Prospective 
Test described 
Singletons pregnancies, intact 
membrane, cervical dilatation 
<3cm, absence of maternal or fetal 
complication x 24 - 36 Single 5mm width 37 
           
*Unless otherwise stated 
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Table 57 Individual accuracy results of cervical length measurement in predicting spontaneous preterm birth among asymptomatic antenatal women stratified 
according to outcome (weeks’ gestation) and testing gestation (weeks’) 
 
Authors 
Thresholds 
(mm) 
Outcome 
(weeks’ 
gestation) TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                   
<20 weeks’ gestation                  
Andrews* 322 25 35 5 0 10 38 0.33 0.12 0.62 1.00 0.91 1.00 26.81 1.57 457.07 0.66 0.47 0.95 
Andrews* 322 22 35 4 0 11 38 0.27 0.08 0.55 1.00 0.91 1.00 21.94 1.25 384.29 0.73 0.53 0.99 
Leung326 25 34 5 48 15 2884 0.25 0.09 0.49 0.98 0.98 0.99 15.27 6.80 34.30 0.76 0.59 0.98 
Leung326 15 34 2 0 18 2932 0.10 0.01 0.32 1.00 1.00 1.00 698.33 34.56 14109.00 0.88 0.75 1.03 
Leung326 30 34 7 288 13 2644 0.35 0.15 0.59 0.90 0.89 0.91 3.56 1.94 6.54 0.72 0.52 0.99 
Leung326 35 34 12 1021 8 1911 0.60 0.36 0.81 0.65 0.63 0.67 1.72 1.20 2.47 0.61 0.36 1.05 
Leung326 27 34 7 111 13 2821 0.35 0.15 0.59 0.96 0.95 0.97 9.25 4.95 17.26 0.68 0.49 0.93 
Leung326 20 34 2 4 18 2928 0.10 0.01 0.32 1.00 1.00 1.00 73.30 14.23 377.66 0.90 0.78 1.04 
Owen328 20 35 5 1 42 135 0.11 0.04 0.23 0.99 0.96 1.00 14.47 1.73 120.69 0.90 0.81 0.99 
Owen328 25 35 9 3 39 132 0.19 0.09 0.33 0.98 0.94 1.00 8.44 2.38 29.88 0.83 0.72 0.95 
Owen328 30 35 12 24 29 118 0.29 0.16 0.46 0.83 0.76 0.89 1.73 0.95 3.15 0.85 0.69 1.05 
Owen328 15 35 5 0 43 135 0.10 0.03 0.23 1.00 0.97 1.00 30.53 1.72 542.02 0.89 0.81 0.98 
Hibbard325 27 35 15 25 36 684 0.29 0.17 0.44 0.96 0.95 0.98 8.34 4.70 14.80 0.73 0.61 0.87 
Hibbard325 22 35 11 16 40 693 0.22 0.11 0.35 0.98 0.96 0.99 9.56 4.68 19.50 0.80 0.69 0.93 
Hibbard325 30 35 21 66 30 643 0.41 0.28 0.56 0.91 0.88 0.93 4.42 2.96 6.60 0.65 0.51 0.82 
Mara327 20 34 3 0 6 238 0.33 0.07 0.70 1.00 0.98 1.00 167.30 9.25 3024.97 0.65 0.41 1.03 
                   
20 – 24 week’ gestation                  
Iams* 322 20 35 29 84 97 2705 0.23 0.16 0.31 0.97 0.96 0.98 7.64 5.21 11.20 0.79 0.72 0.87 
Andrews* 322 22 35 4 3 9 41 0.31 0.09 0.61 0.93 0.81 0.99 4.51 1.15 17.64 0.74 0.51 1.08 
Iams* 322 25 35 47 218 79 2571 0.37 0.29 0.46 0.92 0.91 0.93 4.77 3.68 6.19 0.68 0.59 0.78 
Andrews* 322 25 35 5 5 8 39 0.38 0.14 0.68 0.89 0.75 0.96 3.38 1.16 9.91 0.69 0.45 1.08 
Iams* 322 30 35 68 661 58 2128 0.54 0.45 0.63 0.76 0.75 0.78 2.28 1.91 2.71 0.60 0.50 0.73 
To331 15 33 21 80 38 6195 0.36 0.24 0.49 0.99 0.98 0.99 27.92 18.59 41.92 0.65 0.54 0.79 
deCarvalho59 10 34 3 3 38 1734 0.07 0.02 0.20 1.00 0.99 1.00 42.37 8.81 203.65 0.93 0.85 1.01 
deCarvalho59 10 34 5 5 61 1887 0.08 0.03 0.17 1.00 0.99 1.00 28.67 8.51 96.62 0.93 0.86 0.99 
deCarvalho59 10 34 2 2 23 153 0.08 0.01 0.26 0.99 0.95 1.00 6.20 0.91 42.03 0.93 0.83 1.05 
deCarvalho59 15 34 23 16 43 1876 0.35 0.24 0.48 0.99 0.99 1.00 41.21 22.87 74.26 0.66 0.55 0.78 
 
 
282
deCarvalho59 15 34 11 6 14 149 0.44 0.24 0.65 0.96 0.92 0.99 11.37 4.62 27.97 0.58 0.41 0.83 
deCarvalho59 15 34 12 10 29 1727 0.29 0.16 0.46 0.99 0.99 1.00 50.84 23.31 110.90 0.71 0.58 0.87 
Pires329 20 37 4 10 17 307 0.19 0.05 0.42 0.97 0.94 0.98 6.04 2.07 17.64 0.84 0.68 1.03 
deCarvalho59 20 34 34 47 32 1845 0.52 0.39 0.64 0.98 0.97 0.98 20.74 14.37 29.92 0.50 0.39 0.64 
deCarvalho59 20 34 18 17 7 138 0.72 0.51 0.88 0.89 0.83 0.93 6.56 3.94 10.94 0.31 0.17 0.59 
deCarvalho59 20 34 16 30 25 1707 0.39 0.24 0.55 0.98 0.98 0.99 22.60 13.41 38.07 0.62 0.49 0.79 
Pires329 20 35 3 7 8 320 0.27 0.06 0.61 0.98 0.96 0.99 12.74 3.79 42.80 0.74 0.52 1.07 
deCarvalho59 25 34 38 171 28 1721 0.58 0.45 0.70 0.91 0.90 0.92 6.37 4.95 8.19 0.47 0.35 0.62 
deCarvalho59 25 34 19 38 6 117 0.76 0.55 0.91 0.75 0.68 0.82 3.10 2.18 4.41 0.32 0.16 0.64 
deCarvalho59 25 34 19 134 22 1603 0.46 0.31 0.63 0.92 0.91 0.93 6.01 4.16 8.67 0.58 0.44 0.77 
deCarvalho59 30 34 42 442 24 1450 0.64 0.51 0.75 0.77 0.75 0.79 2.72 2.23 3.33 0.47 0.34 0.65 
deCarvalho59 30 34 22 372 19 1365 0.54 0.37 0.69 0.79 0.77 0.80 2.51 1.86 3.38 0.59 0.42 0.82 
deCarvalho59 30 34 20 71 5 84 0.80 0.59 0.93 0.54 0.46 0.62 1.75 1.35 2.27 0.37 0.17 0.82 
                   
<20 weeks’ gestation                  
Hibbard325 22 37 11 10 74 665 0.13 0.07 0.22 0.99 0.97 0.99 8.74 3.82 19.96 0.88 0.81 0.96 
Taipale330 25 37 5 8 83 3598 0.06 0.02 0.13 1.00 1.00 1.00 25.61 8.55 76.72 0.95 0.90 1.00 
Hibbard325 27 37 17 23 68 652 0.20 0.12 0.30 0.97 0.95 0.98 5.87 3.27 10.53 0.83 0.74 0.92 
Taipale330 29 37 14 96 74 3510 0.16 0.09 0.25 0.97 0.97 0.98 5.98 3.56 10.04 0.86 0.79 0.95 
Hibbard325 30 37 28 59 57 616 0.33 0.23 0.44 0.91 0.89 0.93 3.77 2.55 5.56 0.73 0.63 0.85 
Taipale330 35 37 31 962 57 2644 0.35 0.25 0.46 0.73 0.72 0.75 1.32 0.99 1.76 0.88 0.76 1.03 
Andersen321 39 37 13 39 4 56 0.76 0.50 0.93 0.59 0.48 0.69 1.86 1.30 2.66 0.40 0.17 0.96 
Taipale330 40 37 53 1875 35 1731 0.60 0.49 0.71 0.48 0.46 0.50 1.16 0.97 1.38 0.83 0.64 1.07 
Taipale330 45 37 78 2731 10 875 0.89 0.80 0.94 0.24 0.23 0.26 1.17 1.08 1.26 0.47 0.26 0.84 
Taipale330 50 37 87 3261 1 345 0.99 0.94 1.00 0.10 0.09 0.11 1.09 1.07 1.12 0.12 0.02 0.84 
                   
20 – 24 week’ gestation                  
Yazici332 32.5 36 16 61 6 274 0.73 0.50 0.89 0.82 0.77 0.86 3.99 2.84 5.62 0.33 0.17 0.66 
Dilek324 33.15 37 14 29 4 203 0.78 0.52 0.94 0.88 0.83 0.91 6.22 4.09 9.48 0.25 0.11 0.60 
                   
*Women were scanned twice, a few weeks apart within the testing gestation 
 
 
 
 
283
Table 58 Individual accuracy results of cervical length measurement in predicting spontaneous preterm birth among women symptomatic with threatened preterm 
labour stratified according to outcome (within days of testing and according to weeks’ gestation) 
 
Authors 
Thresholds 
(mm) TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                  
<48 hours of testing                 
Tsoi346 5 9 11 12 478 0.43 0.22 0.66 0.98 0.96 0.99 19.05 8.87 40.94 0.58 0.40 0.85 
Tsoi346 10 17 31 4 458 0.81 0.58 0.95 0.94 0.91 0.96 12.77 8.57 19.03 0.20 0.08 0.49 
Tsoi346 15 21 74 0 415 1.00 0.84 1.00 0.85 0.81 0.88 6.43 5.17 8.00 0.03 0.00 0.42 
Tsoi346 20 21 150 0 339 1.00 0.84 1.00 0.69 0.65 0.73 3.18 2.75 3.69 0.03 0.00 0.51 
Gomez106 15 11 19 6 179 0.65 0.38 0.86 0.90 0.85 0.94 6.74 3.88 11.72 0.39 0.20 0.74 
Gomez106 30 15 93 2 105 0.88 0.64 0.99 0.53 0.46 0.60 1.88 1.50 2.36 0.22 0.06 0.82 
                  
<7 days of testing                 
Tsoi346 5 16 4 27 463 0.37 0.23 0.53 0.99 0.98 1.00 43.44 15.20 124.17 0.63 0.50 0.80 
Tsoi346 10 28 20 15 447 0.65 0.49 0.79 0.96 0.93 0.97 15.20 9.40 24.61 0.36 0.24 0.55 
Tsoi346 15 42 53 1 414 0.98 0.88 1.00 0.89 0.85 0.91 8.61 6.65 11.14 0.03 0.00 0.18 
Tsoi346 20 42 129 1 338 0.98 0.88 1.00 0.72 0.68 0.76 3.54 3.03 4.12 0.03 0.00 0.22 
Schmitz342 15 12 45 11 291 0.52 0.31 0.73 0.87 0.82 0.90 3.90 2.42 6.27 0.55 0.36 0.85 
Schmitz342 25 20 131 3 205 0.87 0.66 0.97 0.61 0.56 0.66 2.23 1.81 2.74 0.21 0.07 0.62 
Schmitz342 30 23 193 0 143 1.00 0.85 1.00 0.43 0.37 0.48 1.71 1.53 1.90 0.05 0.00 0.76 
Fuchs335 15 17 19 4 213 0.81 0.58 0.95 0.92 0.88 0.95 9.88 6.13 15.95 0.21 0.09 0.50 
Tsoi345 15 16 27 1 172 0.94 0.71 1.00 0.86 0.81 0.91 6.94 4.79 10.05 0.07 0.01 0.46 
Tsoi345 15 20 10 0 33 1.00 0.83 1.00 0.77 0.61 0.88 4.09 2.40 6.96 0.03 0.00 0.49 
Gomez106 15 17 13 11 174 0.61 0.41 0.78 0.93 0.88 0.96 8.73 4.78 15.96 0.42 0.27 0.67 
Gomez106 30 25 83 3 104 0.89 0.72 0.98 0.56 0.48 0.63 2.01 1.64 2.47 0.19 0.07 0.57 
Botsis57 15 10 9 1 84 0.91 0.59 1.00 0.90 0.82 0.95 9.39 4.91 17.97 0.10 0.02 0.65 
Gomez106 15 17 13 17 168 0.50 0.32 0.68 0.93 0.88 0.96 6.96 3.74 12.97 0.54 0.38 0.76 
Gomez106 30 29 79 5 102 0.85 0.69 0.95 0.56 0.49 0.64 1.95 1.57 2.43 0.26 0.11 0.59 
                  
<34 weeks’ gestation                 
Gomez106 15 7 5 2 87 0.78 0.40 0.97 0.95 0.88 0.98 14.31 5.70 35.95 0.23 0.07 0.80 
Gomez106 30 9 40 0 52 1.00 0.66 1.00 0.57 0.46 0.67 2.18 1.66 2.86 0.09 0.01 1.33 
Crane333 30 30 35 7 64 0.81 0.65 0.92 0.65 0.54 0.74 2.29 1.68 3.12 0.29 0.15 0.58 
Daskalakis334 20 21 3 18 60 0.54 0.37 0.70 0.95 0.87 0.99 11.31 3.61 35.42 0.48 0.34 0.68 
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Daskalakis334 25 28 13 11 50 0.72 0.55 0.85 0.79 0.67 0.89 3.48 2.06 5.87 0.36 0.21 0.60 
Daskalakis334 30 39 21 0 42 1.00 0.91 1.00 0.67 0.54 0.78 2.94 2.08 4.16 0.02 0.00 0.30 
Daskalakis334 35 39 47 0 16 1.00 0.91 1.00 0.25 0.15 0.38 1.33 1.15 1.54 0.05 0.00 0.79 
Daskalakis334 20 15 1 10 44 0.60 0.39 0.79 0.98 0.88 1.00 27.00 3.79 192.51 0.41 0.25 0.66 
Daskalakis334 25 16 9 9 36 0.64 0.43 0.82 0.80 0.65 0.90 3.20 1.66 6.16 0.45 0.26 0.77 
Daskalakis334 30 25 15 0 30 1.00 0.86 1.00 0.67 0.51 0.80 2.91 1.93 4.38 0.03 0.00 0.45 
Daskalakis334 35 25 33 0 12 1.00 0.86 1.00 0.27 0.15 0.42 1.35 1.12 1.62 0.07 0.00 1.15 
Rageth339 30 4 25 0 32 1.00 0.40 1.00 0.56 0.42 0.69 2.05 1.36 3.09 0.18 0.01 2.50 
Tsoi346 5 17 3 59 431 0.22 0.14 0.33 0.99 0.98 1.00 32.36 9.72 107.75 0.78 0.69 0.88 
Tsoi346 10 33 15 43 419 0.43 0.32 0.55 0.97 0.94 0.98 12.56 7.18 21.98 0.59 0.48 0.71 
Tsoi346 15 54 41 22 393 0.71 0.60 0.81 0.91 0.87 0.93 7.52 5.44 10.41 0.32 0.22 0.46 
Tsoi346 20 59 112 17 322 0.78 0.67 0.86 0.74 0.70 0.78 3.01 2.46 3.67 0.30 0.20 0.46 
Schmitz342 15 22 35 26 276 0.46 0.31 0.61 0.89 0.85 0.92 4.07 2.63 6.31 0.61 0.47 0.79 
Schmitz342 25 36 115 12 196 0.75 0.60 0.86 0.63 0.57 0.68 2.03 1.63 2.52 0.40 0.24 0.65 
Schmitz342 30 43 173 5 138 0.90 0.77 0.97 0.44 0.39 0.50 1.61 1.40 1.85 0.23 0.10 0.54 
Gomez106 15 19 11 15 170 0.56 0.38 0.73 0.94 0.89 0.97 9.20 4.82 17.54 0.47 0.32 0.69 
Gomez106 30 30 78 4 103 0.88 0.73 0.97 0.57 0.49 0.64 2.05 1.66 2.52 0.21 0.08 0.52 
                  
<37 weeks’ gestation                 
Crane333 30 30 35 7 64 0.81 0.65 0.92 0.65 0.54 0.74 2.29 1.68 3.12 0.29 0.15 0.58 
Gomez106 18 16 8 6 29 0.73 0.50 0.89 0.78 0.62 0.90 3.36 1.73 6.54 0.35 0.17 0.70 
Onderoglu75 28 25 10 7 48 0.78 0.60 0.91 0.83 0.71 0.91 4.53 2.50 8.20 0.26 0.14 0.51 
Tekesin343 25 17 22 6 40 0.74 0.52 0.90 0.65 0.51 0.76 2.08 1.38 3.15 0.40 0.20 0.82 
Rozenberg128 26 14 6 2 6 0.88 0.62 0.98 0.50 0.21 0.79 1.75 0.96 3.17 0.25 0.06 1.03 
Venditelli347 30 55 53 12 54 0.82 0.71 0.90 0.50 0.41 0.60 1.66 1.33 2.07 0.35 0.21 0.61 
Rizzo340 20 32 13 15 48 0.68 0.53 0.81 0.79 0.66 0.88 3.19 1.90 5.38 0.41 0.26 0.63 
Goffinet336 26 19 28 5 56 0.79 0.58 0.93 0.67 0.56 0.77 2.38 1.65 3.42 0.31 0.14 0.69 
Murakawa338 25 7 3 4 18 0.64 0.31 0.89 0.86 0.64 0.97 4.45 1.43 13.91 0.42 0.19 0.95 
Murakawa338 30 11 6 0 15 1.00 0.72 1.00 0.71 0.48 0.89 3.24 1.68 6.25 0.06 0.00 0.90 
Murakawa338 35 11 14 0 7 1.00 0.72 1.00 0.33 0.15 0.57 1.45 1.05 2.01 0.12 0.01 1.96 
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Table 59 Individual accuracy results of cervical funnelling assessment in predicting spontaneous preterm birth among women symptomatic with threatened 
preterm labour stratified according to outcome (weeks’ gestation) 
 
Authors Thresholds 
Outcome 
(weeks’ 
gestation) TP FP FN TN SENS SENS_LB SENS_UB SPECS SPEC_LB SPEC_UB LR+ LR+_LB LR+_UB LR- LR-_LB LR-_UB 
                   
Asymptomatic                   
Leung*326 any 34 6 175 14 2757 0.30 0.12 0.54 0.94 0.93 0.95 5.03 2.53 9.97 0.74 0.56 0.99 
Andrews**+ 322 any 35 4 5 9 39 0.31 0.09 0.61 0.89 0.75 0.96 2.71 0.85 8.64 0.78 0.54 1.14 
Andrews**+ 322 any 35 5 0 10 38 0.33 0.12 0.62 1.00 0.91 1.00 26.81 1.57 457.07 0.66 0.47 0.95 
Andrews**+ 322 any 35 7 8 2 24 0.78 0.40 0.97 0.75 0.57 0.89 3.11 1.55 6.23 0.30 0.09 1.02 
To**331 5mm width 33 16 215 43 6103 0.27 0.16 0.40 0.97 0.96 0.97 7.97 5.14 12.35 0.75 0.65 0.88 
Pires*329 any 37 3 11 18 324 0.14 0.03 0.36 0.97 0.94 0.98 4.35 1.31 14.42 0.89 0.74 1.06 
Pires*329 any 35 3 11 8 316 0.27 0.06 0.61 0.97 0.94 0.98 8.11 2.63 25.01 0.75 0.52 1.08 
Mara*327 any 34 7 33 2 205 0.78 0.40 0.97 0.86 0.81 0.90 5.61 3.50 8.99 0.26 0.08 0.88 
Mara*327 any 37 22 18 11 196 0.67 0.48 0.82 0.92 0.87 0.95 7.93 4.79 13.12 0.36 0.22 0.59 
                   
Symptomatic                   
Crane333 V-shaped 37 7 9 25 95 0.22 0.09 0.40 0.91 0.84 0.96 2.53 1.02 6.25 0.86 0.71 1.04 
Crane333 V-shaped 34 4 12 5 115 0.44 0.14 0.79 0.91 0.84 0.95 4.70 1.90 11.66 0.61 0.34 1.10 
Gomez337 any 36 17 17 5 20 0.77 0.55 0.92 0.54 0.37 0.71 1.68 1.11 2.55 0.42 0.18 0.96 
Gomez337 6mm width 36 14 8 7 25 0.67 0.43 0.85 0.76 0.58 0.89 2.75 1.40 5.40 0.44 0.23 0.83 
Gomez337 9mm length 36 15 3 6 30 0.71 0.48 0.89 0.91 0.76 0.98 7.86 2.58 23.90 0.31 0.16 0.62 
Rizzo340 5mm width 37 34 20 13 41 0.72 0.57 0.84 0.67 0.54 0.79 2.21 1.48 3.29 0.41 0.25 0.67 
Okitsu320 5mm width 36 9 18 4 46 0.69 0.39 0.91 0.72 0.59 0.82 2.46 1.44 4.20 0.43 0.19 0.98 
                   
*Testing <20 weeks’ gestation **Testing between 20 – 24 weeks’ gestation + Tested twice within a two weeks apart 
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Appendix V – Guide to summary ROC & funnel plots interpretations 
 
A graphical method for assessment of heterogeneity is to plot sensitivity and specificity of the 
various studies in a summary receiver operating characteristics (ROC) space. A summary 
ROC space plot will show, as a minimum, distribution of studies along with the summary 
point the accuracy estimate and summary curve for estimates of the test’s accuracy from the 
various studies but it is usually accompanied by the 95% confidence region. A representation 
is shown below with key explanations. 
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Studies whose results showed accurate 
estimates would be found aggregated and 
distributed on the top left corner of this plot. 
Consequently, the summary point and summary 
curve’ inflexion point would be found in this area 
too (illustrated). A widely scattered studies 
indicates possible heterogeneity compared to 
studies closely aggregated. 
A summary curve from the hierarchical summary receiver 
operating characteristic (HSROC) model indicating a 
test’s summary accuracy estimates. An accurate test 
would have the inflexion point on the top left hand corner 
of this plot (see above in this same figure).
A summary operating 
point (i.e. summary 
value for sensitivity and 
specificity
The figure showed 
an example of a  
summary receiver 
operating 
characteristics 
(ROC) space (plot 
of sensitivity v. 
specificity)
A 95% confidence region for the summary 
operating point of sensitivity and specificity. 
The more precise the confidence intervals 
estimate is the smaller the region would be. 
A 95% prediction region (boundary)  (i.e. 
confidence region for a forecast of the 
true sensitivity & specificity in a future 
study). The more precise the forecast is 
the smaller the region would be
A study accuracy estimate, circle’s size 
proportional to study size (i.e. the larger the 
circle, the larger the study by enrolment..
An ‘imaginary’ line (dashed) of a 
summary test’ accuracy that is no better 
than ’50:50’ i.e. an ‘even chance’
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Another method for assessing heterogeneity (esp. publication and related biases) is to perform 
a simple, but commonly used method, funnel plot. To make a meaningful analysis and 
interpretation of a funnel plot requires inclusion of numerous studies (≥10 studies), preferably 
larger studies. The result is interpreted as either an asymmetrical (indicative of a possible 
presence of publication and related biases) or a symmetrical funnel plot (indicative of a 
possible absence of publication and related biases). Their representations are shown below 
with key explanations. 
 
An asymmetrical funnel plot analysis 
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A symmetrical funnel plot analysis 
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Studies are distributed 
equally on either side of the 
summary estimate.
 
Neither summary ROC nor funnel plot individually or jointly provides a conclusive evidence 
of heterogeneity or the presence of publication and related biases. Instead both are 
complementary and should be used as adjunct to studies’ methods and quality assessments, 
and forest plots to draw an inference regarding presence of heterogeneity, publication and 
related biases. 
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